Atezolizumab —F. Hoffmann -La Roche Ltd
2/Protocol WO41994, Version 3PROTOCOL HISTORY
Protocol
Version Date Final
2 24 June 2020
1 13 March 2020
Atezolizumab —F. Hoffmann -La Roche Ltd
3/Protocol WO41994, Version 3PROTOCOL A MENDMENT, VERSION 3:
RATIONA LE
Protocol WO41994 has been amended to primarily modify inclusion and exclusion 
criteria, and to update severe cutaneous adverse reactions (SCARs) from a potential risk 
to an identified risk associated with atezolizumab . Additional c hanges to the protocol, 
along with a rationale for each chang e, are summarized below. The synopsis has been 
updated to reflect changes made to the body of the protocol.
Sections 1.4, 5.1, and Appendix 10 have been revised to include COVID 19
-specific
risk language to ensure the safety of study participants during t he COVID -19
pandemic
Sections 2.1.3 and 6.4.3 , Exploratory Efficacy Objectives ,now include clarification
of timepoints and instruments for patient -reported outcomes (PROs)
Section 3.1 , Description of the Study,hasbeen revised :
–To clarify s ites must continue to provide images until the Independent Review
Facility (IRF) determines disease progression
–To align the key eligibility criteria changes in the study schema with inclusion
and exclusion criteria
Section 4.1.1 , Inclusion Criteria ,hasbeen revis ed:
–To allow inclusion of patients with the chromophobe subtype ofnonclear -cell
renal cell carcinoma ( non-ccRCC) if there is sarcomatoid differentiation
because studies have shown improved survival for patients with sarcomatoid
differentiation after treatment with immune checkpoint inhibitors (ICI s)
–Patients must have been treated with ICI sfor at least 2 cycles prior to study
enrollment to reflect a biologically -relevant minimum exposure
–To allow inclusion of patients who have received ICI sin the adjuvant setting ,
provided they progres sedduring or within 6months after the last dose of
adjuvant ICI. Phase III renal cell carcinoma (RCC) trials are ongoing in the
adjuvan t set
ting with ICIs. Thus,ICIs are becom ingthe standard of care in the
adjuvant setting for patients with RCC. Progression during or within 6 months
after the last dose of ICI in the adjuvant setting is a commonly applied inclusion
criterion in oncology clinical trials .
–Patients must have recovered to baseline or National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI CTCAE) , Version 5 Grade 1
from toxicities related to any prior treatments, unless adverse events are
clinically nonsignificant and/or stable in the opinion of the investigator to ensure
patient safety .Grade 2 alopecia is allowed for study participation. Exception:
Patients who have r eceived systemic corticosteroids for a prior immune -related
adverse event sfor 30 days consecutively prior to initiation of study treatment
are excluded to ensure patient safety .
Atezolizumab —F. Hoffmann -La Roche Ltd
4/Protocol WO41994, Version 3Section 4.1.2 , Exclusion Criteria ,hasbeen revised :
–The time window has been shortened for“treatment with anti -cancer therapy
prior to initiation of study treatment ”from “within 28 days” to “within 14 days .”
The rationale is to “ shorten ”the 28-day washout period requirement
considering that many RCC- targeted agents have a short half -life.
–Patients who have received a mammalian target of rapamycin ( mTOR )inhibitor
in any setting are excluded from the study to redu ce heterogeneity of the study
population . Previously only patients who received a nmTOR inhibitor in the
advanced or metastatic settings were excluded.
–The time window for excluding patient swith prior ischemic events or significant
cardiovascular disease risks has been clarified
–Additional standard language has been added to exclusion criteria.
This language serves to address cabozantinib risks ,including hemorrhage,
perforation, and fistulas.
Section 4.3.2.2 ,Cabozantinib ,has been revised sothat the requirement for the
1-hour wait time in the clinic after the first dose of cabozantinib has been removed
because it was deemed clinically unnecessary
Section 4.5.10.3 ,Research Biosample Repository (RBR) ,and Appendix 2 have
been updated to clarify that RBR sample collection should occur preferabl ypredose
on Day 1 of Cycle 1 but may also be collected anytime thereafter
Section 5.1.1 and Appendix 10 have been updated because SCARs have been
upgraded to an identified risk associated with atezolizumab
Section 5.2.3 ,Adverse Events of Special Interest ,has been updated to reflect the
most up-to-date listing of these events for immediate reporting purposes
Section 5.4.1 ,Emergency Medical Contacts ,hasbeen updated.
TheMedical Monitor has been changed.
Section 9. 6,Dissemination of Data and Protection of Trade Secrets , has been
updated to correct thename of a Roche policy on data sharing
Appendix 1 and Appendix 2 have been updated:
–Theurine protein- to-creatinin e ratio (UPCR) sampling schedule has been
clarified (Appendix 1)
–Aurine biomarker sample is now required for specific visits (Appendix 1 and
Appendix 2)
Appendix 7 has been updated to add language clarifying that hemophagocytic
lymphohistiocytosis and macrophage activa tion syndrome are considered potential
risks for atezolizumab
Substantive new information appears in italics.  This amendment represents cumulative 
changes to the original protocol.
Atezolizumab —F. Hoffmann -La Roche Ltd
5/Protocol WO41994, Version 3TABLE OF CONTENTS
PROTOCOL ACCEPTANCE FORM .................................................................. 14
PROTOCO L SYNOPSIS .................................................................................... 15
1. BACKGROUND .......................................................................................... 32
1.1 Background on Renal Cell Carcinoma ................................... 32
1.2 First-Line Treatment for Renal Cell Carcinoma ..................... 32
1.3 Second -Line and Third -Line Treatment ................................ .34
1.4 Background on Atezolizumab ................................................ 35
1.4.1 Efficacy in Metastatic Renal Cell Carcinoma ......................... 36
1.5 Background on Cabozantinib ................................................. 37
1.6 Background on Combination Therapy of 
Atezolizumab and Cabozantin ib............................................ 39
1.7 Rationale for Immune Checkpoint Re -Challenge ................... 42
1.8 Study Rationale and Benefit Risk Assessment ..................... 42
2. OBJECTIVES AND EN DPOINTS ............................................................... 43
2.1 Efficacy Objectives ................................................................ 43
2.1.1 Primary Efficacy Objective ..................................................... 44
2.1.2 Secondary Efficacy Objective ................................................ 44
2.1.3 Exploratory Efficacy Objective ............................................... 44
2.2 Safety Objectives ................................................................... 45
2.3 Pharmacokinetic Objectives .................................................. 46
2.4 Immunogenicity Objectives .................................................... 46
2.5 Biomarker Objective .............................................................. 46
2.6 Health Status Utility Objective ............................................... 46
3. STUDY DESIGN ......................................................................................... 47
3.1 Description of the Study ......................................................... 47
3.1.1 Independent Data Monitoring Committee .............................. 50
3.2 End of Study and Length of Study ......................................... 50
3.3 Rationale for Study Design .................................................... 51
3.3.1 Rationale for Atezolizumab Dose and Schedule .................... 51
3.3.2 Rationale for Cabozantinib Dose and Schedule .................... 51
Atezolizumab —F. Hoffmann -La Roche Ltd
6/Protocol WO41994, Version 33.3.3 Rationale for Patient Population ............................................ 52
3.3.4 Rationale for Control Group ................................................... 53
3.3.5 Rationale for Stratification Factors ......................................... 53
3.3.6 Rationale for Open -Label Study ............................................ 54
3.3.7 Rationale for Progression -Free Survival and 
Overall Survival as Multiple Primary Endpoints ..................... 55
3.3.8 Rationale for Atezolizumab or Cabozantinib 
Treatment beyond Initial Radiographic 
Progression per RECIST v1 .1 ............................................... 55
3.3.9 Rationale for the Use of iRECIST .......................................... 56
3.3.10 Rationale for Clinical Outcome Assessments ........................ 56
3.3.11 Rationale for Biomarker Assessmen ts................................... 57
4. MATERIALS AND MET HODS .................................................................... 58
4.1 Patients.................................................................................. 58
4.1.1 Inclusion Crit eria.................................................................... 58
4.1.2 Exclusion Criteria ................................................................... 61
4.2 Method of Treatment Assignment and Blinding ..................... 67
4.2.1 Treatment Assignment ........................................................... 67
4.3 Study Treatment and Other Treatments Relevant 
to the Study Design ............................................................... 67
4.3.1 Study Treatment Formulation, Packaging, and 
Handling ................................................................................ 67
4.3.1.1 Atezolizumab ......................................................................... 67
4.3.1.2 Cabozantinib .......................................................................... 68
4.3.2 Study Treatment Dosage, Administration, and 
Compliance ............................................................................ 68
4.3.2.1 Atezolizumab ......................................................................... 68
4.3.2.2 Cabozantinib .......................................................................... 69
4.3.3 Investigational Medicinal Product Accountability ................... 70
4.3.4 Continued Access to Atezolizumab and 
Cabozantinib .......................................................................... 71
4.4 Concomitant Therapy ............................................................ 71
4.4.1 Permitted Therapy ................................................................ .72
4.4.2 Caut ionary Therapy for All Patients ....................................... 74
4.4.2.1 Herbal Therapies ................................................................... 74
Atezolizumab —F. Hoffmann -La Roche Ltd
7/Protocol WO41994, Version 34.4.3 Cautionary Therapy for Atezolizumab -Treated 
Patients.................................................................................. 74
4.4.3.1 Corticosteroids, Immunosuppressive Medications, 
and TNF -Inhibitors .............................................................. 74
4.4.4 Cautionary Therapy for Cabozantinib -Treated 
Patients.................................................................................. 74
4.4.4.1 Cytochrome P450 .................................................................. 74
4.4.4.2 Protein Binding ...................................................................... 75
4.4.4.3 Concomitant Medications that are Known to 
Prolong the Corrected QT Interval ......................................... 75
4.4.4.4 Other Interactions .................................................................. 76
4.4.5 Prohibited Therapy for All Patients ........................................ 76
4.4.6 Prohibited Therapy for Atezolizumab- Treated 
and Cabozantin ib-Treated Patients ....................................... 77
4.5 Study Assessments ............................................................... 77
4.5.1 Informed Consent Forms and Screening Log ........................ 77
4.5.2 Medical History, Baseline Conditions, 
Concomitant Medication, and Demographic Data ................. 78
4.5.3 Physical Examinations ........................................................... 78
4.5.4 Vital Signs .............................................................................. 78
4.5.5 Tumor and Response Evaluations ......................................... 79
4.5.5.1 Independent Review Facility .................................................. 80
4.5.6 Survival Assessments ............................................................ 80
4.5.7 Laboratory, Biomarker, and Other Biological 
Samples ................................................................................. 81
4.5.8 Electrocardiograms and Echocardiograms ............................ 84
4.5.9 Clinical Outcome Assessments ............................................. 85
4.5.9.1 Data Collection Methods for Clinical Outcome 
Assessments ......................................................................... 86
4.5.9.2 Description of Clinical Outcome Assessment 
Instruments ............................................................................ 86
4.5.10 Blood Samples for Whole-Genome Sequencing 
or W hole-Exome Sequencing (Patients at 
Participating Sites) ................................................................ .87
4.5.11 Optional Tumor Biopsies ....................................................... 88
Atezolizumab —F. Hoffmann -La Roche Ltd
8/Protocol WO41994, Version 34.5.12 Optional Sample s for Research Biosample 
Repository ............................................................................. 89
4.5.12.1 Overview of the Research Biosample Repository .................. 89
4.5.12.2 Approval by the Institutional Review Board or 
Ethics Committee .................................................................. 89
4.5.12.3 Sample Collection .................................................................. 90
4.5.12 .4 Confidentiality ........................................................................ 90
4.5.12.5 Consent to Participate in the Research 
Biosample Repository ............................................................ 91
4.5.12.6 Withdrawal from the Research Biosample 
Repository ............................................................................. 91
4.5.12.7 Monitoring and Oversight ....................................................... 92
4.6 Treatment, Patient, Study, and Site 
Discontinuation ...................................................................... 92
4.6.1 Study Treatment Discontinuation ........................................... 92
4.6.2 Patient Discontinuation from the Study .................................. 93
4.6.3 Study Discontinuation ............................................................ 93
4.6.4 Site Discontinuation ............................................................... 94
5. ASSESSMENT OF SAF ETY....................................................................... 94
5.1 Safety Plan ............................................................................ 94
5.1.1 Risks Associated with Atezolizumab ..................................... 95
5.1.2 Risks Associated with Cabozantinib ...................................... 95
5.1.3 Management of Patients who Experience 
Adverse Events and Potential Overlapping 
Toxicities ................................................................................ 95
5.1.3.1 Dose Modification .................................................................. 96
5.1.3.2 Treatment Interruption ........................................................... 98
5.2 Safety Parameters and Definitions ........................................ 99
5.2.1 Adverse Events ..................................................................... 99
5.2.2 Serious Adverse Events (Immediately Reportable 
to the Sponsor) .................................................................... 100
5.2.3 Adverse Events of Special Interest (Immediately 
Reportable to the Sponsor) .................................................. 101
5.3 Methods and Timing for Capturing and 
Assessing Safety Parameters .............................................. 101
5.3.1 Adverse Event Reporting Period ......................................... 102
Atezolizumab —F. Hoffmann -La Roche Ltd
9/Protocol WO41994, Version 35.3.2 Eliciting Adverse Event Information ..................................... 102
5.3.3 Assessment of Severity of Adverse Events ......................... 102
5.3.4 Assessment of Causality of Adverse Events ....................... 103
5.3.5 Procedures for Recording Adverse Events .......................... 104
5.3.5.1 Infusion -Related Reactions .................................................. 104
5.3.5.2 Diagnosis versus Signs and Symptoms ............................... 104
5.3.5.3 Adverse Events that are Secondary to Other 
Events.................................................................................. 105
5.3.5.4 Persistent or Recurrent Adverse Events .............................. 105
5.3.5.5 Abnormal Laboratory Values ............................................... 106
5.3.5.6 Abnormal Vital Sign Values ................................................. 106
5.3.5.7 Abnormal Liver Function Tests ............................................ 107
5.3.5.8 Deaths ................................................................................. 107
5.3.5.9 Preexisting Medical Conditions ............................................ 108
5.3.5.10 Lack of Efficacy or W orsening of Renal Cell 
Carcinoma ........................................................................... 108
5.3.5.11 Hospitalization or Prolonged Hospitalization ........................ 108
5.3.5.12 Cases of Overdose, Medication Error, Drug 
Abuse, or Drug Misuse ........................................................ 109
5.3.5.13 Patient -Reported Outcome Data ......................................... 111
5.3.5.14 Safety Biomarker Data ......................................................... 111
5.4 Immediate Reporting Requirements from 
Investigator to Sponsor ........................................................ 111
5.4.1 Emergency Medical Contacts .............................................. 112
5.4.2 Reporting Requirements for Serious Adverse 
Events and Adverse Events of Special Interest ................... 112
5.4.2.1 Events that Occur prior to Study Treatment 
Initiation ............................................................................... 112
5.4.2.2 Events that Occur after Study Treatment Initiation .............. 112
5.4.3 Reporting Requirements for Pregnancies ............................ 113
5.4.3.1 Pregnancies in Female Patients .......................................... 113
5.4.3.2 Pregnancies in Female Partners of Male Patients ............... 113
5.4.3.3 Abortions ............................................................................. 114
5.4.3.4 Congenital Anomalies/Birth Defects .................................... 114
5.5 Follow -Up of Patients after Adverse Events ........................ 114
Atezolizumab —F. Hoffmann -La Roche Ltd
10/Protocol WO41994, Version 35.5.1 Investigator Follow -Up......................................................... 114
5.5.2 Sponsor Follow -Up.............................................................. 115
5.6 Adverse Events that Occur after the Adverse 
Event Reporting Period ........................................................ 115
5.7 Expedited Reporting to Health Authorities, 
Investigators, Institutional Review Boards, 
andEthics Committees ........................................................ 115
6. STATISTICAL CONSI DERATIONS AND ANALYS IS PLAN ..................... 116
6.1 Determination of Sample Size ............................................. 116
6.2 Summarie s of Conduct of Study .......................................... 117
6.3 Summaries of Demographic and Baseline 
Characteristics ..................................................................... 118
6.4 Efficacy Analyses ................................................................ 118
6.4.1 Multiple Primary Efficacy Endpoints .................................... 118
6.4.2 Secondary Efficacy Endpoints ............................................. 119
6.4.2.1 Objective Response Rate .................................................... 119
6.4.2.2 Duration of Response .......................................................... 119
6.4.3 Exploratory Efficacy Endpoints ............................................ 120
6.4.3.1 Analyses at Landmark Timepoints ....................................... 120
6.4.3.2 Subgroup Analyses ............................................................. 120
6.4.3.3 Time to Response ............................................................... 120
6.4.3.4 Time to Deterioration of Disease -Related 
Symptoms ............................................................................ 120
6.4.3.5 Time to Deterioration of Physical Functioning ..................... 120
6.4.3.6 Time to Deterioration of Global Health 
Status/Quality of Life ........................................................... 121
6.4.3.7 Patient -Reported Outcome Descriptive 
Summaries .......................................................................... 121
6.5 Safety Analyses ................................................................... 121
6.5.1 Analyses of Exposure, Adverse Event, 
Laboratory, Vital Signs, and Data ........................................ 121
6.5.2 Exploratory Analyses of Patient -Reported 
Treatment Side -Effect Burden ............................................. 122
6.6 Pharmacokinetic Analyses ................................................... 122
6.7 Immunogenicity Analyses .................................................... 122
Atezolizumab —F. Hoffmann -La Roche Ltd
11/Protocol WO41994, Version 36.8 Biomarker Analyses ............................................................. 123
6.9 Health Status Utility Analyses .............................................. 123
6.10 Interim Analyses .................................................................. 123
6.10.1 Planned Interim Analyses .................................................... 123
7. DATA COLLECTION A ND MANAGEMENT ............................................. 124
7.1 Data Quality Assurance ....................................................... 124
7.2 Electronic Case Report Forms ............................................. 125
7.3 Source Data Documentation ................................................ 125
7.4 Use of Computerized Systems ............................................ 126
7.5 Retention of Records ........................................................... 126
8. ETHICAL CONSIDERA TIONS .................................................................. 126
8.1 Compliance with Laws and Regulations .............................. 126
8.2 Informed Consent ................................................................ 126
8.3 Institut ional Review Board or Ethics Committee .................. 128
8.4 Confidentiality ...................................................................... 128
8.5 Financial Disclosure ............................................................ 129
9. STUDY DOCUMENTATI ON, MONITORING, AND
ADMINISTRATION ................................................................................... 129
9.1 Study Documentation .......................................................... 129
9.2 Protocol Deviations .............................................................. 129
9.3 Management of Study Quality ............................................. 129
9.4 Site Inspections ................................................................... 130
9.5 Administrative Structure ....................................................... 130
9.6 Dissemination of Data and Protection of Trade 
Secrets ................................................................................ 130
9.7 Protocol Amendments ......................................................... 131
10. REFERENCES ......................................................................................... 132
Atezolizumab —F. Hoffmann -La Roche Ltd
12/Protocol WO41994, Version 3LIST OF TA BLES
Table 1 First-Line Therapy Results for Advanced Renal Cell 
Carcinoma ................................................................................... 33
Table 2 Second -Line Therapy Results for Advanced Renal Cell 
Carcinoma ................................................................................... 35
Table 3 COSMIC -021 Study ccRCC Expansion Cohort:  
Objective Response Rate (per RECIST v1.1) in 
Cabozantinib 60mgAtezolizumab -Treated Patients ................. 40
Table 4 COSMIC -021 Study ccRCC Cohort:  Summary of Common 
Adverse Events ( 30% of Patients) in 
Cabozantinib 60mgAtezolizumab -Treated Patients ................. 41
Table 5 Administration of First and Subsequent Atezolizumab 
Infusions ...................................................................................... 69
Table 6 Timing for Vital Sign Measurements for First and 
Subsequent Infusions ................................................................ .79
Table 7 Guidance for Managing Overlapping Toxicities ........................... 96
Table 8 Dose Reduction Levels fo r Cabozantinib (Oral Dosing) .............. 97
Table 9 Dose Modifications for Cabozantinib -Related Adverse 
Events ......................................................................................... 98
Table 10 Adverse Event Severity Grading Scale for Events Not 
Specifically Listed in NCI CTCAE ............................................. 103
Table 11 Causal Attribution Guidance ..................................................... 104
Table 12 Operating Characteristics for Proposed Study Design for 
Several Possible True Underlying Hazard Ratios ..................... 123
LIST OF FIGURES
Figure 1 Study Schema ............................................................................. 48
Atezolizumab —F. Hoffmann -La Roche Ltd
14/Protocol WO41994, Version 3PROTOCOL A CCEPTA NCE FORM
TITLE: A PHA SE III, MULTICENTER, RA NDOMIZED, 
OPEN -LABEL STUDY TO EVA LUATE THE 
EFFICA CY AND S AFETY OF A TEZOLIZUMA B 
GIVEN IN COMBINA TION WITH CA BOZA NTINIB 
VERSUS CA BOZA NTINIB A LONE IN PA TIENTS 
WITH INOPERA BLE, LOCA LLY ADV ANCED, OR
METAST ATIC RENA L CELL CA RCINOMA  WHO 
EXPERIENCED RA DIOGRA PHIC TUMOR 
PROGRESSIO N DURING OR A FTER IMMUNE 
CHECKPOINT INHIBITOR TREA TMENT
PROTOCOL NUMBER: WO41994
VERSION NUMBER: 3
EUDRA CT NUMBER: 2020 -000502 -29160
IND NUMBER: 119039
NCT NUMBER: [STUDY_ID_REMOVED]
TEST PRODUCT: Atezolizumab (RO5541267)
MEDICA L MONITOR: , M.D.
SPONSOR: F. Hoffmann -La Roche Ltd
I agree to conduct the study  in accordance with the current protocol.
Principal Investigator's Name (print)
Principal Investigator's Signature Date
Please retain the signed original of this form for your study files.  Please return a copy of 
the signed form as instructed by your local study monitor .

Atezolizumab —F. Hoffmann- La Roche Ltd
15/Protocol WO41994, Version 3PROTOCOL SYNOPSIS
TITLE: A PHA SE III, MULTICENTER, RA NDOMIZED, OPEN -LABEL 
STUDY TO EVA LUATE THE EFFICA CY A ND SA FETY OF 
ATEZOLIZUM AB GIVEN IN COMBINA TION WITH CA BOZA NTINIB 
VERSUS CA BOZ ANTINIB A LONE IN PA TIENTS WITH 
INOPERABLE, LOCA LLY A DVA NCED, ORMETASTATIC RENA L 
CELL C ARCINOM A WHO EXPERIENCED RA DIOGRAPHIC 
TUMOR PROGRESSION DURING OR A FTER IMMUNE 
CHECKPOINT INHIBITOR TREA TMENT
PROTOCOL NUMBER: WO41994
VERSION NUMBER: 3
EUDR ACT NUMBER: 2020- 000502 -29160
IND NUMBER: 119039
NCT NUM BER: [STUDY_ID_REMOVED]
TEST PRODUCT: Atezolizumab (RO5541267)
PHASE: Phase III
INDIC ATION: Renal cell carcinoma
SPONSOR: F. Hoffmann -La Roche Ltd
Objectives and Endpoints
This study will evaluate the efficacy andsafety of atezolizumab when given in combination with 
cabozantinib compared with cabozantinib alone in patients with advanced clear -cell or 
non clear -cellrenal cell carcinoma ( RCC ; papillary , chromophobe or unclassified only) who 
experienced radiographic tumor progression during or after immune checkpoint inhibitor ( ICI)
treatment in the adjuvant and/or locally advanced/ metastatic setting.  Patients with RCC with 
sarcomatoid features are also allowed into thi s study .  Patients with the chromophobe subtype 
of non clear -cell RCC must have sarcomatoid differentiation. Specific objectives and 
corresponding endpoints for the study are outlined below.
In this protocol, "study treatment" refers to the combination of treatments assigned to patients 
as part of this study (i.e., atezolizumab in combination with cabozantinib or cabozantinib
monotherapy ).
Efficacy Objectives
Response will be assessed according to Response Evaluation Criteria in Solid Tumors
(RECIST) Versi on1.1.  Objective response at a single time point will be determined by 
theinvestigator and I ndependent Review Facility (IRF) according to RECIST v1.1.  
Objective response rate (ORR) per modified RECIST for immune -based therapeutics 
(iRECIST )v1.1 may be calculated programmatically by the Sponsor on the basis of investigator 
assessments of individual lesions at each specified timepoint .
Atezolizumab —F. Hoffmann- La Roche Ltd
16/Protocol WO41994, Version 3Primary Efficacy Objective
The primary  efficacy  objective for this study isto evaluate the efficacy of atezolizumab in 
combination with cabozantinib compared with cabozan tinib alone inthe intent- to-treat ( ITT)
population based on the following endpoints:
Progression -free survival (PFS) , defined as the time from randomization to the first 
occurrence of disease progressi on according to RECIST v1.1, as assessed by an IRF 
(e.g., IRF-PFS) or death from any  cause , whichever occurs first
Overall survival (OS), defined as the time from randomization to death from any cause
Secondary Efficacy Objective
The secondary efficacy  objective for this study is to evaluate the efficacy  of atezolizumab in 
combination with cabozantinib compared with cabozantinib alone on the basis of the following 
endpoints:
PFS assessed by the investigators ( investigator -assessed PFS) ,defined as the ti me from  
randomization to the first occurrence of disease progression according to RECIST v1.1 or 
death from any cause (whichever occurs first)
Investigator -and IRF-assessed ORR (investigator -assessed ORR and IRF-assessed ORR) ,
defined as the proportion of patients with a complete response or partial response on 
twoconsecutive occasions at least 4 weeks apart according to RECIST v1.1
Investigator -and IRF -assessed duration of response ( DOR; investigator -assessed -DOR
and IRF -DOR ), defined as the time from t he first occurrence of a documented objective 
response to disease progression or death from any cause (whichever occurs first) 
according to RECIST v1.1
Exploratory Efficacy Objective
The exploratory efficacy  objective for this study is to evaluate the efficacy  of atezolizumab in 
combination with cabozantinib compared with cabozantinib alone on the basis of the following 
endpoints :
PFS, OS, and ORR in subgroups, defined by demographic and baseline characteristics 
(e.g., PD- L1 status, prior vascular endothelial growth factor receptor [VEGFR]- tyrosine 
kinase inhibitor [ TKI]use, most recent ICI therapy [ adjuvant vs. first -line vs. second -line], 
tumor histology , or International Metastatic Renal Cell Carcinoma Database Consortium 
[IMDC ]risk group)
Time to response
Time to confirmed deterioration of disease -related symptoms, defined as the time from 
randomization date to the date of a patie nt’s first 4-point score decrease from baseline on
theFunction al Assessment of Cancer Therapy Kidney S ymptom Index 19 (FKSI -19) 
Disease -Related Sy mptom-Physical (DRS -P) scale held for at least two consecutive 
timepoints, or followed by death within 3 weeks (if Cycles 112) or 6 weeks (if after 
Cycle 12) from the last patient -reported outcome ( PRO )assessment
Change from baseline in patient -reported disease -related sy mptoms by visit, measured with 
use of the FKSI -19 DRS -P scale
Time to confirmed deterioration of physical functioning, defined as the time from 
randomization date to the date of a patient ’s first 10-point score decrease from baseline
ontheEuropean Organisation for Research and Treatm ent of Cancer (EORTC) Quality of 
LifeCore 30 Questionnaire (QLQ -C30) phy sical functioning scale held for at least 
two consecutive timepoints, or followed by death within 3 weeks (if Cycles 1 12) or 
6weeks (if after Cycle 12) from the last PRO assessment
Time to confirmed deterioration of global health status /quality of life (GHS/QoL), defined 
as the time from randomization date to the date of a patient’ s first 10-point score decrease 
from baseline on the EORTC QLQ -C30 GHS/QoL scale held for at least two consecutive 
timepoints, or followed by death within 3 weeks (if Cycles 1 12) or 6 weeks (if after 
Cycle 12) from the last PRO assessment
Atezolizumab —F. Hoffmann- La Roche Ltd
17/Protocol WO41994, Version 3Change from baseline in patient -reported physical functioning and global health status by 
visit, measured with use of the EORTC QLQ -C30 physical functioning and GHS/QoL scales
Descriptive summary  statistics by visit for the remaining FKSI -19 and EORTC QLQ -C30 
scales
Cumulative distribution function curves of score change from baseline to Month 6 for each 
key scale (FKSI -19 DRS -P, EORTC QLQ -C30 physical function, EORTC QLQ -C30 
GHS/QoL )
Safety Objective
The safety  objective for this study is to evaluate the safety of atezolizumab in combination with 
cabozantinib compared with cabozantinib alone on the basis of the following endpoints :
Incidence and severity of adverse events , with severity determined according to 
National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
v5.0
Change from baseline in targeted vital signs
Change from baseline in targe ted clinical laboratory test results
The exploratory safety objective for this study is to evaluate the overall side -effect burden of 
atezolizumab in combination with cabozantinib compared with cabozantinib alone from the 
patient's perspective, on the bas is of the following endpoint:
Patient- reported overall bother with treatment side effects during study tre atment, measured 
with use of the FKSI -19 GP5 item
Pharmacokinetic Objective
The pharmacokinetic (PK) objective for this study is to characterize the PK profile of 
atezolizumab and cabozantinib administered in combination on the basis of the following 
endpoint s:
Atezolizumab concentrations at specified timepoints
Cabozantinib concentrations at specified timepoints
Immunogenicity Objective
The immunogenicity objective for this study is to evaluate the immune response to atezolizumab
on the basis of the following endpoint :
Prevalence of anti -drug antibodies (ADAs) to atezolizumab at baseline and incidence of 
ADAs to atezolizumab during the st udy
The exploratory immunogenicity objective for this study is to evaluate potential effects of ADAs 
on the basis of the following endpoint :
Relationship between ADA status and dem ographics, efficacy , safety, or PK endpoints
Biomarker Objective
The explo ratory biomarker objective for this study is to identify and/or evaluate biomarkers that 
are predictive of response to atezolizumab in combination with cabozantinib or cabozantinib 
alone (i.e., predictive biomarkers), are early surrogates of efficacy, are associated with 
progression to a more severe disease state (i.e., prognostic biomarkers), are associated with 
acquired resistance to atezolizumab in combination with cabozantinib or cabozantinib alone , 
can provide evidence of atezolizumab in combination wi th cabozantinib or cabozantinib alone
efficacy (i.e., pharmacodynamic biomarkers), or can increase the knowledge and understanding 
of disease biology and drug safety, on the basis of the following endpoint:
Relationship between biomarkers in blood ,tumor t issue , and urine and efficacy , PK, 
immunogenicity, or other biomarker endpoints
Atezolizumab —F. Hoffmann- La Roche Ltd
18/Protocol WO41994, Version 3Health Status Utility Objective
The exploratory health status utility objective for this study is to evaluate health status utility 
scores of patients treated with atezolizumab in combination with cabozantinib compared with 
cabozantinib alone to inform economic modeling on the basis of t he following endpoint:
Change from baseline in the EuroQol 5 -Dimension, 5 -Level Questionnaire (EQ -5D-5L) 
index -based and visual analog scale (VAS)scores by visit
Study Design
Description of Study
This is a Phase III, multicenter, randomized, open -label s tudy designed to evaluate the efficacy  
and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in 
patients with inoperable, locally advanced, or metastatic RCC who experienced radiographic 
tumor progression during or aft er ICI treatment in the adjuvant and/or locally 
advanced/ metastatic se tting.  The study will enroll approximately 500 patients at approximately 
140 180 sites globally.
Key inclusion criteria include:
Male and female patients aged  18 years with Karnofsky  Performance S tatus (KPS) score 
70 who have histologically -confirmed locally advanced or metastatic clear -cellor 
non clear -cell RCC ( papillary , chromophobe, or unclassified only)
Sarcomatoid features are allowed.  Patients with the chromophobe subty pe of 
non clear -cell RCC mu sthave sarcomatoid differentiation.
Other subtypes of non clear- cell RCC (e.g., collecting duct carcinoma, renal medullary 
carcinoma) are not eligible .
Patients who have experienced radiographic tumor progression during or
following ICI treatment for locally advanced or metastatic RCC either in 
first -line or second -line treatment.  Patients who experienced radiographic tumor 
progression during or within 6 months after last dose of adjuvant ICI are also 
eligible.
Patients who do not meet the criteria for participation in this study (screen failure) may  qualify 
for onere-screening (for a total of two screenings per participant) at the investigator's discretion.
Patients are not required to re -sign the consent form if they are re -screened within 28 days after 
previously signing the consent form .  The investigator will record reasons for screen failure in 
the screening log.
Patients will be randomized in a 1:1 ratio to oneof the following twotreatments arms:
Experi mental arm:  Atezolizumab 1200 mg IV infusions every 3 weeks ( Q3W)on Day 1 of 
each 21 -day cycleplus cabozantinib 60 -mg oral tablets taken once a day 
(QD; 1cycle21days)
Control arm:  Cabozantinib 60 -mg oral tablets taken QD (1 cycle 21 days)
Rando mization will be stratified by:
IMDC risk groups ( favorable , intermediate or poor risk; 0, 1 2, or 3), which comprises the 
following sixrisk factors :  time from  diagnosis to systemic therapy, KPS, hemoglobin, 
corrected calcium, neutrophil and platelet count
Most recent ICI therapy ( adjuvant vs. first-line vs. second -line)
Histology:  dominant clear -cell without sarcomatoid versus dominant non clear -cell 
(papillary or unclassified only) without sarcomatoid versus any sarcomatoid component 
(clear -cell or nonclear -cell)
Atezolizumab will be administered by IVinfusion at a fixed dose of 1200 mg on Day 1 of each 
21-day cycle and cabozantinib will be taken orally at a starting dose of 60mg/day on Days 1 21 
of each 21 -day cycle.  Patients randomized to the atezolizumab and cabozantinib arm who 
transiently withhold or permanently discontinue either atezolizumab or cabozantinib may 
continue on single -agent therapy u ntil disease progression (i.e., patients being withheld from
Atezolizumab —F. Hoffmann- La Roche Ltd
19/Protocol WO41994, Version 3cabozantinib transiently for adverse effects may  continue atezolizumab monotherapy and vice 
versa). Guidelines for dosage modification, treatment interruption or discontinuation .
Patients will receive atezolizumab and/or cabozantinib until disease progres sion per 
RECIST v1.1, unacceptable toxicity , or sy mptomatic deterioration attributed to disease 
progression (e.g., pain secondar y to disease or unmanageable ascites) as determined by the 
investigator after an integrated assessment of radiographic and bioch emical data, local biopsy 
results (if available), and clinical status .
No crossover will be allowed from the control arm to the experimental arm.
Patients will undergo scheduled tumor assessment at baseline, ever y 9 weeks ( 7days) for the 
first 1 8months and ever y 12 weeks ( 7 days) thereafter.  Tumor assessments will continue 
until disease progression as assessed by the investigator per RECIST v1.1 or, for patients who 
continue study treatment after radiographic disease progression, loss of clinical ben efit as 
determined by the investigator .  In the absence of disease progression, tumor assessments 
should continue regardless of whether treatment has been discontinued (e.g., for toxicity ) or 
whether patients start new anti -cancer therapy, until consent is withdrawn, death , or the study is 
terminated by the Sponsor, whichever occurs first. Following treatment discontinuation (even in 
the absence of disease progression per RECIST v1.1.), patients will be followed for survival and 
subsequent anti -cancer ther apies until death, loss to follow -up, withdrawal of consent, or study 
termination by Sponsor, whichever occurs first. The following information regarding all 
subsequent anti -neoplastic agents upon treatment discontinuation will be collected: line of 
therapy, date of first dose of agent, date of final dose of agent (or if ongoing), patient's best 
response, and date of disease progression.
Sites must continue to provide images until the IRF determines disease progression .  
However, treatment decisions will be made based on investigator assessment of 
disease progression.  Independent Review Facility procedures will be detailed in an 
IRF Charter.
Because of the possibility of an initial increase in tumor burden caused by immune -cell 
infiltration in the setting of a T -cell response (termed pseudo progression) with atezolizumab 
treatment, radiographic progression per RECIST v1.1 may not be indicative of true disease 
progression.   In the absence of unacceptable toxicity, patients who meet criteria for disease 
progression per RECIST v1.1 while receiving atezolizumab and/or cabozantinib will be 
permitted to continue treatment, until loss of clinical benefit, if they meet all of the following 
criteria:
Evidence of clinical benefit, as determined by the investigator fo llowing a review of all 
available data
Absence of sy mptoms and signs (including laboratory values, such as new or worsening 
hypercalcemia) indicating unequivocal progression of disease
Absence of decline in KPS that can be attributed to disease progression
Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal disease) that 
cannot be managed by protocol -allowed medical interventions
Patients for whom other treatment options/standard therapies exist must provide written 
consent to ac knowledge deferring these treatment options in favor of continuing study 
treatment at the time of progression
Tumor tissue will also be collected by biopsy, unless not clinically feasible as assessed and 
documented by the investigator, at the time of first evidence of radiographic disease 
progression per RECIST v1.1 (within 40 days after radiographic progression or prior to the start 
of new anti -cancer treatment, whichever is sooner.  These samples will enable analy sis of tumor 
tissue biomarkers relate d to resistance, disease progression, and clinical benefit of 
atezolizumab and/or cabozantinib.
Number of Patients
Approximately 500 patients will be enrolled in this study at approximately 140 180 sites globally .
Atezolizumab —F. Hoffmann- La Roche Ltd
20/Protocol WO41994, Version 3Target Population
Inclusion Criteria
Patients must meet the following criteria for study entry:
Signed Informed Consent Form
Age 18 years at time of signing Informed Consent Form
Ability to comply with the study protocol
Histologically -confirmed locally advanced or metastatic clear -cell or non clear -cell (papillary , 
chromophobe, unclassified only) RCC
– Other subtypes of non clear- cell RCC (e.g., collecting duct carcinoma, renal medullary 
carcinoma) are not eligible .
– RCCwith sarcomatoid features is allowed.  Patients with the chromophobe 
subtype of non -clear -cell RCC must have sarcomatoid differentiation .
Radiographic d isease progression to prior ICI therapy for RCC
–ICI for metastatic disease:  Radiographic disease progression during or 
following ICI treatment for locally advanced or metastatic RCC either in 
first -or second -line treatment
–ICI for adjuvant therapy:  Patients who experienced radiographic tumor 
progression during or within 6 months after last dose of adjuvant ICI are 
also eligible
– Examples of ICI regimens include oneICIregimen in first -line treatment 
(e.g., nivolumab plus ipilimumab, pembrolizumab plus axitinib, axitinib plus avelumab) , 
or second -line treatment (e.g., TKI as first- line treatment and ICI as second -line 
treatment)
– ICI is defined by anti PD-L1 or anti PD1 antibody, including atezolizumab, avelumab, 
pembrolizumab, durvalumab, or nivolumab.  Ipilimumab monotherapy is not 
considered an anti PD-L1 or anti PD1 therapy.
– Patients must have received at least 2 cycles of ICI treatment
– ICI must have been used in the immediate preceding line of therapy (patients with an 
intervening treatment between ICI and study screening are excluded)
– Adjuvant treatment with VEGFR -TKIs, except cabozantinib, is allowed
Measurable disease per RECIST v1.1
Evaluable IMDC risk score s
Representative pretreatment tumor specimen (s), for explorator y biom arker research
− A rchival tumor specimen (e.g.,at diagnosis, surgery, or prior to initiation of previous 
line of therapy )
−Pretreatment tumor tissue fro m fresh biopsy at screening, if clinically feasible .  
Biopsies collected via minor surgery must be performed at least 10 day s prior to Day 1 
of Cy cle 1 and must be completely healed before first dose .
Availability of tissue sample (s)must be confirmed befo re randomization.  
Tissue samples must be submitted before or within 4 weeks of random ization.  
Both archival and fresh samples are preferred, if feasible.
KPS score of 70
Recovery to baseline or Grade 1 NCI CTCAE v5.0 from toxicities related to any 
prior treatments, unless adverse events are clinically nonsignificant and/or 
stable in the opinion of the investigator
– Grade 2 alopecia is allowed for study participation
– Exception:  Patients who have received systemic corticosteroids for a prior 
immune -related adverse event for 30 days consecutively prior to initiation of 
study treatment are not eligible.  Additional criteria on steroid use for prior 
immune -related adverse events is described in the exclusion criteria.
Atezolizumab —F. Hoffmann- La Roche Ltd
21/Protocol WO41994, Version 3Adequate hematologic and end -organ function, defined by the following laboratory test 
results, obtained within 14 days prior to initiation of study treatment:
−ANC  1.5109/L(1500 cells/ L) without granuloc yte colony -stimulating factor support 
within 14 days prior to Day 1 of Cycle 1
− L ymphoc yte count 0.3109/L (300 /L)
−Platelet count 100109/L(100,000/ L) without transfusion within 14 days prior to 
Day 1 of Cycle 1
−WBC counts 2500 cells/ L
−Hemoglobin  90 g/L (9 g/dL) (without transfusion within 14 day s prior to Day 1 of 
Cycle1)
−AST, ALT, and ALP 2.5upper limit of normal ( ULN), with the following exceptions:
Patients with documented liver metastases:  AST and ALT 5ULN
Patients with documented liver or bone metastases:  ALP 5ULN
− B ilirubin 1.5ULN with the following exception:
Patients with known Gilbert disease:  bilirubin 3ULN
−Creatinine clearance  40 mL/min (calculated with use of the Cockcroft -Gault formula, 
or based on 24 -hour urine collection)
−Albumin 25 g/L (2.5 g/dL)
−For patients not rece iving therapeutic anticoagulation:  INR or aPTT 1.5ULN
− P roteinuria, as demonstrated by urine protein -to-creatinine ratio 1mg/mg 
(113.2 mg/mmol)
Negative HIV test at screening
Negative hepatitis B testing at screening:
−Negative hepatitis B surface antigen (HBsAg) test at screening
−Negative total hepatitis B core antibody (HBcAb) test at screening, or positive total 
HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening. 
TheHBV DNA test will be performed only for patients who have a negative HBsAg test 
and a positive total HBcAb test.
Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test 
followed by a negative HCV RNA test at screening
The HCV RNA test will be performed only for patients who have a positive 
HCV antibody test.
For women of childbearing potential:  agreement to remain abstinent (refrain from 
heterosexual intercourse) or use contraception and agreement to refrain from donating 
eggs, as defined below:
Women must remain abstin ent or use contraceptive methods with a failure rate of 
1%per year during the treatment period and for 4 months after the final dose of 
cabozantinib and for 5 months after the final dose of atezolizumab. W omen m ust 
refrain from donating eggs during this same period.
A woman is considered to be of childbearing potential if she is postmenarchal, has not 
reached a postmenopausal state (12continuous months of amenorrhea with no 
identified cause other than menopause), and is not permanently infertile due to surgery 
(i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as 
determined by the investigator (e.g., Müllerian agenesis).  The definition of 
childbearing potential may be adapted for alignment with local guidelines or regulations .
Examples of contraceptive methods with a failure rate of 1% per year include bilateral 
tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, 
hormone -releasing intrauterine devices, and copper intrauterine devices.
Hormonal contraceptive methods mu stbe supplemented by a barrier method.
Atezolizumab —F. Hoffmann- La Roche Ltd
22/Protocol WO41994, Version 3The reliability of sexual abstinence should be evaluated in relation to the duration of 
the clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence 
(e.g., calendar, ovulation, sy mptothermal, or postovulation methods) and withdrawal 
are not adequate methods of contraception.  If required per local guidelines or 
regulations, locally recognized adequate methods of contraception and information 
about the reliabi lity of abstinence will be described in the local Informed Consent Form .
For men:  agreement to remain abstinent (refrain from heterosexual intercourse) or use a 
condom, and agreement to refrain from donating sperm, as defined below:
With a female partner of childbearing potential or pregnant female partner, men must 
remain abstinent or use a condom during the treatment period and for 4 months after 
the final dose of cabozantinib to avoid exposing the embryo.  Men must refrain from 
donating sperm during thi s same period .  Females of childbearing potential who are 
partners of male patients should also use contraceptive methods with a failure rate of 
1% per year during their male partner’s therapy and for at least 4 months after 
completing therapy.  Examples of contraceptive methods with a failure rate of 1% per 
year include bilateral tubal ligation, male sterilization, hormonal contraceptives that 
inhibit ovulation, hormone- releasing intrauterine devices, and copper intrauterine 
devices.
Hormonal contracepti ve m ethods mustbe supplemented by a barrier method.
The reliability of sexual abstinence should be evaluated in relation to the duration of 
the clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence 
(e.g., calendar, ovulation, sy mptothermal, or postovulation methods) and withdrawal 
are not adequate methods of preventing drug exposure.  If required per local 
guidelines or regulations, information about the reliability of abstinence will be 
described in the local Inform ed Consent Form.
Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:
Treatment with anti-cancer therapy within 14 days prior to initiation of study treatment
Patients received cabozantinib at any time prior to screening 
Patients who received more than one ICI treatment in the locally advanced or metastatic 
setting (e.g., pembrolizumab and axitinib as first -line treatment and nivolumab as 
second -line treatment)
Patients who received more than two prior line s of therapy in the locally advanced or 
metastatic setting
Patients who have received a mTOR inhibitor in any setting
Symptomatic, untreated, or actively progressing CNS metastases
Asymptomatic patients with treated CNS lesions are eligible, provided that allof the 
following criteria are met:
−Measurable disease, per RECIST v1.1, must be present outside the CNS
−The patient has no history of intracranial hemorrhage or spinal cord hemorrhage
−The patient has not undergone stereotactic radiotherapy within 7days prior to 
initiation of study treatment, whole- brain radiotherapy within 14days prior to 
initiation of study treatment, or neurosurgical resection within 28 days prior to 
initiation of study treatment.
−No evidence of significant vasogenic edema
−The p atient has no ongoing requirement for corticosteroids as therapy for CNS 
disease.  Anticonvulsant therapy at a stable dose is permitted.
−Metastases are limited to the cerebellum or the supratentorial region (i.e., no 
metastases to the midbrain, pons, me dulla, or spinal cord).
Atezolizumab —F. Hoffmann- La Roche Ltd
23/Protocol WO41994, Version 3−There is no evidence of interim progression between completion of CNS- directed 
therapy and initiation of study treatment.
Asymptomatic patients with CNS metastases newly detected at screening are eligible 
for the study after recei ving radiotherapy or surger y, with no need to repeat the 
screening brain scan.
History of leptomeningeal disease
Uncontrolled tumor -related pain
Symptomatic lesions (e.g., bone metastases or metastases causing nerve 
impingem ent) amenable to palliative radi otherapy should be treated prior to enrollment.  
Patients should be recovered from the effects of radiation.  There is no required 
minimum recovery period.
Asymptomatic metastatic lesions that would likely cause functional deficits or 
intractable pain with further growth (e.g., epidural metastasis that is not currently 
associated with spinal cord compression) should be considered for loco-regional 
therapy if appropriate prior to enrollment.
Uncontrolled pleural effusion, pericardial effusion, or ascites req uiring recurrent drainage 
procedures (once monthly or more frequently)
Patients with indwelling catheters (e.g., PleurX) are allowed .
Moderate to severe hepatic impairment (Child -Pugh B or C)
Uncontrolled or s ymptomatic hypercalcemia (ionized calcium 1.5 mmol/L, calcium
12mg/dL, or corrected calcium  ULN) or sy mptomatic hypercalcemia requiring continued 
use of bisphosphonate therapy or denosumab
Patients who are receiving bisphosphonate therapy or denosumab specifically to 
prevent skeletal events and who do not have a histor y of clinically significant 
hypercalcemia are eligible.
History of malignanc y other than renal carcinoma within 5 years prior to screening, with the 
exception of malignancies with a negligible ris k of metastasis or death (e.g., 5-year OS 
rate90%), such as adequately treated carci noma in situ of the cervix, non -melanoma skin 
carcinoma, localized prostate cancer, ductal carcinoma in situ , or Stage Iuterine cancer
Radiotherapy for RCC within 14 day s prior to Day 1 of Cycle 1
Patients who are receiving s ingle -fraction radiotherapy given for the indication of pain 
control are eligible.
Active tuberculosis
Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study 
treatment, or anticipation of ne ed for a major surgical procedure during the study
Minor surgeries (e.g .,tumor biops y, placement of vascular access device ) should be 
performed at least 10 day s prior to initiation of study treatment . Patients must have 
complete wound healing from major surgery  or minor surgery before randomization. 
Patients with clinically relevant ongoing complications from prior surgery are not 
eligible.
Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or 
within 5 months after final dose of atezolizumab and 4 months after final dose of 
cabozantinib
Women of childbearing potential must have a negative serum pregnancy test result 
within 14days prior to initiation of study treatment.
Severe infection within 4 weeks prior to initiation of study treatment, including, but not 
limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia , 
or any active infection that, in the opinion of the investigator, could impact patient safety
Treatment with a live, attenua ted vaccine within 4 weeks prior to initiation of study treatment, 
or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months 
after the final dose of atezolizumab
Atezolizumab —F. Hoffmann- La Roche Ltd
24/Protocol WO41994, Version 3Treatment with s ystemic immunostimulatory agents (including, but not limited to, interferon 
and interleukin -2) within 4 weeks or 5 drug -elimination half -lives (whichever is longer) prior 
to initiation of study treatment
Treatment with s ystemic immunosuppressive medication (including, but not limited to, 
corticoster oids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and 
antiTNF-agents ) within 2 weeks prior to initiation of study treatment, or anticipation of 
need for sy stemic immunosuppressive medication during study treatment, with the following 
exceptions:
Patients who received acute, low -dose s ystemic immu nosuppressant medication 
(e.g., 10 mg/day oral prednisone or equivalent) or a one -time pulse dose of sy stemic 
immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast al lergy) 
are eligible for the study after Medical Monitor confirmation has been obtained .
Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for 
chronic obstructive pulmonary disease (COPD) or asthma, or low -dose corticosteroid s 
for orthostatic hypotension or adrenal insufficiency are eligible for the study .
Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study 
treatment
Patients receiving prophylactic antibiotics (e.g., to prevent a urinary  tract infection or 
COPD exacerbation) are eligible for the study.
Prior allogeneic stem cell or solid organ transplantation
Any other disease, metabolic dysfunction, phy sical examination finding, or clinical 
laborator y finding that contraindicates the u se of an investigational drug, may  affect the 
interpretation of the results, or may  render the patient at high risk from treatment 
complications
Current treatment with anti -viral therapy for HBV or HCV
Active or histor y of autoimmune disease or immune defi ciency, including, but not limited to, 
myasthenia gravis, m yositis, autoimmune hepatitis, systemic lupus erythematosus, 
rheumatoid arthritis, inflammatory  bowel disease, antiphospholipid antibody s yndrome, 
Wegener granulomatosis, Sjögren s yndrome, Guillain -Barré syndrome, vasculitis, or 
glom erulonephritis, or multiple sclerosis, with the following exceptions:
Patients with a histor y of autoimmune -related hypothy roidism who are on 
thyroid- replacement hormone are eligible for the study.
Patients with controll ed Type 1 diabetes mellitus who are on an insulin regimen are 
eligible for the study.
Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic 
manifestations only (e.g., patients with psoriatic arthritis are excluded) are el igible for 
the study provided allof following conditions are met:
−Rash must cover 10% of body surface area
−Disease is well -controlled at baseline and requires only low -potency topical 
corticosteroids
−No occurrence of acute exacerbations of the underlying condition requiring 
psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral 
calcineurin inhibitors, or high -potency or oral corticosteroids within the previous 
12months
Pharmacologically uncompensated, symptomatic hypothyroidism
History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), 
drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on 
screening chest computed tomography scan
History of ra diation pneumonitis in the radiation field (fibrosis) is permitted.
Malabsorption syndrome
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficienc y 
or glucose -galactose malabsorption
Atezolizumab —F. Hoffmann- La Roche Ltd
25/Protocol WO41994, Version 3Uncontrolled hypertension defined as sustained blood pressure 150 mm Hg sy stolic or 
90 mm Hg diastolic despite optimal antihypertensive treatment
Tumors invading the gastroin testinal (GI) tract, active peptic ulcer disease, 
acute pancreatitis, acute obstruction of the pancreatic or biliary duct, 
appendicitis, cholangitis, cholecystitis, diverticulitis, gastric outlet obstruction, 
or inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
Stroke (including transient ischemic attack), myocardial infarction, or other sy mptomatic 
ischemic event, or thromboembolic event (e.g., deep venous thrombosis [DVT], pulmonary 
embolism [PE]) within 6 months before randomization
Upon Sponsor approval, subjects with a diagnosis of incidental PE or DVT within 
6months are allowed if asymp tomaticand stable at screening treated with 
lowmolecular -weight heparins (LMW Hs) or the direct factor Xa inhibitors 
rivaroxaban, edoxaban, or apixaban for at least 1 week before first dose.
Significant cardiovascular disease (such as New York Heart Assoc iation Class II or greater 
cardiac disease, unstable arrhythmia, or unstable angina) within 3 months prior to initiation 
of study treatment
History of clinically significant ventricular dysrhythmias or risk factors for ventricular 
dysrhythmias such as stru ctural heart disease (e.g., severe left ventricular s ystolic 
dysfunction, left ventricular hypertrophy), coronary heart disease (s ymptomatic or with 
ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities 
(e.g., hypok alem ia, hypomagnesemia, hypocalcemia), or family histor y of sudden 
unexplained death or long QT syndrome
History of congenital QT syndrome
History or presence of an abnormal ECG that is clinically significant in the investigator's 
opinion, including complete left bundle branch block, second- or third -degree 
atrioventricular heart block, or evidence of prior myocardial infarction that is considered as 
clinically significant by investigator
QT interval corrected with use of Fridericia's formula (QTcF) 480 ms per ECG within 
14days before randomization
Note: If a single ECG shows a QTcF with an absolute value 480 ms, 2additional 
ECGs at intervals of approximately 3 minutes must be performed within 30 minutes 
after the initial ECG, and the average of the 3consecutive results for QTcF must 
be480 ms for the patient to be eligible.
Significant vascular disease (e.g., aortic aneurysm or arterial dissection requiring surgical 
repair or recent peripheral arterial thrombosis) within 6 months prior to Day1 of Cycle 1
Evidence of bleeding diathesis or significant coagulopathy
Abdominal or tracheoesophageal fistula , bowel obstruction, or GI perforation , or 
intra -abdominal abscess within 6 months before initiation of study treatment
Complete healing of an intra -abdominal abscess must be confirmed before initiation 
of study treatment .
Concomitant anticoagulation with coumarin agents (e.g., warfarin) , direct thrombin inhibitor 
dabigatran, direct factor Xa inhibitor betrixaban , or platelet inhibitors (e.g .,clopidogrel)
The following are a llowed anti coagulants :
Prophylactic use of l ow-dose aspirin for cardio protection (per local applicable 
guidelines) and low -dose LM WHs.
Therapeutic doses of LMW H or anticoagulation with direct factor Xa inhibitors 
rivaroxaban, edoxaban, or apixaban in patients without known brain metastases 
who are on a stable dose of the anti -coagulant for at least 1 week before 
randomization without clinically significant hemorrhagic complications from the 
anticoagulation regimen or the tumor. 
Clinical signs or sy mptoms of GIobstruction or requirement for routine parenteral hydration, 
parenteral nutrition, or tube feeding
Atezolizumab —F. Hoffmann- La Roche Ltd
26/Protocol WO41994, Version 3Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
Known cavitating pu lmonary lesion(s) or known endobronchial disease 
manifestations
Lesions invading major pulmonary blood vessels
Clinically significant hematuria, hematemesis, hemoptysis of 0.5 teaspoon 
(2.5 mL) of red blood, coagulopathy, or other history of significant bleeding 
(e.g., pulmonary hemorrhage) within 3 months before initiation of study 
treatment
Serious, non -healing or dehiscing wound, active ulcer, or untreated bone fracture
Prior histor y of hypertensive crisis or hypertensive encephalopathy
Requirement for hemodialysis or peritoneal dialysis
Known hypersensitivity to Chinese hamster ovary cell products or to any component of the 
atezolizumab formulation 
History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or 
fusion proteins
Known allergy or hypersensitivity to any component of the cabozantinib formulation
Patients who are not able to swallow a tablet
End of Study
The end of this study is defined as the date when the required numbers of events for the fina l 
analysis of OS inthe ITT population has occurred.
In addition, the Sponsor may decide to terminate the study at any time .
Length of Study
The total length of the study, from screening of the first patient to the end of the study, is 
expected to be approximately 55 months .
Investigational Medicinal Products
The investigational medicinal products for this study are atezolizumab and cabozantinib.
Test Product s(Investigational Drug s)
Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg Q3W.
Cabozantinib will be administered or allyQD at a dose of 60 mg ( three 20-mg tablets ).
Comparator
The comparator of this study is cabozantinib 60 mg(three 20 -mg tablets) administered orally 
QD.
Statistical Methods
Efficacy A nalyse s
The analysis population for the efficacy analyses will consist of all randomized patients, with 
patients grouped according to their assigned treatment.
Multiple Primary Efficacy  Endpoints
The multiple primary  efficacy endpoints are IRF -assessed PFS per RECIST v1.1 and OS.
Progression -free survival is defined as the time from randomization to disease progression, as 
determined by the IRF per RECIST v1.1, or death from any  cause, whichever occurs first.  
Data for patients who have not experienced disease progression or death will be censore d at 
the last tumor assessment date.  Data for patients with no post -baseline tumor assessments will 
be censored at the randomization date.
Overall survival is defined as the time from randomization to death due to any cause.  Data for 
patients who are not reported as having died at the date of analy sis will be censored at the date 
when they were last known to be alive.  Patients who do not have post -baseline information will 
be censored at the date of randomization.
The following analyses will be performed for both PFS and OS endpoints described above.  
Progression -free survival and OS will be compared between treatment arms with use of the 
Atezolizumab —F. Hoffmann- La Roche Ltd
27/Protocol WO41994, Version 3stratified log -rank test at the 2-sided level of significance. The hazard ratio ( HR)with a 95% CI 
will be estimated with use of a stratified Cox regression model with the same stratification 
variables used for the stratified log -rank test.  The randomization stratification factors are most 
recent ICI therapy ( adjuvant vs. first-line vs. second -line), histology (dominant clear- cell without 
sarcomatoid vs. dominant nonclear -cell [papillar y or unclassified only] without sarcomatoid vs. 
any sarcomatoid component [clear -cell or non clear -cell]), and the IMDC score (0, 1 2, 3).
Ifat least 1stratum has less than 10 events at the time of analysis, the stratification factor that
contains the level with the smallest number of patients will be removed from the stratified 
analyses.   The final set of stratification factors used for the multiple primary  endpoints will be 
applied to all other endpoints where stratified analyses are planned.   The stratification factors 
will be obtained from the interactive voice or W eb-based response s ystem  (IxRS )at the time of 
randomization.  Results from an unstratified analysis will also b e provided.  Kaplan -Meier 
methodology will be used to estimate the median PFS and OS for each treatment arm, and 
Kaplan -Meier curves will be produced.  The Brookmey er Crowley methodology will be used to 
construct the 95% CI for the median PFS and OS for ea ch treatment arm .
Determination of Sample Size
Approximately 500 patients are planned for enrol lment globally over 20 months.  The sample 
size calculation is determined based on the below considerations.
Type I Error Control
The type I error ( ) for the en tire study is 0.05 ( 2-sided).  There are mu ltiple primary efficacy 
endpoints for this study:  PFS by IRF assessment per RECIST v1.1 and OS in the 
ITTpopulation. To control the overall type I error rate at 0.05 while accounting for 2primary  
endpoints, is split between PFS ( 0.02) and OS (  0.03).  Thetype I error can be rec ycled 
if PFS results in the ITT population are statistically significant at 0.02, then 0.02 will be 
recycled to OS in the ITT population, and OS in the ITT population will be evaluated at 0.05. 
The study will be considered as a positive study if statistical significance is achieved in favor of 
the experimental arm for either of the multiple primary endpoints, since the type I error ( ) for 
the e ntire study is controlled at 0.05.
Primary Endpoint:  Progression -Free Survival by Independent Review Facility Assessment per 
RECIST v1.1 in the Intent -to-Treat Population
The analysis of the primary endpoint of PFS by IRF assessment per RECIST v1.1 will t ake 
place when approximately 325 IRF -assessed PFS events have occurred in the ITT population 
(65% events patient rate) based on the following assumptions:
Two-sided, stratified log -rank test
  0.02 ( 2-sided)
Approximately 90% power
Median PFS for the cabozantinib arm of 8.0 months and estimated median PFS in the 
atezolizumab and cabozantinib arm of 11.9 months (corresponding to HR of 0.67)
5% annual loss to follow -up for PFS
No interim analysis
On the basis of these assumptions, it is projected that a n observed HR of 0.77 or lower will 
result in a statistically significant difference between treatment arms (i.e., an HR of 0.77 will be 
the minimumdetectable difference [MDD] for the analysis; this corresponds to an improvement 
of 2.4 months in median PF S from 8.0 months in the cabozantinib arm to 10.4 months in the 
atezolizumab and cabozantinib arm).
Primary Endpoint:  Overall Survival in the Intent -to-Treat Population
The final analysis of the primary  endpoint of OS will take place when approximately 32 5OS 
events have occurred in the ITT population (65% events patient rate) based on the following 
assumptions:
Two-sided, stratified log -rank test
  0.03 ( 2-sided)
Approximately 85% power
Atezolizumab —F. Hoffmann- La Roche Ltd
28/Protocol WO41994, Version 3Median OS in the cabozantinib arm of 22 months and e stimated median OS in the 
atezolizumab and cabozantinib arm of 31.4 months (an increase of 9.4 months, 
corresponding to an HR of 0.70)
1% annual loss to follow -up for OS
Two interim OS analy ses
At the final OS analy sis, on the basis of these assumptions, it is projected that an observed OS 
HR of 0.78 or lower in the ITT population will result in a statistically significant difference 
between treatment arms (i.e., the MDD at the analy sis; this corresponds to an improvement of 
6.2 months in median OS, from 22 months in the control arm to 28.2 months in the 
atezolizumab and cabozantinib arm).
Sample Size
With the above assumptions on PFS and OS, the s ample size is determined at 500 patients, 
where the PFS and OS final anal ysis will be conducted when 325 events occur (65% events 
patient rate), respectively. The 500 patients are planned for enrollment globally over 20 months.
Interim A nalyses
Primary Endpoint of Progression -Free Survival
There is no planned interim analysis of the primary  endpoint of PFS.
Primary Endpoint of Overall Survival
A total of three analyses of OS will be performed, including twointerim analyses and one final 
analysis.  The boundar y for statistical significance at each OS analysis will be determined based 
on the Lan -DeMets impleme ntation of the O’Brien -Fleming (OBF) function to maintain the 
overall type I error rate at either 0.03 or 0.05 level, depending on whether primary  endpoint of 
PFS is significant at 0.02 level.  The OS endpoint will be considered positive in the 
ITTpopulation if statistical significance is achieved in favor of the experimental arm for any of 
the twoOS interim analyses or the final analysis.
The first interim analysis of OS will be performed at the time of the PFS primary analy sis.  
Atotal of 175 OS events are expected at the first interim analy sis of OS, which corresponds to 
53% of the events information required for the final analysis of OS in the ITT population.  
Statistical significance will be declared if p 0.0019.  If there are significantly fewer ( 160) OS 
events than the expected 175 OS events, then the first interim analy sis will be delay eduntil
175OS events occur. An administrative of 0.000001 (negligible impact on overall type I error 
rate) will be spent on the OS hypothesis at the time of the planned PFS.
The second interim analysis of OS will be performed when approximately 260 deaths have 
occurred, which corresponds to approximately 80% of the events information required for the 
final analysis of OS in the ITT population.  Statistical significance will be declared if p 0.0125.
The final analysis of OS will be performed when 325 deaths (65% of 500 patients in the 
ITTpopulation) have occurred.  Statistical significance will be declared if p 0.0259 when 
exactly 325 deaths have occurred at the time of the final OS analy sis.
The actual OBF boundary will be calculated at time of analysis based on actual number of 
events observed.
Atezolizumab —F. Hoffmann- La Roche Ltd
29/Protocol WO41994, Version 3LIST OF A BBREVIA TION S AND DEFINITIONS OF TERMS
Abbreviation Definition
ADA anti-drug antibody
aRCC advanced renal cell carcinoma
AUC area under the concentration -time curve
BP blood pressure
ccRCC clear -cell renal cell carcinoma
COPD chronic obstructive pulmonary disease
CR complete response
CRS cytokine release s yndrome
CSR Clinical Study Report
CT computed tomography (scan)
ctDNA circulating tumor DNA
DLT dose -limiting toxicity
DOR duration of response
DRS -P Disease -Related Sy mptom-Physical
DVT deep venous thrombosis
EC Ethics Committee
eCRF electronic Case Report Form
EDC electronic data capture
EMA European Medicines Agency
EORTC European Organisation for Research and Treatment of Cancer
EQ-5D-5L EuroQol 5 -Dimension , 5-Level Questionnaire
Fc fragment cry stallizable
FDA U.S. Food and Drug Administration
FKSI- 19 Function al Assessment of Cancer Therapy Kidney S ymptom  
Index 19
GI gastrointestinal
GHS/QoL global health status/quality of life
HBcAb hepatitis B core antibody
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HIPAA Health Insurance Portability and Accountability Act
HR hazard ratio
ICH International Council for Harmonisation
ICI immune checkpoint inhibitor
iDMC independent Data Monitoring Committee
Atezolizumab —F. Hoffmann- La Roche Ltd
30/Protocol WO41994, Version 3Abbreviation Definition
IL interleukin
IMDC International Metastatic Renal Cell Carcinoma Database 
Consortium
IMP investigational medicinal product
IND Investigational New Drug (Application)
IRB Institutional Review Board
iRECIST modified RECIST for immune -based therapeutics
IRF Independent Review Facility
IRR infusion -related reaction
ITT intention -to-treat
IxRS interactive voice or Web-based response system
KPS Karnofsk y Performance S tatus
LMW H low-molecular -weight heparin
LVEF left ventricular ejection fraction
MDD minimumdetectable difference
MDSC myeloid -derived suppressor cell
mOS median overall survival
MRI magnetic resonance imaging
MRP2 multidrug resistance -associated protein 2
MSKCC Mem orial Sloan Kettering Cancer Center
mTOR mammalian target of rapamycin
NCI CTCAE National Cancer Institute Common Terminology Criteria for 
Adverse Events
NGS next-generation sequencing
non ccRCC non clear -cell renal cell carcinoma
NSAID nonsteroidal anti -inflammatory inhibitor
NSCLC non small -cell lung cancer
OBF O’Brien -Fleming
ORR objective response rate
OS overall survival
PBMC peripheral blood mononuclear cell
PE pulm onary embolism
PFS progression -free survival
P-gp P-glycoprotein
PK pharmacokinetic
PPI proton pump inhibitor
PPE palm ar-plantar erythrodysesthesia
Atezolizumab —F. Hoffmann- La Roche Ltd
31/Protocol WO41994, Version 3Abbreviation Definition
PR partial response
PRO patient -reported outcome
Q3W every 3 weeks
QD once a day
QLQ -C30 Quality of LifeCore 30 Questionnaire
QTc corrected QT interval
QTcF QTinterval corrected with us e of Fridericia’s formula
RBR Research Biosample Repository
RCC renal cell carcinoma
RECIST Response Evaluation Criteria in Solid Tumors
SmPC Summary  of Product Characteristics
TKI tyrosine kinase inhibitor
ULN upper limit of normal
UPCR urine protein -to-creatinine ratio
USPI U.S. Package Insert
VAS visual analog scale
VEGF vascular endothelial growth factor
VEGFR vascular endothelial growth factor receptor
WES whole -exome sequencing
WGS whole -genome sequencing
Atezolizumab —F. Hoffmann- La Roche Ltd
32/Protocol WO41994, Version 31. BACKGROUND
1.1 BACKGROUND ON RENA L CELL C ARCINOMA
Renal cell carcinoma (RCC) was diagnosed in more than 400,000 people and was 
associated with approximately 175,000 deaths worldwide in 2018.  R enal cell carcinoma
is the 9thmost common ca ncer occurring in men, and the 14th most common cancer in 
women (GLOBACON 2018) . The incidence of RCC is predominant in men with a peak 
age of 60 70 years (Capitanio and Montorsi 2016).  Renal cell carcinoma comprises a 
heterogeneous group of cancers with clear -cell renal cell carcinoma (ccRCC) being the 
most common histologic subtype (75%), followed by non clear -cell renal cell carcinoma 
(nonccRCC) subtypes of papillary (15%), and chromophobe and oncocytoma (5% each;
Motzer et al. 1996). With the exception oncocytoma, a sarcomatoid component can 
develop in each of these subtypes.
While the majority of patients will present with localized disease, approximately 30% of 
those treated with curative intent will develop distant disease, and approximately
20%25% of patients present with metastatic disease at initial diagnosis 
(Dabestani etal.2016).   The models to predict survival such as theMemorial Sloan 
Kettering Cancer Center (MSKCC ;Motzer et al. 2004 ) risk stratification model and t he
Internationa l Metastatic R enal Cell Carcinoma Database Consortium
(IMDC;Heng etal.2009) risk score have been developed . These models are used as a 
stratification factor for the clinical trials with use of immune checkpoint inhibitors (ICIs) .
The IMDC risk category is also validated for the patients receiving second -line targeted 
therapy (Ko et al. 2015) .
1.2 FIRST -LINE TREA TMENT FOR RENA L CELL C ARCINOMA
The tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor (VEGF), 
sunit inib, was the sta ndard of care for treatment -naive patients with RCC for many years 
because of the data showing superior efficacy over conventional cytokines (Table 1 ).  
However, the first -line treatment landscape has evolved significantly in recent years with 
the upfront use of ICIsand the results suggest that the upfront use of ICIsimprove s
overall survival (OS) when compared with sunitinib ( Table 1 ).
Atezolizumab —F. Hoffmann- La Roche Ltd
33/Protocol WO41994, Version 3Table 1First -Line Therapy  Results for A dvanced Renal Cell Carcinoma
Agent and 
Population ComparisonPFS
(months)HR
(95% CI)OS
(months)HR
(95% CI)
NivoIpi
(intpoor risk)aSunitinib 11.6 vs. 8.4 0.82
0.64 1.05NR vs. 26 .0 0.63
0.44 0.89
Atezo Bev
(PD-L1)bSunitinib 11.2 vs. 7.7 0.83
0.70 0.97N/A N/A
AveAxicSunitinib 13.8 vs. 8.4 0.69
0.56 0.84NR vs. NR 0.78
0.55 1.08
PembroAxidSunitinib 15.1 vs. 11.1 0.69
0.57 0.84NR vs. NR 0.53
0.38 0.74
SunitinibeIFN- 11.0 vs. 5 0.42
0.32 0.5424.5 vs. 20.4 0.82
0.67 1.00
BevIFN-fIFN- 10.2 vs. 5.4 0.63
0.52 0.7523.0 vs. 21 .0 0.96
0.73 1.04
PazopanibgPlacebo 9.2 vs. 4.2 0.46
0.34 0.6222.9 vs. 20.5 0.91
0.71 1.16
Temsirolimush
(poor risk)IFN- 5.6 vs. 3.2 0.74
0.60 0.9110.9 vs. 7.3 0.78
0.63 0.97
Cabozantinib
(intpoor risk)Sunitinib 8.2 vs. 5.6i0.66
0.46 0.9526.6 vs. 21. 2j0.80
0.53 1.21
Cabo Nivok Sunitinib 16.6 vs. 8.3 0.51
0.410.64NR vs. NR 0.60
0.400.89m
Lenv Pembrol Sunitinib 23.9 vs 9.2 0.39
0.320.49NR vs NR 0.66
0.490.88
Lenv Evel Sunitinib 14.7 vs 9.2 0.65
0.530.80NR vs NR 1.15
0.881.50
Atezo atezolizumab; Ave avelumab; Axi axitinib; Bev bevacizumab; Cabocabozantinib; 
Eveeverol imus; HR hazard ratio; int poorintermediate poor; Ipi ipilim umab; 
Lenv lenvatinib; N/A not available; Nivo nivolumab; NRnot reached ;OSoverall survival; 
Pembropembrolizum ab; PFS progression -free survival.
aSource:  Motzer et al. 2018a.
bSource:  Rini et al. 2019a.
cSource:  Motzer et al. 2019b.
dSource:  Rini et al. 2019b.
eSource:  Motzer et al. 2007.
fSource:  Escudier et al. 2007.
gSource:  Sternberg et al. 2010.
hSource:  Hudes et al. 2007.
iSource:  Choueiri et al. 2017a.
jSource:  Choueiri et al. 2018.
kSource:  Cabometyx U.S. Package Insert .
lSource:  Motzer et al. 2021 .
mHazard ratio (98.89% CI).
Atezolizumab —F. Hoffmann- La Roche Ltd
34/Protocol WO41994, Version 31.3 SECOND -LINE AND THIRD- LINE TRE ATMENT
There are several options available for patients with RCC who received prior systemic 
therapy ( Table 2 ). Everolimus and sorafeni b have shown a progression- free survival 
(PFS)benefit for patients previously treated with anti -angiogenic agents over placebo 
(Escudier et al. 2009; Motzer et al . 2010) . Later, axitinib demonstrated a longer PFS 
against sorafenib for those previously tr eated with anti -angiogenic agents or interleukin
(IL)-2 (Rini et al. 2011 ). Similarly, in a Phase II study, lenvatinib plus everolimus
demonstrated PFS benefit in comparison with everolimus alone in patients with ccRCC 
previously treated with anti VEGF -targeted therapy and progressed in or within 
9months of stopping the previous treatment. However, the numerical increase seen in 
OS was not statistically significant. Cabozantinib demonstrated a longer PFS and OS 
over everolimus in patients previously t reated with VEGF receptor ( VEGF R)-TKI 
(Choueiri et al .2015). Nivolumab demonstrated an OSbenefit for those patients 
previously treated with anti -angiogenic therapy in ccRCC regardless of PD -L1 status, 
prior therapy or MSKCC risk group (Motzer et al. 201 5a).
With the shift to immunotherapy combinations increasingly being used in first -line 
therapy, there have been no completed Phase III studies in the post -immunotherapy 
setting for RCC . In the pre- immunotherapy era, a report suggest edthat only 55 patients 
received third- line therapy out of 257 patients who received second- line therapy, and 
treatments vary,including sorafenib, everolimus, axitinib, temsirolimus, and 
bevacizumab (Maroun et al. 2018).   Another report revealed that third -line therapy was 
given to 21% of patients who received first -line therapy. Everolimus was the most 
prevalent therapy, and other treatments included in the third -line therapy were sunitinib, 
sorafenib, pazopanib, temsirolimus, and axitinib. Overall survi val for the patients who 
received third -line therapy was 12.4 months and PFS was 3.9 months ( Wells et al . 2017 ).
Atezolizumab —F. Hoffmann- La Roche Ltd
35/Protocol WO41994, Version 3Table 2 S econd -Line Therapy Results for A dvanced Renal Cell 
Carcinoma
Agent and 
Population ComparisonPFS
(months)HR
(95% CI)OS
(months)HR
(95% CI)
NivoaEverolimus 4.6 vs. 4.4 0.88
0.75 1.0325.0 vs. 19.6 0.73
0.57 0.93
EverolimusbPlacebo 4.9 vs. 1.9 0.33
0.25 0.4314.8 vs. 14.4 0.87
0.65 1.17
SorafenibcPlacebo 5.5 vs. 2.8 0.44
0.35 0.5517.8 vs. 15.2 0.88
0.74 1.04
AxitinibdSorafenib 6.7 vs. 4.7 0.67
0.54 0.8120.1 vs. 19.2 0.97
0.80 1.17
Lenva EverolimuseEverolimus 14.6 vs. 5.5 0.44
0.24 0.6825.5 vs. 18.4 0.55
0.30 1.01
CabozantinibfEverolimus 7.4 vs 3.8 0.58
0.45 0.7521.4 vs. 16.5 0.66
0.530.83a
HRhazard ratio; Lenva Lenvatinib; NA not assessed; Nivo nivolumab; OS overall survival; 
PFSprogression -free survival.
aSource:  Motzer et al. 2015a.
bSource:  Motzer et al. 2010.
cSource:  Escudier et al. 2009.
dSource:  Rini et al. 2011.
eSource:  Motzer et al. 2015b.
fSource:  Cabomety xU.S. Package Insert.
1.4 BACKGROUND ON ATEZOLIZUMA B
Atezolizumab is a human ized IgG1 monoclonal antibody that targets PD -L1 and inhibits 
theinteraction between PD -L1 and its receptors, PD -1 and B7-1 (also known as CD80) , 
both of which function as inhibitory receptors expressed on T cells.  Therapeutic 
blockade of PD -L1 binding by atezolizumab has been shown to enhance the magnitude 
and quality of tumor -specific T -cell respon ses, resulting in imp roved anti -tumor activity
(Fehrenbacher et al. 2016; Rosenberg et al. 2016) .  Atezolizumab has minimal binding
to fragment crystallizable (Fc)receptors, thus eliminating de tectable F c-effector function
and associated antibody -mediated cl earance of activated effector T cells.
Atezolizumab shows anti -tumor activity in both nonclin ical models and patients with 
cancer and is being investigated as a potential therapy in a wide variety of malignancies.  
Atezolizumab is being studied as a single -agent therapy, as well as in combination with 
chemotherapy, targeted therapy, and cancer immunotherapy and is approved for the 
treatment of urothelial carcinoma, nonsmall -cell lung cancer (NSCLC) , small -cell lung 
cancer, and triple- negative breast cancer .
Atezolizumab —F. Hoffmann- La Roche Ltd
36/Protocol WO41994, Version 3Refer to the Atezolizumab Investigator's Brochure for details on nonclinical and clinical 
studies.
In the setting of the COVID -19 pandemic, patients with comorbidities, including those 
with cancer, are considered a more vulnerable population, with the potential for more 
severe clinical outcomes from COVID -19.  However, it is unclear whether or how 
systemic cancer therapies such as chemotherapy, targeted therapy, or immunotherapy 
impact the incidence or severity of COVID -19.
A possible consequence of inhibiting the P D-1/PD -L1 pathway may be the modulation 
of the host immune response to acute infection, which may result in immunopathology 
or dysregulated immune system defenses.  In nonclinical models, PD -1/PD -L1 blockade 
appears to be associated with serious exacerbation of inflammation in the setting of 
acute (as opposed to chronic) viral infection with lymphocytic choriomeningitis virus 
(Clone 13; Frebel et al. 2012).  However, there are insufficient an d inconsistent clinical 
data to assess if outcome from COVID -19 is altered by cancer immunotherapy.
Severe COVID -19 appears to be associated with a cytokine release syndrome (CRS) 
involving the inflammatory cytokines IL -6, IL -10, IL- 2, and interferon -
(Merad and Martin 2020).  While it is not known ,there may be a potential for an 
increased risk of an enhanced inflammatory response if a patient develops acute 
SARS -CoV -2 infection while receiving atezolizumab.  At this time, there is insufficient 
eviden ce for causal association between atezolizumab and an increased risk of severe 
outcomes from COVID -19.
There may be potential synergy or overlap in clinical and radiologic features for 
immune -mediated pulmonary toxicity with atezolizumab and clinical and r adiologic 
features for COVID -19related interstitial pneumonia.  Thus, investigators should use 
their clinical judgment when evaluating and managing patients with pulmonary 
symptoms.
Neutropenia and lymphopenia associated with chemotherapy may increase the risk for 
developing an infection in patients receiving atezolizumab in combination with 
chemotherapy.
1.4.1 Efficacy  in Metastatic Renal Cell Carcinoma
Atezolizumab monotherapy (1200 mg, every 3 weeks [Q3W]) with or without 
bevacizumab (15 mg/kg, Q3W) was compared with sunitinib for treatment -naive 
metastatic RCC in the Phase IIStudy W O29074(IMmotion150). In the i ntent -to-treat 
(ITT) population, PFS hazard ratios (HRs) for atezolizumab  in combination with
bevacizumab or atezolizumab monotherapy ver sus sunitinib wer e 1.0 (95% CI : 
0.691.45) and 1.19 (95% CI: 0.821.71), respectively; PD -L1PFS HRs were 
0.64 (95% CI:0.381.08) and 1.03 (95% CI: 0.63 1.67), respectively. The objective 
response rates (ORRs) in the ITT population were 32% (7% complete response [CR], 
Atezolizumab —F. Hoffmann- La Roche Ltd
37/Protocol WO41994, Version 325% partial response [PR] ), 25% (11% CR, 14% PR), and 29% (5% CR, 24% PR) with 
atezolizumab  in combination with  bevacizumab, atezolizumab monotherapy, and 
sunitinib, respectively.  In PD -L1patients, the ORRs were 46% (12% CR, 34% PR), 
28% (15% C R, 13% PR), and 27% (7% CR, 20% PR) with atezolizumab  in combination 
with bevacizumab, atezolizumab monotherapy, and sunitinib, respectively 
(McDermott et al.2018). This trial allo wed crossover to atezolizumab andbevacizumab
treatment after treatment failure withsunitinib or atezolizumab monotherapy. The ORRs 
in atezolizumab plus bevacizumab for patients previously treated with sunitinib or 
atezolizumab monotherapy was 28% and 24%, respect ively.  The PFS in atezolizumab 
plusbevacizumab for patients previously treated with sunitinib or atezolizumab 
monotherapy was 8.3 months and 12.6 months, respectively (Atkins et al. 2017). 
Theseresult sappear to suggest potential use of atezolizumab combination therapy after 
atezolizuma b treatment failure, although the result s are preliminary.
The Phase IIIStudy W O29637 ( IMmotion151) was designed to demonstrate the 
superiority of atezolizumab in combination with bevacizumab compared with sunitinib for 
advanced, treatment -naive patients with ccRCC or RCC with sarcomatoid component
(Rini et al. 2019a ).The study met its co -primary endpoint of investigator -assessed PFS 
in PD -L1patients ,but OS data was immature at the time of analysis (m edian PFS for 
atezolizumab plus bevacizumab vs. sunitinib: 11.2 months vs. 7.7 months ;HR0.74;
p0.0217 ; median OS HR 0.93). In addition, PFS results with anindependent 
radiology committee showed a HR 0.93 (95% CI :0.721.21) in the PD -L1population.
Atezolizumab administered in combination with bevacizumab was also assessed in 
patients with advanced renal cell carcinoma (aRCC) with non ccRCC or RCC with 
sarco matoid histology in a P hase II study. In this study, 42 patients had non ccRCC 
histology ,including papillary, chromophobe, unclassified ,and others with or without 
sarcomatoid component. The ORR in papillary was 26% while it was 10% in 
chromophobe (McGregor et al. 2020 ). In addition, Study WO29637 ( IMmotion151)
subgroup analysis for RCC with sarcomatoid component showed longer PFS in patients 
receiving atezolizumab in combination with bevacizumab compared withsunitinib 
(median PFS 8.3months [95% CI :5.412.9 months ] vs.5.3months 
[95% CI:3.36.7months] ;Rini et al . 2019a ).
1.5 BACKGROUND ON C ABOZA NTINIB
Cabozantinib is an orally bioavailable TKI with potent activity against MET and VEGFR2, 
as well as a number of other receptor tyrosine kinases that have also been implicated in 
tumor pathobiology, including RET, KIT, AXL, and FLT. Cabozantinib suppresses MET 
and VEGFR2 signaling, rapidly inducing apoptosis of endothelial and tumor cells, 
resulting in tumor regression in a variety of xenograft models (Sennino et al. 2009;
Yakes et al. 2011 ).
Atezolizumab —F. Hoffmann- La Roche Ltd
38/Protocol WO41994, Version 3Cabozantinib has shown efficacy in patients with aRCC previously t reated with 
VEGF -targeted therapies as well as treatment -naive patients with RCC 
(Choueiri etal.2017b) . The METEOR trial ([STUDY_ID_REMOVED]) was a Phase III study
comparing cabozantinib administered 60mgonce a day ( QD)versus everolimus in 
patients with advanced RCC who progressed after a previous VEGFR -TKI treatment.   
The estimated median PFS was 7.4 months (95% CI: 5.69.1months ) with cabozantinib
and 3.8 months (95% CI: 3.75.4months ) with everolimus (OS HR 0.58; 95% CI:
0.450.75; p0.001).   Median OSwas 21. 4 months (95% CI:18.7 months to not 
estimable) with cabozantinib and 16 .5months (14 .718.8months ) with everolimus 
(HR0.66;95% CI : 0.530.83; p 0.00026).   In this trial, approximately 60% of patients 
previously received sunitinib, and approximately 40% of patients received pazopanib.  
Nivolumab was previously used in 5% of patients.  Patients who received 1prior therapy 
were 71%, while 29% of patients received more than onetreatment . In thi s trial , 
subgroup analyses showed efficacy across different lines of therapy and different types 
of prior therapies ,including VEGFR -TKIs and immunotherapy.  Cabozantinib improved 
survival in patients previously treated with sunitinib ( PFS: HR0.43; OS:HR0.66) or 
pazopanib (PFS:  HR 0.67; OS :HR0.66) irrespective of the number of previous 
treatment lines received. Cabozantinib also improved PFS in patients previously treated 
with ICI compared with everolimus (PFS: HR0.22 [95% CI :0.070.65], ORR 22% v s.
0%, OS : HR0.56 [95% CI:0.211.52]).
Also, as indicated in Table 1, in the front -line setting, cabozantinib showed superiority 
against sunitinib in intermediate and poor risk RCC with a median PFS of 8.2 months vs.
5.6months (HR 0.66;95% CI: 0.46 0.95; Choueiri et al. 2017 b).
In a retrosp ective single arm study assessing cabozantinib efficacy in non ccRCC, 
cabozantinib was shown to be active with an ORR 27%, PFS of 7 months ,and OS of 
12months in these patients. The saf ety profile is similar to that of the ccRCC population 
(Chanzá et al .2019 ).
Cabozantinib (60 mg, tablets) is approved as a single agent for patients with advanced 
RCC (CabometyxU.S. Package Insert [U SPI]), and in combination with nivolumab as 
first -line treatment for patients with advanced RCC (CabometyxUSPI), for adult 
patients with advanced RCC after prior VEGF -targeted therapy or treatment -naïve 
adult patients with intermediate or poor risk RCC (Cabometyx EMA Summary of 
Product Characteristics [SmPC ]), and for patients with hepatocellular carcinoma wh o 
have previously been tr eated with sorafenib (Cabometyx USPI and EMA SmPC).  
Inaddition, cabozantinib (140 mg, capsules) is approved for patients with progressive, 
metastatic medullary thyroid cancer (CometriqUSPI and EMA SmPC).  The capsule 
and tablet formulations are not bioequivalent or interchangeable .
The approval of cabozantinib for the treatment of a RCC is based on the results 
described in Table 1 and Table 2 as well as in advanced hepatocellular carcinoma after 
prior sorafenib therapy .
Atezolizumab —F. Hoffmann- La Roche Ltd
39/Protocol WO41994, Version 3Refer to the Cabozantinib Investigator's Brochure for details on nonclinical and clinical 
studies.
1.6 BACKGROUND ON COMBINA TION THER APY OF 
ATEZOLIZUMA B AND CABO ZANTINIB
Although the main anti -tumor efficacy with cabozantinib is driven by anti -VEGF, 
anti-MET, and other TKIs, cabozantinib also appears to modulate the immune -tumor 
microenvironment and enhance sinnate immunity (Patnaik et al. 2017 ).  
Cabozantinib showed a reduction of tumor vascularity and improves T -cell infiltration as 
well as showed a reduction of T regulatory cells (Tregs), myeloid -derived suppressor 
cells (MDSCs) ,and tumor -associated macrophages when combined with 
immunotherapy (Kwilas et al. 2014 ). In addition, a report suggests that cabozantinib in 
combination with anti PD-1 treatment suppressed MDSCs, which is known to promote 
tumor infiltration in prostate cancer (Lu et al.2017 ). In summary ,cabozantinib promotes 
an immune- permissive environment that may enhance response to ICIs.
COSMIC -021([STUDY_ID_REMOVED]) is a P hase Ib study of cabo zantinib in combination with 
atezolizu mab to assess the safety and efficacy of this combination in multiple tumor 
types ,including RCC (i.e. ,treatment -naive patients with RCC ).Patients receive deither 
40mg or 60 mg of cabozantinib QDorally in combination with 1200 mg of atezolizumab 
IV Q3 W. In the dose -escalation stage ,12 patients with RCC (10 clear -cell and 
2non clear -cell histology) were enrolled :  6 patients received cabozantinib 40 mg 
(QD orally) and 6 patient sreceived cabozantinib 60 m g (QD orally) in combination with 
1200 mg of atezolizumab IV Q3Wfor a total of 12 patients .  There were no dose -limiting 
toxicities (DLTs) observed ateither dose level. As of 21 August 2018, with a median 
follow -up of 33.4 weeks (range : 2650weeks ), most adverse event s were of 
Grade 1or2,including immune -related adverse event s.  Grade 3 adverse event s 
included 5events of hypertension, 2 events each of diarrhea and hypophosphatemia, 
1event each of ALT, AST, lymphopenia, hyperglycemia, gamma -glutamy l transferase 
(GGT )increased, pulmonary embolism (PE), oral pain, myositis, and lipase increased . 
There were no Grade 4 or 5 adverse event s.  Among 12patients, investigator -assessed
confirmed ORR was 67% (1 CR, 7 PRs ); 4additional patients had stable disease witha 
disease control rate of 100% (Agarwal et al. 2018).  Based on a favorable safety profile 
and encouraging anti -tumor activity, cabozantinib 40 mg in combination with 
atezolizumab 1200 mg was selected as the recommended dose for expansion coho rts in 
multiple solid tumor cohorts.  Upon evaluation of safety and efficacy data of 
approximately 30 initially -enrolled patients in an expansion cohort, the Study Oversight 
Committee could extend e nrollment with an additional 30 patients to explore whether 
cabozantinib 60 mg in combination with atezolizumab will lead to improved clinical 
efficacy and maintain an acceptable safety profile.
Atezolizumab —F. Hoffmann- La Roche Ltd
40/Protocol WO41994, Version 3The expansion stage of the COSMIC -021 study has been initiated, enrolling patients 
across 12 different solid tumor type s,including RCC of clear -cell and non clear -cell 
histology across all three IMDC risk categories. The ccRCC expansion cohort initially 
enrolled 30 treatment -naive patients receiving cabozantinib 40 mg in combination with 
1200 mg of atezolizumab. Prelimi nary data of this cohort indicated that the combination 
therapy was well -tolerated and showed encouraging clinical efficacy .
As of 20 December 2019, 30 patients with ccRCC were enrolled in the cohort receiving 
60-mg cabozantinib in combination with atezolizumab. The median f ollow -upwas 
7.9months (range : 311months ). Twenty-three (77%) of the 30 patients were active ly
on study treatment and 7patients discontinued all study treatment. The reasons for 
treatment discontinuation were radiographic progression (5 patients), adverse event 
unrelated to disease progression (1 event), and withdrawal (1 patient).  An overview of 
the efficacy data of the 60- mg cabozantinib RCC cohort is shown in Table 3 .  The ORR 
per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 was 57% 
(including 1 CR) and the disease control rate was 89%.
Table 3COSMIC -021Study  ccRCC Expansion Cohort : 
Objective Response Rate (per RECIST v1.1) in
Cabozantinib 60mgAtezolizumab -Treated Patients
Best ResponseCabo zantinib 60 mg
N31 a
N (%)
ORR , including 17 (57)
Unconfirmed PR 1 (3.3)
CR 1 (3.3)
PR 16(53)
Stable Disease 10(33)
Progressive Disease 2 (6.7)
Not Evaluable 1 (3.3)
ccRC clear -cell renal cell carcinoma; CRcomplete response; ORR objective response rate; 
PRpartial response; RECIST v1.1 Response Evaluation Criteria in Solid Tumors, Version 1.1.
Note:  Clinical cut offdate is 20 December 2019.
aEvaluable patients are defined as those with at least 1post-baseline response assessed by 
the investigator or, if discontinued, prior to assessm ent.
The most common adverse events of any grade regardless of ca usality inthe 
60-mgcabozantinib ccRCC cohort are provided in Table 4 .  Grade 3 adverse events 
regardless of causality were observed in 1 8 patients (60%) , the most common of which 
were ALT increased (13%), hypertension (10%); diarrhea (10%); and hyponatremia 
(10%).  There were 5Grade 3 immune -related adverse events reported ( 1event each of 
AST increased, lipase increased, immune -mediated enterocolitis, t ransaminases 
Atezolizumab —F. Hoffmann- La Roche Ltd
41/Protocol WO41994, Version 3increased, and fatigue).  There were no Grade 4 or Grade 5 adverse event s.  
Adverse events that led to a dose reduction or treatment discontinuation were observed 
in 60% and 10% of patients, respectively .
Table 4COSMIC -021Study  ccRCC Cohort : Summary  of Common 
Adverse Event s (30% of Patients) in
Cabozantinib 60mgAtezolizumab -Treated Patients
Adverse Events of any GradeCabo zantinib 60 mg Atezolizumab
N30
N (%)
Palm ar-plantar erythrodys esthesia s yndrom e 15 (50%)
Aspartate aminotransferase increased 14(47%)
Diarrhea 14(47%)
Fatigue 14(47%)
Alanine aminotransferase increased 13 (43%)
Dysgeusia 13(43%)
Nausea 13(43%)
Decreased appetite 12 (40 %)
ccRC clear -cell renal cell carcinoma.
Note:  Clinical cut offdate is20 December 2019 .
In addition , the COSMIC -021 study isevaluating an expansion cohort of cabozantinib 
40mg in combination with atezolizumab in patients with non ccRCC. At the cut offdate 
of 20 December 2019, 30 patients were enr olled . The median follow -up was 6 months 
(range : 113months ). Eighteen patients (60%) were active on study treatment, 
7patients had discontinued all study treatment due to radiographic progression, 
5patients due to other reasons (2 adverse events unr elated to progression, 1 adverse 
event related to progression, 2 due to lack of clinical benefit). The majority of enrolled 
patients with non ccRCC , 25patients (83%), had not yet received prior systemic therapy. 
The ORR by the investigator per RECIST v1.1 was27%.Eight patients exhibited a PR, 
an additional 2patients had an unconfirmed PR. Nineteen patients (63%) experienced 
stable disease; the disease control rate was 90%. The most common adverse events of 
any grade regardless of causality include ddiarrhea ( 37%), palmar -plantar 
erythrodysesthesia (PPE; 30%), dysgeusia (20%), headache (20%), abdominal pain 
(17%), amylase increased (1 7%), AST increased (1 7%), back pain (17%), fatigue (1 7%), 
and nausea (17%).   One Grade 4 event of myocarditis (relate d) was reported, and
2Grade 5 event s(both unrelated, 1death from RCC progression , 1event of 
hemoptysis) .
Atezolizumab —F. Hoffmann- La Roche Ltd
42/Protocol WO41994, Version 3While Study COSMIC -021is still ongoing, the current results suggest that atezolizumab 
1200 mg in combination with cabozantinib 60 mg is tolerable and potentially active in 
patients with clear -cell and non clear -cell RCC.
1.7 RATIONA LE FOR IMMUNE C HECKPOINT RE-C HALLENGE
There is evidence to support the use of an ICI in combination therapy after progression 
with a prior ICI. Preliminary efficacy of atezo lizumab in combination with bevacizumab in 
patients treated beyond progression was seen in Study WO29074 (IMmotion150; 
Atkins etal.2017) .  In Study WO29074 , patients who progressed on either sunitinib or 
atezolizumab and had crossed over to the combination of atezolizumab with 
bevacizumab achieved an ORR of 28% and 24% with a median PFS 8.3 months and 
12.6 months, respectively . Similarly, in a cohort of patients with RCC who progressed 
with prior ICI therapy, pembrolizumab in combination with le nvatinib produced an ORR 
of 64% witha median PFS by modified RECIST for immune- based therapeutics 
(iRECIST) v1.1 of 11.3 months (95% CI :7.3to not estimable). The most common prior 
ICI therapies were nivolumab monotherapy, nivolumab/ipilimumab, and 
avelumab/axitinib (Lee et al. 2019). These results support the hypothesis that ICIsmay 
be effective for patients who experienced progression while on or after receiving ICIs, if 
combined with different agents. Similar phenomena are being observed across tum or 
types. Preliminary results from a combination of sitravatinib (multi -TKIof VEGFR2, KIT, 
MET, A XL, MER, and Tyro) with nivolumab in non-squamous NSCLC after progression 
while on or after receiving an ICI ( Leal et al. 2017 )produced an ORR of 32% 
(including unconfirmed) .In addition, mocetinostat ( histone deacetylase inhibitor) in 
combination with durvalumab inpatients with NSCLC who have experienced 
documented disease progression following prior treatment with an ICI (N 29) produced 
an ORR of 17% (Johnson et al. 2018 ).
1.8 STUDY RA TIONA LE A ND BENEFIT RISK A SSESSMENT
With the rapidly evolving landscape of treatments for metastatic RCC, the use of 
ICI-based treatments ismoving to earlier lines of therapy and is becoming the standard 
of care for first-and second -linetreatments in most countries .  Thus, there remains a 
need to better understand the sequential use of all available RCC treatments and 
develop effective treatments that fit this evolving landscape (Motzer et al. 2015a ; 
Motzeret al. 2018 b;Motzer et al. 2019 a;Rini et al. 2019a ).  A Phase IIstudy of 
lenvatinib in combination with pembrolizumab has already shown promising ac tivity in 
patients with prior ICI treatment, supporting the notion of administering anICI in 
combination with a VEGFR -TKI in patients previously treated with a nICI.
Both cabozantinib and atezolizumab have shown clinical efficacy in aRCC. 
Cabozantinib single -agent treatment and treatment with atezolizumab in combination 
with bevacizumab have s hown clinical efficacy in the post -ICIsetting in subgroup 
analys es of prior studies as described in previous sections. These 2agents are also 
active for patients with clear as well as non clear -cellRCC (see S ection s1.4and 1.5).
Atezolizumab —F. Hoffmann- La Roche Ltd
43/Protocol WO41994, Version 3The combination of a VEGFR -TKI with immunotherapy may offer an advantage over 
individual treatment. Cabozantinib contributes to modulation of the immune- tumor 
microenvironment and may enhan ce the efficacy of immu notherapy (Kwilas et al .2014 ; 
Lu et al .2017 ; Patnaik et al. 2017 ).
Preliminary results of t he administration of the combination of atezolizumab and 
cabozantinib in treatment -naive patients with aRCC in the COSMIC -021 study suggest 
that atezolizumab 1200 mg in combination with cabozantinib 60 mg is tolerable with 
encouraging efficacy ,thus wa rranting further investigation, especially in the patient 
population with prior ICI treatment. However, given the potential for overlapping 
toxicities (e.g., diarrhea), an open -label study would allow for better adverse event 
management. Itis anticipated that atezolizumab administered in combination with 
cabozantinib will have a manageable safety profile and ha s an acceptable benefit risk 
balance to justify the conduct of the study .
Cabozantinib is an already approved and established therapy for the treatment ofRCC 
(METEOR [[STUDY_ID_REMOVED]] and CABOSUN trials [[STUDY_ID_REMOVED]] ). The single 
cabozantinib control arm allows for an evaluation of the contribution of atezolizumab in
the combination treatment (experiment arm).
2. OBJECTIVES AND ENDPOINTS
This study will evaluate the efficacy andsafety of atezolizumab when given in 
combination with cabozantinib compared with cabozantinib alone in patients with 
advanced clear -cell or non clear -cellRCC (papillary ,chromophobe or unclassified only) 
who experienced radiographic tumor progression during or after ICI treatment in the
adjuvant and/or locally advanced/ metastatic setting. Patients with RCC with 
sarcomatoid features are also allowed into t his study . Patients with the chromophobe 
subtype of nonclear -cell RCC must have sarcomatoid differentiation .
Specific objectives and corresponding endpoints for the study are outlined below.
In this protocol , "study treatment" refers to the combination of treatments assigned to 
patients as part of this study (i.e., atezolizumab in combination with cabozantinib or 
cabozant inibmonotherapy ).
2.1 EFFICA CY OBJECTIVES
Response will be assessed according to RECIST v1.1 (see Appendix 3).  
Objective response at a single timepoint will be determined by the investigator and 
Independent Review Facility (I RF)according to RECIST v1.1.  Objective response per 
iRECIST (see Appendix 4)may be calculated programmatically by the Sponsor on the 
basis of the investigator assessments of individual lesions at each specified timepoint .
Atezolizumab —F. Hoffmann- La Roche Ltd
44/Protocol WO41994, Version 32.1.1 Primary  Efficacy  Objective
The primary effica cy objective for this study isto evaluate the efficacy of atezolizumab in 
combination with cabozantinib compared with cabozan tinib alone inthe ITT population 
based on the following endpoint s:
PFS, defined as the time from randomization to the first occurrence of disease 
progression according to RECIST v1.1, as assessed by an IRF (e.g., IRF-PFS) or 
death from any cause , whichever occurs first
Overall survival ,defined as the time from randomization to death from any cause
2.1.2 Secondary  Efficacy Objective
The secondary efficacy objective for this study is to evaluate the efficacy of atezolizumab 
in combination with cabozantinib compared with cabozantinib alone on the basis of the 
following endpoints:
PFS assessed by the investigators ( investigator -assessed PFS) ,defined as the time 
from randomization to the first occurrence of disease progression according to 
RECIST v1.1 or death from any cause (whichever occurs first)
Investigator -and IRF- assessed ORR ( investigator -assessed ORR and 
IRF-assessed ORR) ,defined as the proportion of patients with a CRor PR on 
twoconsecutive occasions at least 4 weeks apart according to RECIST v1.1
Investigator -and IRF- assessed duration of response ( investigator assessed -DOR
and IRF -DOR ), defined as the time from the fi rst occurrence of a documented 
objective response to disease progression or death from any cause (whichever 
occurs first) according to RECIST v1.1
2.1.3 Exploratory  Efficacy  Objective
The exploratory efficacy objective for this study is to evaluate the efficacy of 
atezolizumab in combination with cabozantinib compared with cabozantinib alone on the 
basis of the following endpoints:
PFS, OS, and ORR in subgroups ,defined by demographic and baseline 
characteristics (e.g.,PD-L1 status, prior VE GFR-TKI use, most recent IC Itherapy 
[adjuvant vs. first-linevs. second -line], tumor histology ,or IMDC risk group)
Time to response
Time to confirmed deterioration of disease -related symptoms, defined as the time 
from randomization date to the date of a patient ’s first 4-point score decrease from 
baseline ontheFunction al Assessment of Cancer Therapy Kidney S ympto m 
Index 19 (FKSI -19) Disease -Related Symptom -Physical (DRS -P) scale (Appendix 7)
held for at least two consecutive timepoints, or followed by death within 3 weeks 
(ifCycle s 112) or 6 weeks (if after Cycle 12) from the last PRO assessment
Change from baseline in patient -reported disease -related symptoms by visit, 
measured with use of the FKSI -19 DRS- P scale
Atezolizumab —F. Hoffmann- La Roche Ltd
45/Protocol WO41994, Version 3Time to confirmed deterioration of physical functioning, defined as the time from 
randomization date to the date of a patient ’s first 10-point score decrease from 
baseline ontheEuropean Organisation for Research and Treatment of Cancer 
(EORTC ) Quality of Life Core 30 Questionnaire (QLQ -C30) physical functioning 
scale held for at least two consecutive timepoints , or followed by death within 
3weeks (if Cycle s 112) or 6 weeks (if after Cycle 12) from the last 
PRO assessment
Time to confirmed deterioration of global health status /quality of life (GHS/QoL) , 
defined as the time from randomization date to the date of a patient ’s first 10-point 
score decrease from baseline on the EORTC QLQ -C30 GHS/QoL scale held for at 
least two consecutive timepoints, or followed by death within 3 weeks 
(ifCycle s 112) or 6 weeks (if after Cycle 12) from the last PRO assessment
Change from baseline in patient -reported physical functioning and global health 
status by visit, measured with use of the EORTC QLQ -C30 physical functioning and 
GHS/QoL scales
Descriptive summary statistics by visit for the remaining FKSI -19 and 
EORTC QLQ -C30 scales
Cumulative distribution function curves of score change from baseline to Month 6 for 
each key scale (FKSI -19 DRS- P, EORTC QLQ -C30 physical function, 
EORTC QLQ -C30 GHS/QoL)
2.2 SAFETY OBJECTIVE
The safety objective for this study is to evaluate the safety of atezolizumab in 
combination with cabozantinib compared with cabozantinib alone on the basis of the 
following endpoints:
Incidence and severity of adverse events , with severity determined according to 
National Cancer Institute Common Terminology Criteria for Adverse Events
(NCI CTCAE) , Version 5.0
Change from baseline in targeted vital signs
Change from baseline in targeted clinical laboratory test results
The exploratory safety objective for this study is to evaluate the overall side -effect 
burden of atezolizumab in combination with cabozantinib compared with cabozantinib 
alone from the patient's perspective, on the basis of the following endpoint:
Patient -reported overall bother with treatment side effects during study tre atment, 
measured with use of the FKSI -19 GP5 item
Atezolizumab —F. Hoffmann- La Roche Ltd
46/Protocol WO41994, Version 32.3 PHA RMA COKINETIC OBJE CTIVE
The pharmacokinetic (PK) objective for this study is to characterize the PK profile of 
atezolizumab and cabozantinib administered in combination on the basis of the following 
endp oints:
Atezolizumab concentrations at specified timepoints
Cabozantinib concentrations at specified timepoints
2.4 IMMUNOGENICITY OBJEC TIVE
The immunogenicity objective for this study is to evaluate the immune response to 
atezolizumab on the basis of the following endpoint :
Prevalence of anti -drug antibodies (ADAs) to atezolizumab at baseline and 
incidence of ADAs to atezolizumab during the study
The exploratory immunogenicity objective for this study is to evaluate potential effects of 
ADAs on the basis of the following endpoint:
Relationship between ADA status and demographics, efficacy, safety, or 
PKendpoints
2.5 BIOMA RKER OBJECTIVE
The exploratory biomarker objective for this study is to identify and/or evaluate 
biomarkers that are p redictive of response to atezolizumab in combination with 
cabozantinib or cabozantinib alone (i.e., predictive biomarkers), are early surrogates of 
efficacy, are associated with progression to a more severe disease state (i.e., prognostic 
biomarkers), are associated with acquired resistance to atezolizumab in combination 
with cabozantinib or cabozantinib alone , can provide evidence of atezolizumab in 
combination with cabozantinib or cabozantinib alone efficacy (i.e., pharmacodynamic 
biomarkers), or can incr ease the knowledge and understanding of disease biology and 
drug safety, on the basis of the following endpoint :
Relationship between biomarkers in blood ,tumor tissue , and urine (listed in 
Section 4.5.7 )and efficacy, PK, immunogenicity, or other biomarker endpoints
2.6 HEA LTH STA TUS UTILIT Y OBJECTIVE
The exploratory health status utility objective for this study is to evaluate health status 
utility scores of patients treated with atezolizumab in combination with cabozantinib 
compared with cabozantinib alone to inform economic modeling on the basis of the 
following endpoint:
Change from baseline in the EuroQol 5 -Dimension , 5-Level Questionnaire 
(EQ-5D-5L) index -based and visual analog scale (VAS) scores by visit
Atezolizumab —F. Hoffmann- La Roche Ltd
47/Protocol WO41994, Version 33. STUDY DESIGN
3.1 DESCRIPTION OF THE S TUDY
This is a Phase III, multicenter, randomized, open -label study designed to evaluate the 
efficacy and safety of atezolizumab given in combination with cabozantinib versus 
cabozantinib alone in patients with inoperable, locally advanced, or metastatic RCC who 
experienced radiographic tumor progression during or after ICI treatment in the adjuvant 
and/or locally advanced/ metastatic se tting.  The study will enroll approximately 
500patients at approximately 140180sites globally.
Key inclusion criteria include (for more details please seeSection 4.1.1 ):
Male and female patients aged 18 years withKarnofsky Performance Status (KPS) 
score 70 who have histologically -confirmed locally advanced or metastatic 
clear -cellor non clear -cell RCC (papillary , chromophobe ,or unclassified only)
Sarcomatoid features are allowed .Patients with the chromophobe subtype of 
nonclear -cell RCC must have sarcomatoid differentiation .
Other subtypes of n onclear -cell RCC (e.g., collecting duct carcinoma , renal 
medullary carcinoma ) are not eligible .
 Patients who have experienced radiographic tumor progression during or following
ICI treatment for locally advanced or metastatic RCC either in first -line or 
second -line treatment.  Patients who experienced r adiographic tumor progression 
during or within 6 months after last dose of adjuvant ICI are also eligible .
Patients who do not meet the criteria for participation in this study (screen failure) may 
qualify for onere-screening (for a total of twoscreenin gs per participant) at the 
investigator's discretion. Patients are not required to re -sign the consent form if they are 
re-screened within 28 days after previously signing the consent form .  The investigator 
will record reasons for screen failure in the screening log (see Section 4.5.1 ).
Figure 1presen ts an overview of the study design.  A schedule of activities is provided in 
Appendix 1.
Atezolizumab —F. Hoffmann- La Roche Ltd
48/Protocol WO41994, Version 3Figure 1 Study Schema
1L first -line (treatment); 2L second -line (treatment) ; ICIimmune checkpoint inhibitor ; 
IMDC International Metastatic Renal Ce ll Carcinoma Database Consortium; POby mouth; 
Q3Wevery 3 weeks; R CCrenal cell carcinoma .
Patients will be randomized in a 1:1 ratio to oneof the following twotreatments arms:
Experimental arm: Atezo lizumab 1200 mg IV infusions Q3Won Day 1 of each 
21-day cycle plus cabozantinib 60-mg oral tab lets taken QD(1cycle 21 days)
Control arm: Cabozantinib 60 -mg oral tablets taken QD(1 cycle 21 days)
Randomization will be stratified by:
IMDC risk groups ( favorable , intermediate or poor risk; 0, 1 2, or 3), which 
comprises the following 6 risks factors : time from diagnosis to systemic therapy, 
KPS, hemoglobin, corrected calcium, neutrophil and platelet count (see Appendix 12)
Most recent ICItherapy ( adju vant vs. first-line vs.second- line)
Histology :  dominant clear -cell without sarcomatoid versus dominant nonclear -cell 
(papillary or unclassified only) without sarcomatoid versus any sarcomatoid
component (clear -cell or non clear -cell)
Atezolizumab will be administered by IVinfusion at a fixed dose of 1200 mg on Day 1 of 
each 21 -day cycle and cabozantinib will be taken orally at a starting dose of 60mg/day
on Days 1 21of each 21-day cycle . Patients randomized to the atezolizumab and 
cabozantinib arm who transiently withhold or permanently discontinue either 
atezolizumab or cabozantinib may continue on single -agent therapy u ntil disease 
progression (i.e., patients being withheld from cabozantinib transiently for adverse 
effects may con tinue atezolizumab monotherapy and vice versa). Guidelines for dosage 
modification, treatment interruption or discontinuation, and the management of specific 
adverse events are provided in Sections 5.1.3.1 and 5.1.3.2 .

Atezolizumab —F. Hoffmann- La Roche Ltd
49/Protocol WO41994, Version 3Patients will receive atezolizumab and/or cabozantinib until disease progression per 
RECIST v1.1, unacceptable toxicity ,or symptomatic deterioration attributed to disease 
progression (e.g., pain secondary to disease or unmanageable ascites) as determined 
by the investigator after an integrated assessment of radiogr aphic and biochemical data, 
local biopsy results (if available), and clinical status .
No crossover will be allowed from the control arm to the experimental arm.
Patients will undergo scheduled tumor assessment at baseline, every 9 weeks (7days) 
for the first 1 8months and every 12 weeks ( 7 days) thereafter. Tumor assessments 
will continue until disease progression as assessed by the investigator per RECIST v1.1
(see Appendix 3) or,for patients who continue study treatment after radiographic 
disease progression, loss of clinical benefit as determined by the investigator 
(see Section 3.1for details) .  In the absence of disease progression, tumor assessments 
should continue regardless of whether treatment has been discontinued (e.g.,for toxicity) 
orwhether patients start new anti -cancer therapy, until consent is withdrawn, death, or 
the study is terminated by the Sponsor, whichever occurs first (seeSection 4.5.5 for 
more details) . Following treatment discontinuation (even in the absence of disease 
progression per RECIST v1.1.), patients will be followed for survival and subsequent 
anti-cancer therapies until death, loss to follow -up, withdrawal of consent, or study 
termination by Sponsor, whichever occurs first. The following information regarding all 
subsequent anti -neoplastic agents upon treatment discontinuation will be collected:
lineof therapy, date of first dose of agent, date of final dose of agent (or if ongoing), 
patient's best response, and date of disease progression.
Schedules of activities are provided in Appendix 1andAppendix 2.
Sites must continue to provide images until the IRF determines disease 
progression . However, treatment decisions will be made based on investigator 
assessment of disease progression.   Independent Review Facility procedures will 
be detailed in theIRF Charter.
Because of the possibility of an initial increase in tumor burden caused by immune -cell 
infiltration in the setting of a T -cell response (termed pseudo progression ) with 
atezolizumab treatment, radiographic progression per RECIST v1.1 may not be 
indicative of true disease progression .  In the absence of unacceptable toxicity, pati ents
who meet criteria for disease progression per RECIST v1.1 while receiving atezolizumab
and/or cabozantinib will be permitted to continue treatment , until loss of clinical benefit, if 
they meet all of the following criteria:
Evidence of clinical benefit, as determined by the investigator following a review of 
all available data
Absence of symptoms and signs (including laboratory values, such as new or 
worsening hypercalcemia) indicating unequivocal progression of disease
Atezolizumab —F. Hoffmann- La Roche Ltd
50/Protocol WO41994, Version 3Absence of decline in KPS that can be attributed to disease progression
Absence of tumor progression at critical anatomical sites (e.g., leptomeningeal 
disease) that cannot be managed by protocol -allowed medical interventions
Patients for whom other treatment options/standard therapies exist must provide 
written consent to acknowledge deferring these treatment options in favor of 
continuing study treatment at the time of progression
Tumor tissue will also be collected by biopsy, unless not clinically feasible as assessed 
and documented by the investigator, at the time of first evidence of radiographic disease 
progression perRECIST v1.1 (within 40 days after radiographic progression or prior to 
the start of new anti-cancer treatment, whichever is sooner ; see Section 4.5.7 for more 
details) .  These samples will enable analysis of tumor tissue biomarkers related to 
resistance, disease progression, and clinical benefit of atezolizumab and/or cabozantinib .
3.1.1 Independent Data Monitoring Committee
An independent Data Monitoring Committee (iDMC) will evaluate safety data during the 
study.  Sponsor affiliates will be excluded from iDMC membership.  The iDMC will follow 
a charter that outlines the iDMC roles and responsibilities .
Safety data will be reviewed on a periodic basis, approximately every 6 months from the 
time of enrollment of the first patient until the time of the analysis of the primary efficacy 
endpoint of PFS according to policies and procedures detailed in an iDMC Charter. 
Nointerim efficacy analyses are planned for PFS.
All summaries and analyses for the iDMC review will be prepared by an 
independent Data Coordinati ng Center .  The safety sum maries will include demographic 
data, adverse events, serious adverse events, and relevant laboratory data.
After reviewing the data, the iDMC will provide a recommendation to the Sponsor as 
described in the iDMC Charter .  Final decisions will rest with th e Sponsor.
Any outcomes of these data reviews that affect study conduct will be communicated in a 
timely manner to the investigators for notification of their respective Institutional Review 
Boards (IRBs) /Ethics Committees (ECs).
3.2 END OF STUDY AND LENGTH OF STUDY
The end of this study is defined as the date when the required numbers of events for the 
final analysis of OS in the ITT population has occurred (see Section 6).
In addition, the Sponsor may decide to terminate the study at any time.
The total length of the study, from screening of the first patient to the end of the study, is 
expected to be approxim ately 55 months.
Atezolizumab —F. Hoffmann- La Roche Ltd
51/Protocol WO41994, Version 33.3 RATIONA LE FOR STUDY DESIGN
3.3.1 Rationale for Atezolizumab Dose and Schedule
Atezolizumab will be administered at a fixed dose of 1200 mg Q3 W (1200 mg on Day 1 
of each 21- day cycle), which is an approved dosage for atezolizumab, as outlined in the 
prescribing information.  Anti -tumor activity has been observed across doses ranging 
from 1 20 mg/kg Q3 W.  In Study PCD4989g, the maximum tolerated dose of 
atezolizumab was not reached and no DLTs were observed at any dose.  The fixed dose 
of 1200 mg Q 3W (equivalent to an average body weight based dose of 15 mg/kg Q3 W) 
was selected on the basis of both nonclinical studies (Deng etal.2016) and available 
clinical PK, efficacy, and safety data (refer to the Atezolizumab Investigator's Brochure 
for detail s).
3.3.2 Rationale for Cabozantinib Dose and Schedule
Cabozantinib will be administered orally at a starting dose of 60 mg/day starting on 
Day1.This is the approved dosage for cabozantinib, as outlined in the Cabometyx 
prescribing information.
From the Phase IIIMETEOR trial ([STUDY_ID_REMOVED]) of cabozantinib in patients with RCC, 
exposure -response analyses have shown that the 60 -mg starting dose would provide 
greater anti -tumor activity compared withstarting doses at 40 mg or 20 mg 
(Lacy etal.2018). In the Phase I b COSMIC -021study ( [STUDY_ID_REMOVED] ),no DLTs were 
observed in either the 40-mg or 60- dose dose -escalation cohorts .  As described in 
Section 1.6, among the 12patients enrolled in the dose -escalation stage , the 
investigator -assessed confirmed ORR was 67%. When looking at each dose cohort 
separately, the ORR for patients with RCC treated with 40 mg cabozantinib was 50% 
(1CR and 2 PRs in6patients ) and 83% (5 PRs in6 patients )at 60 mg
(Agarwal etal.2018). When looking at the total pop ulation of patients in the 
dose- escalation stage (6patients at each dose level of 40 mg and 60 mg)and the 
expansion stage (30patients at each dose level of 40 mg and 60 mg), the totality of the 
efficacy data in patients with RCC suggests greater efficacy in the 60 -mg patient cohort 
compared with the 40- mg cohort, with manageable safety profile sateither dose level.
Tooptimize the benefit of the combination therapy for patients with aRCC, a starting 
dose of 60mg cabozantinib (as per the current recommended dose as monotherapy)
was selected in combination with atezolizumab for this trial. Dose re duction sare 
allowed to manage side effects according to guidelines outlined in Appendix 11.
Please refer to the Cabozantinib Investigator's Brochure for details .
Atezolizumab —F. Hoffmann- La Roche Ltd
52/Protocol WO41994, Version 33.3.3 Rationale for Patient Population
Immunotherapy with ICIshave become standard of care in aRCC. Currently available 
data in the pre- treated population do not reflect this evolving landscape and ;therefore ,
there is no established treatment paradigm for patients who have previously been 
treated with an ICI. In addition, it is critical to understand whether immunotherapy can 
be used again after progression, and whether the sequential use of different 
immunotherapies, when combined with other agents, is beneficial . Therefore, the study 
will enroll patients who have progressed on an ICI as their most recent prior therapy in 
theaRCC setting. However, since ICI sare used both in the front -line and second -line
treatment setting, this study will allow up to twoprior lines of therapy. Vascular
endothelial growth factor receptor -TKIs are used in the front and subsequent lines of 
therapy either as a single agent or in combination with ICIs. Therefore, this study will 
include patients who have previously received such TKIs, provided that the therapy 
preceding trial enrollment is an ICI. However, t his study will exclude patient s who have 
previously received a mammalian target of rapamycin (mTOR )inhibitor to reduce 
heterogeneity in the patient population and to enable the assessment of the scientific 
hypothesis driving this study .
As seen in the Phase IIIstudies of the combinat ion of pembrolizumab with axitinib or 
avelumab with axitinib, benefit of the ICI in combination with the VEGF R-TKIwas seen 
regardless of PDL- 1 expression (Rini et al. 2019 b). Therefore , this study will enroll 
patients with RCC regardless of tumor PD-L1 status .  The PD-L1 status is not expected 
to impact treatme nt efficacy for either cabozantinib monotherapy or atezolizumab in 
combination with cabozantinib treatment. However , archival tumor tissue and fresh 
samples collected at baseline (if feasible) will be evaluated for potential impact on 
outcomes.
This trial will enroll patients withboth ccRCC and non ccRCC .Clinical trial data for 
non ccRCC are limited since these patients are often excluded from clinical trials .
There is preliminary data showing the benefit of atezolizumab as well as cabozantinib in 
this subtype of RCC, both in trials of these individual agents and also in combination as 
seen in the n onccRCC cohort of the COSMIC -021 study (see Section s1.4and1.5).
Inaddition, both nivolumab and pembrolizumab have shown efficacy in nonccRC C with
anORR of 2025%,demonstrating the efficacy of immunotherapy in n onccRCC 
(Koshkin et al .2018 ; McDermott et al. 2019 ).
However, as seen in all immunotherapy trials mentioned above, including with the 
combin ation of atezolizumab with beva cizumab , the ORR in the chromophobe subtype 
of nonccRCC have much lower responses (010%) than other subtypes . Due to the 
perceived lack of benefit of immunotherapy in the chromophobe subtype, and the 
benefit of ICI therapy in sarcomatoid subtypes (Rini et al. 20 19a and 2019b), only the 
chromophobe subtype with sarcomatoid differentiation will be allowed in the study.
Atezolizumab —F. Hoffmann- La Roche Ltd
53/Protocol WO41994, Version 33.3.4 Rationale for Control Group
There is currently no approved treatment or well -recognized standard of care for patients 
with aRCC who have progressed during or after receiving ICI-based treatment (with or 
without VEGF R-TKI treatment). The use of a VEGF R-TKI after first -line treatment with 
ipilimumab/nivolumab in patients with aRCC was reported in a subset of the 
CheckMate 214study ([STUDY_ID_REMOVED]) patien ts (N33). A best response of 36% 
(i.e., unconfirmed) was reported (Auvray et al. 2019), suggesting that VEGF R-TKI is an 
option after receiving first-line ICI-based treatment.
Although the use of ip ilimumab/nivolumab and ICIVEGF R-TKIs as first -line treatment 
for patients with aRCC continues to increase, pazopanib and sunitinib (VEGF R-TKIs) 
are still frequently used as initial treatment. Thus, use of pazopanib and sunitinib would 
not be appropriate as a comparator for patients in s econd- or third -linetherapy in the 
proposed S tudy W O41994. The increasing use of a xitinib in combination with ICI-based 
combinations in the initial treatment of aRCC, also reduces the suitability of this 
VEGF R-TKI as a control arm in this second -or thir d-linepatient population 
(Motzer etal.2019b; Rini et al. 2019a ).  In addition, both cabozantinib and nivolumab 
have shown superior effi cacy to the standard of care second -line agent everolimus 
(Motzer et al .2015 a;Choueiri et al .2016) and ; therefore, everolimus is also not the ideal 
control arm in this study.
Cabozantinib 60 mg QDoral dose has a broad indication for use in patients with aRCC
in the United States .In the European Union , cabozantinib is approved for use in adult 
patients with aRCC as first-line treatment for intermediate or poor risk disease and
following prior VEGF R-TKI treatment (regardless of risk category). Given the clinical 
efficacy data in this study population described in Section s 1.4.1and3.3.3 , cabozantinib 
is the ideal choice for a control arm for this study population , especially since the safety 
and efficacy of this agent in combination with atezolizumab has already been tested .
3.3.5 Rationale for Stratification Factors
Clinical factors known to affect outcomes in aRCC were chosen as stratification factors. 
In the IMDC risk model (Heng et al .2009), sixrisk factors were identified as being 
associated with poorer survival: time from diagnosis to treatment of less than 1year, 
KPS 80%, neutrophils greater than upper limit of normal (ULN), platelets  ULN, 
corrected calcium ULN, and hemoglobin less than lower limit of normal. Three risk 
categories associated with different outcomes were identified based on these risk factors:
favorable risk (0 risk factors) with a median OS(mOS )not reached, intermediate risk 
(12 risk factors) with a mOS of 27 months, and poor risk (3 6riskfactors) with an OS 
of 8.8months.
Atezolizumab —F. Hoffmann- La Roche Ltd
54/Protocol WO41994, Version 3As described in Section1.3,the proport ion of patients receiving third -line therapy is 
much less than second -line therapy.  In addition ,outcomes in third -line therapy are 
worse. Therefore, stratification by line of therapy is important in this study which plans to 
enroll patients in second -and third- line therapy. Since only patients whose immediate 
preceding therapy wasan ICI are eligible, the differenc e in line of therapy (second -line or 
third-line) will be represented by the most recent ICI ( adjuvant or first-lineor 
second- line).
Several Phase III trials in the adjuvant setting with ICIs such as CheckMate 914 
([STUDY_ID_REMOVED]), IMmotion010 ([STUDY_ID_REMOVED]), KEYNOTE 564 ([STUDY_ID_REMOVED]), 
PROSPER RCC ([STUDY_ID_REMOVED]) and RAMPART ([STUDY_ID_REMOVED]) are ongoing .
Thus,ICIs are heading to become standard of care in the adjuvant setting for patients 
with RCC .In oncology, patients who progress soon after adjuvant therapy are 
considered as those with underdiagnosed metastatic disease and hence are commonly 
included in trials evaluating a refractory population. Progression during or within 
6months after last do se of adjuvant setting is commonly applied in these trials
(Rittmeyer et al. 2017 ; Leetal.2019; [STUDY_ID_REMOVED] ).Asimilar approach will be 
adopted for thisstudy.
As described in Section 3.3.3 , this study will enr oll both clear -cell and non clear -cell 
histology. The advances made with VEGFR -directed therapies in ccRCC have only 
produced modest outcomes innon ccRCC (Zhang et al .2017 ).Sarcomatoid histology 
is a feature associated with up to 20% of RCC s(Zhang et al .2017 ) and has a poor 
prognosis with VEGFR -directed therapies. Given that the outcomes of non ccRCC and 
sarcomatoid RCC are worse than ccRCC, the study will use a st ratification factor of 
histology incorporati ng both cell type (ccRCC or non ccRCC) and any sarcomatoid 
component.  It is worthwhile to note that ICIs appear to have a better outcome in the
sarcomatoid variant than in VEGFR -directed therapies as seen in subgroup analyses of 
the study evaluating atezolizumab and bevacizumab compared with sunitinib 
(Rini et al .2019 a) and the study evaluating pemb rolizumab andaxitinib compared with
sunitinib (Rini et al.2019 b).
3.3.6 Rationale for Open -Label Study
An open -label study design was chosen for this trial due to the expectation of 
overlapping toxicities that may require significant unblinding to differentiate and manage 
toxicities.
To ensure the validity of data collected in an open -label study , the prima ry efficacy 
analyses will bebased on IRF assessment of progression . To avoid aggregated data 
review of efficacy in each arm du ring the conduct of the study, the Sponsor will be 
blinded. In addition, the strategy and timing for the final analysis of the primary endpoint ,
including censoring rules and methods for handling missing data, have been 
prespecified in the protocol .
Atezolizumab —F. Hoffmann- La Roche Ltd
55/Protocol WO41994, Version 33.3.7 Rationale for Progression -Free Survival and Overall Survival 
as Multiple P rimary  Endpoints
In this study, the multiple primary efficacy endpoints will be IRF -assessed PFS and OS.  
This study will test the hypothesis that treatment with atezolizumab in combination with 
cabozantinib will prolong PFS and OS compared with treatment with cabozantinib alone .
Overall survival is consider ed the most reliable endpoint for demonstrating clinical 
benefit for cancer drugs. However, OS may be potentially confounded by subsequent 
therapies. Progression- free survival as an endpoint can reflect tumor growth and can be 
assessed before the determi nation of a surviv al benefit ( U.S. Food and Drug 
Administration [FDA]Guidance 2018). Additionally, PFS has proven to be a reasonable 
surrogate for clinical benefit in various indications for TKIs: crizotinib and osimertinib 
have been approved by regulat ory agencies for previously treated patients with 
advanced NSCLC based on an increase in PFS (XalkoriUSPI and European Medicines 
Agency [EMA ]SmPC ; TagrissoUSPI and EMA SmPC); cabozantinib has been 
approved by regulatory agencies for previously treated patients with advanced RCC 
based on an increase in PFS (Cabometyx USPI and EMA SmPC). Whether an 
improvement in PFS represents a direct clinical benefit or a surr ogate for clinical benefit 
depends on the magnitude of the effect and the benefit risk profile of the new treatment 
compared with available therapies ( EMA Guidance 2017 ; FDA Guidance 201 8).
3.3.8 Rationale for Atezolizumab orCabozantinib Treatment beyond 
Initia l Radiographic Progression per RECIST v1.1
In studies of immuno therapeutic agents, CR, PR , and stable disease have each been 
shown to occur after radiographic evidence of an apparent increase in tumor burden.  
This initial increase in tumor burden caused byimmune -cellinfiltration in the setting of a 
T-cell response has been termed pseudo progression (Hales et al. 2010).  
InStudy PCD4989g, evidence of tumor growth followed by a response was observed in 
several tumor types.   In addition, in some respondin g patients with radiographic 
evidence of progression, biopsies of new lesions or areas of new growth in existing 
lesions revealed intracellular staining and no viable cancer cells.
In addition, radiographic disease progression may not be correlated with cl inical 
conditions .Instead, clinical benefit per the i nvestigator can be used to inform whether 
continued study treatment is an acceptable risk. The continuation of cabozantinib 
treatment after radiographic progression is consistent with the prescribing information 
and was permitted in single- agent trials.
For these reasons, this study will allow all patients to continue treatment after apparent 
radiographic progression per RE CIST v1.1, provided the benefit risk ratio is judged to 
be favorable by the investigator (see criteria in Section 3.3.8 ).Patients should be 
discontinued for unacceptable toxicity or loss of clinical benefit as determin ed by the 
investigator after an integrated assessment of radiographic and biochemical data, local 
biopsy results (if available), and clinical status (see Section 3.1.1 for details) .
Atezolizumab —F. Hoffmann- La Roche Ltd
56/Protocol WO41994, Version 33.3.9 Rationale for the Use of iRECIST
Increasing clinical experience indicates that traditional response criteria 
(e.g., RECIST v1.1 and W orld Health Organization criteria) may not adequately assess 
the efficacy of immuno therapeutic agents because initial radiographic evidence of 
disease progression does not necessarily reflect therapeutic failure.  Patients can 
experience a response in the presence of new lesions or after an increase in tumor 
burden.  Thus, in addition to the traditional RECIST v1.1, this study may employ 
iRECIST (Seymour et al. 2017; see Appendix 4),tumor response criteria that have been 
modified for unconventional tumor change patterns associated with cancer 
immunotherapy.
iRECIST was developed by the RECIST working group in an effort to create a common 
set of criteria that the cancer immunotherapy f ield could apply to clinical trials 
(Seymour et al. 2017).   iRECIST account sfor responses that may occur following 
transient radiographic progression caused by immune -cellinfiltration in tumors 
(leading to a transient increase in the size of existing lesions, including those that were 
previously undetectable and consequently appear as new lesions).  iRECIST relies on 
collection of tumor assessment data after initial disease progression per RECIST v1.1.
Given the proposed immunomodulatory mechanism of acti on of atezolizumab and the 
possibility of observing delayed responses, analyses based on iRECIST may be 
considered.  These analyses will allow for evaluation of iRECIST as an improved 
measure of the efficacy of immunotherapies relative to the standard RECI ST v1.1 .
3.3.10 Rationale for Clinical Outcome Assessments
Patient experience data will be collected in this study to inform the benefit risk profile of 
atezolizumab in combination with cabozantinib .  It is important that the addition of 
atezolizumab to cabozantinib can provide survival benefit and delay disease progression 
without impairing patients’ functioning and quality of life. As such, the patient's 
perspective onsymptom and treatment burden , including physical functioning and 
treatment toxicity impacts , is needed to achieve a comprehensive evaluation of clinical 
benefit . 
Patient -reported outcome (PRO )instruments in this study will provide a better 
understanding of the impacts of disease and treatment on patients.  The FKSI -19
(Rao et al. 2009; Rothrock et al. 2013) is a validated disease -specific instrument that 
measures RCC -related symptom burden and health -related quality of life in patients with 
kidney cancer. The FKSI -19GP5 item is a valid summary me asure of overall treatment 
side-effect burden in cancer that complements clinician -reported safety. 
TheEORTC QLQ -C30 (Aaronson et al. 1993; Fitzsimmons et al. 1999 )is a validated 
instrument that has been widely used in assessing the quality of life in patients with 
cancer. This instrument assesses gl obal health status, functioning (physical, role, 
emotional, cognitive, and social), and symptoms associated with cancer and its 
Atezolizumab —F. Hoffmann- La Roche Ltd
57/Protocol WO41994, Version 3treatment (e.g., fatigue). The EQ -5D-5L (EuroQol Group 1990; Brooks 1996; 
Herdman et al. 2011; Janssen et al. 2013 ) is a generi c health status questionnaire that 
will primarily be used to inform health economic modeling.
3.3.11 Rationale for Biomarker A ssessments
Published results suggest that the expression of PD -L1 in tumors correlates with 
response to anti PD-1 and anti PD-L1 therapy (Topalian et al. 2012; Herbst et al. 2014; 
Borghaei et al. 2015; Fehrenbacher et al. 2016; Herbst et al. 2016; 
Rosenberg etal.2016).  In the current study, any tumor samples collected may be 
tested for PD -L1 expression by a central laboratory.  In additi on to the assessment of 
PD-L1 status, other exploratory biomarkers, such as potential predictive and prognostic 
biomarkers related to the clinical benefit and safety of atezolizumab and cabozantinib, 
tumor immunobiology, mechanisms of resistance, or tumor type, may be analyzed.  
DNA and/or RNA extraction and analysis may be performed to enable next-generation 
sequencing ( NGS ), including ,but not limited to ,whole -exome sequencing (W ES), to 
evaluate expression of genes to assess their association with effica cy, and to identify 
somatic mutations to increase understanding of disease pathobiology.
Blood and urine -based biomarkers (including, but not limited to, circulating tumor DNA 
[ctDNA]) may be also evaluated and correlated with atezolizumab and cabozantinib
efficacy and evaluated as potential surrogate markers of efficacy.  This evaluation of 
blood and/or urine -based markers may provide evidence for the biologic activity of 
atezolizumab and cabozantinib in patients with RCC, help to identify patients who may
benefit most from atezolizumab and cabozantinib , and help future development of 
tissue -free diagnostic options for patients who have inadequate quality or insufficient 
quantity of tumor tissue for biomarker testing.
Blood and urine samples will be collect ed in order to better understand the changes in 
biomarker profiles and potential mechanisms of resistance upon progression. 
Blood samples may also be evaluated for additional exploratory biomarkers that may be 
associated with the therapeutic effects of atezolizumab and cabozantinib or the 
pathogenesis of RCC.
Tissue samples will be collected for DNA extraction to enable W ES to identify variants 
that are predictive of response to study drugs, are associated with progression to a more 
severe disease state, are associated with acquired resistance to study drug, are 
associated with susceptibility to developing adverse events, can lead to improved 
adverse event monitoring or investigation, or can increase the knowledge and 
understanding of disease biology and drug safety.  Genomics is increasingly informing 
researcher's understanding of disease pathobiology.  W hole-exome sequencing
provides a comprehensive characterization of the exome and, along with clinical data 
collected in this study, may increase the oppo rtunity for developing new therapeutic 
approaches or new methods for monitoring efficacy and safety or predicting which 
patients are more likely to respond to a drug or develop adverse events.  Data will be 
Atezolizumab —F. Hoffmann- La Roche Ltd
58/Protocol WO41994, Version 3analyzed in the context of this study but may als o be explored in aggregate with data 
from other studies.  The availability of a larger dataset will assist in identification and 
characterization of important biomarkers and pathways to support future drug 
development.
4. MATERI ALS AND METHOD S
4.1 PATIENTS
Approx imately 500patients will be enrolled in this study. Patients with locally advanced 
or metastatic RCC with clear -cell, or non clear -cell (papillary , chromophobe ,or 
unclassified only) histology , and previously treated with an ICI in the adjuvant and/or 
locally advanced/ metastatic setting will be enrolled . Patients with RCC with sarcomatoid 
features are also allowed in this study .Patients with thechromophobe subtype of 
nonclear -cell RCC must have sarcomatoid differentiation .
4.1.1 Inclusion Criteria
Patients must meet the following criteria for study entry:
Signed Informed Consent Form
Age 18years at time of signing Informed Consent Form
Ability to comply with the study protocol
Histologically -confirmed locally advanced or metastatic clear -cell or nonclear -cell 
(papillary , chromophobe, unclassified only) RCC
– Other subtypes of n onclear -cell RCC (e.g., collecting duct carcinoma , 
renal medullary carcinoma) are not eligible .
–RCCwith sarcomatoid features is allowed. Patients with the chromophobe 
subtype of non -clear -cell RCC must have sarcomatoid differentiation
(see Appendix 13for further guidelines regarding the definition of sarcomatoid 
histology ).
Radiographic disease progression to prior ICItherapy for RCC
– ICI for metastatic disease: Radiographic disease progression during or 
following ICI treatment for locally advanced or metastatic RCC either in 
first -or second- line treatment
– ICI for adjuvant therapy: Patients who experienced radiographic tumor 
progression during or within 6 months after last dose of adjuvant ICI are also
eligible
– Examples of ICI regimens include oneICIregimen in first-line treatment
(e.g., nivolumab plus ipilimumab ,pembrolizumab plus axitinib , axitinib plus
avelumab) , orsecond- line treatment (e.g., TKI as first-line treatment and ICI as 
second- linetreatment)
Atezolizumab —F. Hoffmann- La Roche Ltd
59/Protocol WO41994, Version 3–ICI is defined by anti PD-L1 or anti PD1 antibody ,including atezolizumab, 
avelumab, pembrolizumab, durvalumab, or nivolumab. Ipilimumab 
monotherapy is not considered an anti PD-L1 or anti PD1 therapy .
– Patients must have received at least 2 cycles of ICI treatment
– ICI must have beenused in the immediate pr eceding line of therapy
(patients with an intervening treatment between ICI and study screening are 
excluded)
– Adjuvant treatment with VEGFR -TKIs, except cabozantinib, is allowed
Measurable disease per RECIST v1.1
Evaluable IMDC risk score s
Representative pretreatment tumor specimens, for exploratory biomarker research 
(see Section 4.5.7 for information onsuitability of and requirements for tumor 
specimens)
– Archival tumor specimen (e.g., at diagnosis, surgery, or prior to initiation of 
previous line of therapy )
– Pretreatment tumor tissue from fresh biopsy at screening, if clinically feasible .
Biopsies coll ected via minor surgery must be performed at least 10 days prior 
to Day 1 of C ycle1 and must be completely healed before first dose.
Availability of tissue samples must be confirmed before randomization. 
Tissue samples must be submitted before or within 4 weeks of randomization.
Both archival and fresh samples are preferred, if feasible.
KPS score of 70
 Recovery to baseline or Grade 1 NCI CTCAE v5.0 from toxicities related to any 
prior treatments, unless adverse events are clinically nonsignificant and/or stable 
in the opinion of the investigator
–Grade 2 alopecia is allowed for study participation
–Exception: Patients who have received systemic corticosteroids for a prior 
immune- related adverse event for 30 days consecutively prior to 
initiation of study treatment are not eligible. Additional criteria on steroid 
use for prior immune -related adverse events is described in the exclusion 
criteria.
Adequate hematologic and end- organ function, defined by the following laboratory 
test results ,obtained w ithin 14 days prior to initiation of study treatment :
– ANC 1.5109/L(1500 cells/L) without granulocyte colony -stimulating factor 
support within 14 days prior to Day 1 of Cycle 1
– Lymphocyte count 0.3109/L(300/L)
– Platelet count 100109/L(100,000/ L) without transfusion within 14 days
prior to Day 1 of Cycle 1
– WBC counts 2500 cells/ L
Atezolizumab —F. Hoffmann- La Roche Ltd
60/Protocol WO41994, Version 3– Hemoglobin 90 g/ L(9 g/dL) (without transfusio n within 14 days prior to Day1 
of Cycle 1)
– AST, ALT, and ALP 2.5ULN, with the following exceptions:
Patients with documented liver metastases: AST and ALT 5ULN
Patients with documented liver or bone metastases:  ALP 5ULN
– Bilirubin 1.5ULN with the following exception:
Patients with known Gilbert disease: bilirubin 3ULN
– Creatinine clearance 40mL/min (calculated with use of the Cockcroft -Gault 
formula, or based on 24- hour urine collection )
– Albumin 25 g/L ( 2.5 g/dL )
– For patients not receiving therapeutic anticoagulation:  INR or aPTT 1.5ULN
– Proteinuria, as demonstrated by urine protein -to-creatinine ratio ( UPCR)
1mg/mg ( 113.2 mg/mmol)
Negative HIV test at screening
Negative hepatitis B testing at screening:
–Negative hepatitis B surface antigen (HBsAg) test at screening
–Negative total hepatitis B core antibody (HBcAb) t est at screening, or positive 
total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at 
screening . The HBV DNA test will be performed only for patients who have a 
negative HBsAg test and a positive total HBcAb test.
Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV 
antibody test followed by a negative HCV RNA test at screening
The HCV RNA test will be performed only for patients who have a positive 
HCV antibody test.
For women of childbearing potential:  agreement to remain abstinent (refrain from 
heterosexual intercourse) or use contraception and agreement to refrain from 
donating eggs , as defined below:
Women must remain abstinent or use contraceptive methods with a failure rate 
of 1%per year during the trea tment period and for 4 months after the final 
dose of cabozantinib and for 5 months after the final dose of atezolizumab.
Women must refrain from donating eggs during this same period.
A woman is considered to be of childbearing potential if she is postmen archal, 
has not reached a postmenopausal state ( 12continuous months of 
amenorrhea with no identified cause other than menopause), and is not 
permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, 
and/or uterus) or another cause as determined by the investigator 
(e.g., Müllerian agenesis).  The definition of childbearing potential may be 
adapted for alignment with local guidelines or regulations.
Atezolizumab —F. Hoffmann- La Roche Ltd
61/Protocol WO41994, Version 3Examples of contraceptive methods with a failure rate of 1%per year include 
bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit 
ovulation, hormone -releasing intrauterine devices, and copper intrauterine 
devices.
Hormonal contraceptive methods must be supplemented by a barrier method.
The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not a dequate methods of contraception.  
Ifrequired per local guidelines or regulations, locally recognized adequate 
methods of contraception and information about the reliability of abstinence will 
be described in the local Informed Consent Form .
For men:  agreement to remain abstinent (refrain from heterosexual intercourse) or 
use a condom , and agreement to refrain from donating sperm, as defined below:
With a female partner of childbearing potential or pregnant female partner , men 
must remain abs tinent or use a condom during the treatment period and for 
4months after the final dose of cabozantinib to avoid exposing the embryo.  
Men must refrain from donating sperm during this same period.  Females of 
childbearing potential who are partners of mal e patients should also use 
contraceptive methods with a failure rate of 1% per year during their male 
partner’s therapy and for at least 4 months after completing therapy.   Examples 
of contraceptive methods with a failure rate of 1% per year include bi lateral 
tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, 
hormone -releasing intrauterine devices, and copper intrauterine devices.
Hormonal contraceptive methods must be supplemented by a barrier method.
The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not adequate methods of preventing drug 
exposure.  If required per local guidelines or regulations, information about the 
reliability of abstinence will be described in the local Informed Consent Form.
4.1.2 Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:
Treatment with anti-cancer therapy within 14days prior to initiation of study 
treatment
Patients who received cabozantinib at any time prior to screening
Patients who received more than oneICItreatment in the locally advanced or 
metastatic setting (e.g., pembrolizumab and axitini b as first -linetreatment and 
nivolumab as second- linetreatment)
Patients who received more than twoprior lines of therapy in the locally advanced 
or metastatic setting
Atezolizumab —F. Hoffmann- La Roche Ltd
62/Protocol WO41994, Version 3Patients who have received a mTOR inhibitor in any setting
Symptomatic, untreated, or actively progressing CNS metastases
Asymptomatic patients with treated CNS lesions are eligible, provided that allof 
the following criteria are met:
–Measurable disease, per RECIST v1.1, must be present outside the CNS
–The patient has no history of intracranial hemorrhage or spinal cord 
hemorrhage
–The patient has not undergone stereotactic radiotherapy within 7days 
prior to initiation of study treatment ,whole -brain radiotherapy within 
14days prior to initiation of study treatment , or neurosurgical resection 
within 28 days prior to initiation of study treatment
–No e vidence of significant vasogenic edema
–The patient has no ongoing requirement for corticosteroids as therapy for 
CNS disease.  Anticonvulsant therapy at a stable dose is permitted.
–Metastases are limited to the cerebellum or the supratentorial region 
(i.e., no metastases to the midbrain, pons, medulla, or spinal cord)
–There is no evidence of interim progression between completion of 
CNS -directed therapy and initiation of study treatment
Asymptomatic patients with CNS metastases newly detected at screening are 
eligible for the study after receivi ng radiotherapy or surgery, with no need to 
repeat the screening brain scan.
History of leptomeningeal disease
Uncontrolled tumor -related pain
Symptomatic lesions (e.g., bone metastases or metastases causing nerve 
impingement) amenable to palliative radiotherapy should be treated prior to 
enrollment .  Patients should be recovered from the effects of radiation.  There is 
no required minimum recovery period.
Asymptomatic metastatic lesions thatwould likely cause functional deficits or 
intractable pain with f urther growth (e.g., epidural metastasis that is not 
currently associated with spinal cord compression) should be considered 
forloco-regional therapy if appropriate prior to enrollment.
Uncontrolled pleural effusion, pericardial effusion, or ascites requi ring recurrent 
drainage procedures (once monthly or more frequently)
Patients with indwelling catheters (e.g., PleurX) are allowed .
Moderate to severe hepatic impairment (Child -Pugh B or C)
Atezolizumab —F. Hoffmann- La Roche Ltd
63/Protocol WO41994, Version 3Uncontrolled or symptomatic hypercalcemia (ionized calcium 1.5 mmol/L, 
calcium 12 mg/dL ,or corrected calcium ULN) or symptomatic hypercalcemia 
requiring continued use of bisphosphonate therapy or denosumab
Patients who are receiving bisphosphonate therapy or denosumab specifically 
to prevent skeletal events a nd who do not have a history of clinically significant 
hypercalcemia are eligible.
History of malignancy other than renal carcinoma within 5 years prior to screening, 
with the exception of malignancies with a negligible ris k of metastasis or death 
(e.g., 5-year OS rate 90%), such as adequately treated carcinoma in situ of the 
cervix, non- melanoma skin carcinoma, localized prostate cancer, ductal carcinoma 
in situ , or Stage Iuterine cancer
Radiotherapy for RCC within 14 days prior to Day 1 of Cycle 1
Patients who are receiving s ingle -fraction radiotherapy given for the indication 
of pain control are eligible.
Active tuberculosis
Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation 
of study treatment, or anticipation of need for a major surgical procedure during the 
study
Minor surgeries (e.g .,tumor biopsy , placement of vascular access device) 
should be performed at least 10days prior to initiation of study treatment . 
Patients must have complete wound healing from maj or surgery or minor 
surgery before randomization. Patients with clinically relevant ongoing 
complications from prior surgery are not eligible.
Pregnancy or breastfeeding, or intention of becoming pregnant during study 
treatment or within 5 months after fi nal dose of atezolizumab and 4 months after 
final dose of cabozantinib
Women of childbearing potential must have a negative serum pregnancy test 
result within 14days prior to initiation of study treatment.
Severe infection within 4 weeks prior to initiati on of study treatment, including, but 
not limited to, hospitalization for complications of infection, bacteremia, or severe 
pneumonia , or any active infection that, in the opinion of the investigator, could 
impact patient safety
Treatment with a live, atte nuated vaccine within 4 weeks prior to initiation of study 
treatment, or anticipation of need for such a vaccine during atezolizumab treatment 
or within 5 months after the final dose of atezolizumab
Treatment with systemic immunostimulatory agents (includi ng, but not limited to, 
interferon and IL -2) within 4 weeks or 5 drug -elimination half -lives (whichever is 
longer) prior to initiation of study treatment
Atezolizumab —F. Hoffmann- La Roche Ltd
64/Protocol WO41994, Version 3Treatment with systemic immunosuppressive medication (including, but not limited 
to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and 
antiTNF-agents ) within 2 weeks prior to initiation of study treatment, or 
anticipation of need for systemic immunosuppressive medication during study 
treatment, with the following exceptions :
Patients who received acute, low -dose systemic immun osuppressant 
medication (e.g., 10 mg/day oral prednisone or equivalent) or a one -time 
pulse dose of systemic immunosuppressant medication (e.g., 48 hours of 
corticosteroids for a contrast allergy) are eligible for the study after 
Medical Monitor confirmation has been obtained
Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids 
for chronic obstructive pulmonary disease (COPD) or asthma, or low -dose 
corticosteroids for ortho static hypotension or adrenal insufficiency are eligible 
for the study .
Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of 
study treatment
Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract 
infection or COPD exacerbation) are eligible for the study.
Prior allogeneic stem cell or solid organ transplantation
Any other disease, metabolic dysfunction, physical examination finding, or clinical 
laboratory finding that contraindicates the use of an in vestigational drug, may affect 
the interpretation of the results, or may render the patient at high risk from treatment 
complications
Current treatment with anti -viral therapy for HBV or HCV
Active or history of autoimmune disease or immune deficiency , including ,but not 
limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus 
erythematosus, rheumatoid arthritis, inflammatory bowel disease, anti phospholipid 
antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain -Barré 
synd rome, vasculitis, or glomerulonephritis, or multipl e sclerosis (see Appendix 8for 
a more comprehensive list of autoimmune diseases and immune deficiencies ), with 
the following exceptions:
Patients with a history of autoimmune -related hypothyroidism who are on 
thyroid- replacement hormone areeligible for the study.
Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen 
areeligible for the study.
Patients with eczema, psoriasis, lichen simplex chronicus , orvitiligo with 
dermatologic manifestati ons only (e.g., patients with psoriatic arthritis are 
excluded ) are eligible for the study provided alloffollowing conditions are met :
–Rash must cover 10% of  body surface area
–Disease is well-controlled at baseline and requires only low-potency topical 
cortico steroids
Atezolizumab —F. Hoffmann- La Roche Ltd
65/Protocol WO41994, Version 3–No occurrence of acute exacerbations of the underlying condition requiring
psoral en plus ultraviolet A radiation , methotrexate, retinoids, biologic 
agents, oral calcineurin inhibitors, or high -potency or oral corticosteroids
within the previous 12 months
Pharmacologically uncompensated, symptomatic hypothyroidism
History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis 
obliterans), drug -induced pneumonitis, or idiopathic pneumonitis, or evidence of 
active pneumonitis on screening chest computed tomography ( CT)scan
History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
Malabsorption syndrome
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase 
deficiency or glucose- galactose malabsorption
Uncontrolled hypertension defined as sustained blood pressure (BP) 150 mm Hg 
systolic or 90 mm Hg diastolic despite optimal antihypertensive treatment
 Tumors invading the GI -tract, active peptic ulcer disea se, acute pancreatitis, acute 
obstruction of the pancreatic or biliary duct, appendicitis, cholangitis, cholecystitis, 
diverticulitis, gastric outlet obstruction, or in flammatory bowel disease 
(e.g., Crohn's disease, ulcerative colitis)
Stroke (including t ransient ischemic attack), myocardial infarction, or other 
symptomatic ischemic event, or thromboembolic event (e.g. , deep venous 
thrombosis [DVT], PE) within 6 months before randomization
Upon Sponsor approval, subjects with a diagnosis of incidental PE or DVT 
within 6 months are allowed if asymptomatic and stable at screening treated 
with lowmolecular -weight heparin s(LMWHs)or the direct factor Xa inhibitors 
rivaroxaban, edoxaban, or api xaban for at least 1week before first dose.
Significant cardiovascular disease (such as New York Heart Association Class II or 
greater cardiac disease, unstable arrhythmia, or unstable angina ) within 3 months 
prior to initiation of study treatment
History of clinically significant ventricular dysrhythmias or risk factors for ventricular 
dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic 
dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or 
with ischemia demonstrated by diagnostic testing), clinically significant electrolyte 
abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family 
history of sudden unexplained death or long QT syndrome
History of congenital QT syndrome
History or presence of an abnormal ECG that is clinically significant in the 
investigator's opinion, including complete left bundle branch block, second -or 
third-degree atrioventricular heart block, or evidence of prior myocardial infarction 
that is considered as clinically significant by investigator
QT interval corrected withuse of Fridericia's formula (QTcF) 480 ms per ECG 
within 14 days before randomization
Atezolizumab —F. Hoffmann- La Roche Ltd
66/Protocol WO41994, Version 3Note: If a single ECG shows a QTcF with an absolute value 480 ms, 
2additional ECGs at intervals o f approximately 3 minutes must be performed 
within 30 minutes after the initial ECG, and the average of the 3consecutive 
results for QTcF must be 480 ms for the patient to be eligible.
Significant vascular disease (e.g., aortic aneurysm or arterial dissection requiring
surgical repair or recent peripheral arterial thrombosis) within 6 months prior to 
Day1 of Cycle 1
Evidence of bleeding diathesis or significant coagulopathy
Abdominal or tracheoesophageal fistula , bowel obstruction, or gastrointestinal (GI) 
perforation, or intra -abdominal abscess within 6 months before initiation of study 
treatment
Complete healing of an intra -abdominal abscess must be confirmed before 
initiation of study treatment.
Concomitant anti coagulation with coumarin agents (e.g.,warfarin), direct thrombin 
inhibitor dabigatran , direct factor Xa inhibitor betrixaban , or platelet inhibitors 
(e.g.,clopidogrel)
The following are anticoagulants allowed in this study:
Prophylactic use of l ow-dose aspirin for cardio protection (per loca l 
applicable guidelines) and low-dose LMWHs.
Therapeutic doses of LMW H or anti coagulation with direct factor Xa 
inhibitors rivaroxaban, edoxaban, or apixaban in patient s without known 
brain metastases who are on a stable dose of the anti -coagulant for at least 
1 week before randomization without clinically significant hemorrhagic 
complications from the anticoagulation regimen or the tumor.
Clinical signs or symptoms of GIobstruction or requirement for routine parenteral 
hydration, parenteral nutri tion, or tube feeding
Evidence of abdominal free air not explained by paracentesis or recent surgical 
procedure
 Known cavitating pulmonary lesion(s) or known endobronchial disease 
manifestations
 Lesions invading major pulmonary blood vessels
 Clinically sig nificant hematuria, hematemesis, hemoptysis of 0.5 teaspoon 
(2.5 mL) of red blood, coagulopathy, or other history of significant bleeding 
(e.g., pulmonary hemorrhage) within 3 months before initiation of study treatment
Serious, non -healing or dehiscing wound, active ulcer, or untreated bone fracture
Prior history of hypertensive crisis or hypertensive encephalopathy
 Requirement for hemodialysis or peritoneal dialysis
Known hypersensitivity to Chinese hamster ovary cell products or to any component
of the atezolizumab formulation
Atezolizumab —F. Hoffmann- La Roche Ltd
67/Protocol WO41994, Version 3History of severe allergic anaphylactic reactions to chimeric or humanized antibodies 
or fusion proteins
Known allergy or hypersensitivity to any component of the cabozantinib formulation
Patients who are not able to swallo w a tablet
4.2 METHOD OF TREA TMENT ASSIGNMENT A ND BLIND ING
4.2.1 Treatment A ssignment
This is a randomized open -label study.  After written informed consent has been 
obtained, all screening procedures and assessments have been completed, and 
eligibility has been es tablished for a patient, the study site will obtain the patient's 
identification number and treatment assignment from the interactive voice or Web-based 
response system (IxRS).
Patients will be randomly assigned to 1of 2treatment arms: atezolizumab and
cabozantinib orcabozantinib alone. Randomization will occur in a 1:1 ratio withuse of a 
permuted -block randomization method to ensure a balanced assignment to each 
treatment arm.  Randomization will be stratified according to the following criteria:
IMDC score (0 vs. 1 2 vs. 3)
Most recent ICItherapy ( adjuvant vs. first-line vs .second- line)
Histology:  dominant clear -cell without sarcomatoid versus dominant nonclear -cell 
(papillary or unclassified only) without sarcomatoid versus any sarcomatoid
component (with clear -cell or non clear -cell)
4.3 STUDY TRE ATMENT AND OTHER TRE ATMENTS RELEVA NT 
TO THE STUDY DESIGN
The investigational medicinal product s(IMP s) for this study areatezolizumab and 
cabozantinib. The first dosing day ( Day 1 of Cycle 1) shoul d occur within 3 days from 
the date of randomization.
4.3.1 Study Treatment Formulation, Packaging, and Handling
4.3.1.1 Atezolizumab
The atezolizumab Drug Product will be supplied by the Sponsor as a sterile liquid in a 
single -use, 20 -mL glass vial.  The vial contains approximately 20 mL (1200 mg) of 
atezolizumab solution.
The dose of atezolizumab to be used in this study is 1200 mg (equivalent to an average 
body weight -based dose of 15 mg/kg) administered by IV infu sion Q3W(21[3] days).
For information on the formulation and handling of atezolizumab , see the pharmacy 
manual and the Atezolizumab Investigator's Brochure.
Atezolizumab —F. Hoffmann- La Roche Ltd
68/Protocol WO41994, Version 34.3.1.2 Cabozantinib
The comparator of this study is cabozantinib 60 mg(three 20-mgtablets) administered 
orally QD.  Cabozantinib will be supplied by the Sponsor as 20 -mgyellow film -coated 
tablets.  For information on the formulation and handling of cabozantinib , see the 
pharmacy manual and the Cabozantinib Investigator’s Brochure.
4.3.2 Study Treatm entDosage, A dministration, and Compliance
The treatment regimens are summarized in Section s4.3.2.1 and4.3.2.2 .
Refer to the pharmacy manual for detailed instructions on drug preparation, storage, and 
administration.
Details on treatment administration (e.g., dose and timing) should be noted on the 
Study Drug Administration electronic Case Report Form (eCRF) .  Cases of overdose, 
medication error, drug abuse, or drug m isuse, along with any associated adverse events, 
should be reported as described in Section 5.3.5.12 .
Guidelines for dosage modification and treatment interruption or discontinuation for 
patients who experience adverse events are provided in Appendix 10and Appendix 11.
4.3.2.1 Atezolizumab
Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of 
each 21 -day cycle until unacceptable toxicity or loss of clinical benefit as determined by 
the investigator after an integrated assessment of radiographic and biochemical data, 
local biopsy results (if available), and clinical status (see Section 3.1for details) .
Administration of atezolizumab will be performed in a monitored setting where there is 
immediate access to trained personnel and adequate equipment and medicine to 
manage potentially serious reactions.   For anaphyla xis precautions, see Appendix 9.  
Atezolizumab infusions will be administered per the instructions outlined in Table 5 .
Atezolizumab —F. Hoffmann- La Roche Ltd
69/Protocol WO41994, Version 3Table 5Administration of First and Subsequent Atezolizumab Infusions
First Infusion Subsequent Infusions
No premedication is permitted prior to the 
atezolizumab infusion
Vital signs ( pulse rate, respirator y rate, 
blood pressure, and temperature) should be 
measured within 60 minutes prior to the 
infusion
Atezolizumab should be infused over 
60(15) minutes
If clinically indicated, vital signs should be 
measured every15(5)minutes during the 
infusion and at 30(10)minutes after the 
infusion
Patients should be informed about the 
possibility of delayed post -infusion 
symptoms and instructed to contact their 
study phy sician if the y develop such 
symptomsIf the patient experienced an 
infusion -related reaction withany previous 
infusion, premedication with 
antihistamines , anti -pyretics , and/or 
analgesics may  be administered for 
subsequent doses at the discretion of the 
investigator
Vital signs should be me asured within 
60minutes prior to the infusion
Atezolizumab should be infused over 
30(10) minutes if the previous infusion 
was tolerated without an infusion -related 
reaction, or 60 ( 15) minutes if the patient 
experienced an inf usion -related reaction 
with the previous infusion
If the patient experienced an 
infusion -related reaction with the previous 
infusion or if clinically indicated, vital signs 
should be measured during the infusion 
and at 30(10)minutes after the infusion
Guidelines for medical management of infusion -related reactions (IRRs) are provided in 
the Appendix 10.
No dose modification for atezolizumab is allowed.
4.3.2.2 Cabozantinib
Cabozantinib will be taken orally 60 mg QD until unacceptable toxicity or loss of clinical 
benefit as determined by the investigator after an integrated assessment of radiographic 
and biochemical data, local biopsy results (if available), and clinical status 
(see Section 3.1for details).
First Dose of Cabozantinib
The first dose of c abozantinib (on Day 1 of Cycle 1) will be administered in the clinic.  
Forpatients assigned to the atezolizumab and cabozantinib arm, atezolizumab will be 
administered first.
The patient willfast (with the exception of water) for at least 2 hours before receiving 
cabozantinib. Upon completion of the 2- hour fast, the patient willreceive the oral dose 
of cabozantinib with a minimum of 8 oz (240 mL) of water in the clinic and then the 
patient willcontinue to fast for 1 hour.
Atezolizumab —F. Hoffmann- La Roche Ltd
70/Protocol WO41994, Version 3Subsequent Dose of Cabozantinib
Following the first dose of cabozantinib, t he patient should take cabozantinib outside the 
clinic at approximately the same time QD, preferentially before going to bed, and should 
adhere to the fasting requirements described in this section.
Patients should fast (with the exception of water) for at least 2 hours after eating the 
evening meal before taking their dose. After the 2 -hour fast and before going to bed, 
patients are to take cabozantinib with a full glass of water (minimum of 8 oz or 240 mL) 
with no mor e food intake for 1-hour postdose. If the patient's schedule requires taking 
cabozantinib during the day, the patient is to be instructed to follow the same fasting 
recommendations.
Cabozantinib tablets should not be crushed or chewed. Grapefruit and Seville oranges 
(and products made from them) should be avoided while being treated with cabozantinib.
Patients are to be instructed to not make up vomited doses and to maintain the planned 
dosing schedule. Patients arenot to make up f or missed doses if more than 12 hours 
have elapsed after the time the patient would usually take cabozantinib. In the event of 
missed doses, patients arenot to take 2doses to make up for the one the patient
missed.
Any unused study treatment must be returned to the study site for drug accountability 
and disposal.
4.3.3 Investigational Medicinal Product A ccountability
The IMPs for this study are atezolizumab and cabozantinib. All IMPs required for 
completion of this study will be provided by the Sponsor. The study site will 
acknowledge receipt of IMPs supplied by the Sp onsor, with use of the IxRS to confirm 
the shipment condition and content.  Any damaged shipments will be replaced.
Investigational medicinal products will either be disposed of at the study site according to 
the study site's institutional standard operati ng procedure or be returned to the Sponsor 
with the appropriate documentation.  The site's method of destroying Sponsor -supplied 
IMPs must be agreed to by the Sponsor.  The site must obtain written authorization from 
the Sponsor before any Sponsor -supplied IMP is destroyed, and IMP destruction must 
be documented on the appropriate form.
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by 
the study site should be recorded on the Drug Inventory Log.
Atezolizumab —F. Hoffmann- La Roche Ltd
71/Protocol WO41994, Version 34.3.4 Continued A ccess to Atezolizumab and Cabozantinib
The Sponsor will offer continued access to study treatment (atezolizumab and 
cabozantinib ) free of charge to eligible patients in accordance with the Roche Global 
Policy on Continued Access to Investigational Medicinal Product , as outlined below.
A patient will be eligible to receive atezolizumab and cabozantinib after completing the 
study if allof the following conditions are met:
The patient has a life- threatening or severe medical condition and requires 
continued study treatment for his or her well -being
There are no appropriate alternative treatments available to the patient
The patient and his or her doctor comply with and satisfy any legal or regulatory 
requirements that apply to them
A patient will notbe eligible to receive atezolizumab and cabozantinib after completing 
the study if any of the following conditions are met:
The study treatment is commercially marketed in the patient's country and is 
reasonably accessible to the patient (e.g., is covered by the patient's insurance or 
wouldn't otherwise create a financial hardship for the patient)
The Sponsor has discontinued development of the study treatment or data suggest 
that the study treatment is not effective for RCC
The Sponsor has reasonable safety concerns r egarding the IMPas treatment 
forRCC
Provision of thestudy treatment is not permitted under the laws and regulations of 
the patient's country
The Roche Global Policy on Continued Access to Investigational Medicinal Product is 
available at the following website :
https://www.roche.com/policy_continued_access_to_investigational_medicines.pdf
4.4 CONCOMITA NT THERA PY
Concomitant therapy consists of any medication (e.g., prescription drugs, 
over-the-counter drugs, vaccines, herbal or homeopathic remedies, nutritional 
supplements) used by a patient in addition to protocol -mandated treatment from 7 days 
prior to initiation of study treatment until the treatment discontinuation visit .  All such 
medications should be reported to the investigator and recorded on the 
Concomitant Medications eCRF.
Atezolizumab —F. Hoffmann- La Roche Ltd
72/Protocol WO41994, Version 34.4.1 Permitted Therapy
Patients are permitted to use the following therapies during the study:
Oral contraceptives with a failure rate of 1% per year (see Section 4.1.1 )
Hormone replacement therapy
Individualized anti coagulation therapy with heparin or direct factor Xa inhibitors 
rivaroxaban, edoxaban, or apixaban is allowed if it can be provided safely and
effectively under the following circumstances:
Low-dose LM WHsfor prophylactic use are allowed if clinically indicated and the 
bene fit outweighs the risk per the i nvestigator’s discretion.
Therapeutic doses of LMW H or anti coagulation with direct factor Xa inhibitors 
rivaroxaban, edoxaban, or apixaban at the time of the first dose of study 
treatment are allowed if the patient has no evidence of brain metastasis, has 
been on a stable dose of the anti -coagulant for at least 1 week, and has had no 
clinically s ignificant hemorrhagic complications from the anticoagulation 
regimen or the tumor.
Note: Anticoagulation with the direct thrombin inhibitor dabigatran , or the direct 
factor Xa inhibitor betrixaban is not allowed.
Therapeutic doses of LMW H or anti coagulat ionwith direct factor Xa oral 
inhibitors rivaroxaban, edoxaban, or apixaban after first dose of study treatment
are allowed if clinically indicated (e .g., for the treatment of DVT), and the bene fit 
outweighs the risk per the i nvestigator’s discretion.
Note: Anticoagulation with the direct thrombin inhibitor dabigatran or the direct 
factor Xa inhibitor betrixaban is not allowed.
Accepted clinical guidelines regarding appropr iate management while receiving
any kind of anti coagulation therapy must be followed. This includes, but is not 
limited to, patient education regarding the potential adverse drug reactions, 
monitoring laboratory parameters, dose adjustments (e .g., due to kidney 
dysfunction). Caution is warranted in settings as sociated with an increased risk
for bleeding such as GIcancers, urothelial cancers, GImucosal abnormality 
(e.g., mucositis), renal or hepatic impairment, thrombocytopenia, arterial 
hypertension, or prior history of GIbleed. For direct factor Xa inhibitor s, the 
potential for drug -drug interaction with ot her concomitant medications, as well 
as GIabsorption, should be considered. Aspirin and nonsteroidal 
anti-inflammatory drugs (NSAIDs) shouldn’t be used concomitantly with heparin 
or factor Xa inhibitors d ue to the increased risk for bleeding complications. 
Therisks and benefits of the use of anti coagulants should be re -assessed on a 
regular basis. For more information regarding the use of anti coagulants , refer 
to the prescribing information of the anti -coagulant and accepted clinical 
practice guidelines.
Atezolizumab —F. Hoffmann- La Roche Ltd
73/Protocol WO41994, Version 3Accepted clinical guidelines regarding appropriate management while receiving 
anticoagulation therapy with heparins must be followed.  This includes, but is 
not limited to, patient education regarding po tential adverse drug reactions, 
monitoring laboratory parameters, dose adjustments (e.g., due to kidney 
dysfunction, platelet decrease).
Inactiv ated influenza vaccinations
Megestrol acetate administered as an appetite stimulant
Mineralocorticoids (e.g., fludrocortisone)
Inhaled corticosteroids administered for COPD or asthma
Low-dose corticosteroids administered for orthostatic hypotension or adrenocortical 
insufficiency
Palliative radiotherapy (e.g., treatment of known bone metastases or symptomat ic 
relief of pain) as outlined below:
Palliative radiotherapy is permitted, provided it does not interfere with the 
assessment of tumor target lesions (e.g., the lesion to be irradiated must not be 
the only site of measurable disease).  Treatment with atezolizumab and/or 
cabozantinib may be continued during palliative radiotherapy.
Local therapy (e.g., surgery, stereotactic radiosurgery, radiotherapy, radiofrequency 
ablation) as outlined below:
Patients experiencing a mixed response requiring local ther apy f or control of 
3or fewer lesions may still be eligible to continue study treatment after 
Medical Monitor approval has been obtained .  Patients who receive local 
therapy directed at a target lesion will no longer be evaluable for radiographic 
response but will remain evaluable for progression.
Premedication with antihistamines , anti- pyretics, and/or analgesics may be administered 
for the second and subsequent atezolizumab infusions only, at the discretion of the 
investigator.
In general, investigators should manage a patient's care (including preexisting conditions) 
with supportive therapies other than those defined as cautionary or prohibited therapies 
(see Sections 4.4.2 , 4.4.3 , and 4.4.4 )as clinically indicated, per local standard practice .  
Patients who experience infusion -associated symptoms may be treated symptomatically 
with acetaminophen, ibuprofen, diphenhydramine, and/or H 2-receptor antagonist s 
(e.g., famotidine, cimetidine) , or equivalent medications per local standard practice.  
Serious infusion- associated events manifested by dyspnea, hypotension, wheezing, 
bronchospasm, tachycardia, reduced oxygen saturation, or respiratory distress should 
be managed with supportive therapies as clinically indicated (e.g., supplemental oxygen 
and 2-adrenergic agonists; see Appendix 9).
Atezolizumab —F. Hoffmann- La Roche Ltd
74/Protocol WO41994, Version 34.4.2 Cautionary  Therapy for A ll Patients
4.4.2.1 Herbal Therapies
Concomitant use of herbal therapies is not recommended because their 
pharmacokinetics, safety profiles, and potential drug drug interactions are generally 
unknown.  However, herbal therapies not intended f or the treatment of cancer 
(see Section 4.4.3 )may be used during the study at the discretion of the investigator.
4.4.3 Cautionary  Therapy for A tezolizumab -Treated Patients
4.4.3.1 Corticosteroids , Immunosuppressive Medications, and T NF-
Inhibitors
Systemic corticosteroids, immunosuppressive medications, and TNF -inhibitors may 
attenuate potential beneficial immunologic effects of treatment with atezolizumab.  
Therefore, in situations in which systemic corticosteroids , immunosuppressive 
medications, or TNF- inhibitors would be routinely administered, alternatives , including 
antihistamines, should be considered.  If the alternatives are not feasible, systemic 
corticosteroids , immunosuppressive medications, and TNF -inhibitors may be 
administered at the discretion of the investigator.
Systemic corticosteroids or im munosuppressive medications arerecommended, at the 
discretion of the investigator , for the treatment of specific adverse events when 
associated with atezolizumab therapy (seeAppendix 10for details ).
4.4.4 Cautionary  Therapy forCabozantinib -Treated Patients
4.4.4.1 Cytochrome P450
Data from a clinical drug interaction study (XL184 -008) show that clinically relevant 
steady -state concentrations of cabozantinib appear to have no marked effect on the area 
under the concentration time curve (AUC) of coadministered rosiglitazone, a CYP2C8 
substrate. Therefore, cabozantinib is not anticipated to markedly inhibit CYP2C8 in the 
clinic, and, by inference, is not anticipated to markedly inhibit other CYP450 isozymes 
that have lower [I]/ inhibition constant values compared with CYP2C8 (i .e.,CYP2C9, 
CYP2C19, CYP2D6, CYP1A2, and CYP3A4). In vitro data indicate that cabozantinib is 
unlikely to induce CYP enzyme s, except for possible induction of CYP1A1 at high 
cabozantinib concentrations (30 M).
Cabozantinib is a CYP3A4 substrate and a weak substrate for CYP2C9 (but not a 
CYP2D6, CYP2C8, CYP2C19, CYP2B6, or CYP1A2 substrate), based on data from 
invitro studies .Results from a clinical pharmacology study (XL184 -006)showed that 
concurrent administration of cabozantinib with the strong CYP3A4 inducer, rifampin, 
resulted in an approximately 77% reduction in cabozantinib exposure (AUC values) after 
a single dose o f cabozantinib in healthy volunteers. Chronic coadministration of 
cabozantinib with strong inducers of the CYP3A4 family (e.g., phenytoin, carbamazepine, 
rifampin, rifabutin, rifapentine, phenobarbital, and St. John’s W ort) may significantly 
decrease cabozantinib concentrations. The chronic use of strong CYP3A4 inducers 
should be avoided. Other drugs that induce CYP3A4 should be used with caution 
Atezolizumab —F. Hoffmann- La Roche Ltd
75/Protocol WO41994, Version 3because these drugs have the potential to decrease exposure (i.e. , AUC) to 
cabozantinib. Caution must be used when discontinuing treatment with a strong 
CYP3A4 inducer in a patient who has been concurrently receiving a stable dose of 
cabozantinib, as this could significantly increase the exposure to cabozantinib.  
Selection of alternate concomitant medications with no or minimal CYP3A4 enzyme 
induction potential is recommended.
Results from a clinical pharmacology study (XL184 -007) showed that concurrent 
administration of cabozantinib with the strong CYP3A4 inhibitor, ketoconazole, resulted 
in a 38% increase in the cabozantinib exposure (AUC values) after a single dose of 
cabozantinib in healthy volunteers. Coadministration of cabozantinib with strong 
inhibitors of the CYP3A4 family (e .g.,boceprevir, conivaptan, posaconazole, 
ketoconazole, itraconazole, clarith romycin, atazanavir, indinavir, nefazodone, nelfinavir, 
saquinavir, ritonavir, lopinavir, telaprevir, telithromycin, and voriconazole) may increase 
cabozantinib concentrations. Strong CYP3A4 inhibitors should be avoided and other 
drugs that inhibit CYP3A4 should be used with caution because these drugs have the 
potential to increase exposure (i .e.,AUC) to cabozantinib. Selection of alternate 
concomitant medications with no or minimal CYP3A4 enzyme inhibition potential is 
recommended.
Grapefruit and Seville oranges (and products made from them) should be avoided while 
being treated with cabozantinib .
Please refer to the drug interaction tables at the following website for lists of substrates, 
inducers, and inhibitors of selected CYP450 isozyme pathway s:
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/
DrugInteractionsLabeling/ucm080499.htm .
4.4.4.2 Protein Binding
Cabozantinib is highly bound ( 99.7%) to human plasma proteins. Therefore, highly 
protein -bound drugs should be used wit h caution with cabozantinib because there is a 
potential displacement interaction that could increase free concentrations of 
cabozantinib and/or a coadministered highly protein- bound drug (and a corresponding 
increase in pharmacologic effect).
4.4.4.3 Concomitant Medications that a re Know n to Prolong the 
Corrected QT I nterval
Concomitant medications that are known to prolong the corrected QT interval (QTc)
should be avoided in patient s who receive cabozantinib until they have permanently 
discontinued cabozantinib treatment (refer to https://www.qtdrugs.org for a list of drugs 
which have the potential to prolong the QTc).
Atezolizumab —F. Hoffmann- La Roche Ltd
76/Protocol WO41994, Version 34.4.4.4 Other Interactions
Food may increase exposure levels of cabozantinib by 57%, fasting recommendations 
should be followed. In vitro data suggest that cabozantinib is unlikely to be a substrate 
for P -glycoprotein (P-gp), but it does appear to have the potential to inhibit the 
P-gp transport activity. Therefore, cabozantinib may have the potential to increase 
plasma concentrations of co-a dministered substrates of P -gp.  Subjects should be 
cautioned regarding taking P-gp substrate (e.g.,fexofenadine, aliskiren, ambrisentan, 
digoxin, colchicine, maraviroc, posaconazole, ranolazine, saxagliptin, sitagliptin, talinolol, 
tolvaptan).   In addition, cabozantinib was shown to b e asubstrate of drug t ransporter 
multidrug resistance- associated protein 2 (MRP2) in an in vitro assay. Administration of 
MRP2 inhibitors may result in increases in cabozantinib plasma concentrations. 
Therefore, concomitant use of MRP2 inhibitors (e .g.,cyclosporine, efavirenz, 
emtricitabine) should be approached with caution. Additional details related to these 
overall conclusions can be found in the Atezolizumab I nvestigator Brochure.
Administration of the pro ton pump inhibitor (PPI) esomeprazole resulted in no clinically
relevant effect on cabozantinib plasma PK in healthy volunteers. Therefore, concomitant 
use of gastric pH modifying agents (i .e., PPIs, H 2receptor antagonists, and antacids) is 
not contraind icated in patients administered cabozantinib.
Bile salt -sequestering agents such as cholestyramine and cholestagel may interact with 
cabozantinib and may impact absorption (or reabsorption) resulting in potentially 
decreased exposure and should be avoided.
Additional details regarding potential drug interactions with cabozantinib can be found in 
the Cabozantinib Investigator’s Brochure.
4.4.5 Prohibited Therapy for A ll Patients
Use of the following concomitant therapies is prohibited for all patients :
Concomitant therapy intended for the treatment of cancer (including, but not limited 
to, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, and herbal 
therapy), whether health authority approved or experimental, is prohibited for 
various time periods prior to starting study treatment, depending on the agent 
(see Section 4.1.2 ), and during study treatment, until disease progression is 
documented and the patient has discontinued study treatment (see Section 4.4.1 for 
details, with the exception of palliative radiotherapy )
Any investigational therapy is prohibited within 4 weeks prior to initiation of study 
treatment and during study treatment
Atezolizumab —F. Hoffmann- La Roche Ltd
77/Protocol WO41994, Version 34.4.6 Prohibited Therapy  for A tezolizumab -Treated and 
Cabozantinib -Treated Patients
Use of the following concomitant therapies is prohibited for patients treated with 
atezolizumab and cabozantinib:
Live,attenuated vaccines (e.g., FluMist) are prohibited within 4 weeks prior to 
initiation of study treatment ,during atezolizumab treatment , and for 5months after 
the final dose of atezolizumab
Systemic i mmunostimulatory agents ( including ,but not limited to ,interferons and
IL-2)are prohibited within 4 weeks or 5drug-elimination half-lives (whichever is 
longer )prior to initiation of study treatment and during study treatment because 
these agents could potentially increase the risk for autoimmune conditions when 
given in combination with atezolizumab
Systemic immunosuppressive medications (including, but not limited to, 
cyclophosphamide, azathioprine, methotrexate, and thalidomide) are prohibited 
during study treatment because these agents could potentially alter the efficacy and 
safety of atezolizumab
Oral anti coagulation with coumarin agents (e .g., warfarin), direct thrombin inhibitor 
dabigatran, direct factor Xa inhibitor betrixaban, platelet inhibitors (e .g., clopidogrel), 
and chronic use of aspirin above low -dose levels for cardio protection per local 
applicable guidelines), until 4 weeks after cabozantinib has been permanently 
discontinued (for permitted anti coagulants ,seeSection 4.4.1 )
4.5 STUDY ASSESSMENTS
The schedule of activities to be performed during the study is provided in Appendix 1.  
All activities should be performed and documented for each patient.
Patients will be closely monitored for safety and tolerability throughout the study.  
Patients should be assessed for toxici ty prior to each dose; dosing will occur only if the 
clinical assessment and local laboratory test values are acceptable.
4.5.1 Informed Consent Forms and Screening Log
Written informed consent for participation in the study must be obtained before 
performing an ystudy -related procedures (including screening evaluations) .  
Informed Consent Forms for enrolled patients and for patients who are not subsequently 
enrolled will be maintained at the study site.
Evaluations (e .g.,tumor imaging) performed as part of routine care prior to informed 
consent can be utilized as screening evaluations if permitted by the site’s IRB/EC 
policies. Informed consent may be obtained greater than 28 days before randomization.
All screening eval uations must be completed and reviewed to confirm that patients meet 
all eligibility criteria before enrollment .  Certain laboratory values must be obtained closer 
to randomization ,within 14 days .  The investigator will maintain a screening log to record 
Atezolizumab —F. Hoffmann- La Roche Ltd
78/Protocol WO41994, Version 3details of all patients screened and to confirm eligibility or record reasons for screening 
failure, as applicable.
4.5.2 Medical History , Baseline Conditions, Concomitant Medication,
and Demographic Data
Medical history, including clinically significant disease s, surgeries, cancer history 
(including prior cancer therapies and procedures), reproductive status, smoking history , 
will be recorded at baseline .  In addition, all medications (e.g., prescription drugs, 
over-the-counter drugs, vaccines, herbal or homeopa thic remedies, nutritional 
supplements) used by the patient within 28days prior to initiation of study treatment will 
be recorded.   At the time of each follow -up physical examination, an interval medical 
history should be obtained and any changes in medications and allergies should be 
recorded.
Demographic data will include age, sex, IMDC risk assessment, and self -reported 
race/ethni city.
4.5.3 Physical Examinations
A complete physical examination, performed at screening and other specified visits, 
should include an evaluation of the head, eyes, ears, nose, and throat, and the 
cardiovascular, dermatologic , musculoskeletal, respiratory, GI, genitourinary, and 
neurologic systems.  Any abnormality identified at baseline should be recorded on the 
General Medical History and Baseline Conditions eCRF.
Limited, symptom -directed physical examinations should be performed at specified 
post-baseline vi sits and as clinically indicated. The limited physical examination must be 
performed within 96 hours prior to administration of drug .Changes from baseline 
abnormalities should be recorded in patient notes.  New orworsened clinically significant 
abnorma lities should be recorded as adverse events on the Adverse Event eCRF.
4.5.4 Vital Signs
Vital signs willinclude measurements of respiratory rate, pulse rate, systolic and 
diastolic BP, and temperature.   Record abnormalities observed at baseline on the 
General Medical History and Baseline Conditions eCRF.  At subsequent visits, record 
new or worsened clinically significant abnormalities on the Adverse Event eCRF.
Vital signs should be measured within 60 minutes prior to each atezolizumab infusion 
and, if clinically indicated, during or after the infusion.  In addition, vital signs should be 
measured at other specified timepoints as outlined in the schedule of activities 
(see Appendix 1).
Atezolizumab —F. Hoffmann- La Roche Ltd
79/Protocol WO41994, Version 3Table 6 Timing for Vital Sign Measurements for First and Subsequent 
Infusions
DrugTiming for Vital Sign Measurements
First Infusion Subsequent Infusions
Atezolizumab Within 60 minutes prior to the 
atezolizumab infusion
Record patient's vital signs during or 
after the infusion if clinically 
indicatedWithin 60 minutes prior to the 
atezolizumab infusion
Record patient's vital signs during or 
after the infusion if clinically indicated
4.5.5 Tumor and Response Evaluations
Patients will undergo tumor assessments at baseline ,every 9weeks (7 days) for the 
first 18months following treatment initiation, and every 12 (7 days) weeks thereafter, 
regardless of dose delays, until radiographic disease progression per RECIST v1.1 or 
(for patients who continue study treatment after radiographic disease progression) loss 
of clinical benefit as determined by the investigator (see Secti on3.1for details ).
Thus, tumor assessments are to continue according to schedule in patients who 
discontinue treatment for reasons other than disease progression or loss of clinical 
benefit, even if they start new anti -cancer therapy.  At the investigator's discretion, tumor 
assessments may be repeated at any time if progressi ve disease is suspected.
Allpatients, regardless of arm, will also undergo a follow -up post -disease progression
tumor assessment after investigator assessment of radiographic disease progression 
per RECIST v1.1 .  When feasible, this subsequent scan will take place on the same 
schedule as prior to progression (at 9 weeks ( 7 days) ifdisease progression occurred 
inthe first 1 8months, and at 12 weeks (7 days) if disease progression occurred after 
the first 18 months following treatment initiation ).
All measurable and evaluable lesions should be assessed and documented at screening.  
Tumor assessments performed as standard of care prior to obtaining informed consent 
and within 28 days prior to initiation of study treatment do not have to be repeated at 
screening providing the images allow a fu ll RECIST evaluation .
Screening assessments must include CT scans (with oral or IV contrast) or magnetic 
resonance imaging ( MRI)scan s of the chest, abdomen, and pelvis .  A spiral CT scan of 
the chest may be obtained but is not a requirement.   If a CT scan with contrast is 
contraindicated ( e.g., in patients with impaired renal clearance), a non- contrast CT scan 
of the chest may be performed, and MRI scan sof the abdomen and pelvis should be 
performed.   A CT scan with contrast or MRI scan of the head must be done at screening 
to evaluate CNS metastasis in all patients (MRI scan must be performed if CT scan is 
contraindicated) .  An MRI scan of the head is required to confirm or refute the diagnosis 
of CNS metastases at baseline in the event of an equivocal CT scan. Bone scans and 
CT scans of the neck should also be performed if clinically indicated.  At the 
Atezolizumab —F. Hoffmann- La Roche Ltd
80/Protocol WO41994, Version 3investigator's discretion, other methods of assessment of measurable disease as per 
RECIST v1.1 may be used.
If a CT scan for tumor assessment is performed in a po sitron emission tomography /CT 
scanner, the CT acquisition must be consistent with the standards for a full -contrast 
diagnostic CT scan.
All measurable and evaluable lesions identified at baseline should be re -assessed at 
each subsequent tumor evaluation.  The same radiographic procedures used to assess 
disease sites at screening should be used for subsequent tumor assessments (e.g., the 
same contrast protocol for CT scans ).
Objective response at a single timepoint will be determined by the investigator according 
to RECIST v1.1 (see Appendix 3).  Assessments should be performed by the same 
evaluator, if possible, to ensure internal consistency across visits.
Objective response per iRECIST (see Appendix 4) may be calculated programmatically 
by the Sponsor on the basis of investigator assessments of individual lesions at each 
specified timepoint.
To facilitate evaluation of response per iRECIST, a follow -up post -RECIST v1.1 disease 
progression -tumor assessment must be performed in both study arms and tumor 
assessments must be continued until treatment discontinuation for patients who receive 
treatment beyond progression.  This includes continued measurement of target lesions, 
evaluation of non- target lesions (including monitoring for further worsening of any 
non-target lesions that have shown unequivocal progression), and evaluation of any 
newly identified lesions (including measurements, if lesions are measurable; 
seeAppendix 4) at all subsequent assessments .
4.5.5.1 Independent Review  Facility
An IRF will be used to conduct blinded radiology review of the imaging data and will 
provide an independent assessment of tumor response and progression for all patients. 
Independent Review Facility -assessed endpoints will be used for primary and secondary 
analyses.
All scans must be submitted to an IRF for central review until IRF determination of 
progression .
4.5.6 Survival Assessments
Overall survival follow -up information will be collected via telephone calls, patient 
medical records, and/or clinic v isits every 3 months (every 12 weeks [ 1 month ]) or 
more frequently until death, loss to follow -up, or study termination by the Sponsor, 
whichever occurs first.  All patients will be periodically contacted for survival , PRO s
(forthe first 4 survival foll ow-up visit sonly) , and new anti- cancer therapy information 
Atezolizumab —F. Hoffmann- La Roche Ltd
81/Protocol WO41994, Version 3unless the patient requests to be withdrawn from the survival follow -up (this request 
must be documented in the source documents and signed by the investigator).  If the 
patient specifically withd raws from survival follow -up, the study staff may use a public 
information source (e.g., county records), per local regulations, to obtain information 
about survival status only.
See Appendix 1for the schedule of follow -up assessments.
4.5.7 Laboratory , Biomarker, and Other Biological Samples
Samples for the following laboratory tests will be sent to the study site's local laboratory 
for analysis:
Hematology:  WBC count, RBC count, hemoglobin, hematocrit, platelet count, and 
differential count (neutrophils, eosinophils, basophils, monocytes, lymphocytes, 
other cells [if applicable] )
Chemistry panel (serum or plasma):  bicarbonate or total carbon dioxide 
(ifconsidered standard of care for the region), sodium, potassium, magnesium,
chloride, glucose, BUN or urea, creatinine, total protein, albumin, phosphate , 
calcium, total bilirubin, urate, ALP, ALT, AST, and LDH
Note :  Calculated corrected calcium will be collected at screening.
Coagulation:  INR and aPTT
Thyroid function testing:  thyroid -stimulating hormone, T3 (or total T3 for sites where 
free T3 is not performed) , and T4
HIV serology
HBV serology:  HBsAg, total HBcAb, and (if HBsAg test is negative and total HBcAb 
test is positive) HBV DNA
If a patient has a negative HBsAg test and a positive total HBcAb test at 
screening, an HBV DNA test must also be performed to determine if the patient 
has an HBV infection. Hepatitis Bvirus DNA test must be negative.
HCV serology:  HCV antibody and (if HCV antibody test is positive) HCV RNA
If a patient has a positive HCV antibody test at screening, an HCV RNA test 
must also be performed to determine if the patient has an HCV infection .
Pregnancy test
All women of childbearing potential will have a serum pregnancy test at 
screening. Urine pregnancy tests will be performed at every cycle during study 
treatment (predose) , at treatment discontinuation, and as clinically indicated.  
Ifaurine pregnan cy test is positive, it must be confirmed by a serum pregnancy 
test.
Atezolizumab —F. Hoffmann- La Roche Ltd
82/Protocol WO41994, Version 3A woman is considered to be of childbearing potential if she is postmenarchal, 
has not reached a postmenopausal state ( 12continuous months of 
amenorrhea with no identified cause other than menopause), and is not 
permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, 
and/or uterus) or another cause as determined by the investigator 
(e.g., Müllerian agenesis). The definition of childbearing potential may be 
adap ted for alignment with local guidelines or regulations.
Urinalysis (pH, specific gravity, glucose, protein, ketones, and blood); dipstick 
permitted
Urine Chemistry (Protein [spot urine; fully quantitative]; Creatinine [spot urine; 
fullyquantitative]; UPCR [spot urine])
The following samples will be sent to one or several central laboratories or to the 
Sponsor or a designee for analysis:
Serum sample for analysis of C-reactive protein
Serum samples for atezolizumab PK analysis through use of a validated a ssay
Plasma samples for cabozantinib PK analysis through use of a validated assay
Serum samples for assessment of ADAs to atezolizumab through use of a validated 
assay
Blood, plasma , serum , and urine samples for exploratory research on biomarkers 
and biomarker assay development
Blood and urine samples may be processed to obtain derivatives, which may 
include plasma, serum, peripheral blood mononuclear cells (PBMCs) and 
other s(e.g., RNA, DNA, ctDNA, e tc.).
Archival and a newly collected (fresh) tumor tissue sample obtained at baseline
(ifclinically feasible) that is suitable for exploratory research on biomarkers 
(e.g., PD-L1 status via central testing), including biomarker assay development.
Pretreatment tumor biopsies collected via minor surgery must be performed at 
least 10days prior to Day 1 of C ycle 1 and must be completely healed before 
study treatment.
Representative formalin -fixed ,paraffin -embedded tumor specimens in a 
paraffin block (preferred) or slides (15 or more) containing unstained, freshly cut, 
serial sections should be submitted.  If 15 slides are not available, 10 slides are 
acceptable with Medical M onitor confirmation .
Tumor tissue samples must be submitted before or within 4 weeks of 
randomization.
Tumor tissue should be of good quality based on total and viable tumor content. 
Samples must contain tumor cells that preserve cellular context and tissue
architecture regardless of needle gauge or retrieval method.  Samples should 
be collected via resection, core- needle biopsy (at least three , embedded in 
asingle paraffin block), or excisional, incisional, punch, or forceps biopsy 
areacceptable.  Fine- needle aspiration (defined as samples that do not 
Atezolizumab —F. Hoffmann- La Roche Ltd
83/Protocol WO41994, Version 3preserve tissue architecture and yield cell suspension and/or smears), brushing, 
cell pellets from pleural effusion, and lavage samples are not acceptable. 
Tumor tissue from bone metastases that have been decalcified is not 
acceptable.
An optional tumor biopsy while on treatment is discussed further in 
Section 4.5.11 .
Tumor tissue sample obtained at the tim e of progression, if deemed clinically 
feasible, for exploratory research on biomarkers, including biomarker assay 
development
Biopsies at the time of progression should be performed within 40 days after 
progression or prior to the next anti -cancer therapy, whichever is sooner.  
Samples collected via resection, core -needle biopsy, or excisional, incisional, 
punch, or forceps biopsy are preferred.
Cabozantinib must be withheld for biopsies (see Section 4.5.11 for details ).
Exploratory biomarker research may include, but will not be limited to, analysis of 
proteins, genes or gene signatures associated with tumor immunobiology, PD -L1, 
markers associate d with T -cell activation, or density, localization, and activation 
status of immune cells and their subsets, and may involve extraction of DNA, ctDNA , 
or RNA, analysis of somatic mutations, and use of NG S (including ,but not limited to , 
WES)
Screening tumor tissue samples, including those collected from patients who do not 
enroll in the study, may be used for future research and/or development of 
disease- related tests or tools.
For sampling procedures, storage conditions, and shipment instructions, see the
laboratory manual.
Unless the patient gives specific consent for his or her leftover samples to be stored for 
optional exploratory research (see Section 4.5.12 ), biological samples will be destroyed 
no later than the time of completion of the final Clinical Study Report (CSR) , with the 
following exceptions:
Serum samples collected for atezolizumab PK, cabozantinib PK, or atezolizumab 
immunogenicity anal ysismay be needed for additional immunogenicity 
characterization and for PK or immunogenicity assay development and validation ; 
therefore, these samples will be destroyed no later than 5 years after the final CSR
has been completed
Blood , urine, andtumor samples collected for biomarker research and biomarker 
assay development will be destroyed no later than 5 years after the final CSR has 
been completed . However, the storage period will be in accordance with the 
IRB/EC -approved Informed Consent Form and applicable laws (e.g., health 
authority requirements).
Atezolizumab —F. Hoffmann- La Roche Ltd
84/Protocol WO41994, Version 3For enrolled patients, remaining archival tissue blocks will be returned to the site 
upon request or 18 months after final closure of the study database, whichever 
occurs first.  For patients who are not enrolled, remaining archival tissue blocks will 
be returned to the site no later than 6 weeks after eligibility determination.
When a patient withdraws from the study, samples collected prior to the date of 
withdrawal may still be analyzed, unles s the patient specifically requests that the 
samples be destroyed, or local laws require destruction of the samples.   However, if 
samples have been tested prior to withdrawal, results from those tests will remain as 
part of the overall research data.
Data arising from sample analysis, including data on genomic variants, will be subject to 
the confidentiality standards described in Section 8.4.
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses will generally not be provided to study investigators or 
patients unless required by law . The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy on study data publication.
4.5.8 Electrocardiograms and E chocardiogram s
AnECG is required at screening ,and then prior to Day 1 of treatment cycles as 
indicated in Appendix 1. If no clinical symptoms were identified at screening, ECG does 
not need to be repeated on Day 1 of Cycle 1 .
Electrocardiograms for each patient should be obtained from the same machine 
where ver possible.  Lead placement should be as consistent as possible.  
Electrocardiogram recordings must be performed after the patient has been resting in a 
supine position for at least 10 minutes. At screening and during the study, ECGs will be 
performed with standard 12 -lead ECG equipment according to standard procedures to 
determine the corrected QT ccalculated by the QTcF .If at any time a single ECG shows 
a QTcF with an absolute value 480ms or a n increase in the QTcF of 60ms above 
baseline, 2additional ECGs at intervals of approximately 3 minutes must be performed 
within 30 minutes after the initial ECG, and the average of these 3consecutive results 
for QTcF will be used as the value assessed (see Appendix 8).
For safety monitoring purposes, the investigator must review, sign, and date all ECG 
tracings.  Paper copies of ECG tracings will be kept as part of the patient's permanent 
study file at the site.  Any morphologic waveform changes or other ECG abnormalities 
must be documented on the eCRF.
Abnormalities in the ECG that lead to a change in patient management (e .g., dose 
reduced or interrupted, treatment discontinued, requirement for additional medication or 
monitoring) or result in clinical signs and symptoms are considered clinically significant 
for the purposes of this study and will be deemed adverse event s.If values meet criteria 
Atezolizumab —F.Hoffmann- La Roche Ltd
85/Protocol WO41994, Version 3defining them as serious, they must be reported as serious adverse event s 
(see Section 5.4.2 ).
The Fridericia formula is depicted below for calculation of the QTcF value.
QTmeasured QT interval in milliseconds; RR measured R to R interval (which can be derived 
from the heart rate as 60/heart rate) .
Baseline evaluation of left ventricular ejection fraction (LVEF )should be considered for 
all patients, especially in those with cardiac risk factors and/or history of coronary artery 
disease. In countries where additional cardiac monitoring is considered stan dard 
(e.g., France), additional cardiac monitoring ,including baseline evaluation of LVEF in 
those patients with cardiac risk factors ,and/or an abnormal baseline ECG may be 
performed.
4.5.9 Clinical Outcome A ssessments
Patient -reported outcome instruments will be completed t o more fully characterize the 
clinical profile of atezolizumab and cabozantinib .  In addition, PRO instruments will 
enable the capture of each patient's direct experience with atezolizumab and 
cabozantinib .
Patient -reported outcome data will be collected through use of the following instruments:  
EORTC QLQ -C30, EQ-5D-5L, and FKSI19.
Patient -reported outcome instruments will be completed by patients on Day 1 of each 
cycle for the first 12 cycles and then Day 1 of every other cycle during study treatment, 
at the end -of-treatment visit, and at4subsequent survival follow -up visits.
Survival follow -up assessments may be conducted over the telephone.
All patients will complete the EORTC QLQ -C30, FKSI19, and EQ -5D-5L questionnaires 
at 3, 6, 9, and 12 months after radiographic disease progression per RECIST v1.1 or 
(forpatients who continue study treatment after radiographic disease progression) loss 
of clinical benefit as determined by the investigator.
Patients who discontinue study treatment for any reason other than progressive disease 
or loss of clinical benefit will complete the questionnaires at the end- of-treatment visit
and then until disease progression when going to the clinic for any study -related 
assessments.

Atezolizumab —F. Hoffmann- La Roche Ltd
86/Protocol WO41994, Version 34.5.9.1 Data Collection Methods for Clinical Outcome A ssessments
Patient -reported outcome instruments will be self -administered at the clinic at specified 
timepoints during the study and survival follow -up(see schedule of activities in
Appendix 1).  At the clinic, instruments will be administered before the patient receives 
any information on disease status, prior to the performance of non -PRO assessments
that may bias patient response s, and prior to the administration of study treatment, 
unless otherwise specified.
Patient -reported outcome instruments, translated into the local language as appropriate, 
will be completed in pre -printed paper booklets provided by the Sponsor.
Patient -reported outcome instruments should be administered as outlined below:
Patients' health status should not be discussed prior to administration of the 
instruments
Sites must administer the official version of each instrument, as provided by the 
Sponsor.  Instruments must not be copied from the protocol.
Sites should allow sufficient time for patients to complete the instruments, estimated 
to be 23minutes at each specified visit
Sites should administer the instruments in a quiet area with minimal distracti ons and 
disruptions
Patients should be instructed to answer questions to the best of their ability; there 
are no right or wrong answers
Site staff should not interpret or explain questions, but may read questions verbatim 
upon request
Patients should not o btain advice or help from others (e.g., family members or 
friends) when completing the instruments
Site staff should review all completed instruments and should ask the patient to 
rectify any response that is not clearly marked in the appropriate location.   If a 
response is missing, site staff should ask the patient to complete the item or confirm 
that the item was intentionally left blank.
4.5.9.2 Description of Clinical Outcome A ssessment Instruments
EORTC QLQ -C30
The EORTC QLQ -C30 is a validated, reliable self-report measure (Aaronson et al. 1993; 
Fitzsimmons etal.1999 ; see Appendix 5).  It consists of 30 questions that assess 
fiveaspects of patient funct ioning (physical, emotional, role, cognitive, and social), 
3symptom scales (fatigue, nausea and vomiting, and pain), GHS/ QoL, and sixsingle 
items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) 
with a recall period of the previous week.  Scale scores can be obtained for the 
multi -item scales.   The functioning and symptoms items are scored on a 4-point scale 
that ranges from " not at all "to "very much, "and the GHS and QoL items are scored on a 
Atezolizumab —F. Hoffmann- La Roche Ltd
87/Protocol WO41994, Version 37-point scale that rang es from "very poor"to "excellent. "  The EORTC QLQ -C30 module 
takes approximately 10 minutes to complete.
Functional A ssessment of Cancer Therapy -Kidney Symptom Index 19
The FKSI -19 is a validated self -report measure ( Rao et al. 2009 ; Rothrock et al. 2013; 
see Appendix 7).  It consists of 19 questions that assess symptoms and Q oL in kidney 
cancer, including these fourdomains: physical disease- related symptoms 
(score range : 048), emotional disease -related symptoms (score range : 04), 
treatment side effects (score range : 012), and function/well -being (score range : 012). 
A total scale score comprising all 19 items can also be deriv ed (score range : 076).
Each item is scored on a 5- point scale with response categories ranging from “not at all” 
to “very much.” Higher scale scores indicate lower symptom burden. The patient’s 
perspective on overall side -effect burden is captured by the GP5 item, where patients 
self-report how bothered they were by their treatment side effects (Pearman et al. 2018). 
This standalone item is a valid summary measure of the overall impact of 
treatment -related toxicities in cancer and complements safety r eporting by clinicians. 
FKSI -19 items can also be rescored to earlier versions of the FKSI, including the 
FKSI -DRS and the FKSI -15. The FKSI- 19 takes approximately 10 minutes to complete .
EQ-5D-5L
The EQ -5D-5L is a validated self-report health status que stionnaire that isused to 
calculate a health status utility score for use in health economic analyses 
(EuroQol Group 1990; Brooks 1996; Herdman et al. 2011; Janssen et al. 2013 ; 
seeAppendix 6).  There are twocomponents to the EQ-5D-5L:  a 5-item health state 
profile that assesses mobility, self -care, usual activities, pain/discomfort, and 
anxiety/depression, as well as a VAS that measures health state.  The EQ -5D-5L is 
designed to capture the patient's current health status.  Published weighting systems 
allow for creation of a single composite score of the patient's health status .  
TheEQ-5D-5L takes approximately 3 minutes to comp lete.  It will be used in this study
forinformingpharmacoeconomic evaluations .
4.5.10 Blood Samples for Whol e-Genome Sequencing or 
Whole -Exome Sequencing (Patients at Participating Sites)
At participating sites, blood samples will be collected for DNA extraction to enable 
whole -genome sequencing ( WGS)or WES to identif y variants that are predictive of 
response to study drug, are associated with progression to a more severe disease state, 
are associated with acquired resistance to study drug, are associated with susceptibility 
to developing adverse events, can lead to improved adverse event monitoring or 
investigation, or can increase the knowledge and understanding of disease biology and 
drug safety.  Research will be aimed at exploring inherited characteristics.  
DNA extracted from blood may be compared with DNA extracted from tissue to identify 
somatic variants by distinguishing germline variants from somatic variants.  The samples 
may be sent to one or more laboratories for analysis .
Atezolizumab —F. Hoffmann- La Roche Ltd
88/Protocol WO41994, Version 3Collection and submission of blood samples for WGS or WES is contingent upon the 
review and approval of the exploratory research by each site's IRB/EC and, if applicable, 
an appropriate regulatory body.  If a site has not been granted approval fo r WGS or 
WES, this section of the protocol (Section 4.5.7 ) will not be applicable at that site.
Genomics is increasingly informing researc her's understanding of disease pathobiology.  
WGS and WES provide a comprehensive characterization of the genome and exome, 
respectively, and, along with clinical data collected in this study, may increase the 
opportunity for developing new therapeutic app roaches or new methods for monitoring 
efficacy and safety or predicting which patients are more likely to respond to a drug or 
develop adverse events.  Data will be analyzed in the context of this study but may also 
be explored in aggregate with data from other studies.  The availability of a larger 
dataset will assist in identification and characterization of important biomarkers and 
pathways to support future drug development.
For sampling procedures, storage conditions, and shipment instructions, see the
laboratory manual.
Blood samples collected for W GS or WES are to be stored until they are no longer 
needed or until they are exhausted.  However, the storage period will be in accordance 
with the IRB/EC -approved Informed Consent Form and applicable laws ( e.g., health 
authority requirements).
SeeSection 4.5.7 for details on use of samples after patient withdrawal, confidentiality 
standards for data, and availability of data from biomarker analyses.
4.5.11 Optional Tumor Biopsies
In addition to collection of baseline tissue, consenting patients will undergo optional 
tumor biopsies at any time after treatment initiatio n and may undergo additional 
on-treatment biopsies at any other time at the investigator's discretion (if deemed 
clinically feasible by the investigator) .  Samples collected via resection, core -needle 
biopsy (at least three cores preferred), or excisional, incisional, punch, or forceps biopsy 
are preferred.
The Informed Consent Form will contain a separate section that addresses optional 
biopsie s.  A separate, specific signature will be required to document a patient's 
agreement to undergo optional biopsies.  The investigator should document whether or 
not the patient has given consent to participate and (if applicable) the date(s) of consent, 
bycompleting the Optional Biopsy Sample Informed Consent eCRF.
Consenting patients may undergo additional on -treatment biopsies at any time at the 
investigator’s discretion (if deemed clinically feasible by the investigator). 
Biopsies collected at the inve stigator’s discretion are preferred at the time of clinical 
events (e.g., clinical response ).  Optional in-treatment biopsies collected from easily 
Atezolizumab —F. Hoffmann- La Roche Ltd
89/Protocol WO41994, Version 3accessible tumor lesions requiring a minimally invasive approach (skin punch biopsy, 
percutaneous lymph node or liver biopsy) will require study treatment interruption 
48hours prior to collection. Study treatment should not be resumed until a minimum of 
7 days after the in-treatment biopsy, the decision to resume study treatment should be 
based on clinical jud gment of complete wound healing. Biopsies from lesions which 
require major surgery or are deemed not easily accessible and put a patient at an 
unacceptable risk from the procedure are not permitted. Tumor tissue from bone lesions 
is not acceptable unless taken from a soft -tissue component of the bone lesion .
Samples may be used for exploratory biomarker research as described in Section 4.5.7 .  
For sampling procedures, storage conditions, and shipment instructions, see the 
laboratory manual.  SeeSection 4.5.7 for details on duration of sample storage, use of 
samples after patient withdrawal, confidentiality standards for data, and availability of 
data from biomarker analyses.
4.5.12 Optional Samples for R esearch Biosample Repository
4.5.12.1 Overview  of the Research Biosample Repository
The Research Biosample Repository (RBR) is a centrally administered group of facilities 
used for the long- term storage of human biological specimens, including body fluids, 
solid ti ssues, and derivatives thereof (e.g., DNA, RNA, proteins, peptides).  
Thecollection, storage, and analysis of RBR samples will facilitate the rational design of 
new pharmaceutical agents and the development of diagnostic tests, which may allow 
for individ ualized drug therapy for patients in the future.
Samples for the RBR will be collected from patients who give specific consent to 
participate in this optional research.  Research Biosample Repository samples will be 
analyzed to achieve one or more of the f ollowing objectives:
To study the association of biomarkers with efficacy or disease progression
To identify safety biomarkers that are associated with susceptibility to developing 
adverse events or can lead to improved adverse event monitoring or investig ation
To increase knowledge and understanding of disease biology and drug safety
To study drug response, including drug effects and the processes of drug absorption 
and disposition
To develop biomarker or diagnostic assays and establish the performance 
characteristics of these assays
4.5.12.2 Approval by the Institutional Review  Board or Ethics 
Committee
Collection, storage, and analysis of RBR samples is contingent upon the review and 
approval of the exploratory research and the RBR portion of the Informed Cons ent Form 
by each site's IRB/EC and, if applicable, an appropriate regulatory body.  If a site has not 
been granted approval for RBR sampling, this section of the protocol ( Section 4.5.7 ) will 
not be applicable at that site.
Atezolizumab —F. Hoffmann- La Roche Ltd
90/Protocol WO41994, Version 34.5.12.3 Sample Collection
The following samples will be stored in the RBR and used for research purposes, 
including, but not limited to, research on biomarkers related to atezo lizumab, 
cabozantinib, diseases, or drug safety:
Blood and urine samples collected predose on Day 1 of Cycle 1 and anytime 
thereafter
Leftover blood, serum, plasma, PBMC, urine, and tumor tissue samples (with the 
exception of remaining archival tissue blocks, which will be returned to sites) and 
any derivatives thereof (e.g., DNA, RNA, proteins, peptides ), including leftover 
tissue samples from medically indicated procedures 
(e.g., bronchoscopy, esophagogastroduodenoscopy, colonoscopy) performed at the 
investigator's discretion during the course of the study
The above samples may be sent to one or more laboratories for analysis of germline or 
somatic variants via W GS, W ES, or other genomic analysis methods . Genomics is 
increasingly informing researcher's understanding of disease pathobiology.  
Whole-genome sequencing and WES provide a comprehensive characterization of the 
genome and exome, respectively, and, along with clinical data collected in this study, 
may increase the opportunity for developing new therapeutic approaches or new 
methods for monitoring efficacy and safety or predicting which patients are more likely to 
respond to a drug or develop adverse events.
Data generated from RBR samples will be an alyzed in the context of this study but may
also be explored in aggregate with data from other studies.  The availability of a larger 
dataset will assist in identification and characterization of important biomarkers and 
pathways to support future drug dev elopment.
For sampling procedures, storage conditions, and shipment instructions, see the 
laboratory manual.
Research Biosample Repository samples are to be stored until they are no longer 
needed or until they are exhausted.  However, the RBR storage perio d will be in 
accordance with the IRB/EC -approved Informed Consent Form and applicable laws 
(e.g., health authority requirements).
4.5.12.4 Confidentiality
Research Biosample Repository samples and associated data will be labeled with a 
unique patient identification number.
Patient medical information associated with RBR samples is confidential and may be 
disclosed to third parties only as permitted by the Informed Consent Form (or separate 
authorization for use and disclosure of personal health information) signed b y the patient, 
unless permitted or required by law.
Atezolizumab —F. Hoffmann- La Roche Ltd
91/Protocol WO41994, Version 3Given the complexity and exploratory nature of the analyses of RBR samples , data 
derived from these analyses will generally not be provided to study investigators or 
patients unless required by law.  The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy on study data publication.
Data generated from RBR samples must be available for inspection upon request by 
representatives of national and local health authorities, and Sponsor monitors, 
representatives, and collaborators, as appropriate.
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of the RBR data will become and remain the exclusive and unburdened property 
of the Sponsor, except where agreed otherwise.
4.5.12.5 Consent to Participate in the Research Biosample Repository
The Informed Consent Form will contain a sepa rate section that addresses participation 
in the RBR.  The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential hazards of participation in the RBR.  Patients will be 
told that they are free to refuse to p articipate and may withdraw their consent at any time 
and for any reason during the storage period.  A separate, specific signature will be 
required to document a patient's agreement to provide optional RBR samples .  
Patients who decline to participate wil l not provide a separate signature.
The investigator should document whether or not the patient has given consent to 
participate and (if applicable) the date(s) of consent, by completing the RBR Research 
Sample Informed Consent eCRF.
In the event of an RBR participant's death or loss of competence, the participant's 
samples and data will continue to be used as part of the RBR research.
4.5.12.6 Withdrawal from the Research Biosample Repository
Patients who give consent to provide RBR samples have the right to withdr aw their 
consent at any time for any reason.  After withdrawal of consent, any remaining samples 
will be destroyed or will no longer be linked to the patient.  However, if RBR samples 
have been tested prior to withdrawal of consent, results from those test s will remain as 
part of the overall research data.  If a patient wishes to withdraw consent to the testing of 
his or her RBR samples during the study, the investigator must inform the 
Medical Monitor in writing of the patient's wishes through use of the appropriate RBR 
Subject W ithdrawal Form and must enter the date of withdrawal on the RBR Research 
Sample W ithdrawal of Informed Consent eCRF.  If a patient wishes to withdraw consent 
to the testing of his or her RBR samples after closure of the site, the in vestigator must 
inform the Sponsor by emailing the study number and patient number to the following 
e-mail address:
global_rcr -withdrawal@roche.com
Atezolizumab —F. Hoffmann- La Roche Ltd
92/Protocol WO41994, Version 3A patient's withdrawal from this study does not, by itself, constitute withdrawal of consent 
for testing of RBR samples.  Likewise, a patient's withdrawal of consent for testing of 
RBR samples does not constitute withdrawal from this study.
4.5.12.7 Monitoring and Oversight
Research Biosample Repository samples will be tracked in a manner consistent with 
Good Clinical Practice by a quality -controlled, auditable, and appropriately validated 
laboratory information management system, to ensure compliance with data 
confidentiality as well as adherence to authorized u se of samples as specified in this 
protocol and in the Informed Consent Form.  Sponsor monitors and auditors will have 
direct access to appropriate parts of records relating to patient participation in the RBR 
for the purposes of verifying the data provided to the Sponsor.  The site will permit 
monitoring, audits, IRB/EC review, and health authority inspections by providing direct 
access to source data and documents related to the RBR samples.
4.6 TREA TMENT, PATIENT, STUDY, AND SITE DISC ONTINUA TION
4.6.1 Study Treatment Discontinuation
Patients in th e experimental arm ( atezolizumab in combination with cabozantinib ) are 
allowed to discontinue onecomponent of the study treatment but continue to receive the 
other component as described in Section 5.1.3 for management of adverse events .
Patients must permanently discontinue study treatment if they experience any of the 
following:
Intolerable toxicity related to study treatment , including development of an 
immune -mediated adverse event determined by the investigator to be unacceptable 
given the individual patient's potential response to therapy and severity of the event
Any medical condition that may jeopardize the patient's safety if he or she continues 
study treatment
Investigator or Sponsor determination that treatment discontinuation is in the best 
interest of the patient
Use of another non -protocol anti -cancer therapy
Pregnancy
Disease progression per RECIST v1.1. or loss of clinical benefit as determined by 
the investigator after an integrated assessment of radiographic and biochemical 
data, local biopsy results (if available), and clinical status (e.g., symptomatic 
deterioration such as pain secondary to dise ase; see Section 3.1for details)
The primary reason for study treatment discontinuation should be documented on the 
appropriate eCRF.   Patients who discontinue study treatment prematurely will not be 
replaced.
Atezolizumab —F. Hoffmann- La Roche Ltd
93/Protocol WO41994, Version 3Patients will return to the clinic for a treatment discontinuation visit 30days after the 
final dose of study treatment .  The visit at which response assessment shows 
progressive disease may be used as the treatment discontinuation visit.
Patients may choose to withdraw from treatment, thestudy ,or both. Patients who 
withdraw from treatment are encourage dto continue survival follow -up to gather data 
which is valuable to the study.
4.6.2 Patient D iscontinuation from the Study
Patients have the right to voluntarily withdraw from the study at any time for any reason.  
In addition, the investigator has the right to withdraw a patient from the study at any time.
Reasons for patient discontinuation from the study may include, but are not limited to, 
the following:
Patient withdrawal of consent
Study termination or site closure
Adverse event
Loss to follow -up
Patient non -compliance, defined as failure to comply with protocol requirements as 
determined by the investigator or Sponsor
Every effort should be made to obtain a reason for patient discontinuation from the study .  
The primary reason for discontinuation from the study should be documented on the 
appropriate eCRF.  If a patient requests to be withdrawn from the study, this request 
must be documented in the source documents and signed by the investigator.  
Patients who withdraw from the study will not be replaced.
If a patient withdraws from the study, the study staff may use a public informatio n source 
(e.g., county records) to obtain in formation about survival status .
4.6.3 Study Discontinuation
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include, but are not limited to, the following:
The inc idence or severity of adverse events in this or other studies indicates a 
potential health hazard to patients
Patient enrollment is unsatisfactory
The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.
Atezolizumab —F. Hoffmann- La Roche Ltd
94/Protocol WO41994, Version 34.6.4 Site Discontinuati on
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include, but are not limited to, the following:
Excessively slow recruitment
Poor protocol adherence
Inaccurate or incomplete data recording
Non-compliance with the International Council for Harmonisation (ICH) guideline for 
Good Clinical Practice
No study activity (i.e., all patients have completed the study and all obligations have 
been fulfilled)
5. ASSESSMENT OF SA FETY
5.1 SAFETY PLA N
The safety plan for patients in this study is based on clinical experience with 
atezolizumab and cabozantinib in completed and ongoing studies.  The anticipated 
important safety risks are outlined below (see Section 5.1.1 and Section 5.1.2 ).
Measures will be taken to ensure the safety of patients participatin g in this study, 
including the use of stringent inclusion and exclusion criteria and close monitoring of 
patients during the study as indicated below .  Administration of atezolizumab and the 
first dose of cabozantinib will be performed in a monitored setti ng in which there is 
immediate access to trained p ersonnel and adequate equipment and medicine to 
manage potentially serious reactions. Subsequent doses of cabozantinib w ill be 
self-administered at home (Section 4.3.2.2 ).Guidelines for managing patients who 
experience anticipated adverse events, including criteria for dosage modification and 
treatment interruption or discontinuation, are provided in Appendix 10for atezolizumab 
and Appendix 11for ca bozantinib .  See Sections 5.25.7for details on safety reporting 
(e.g., adverse events, pregnancies) for this study .
Patients with active infection are excluded from study participation.  In the setting of a 
pandemic or epidemic, screening for active infections (including SARS -CoV -2) prior to 
and during study participation should be considered according t o local or institutional 
guidelines or guidelines of applicable professional societies (e.g., American Society of 
Clinical Oncology or European Society for Medical Oncology ).
Severe COVID -19 appears to be associated with a CRS involving the inflammatory 
cytokines IL -6, IL -10, IL -2, and IFN -(Merad and Martin 2020).  If a patient develops 
suspected CRS during the study, a differential diagnosis should include COVID -19, 
which should be confirmed or refuted through assessment of exposure history, 
appropriate laboratory testing, and clinical or radiologic evaluations per investigator 
judgment.  If a diagnosis of COVID -19 is confirmed, the disease should be managed as 
per local or institutional guidelines.
Atezolizumab —F. Hoffmann- La Roche Ltd
95/Protocol WO41994, Version 35.1.1 Risks A ssociated with A tezolizumab
Atezolizumab has been associated with risks such as the following:  IRRs and 
immune -mediated hepatitis, pneumonitis, colitis, pancreatitis, diabetes mellitus, 
hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, 
Guillain -Barré syndrome, myasthenic syndrome or myasthenia gravis, 
meningoencephalitis, myocarditis, nephritis, myositis , and severe cutaneous adverse 
reactions .  Immune -mediated reactions may involve any organ system and may lead to 
hemophagocytic lymphohistiocytosis and macrophage activation syndrome .  
SeeAppendix 10of the protocol and Section 6 .4.1of the Atezolizumab 
Investigator's Brochure for a detailed description of anticipated safety risks for
atezolizumab.
5.1.2 Risks A ssociated with Cabozantinib
Cabozantinib has been associated with risks such as the following: GI disorders, non -GI 
fistula formation, hemorrhage, thromboembolic events, hypertension, stomatitis and 
mucositis, skin disorders, osteone crosis, proteinuria, nervous system disorders, 
hepatocellular toxicity, infections and infestations, blood system disorders, fatigue, 
weight loss, QTc prolongation, electrolyte disorders, endocrine disorders, and respiratory 
disorders. SeeAppendix 11of the protocol and the C abozantinib
Investigator's Brochure for a detailed description of anticipated safety risks for 
cabozantinib .
5.1.3 Management of Patients who Experience A dverse E vents and 
Potential Overlapping Toxicities
Atezolizumab and cabozantinib have molecule- specific safety profiles based on their 
mechanism of action and adverse events that may also overlap .  These include, but are 
not limited to, hepa totoxic, endocrine, GI, dermatologic, neurologic, renal, and 
pulmonary events, as well as signs and symptoms such as fatigue and, decreased 
appetite that may be related to multiple system organ class events. The attribution of 
each drug in certain adverse events may be uncertain when the products are 
administered as combination treatment and warrant diagnostic work up. For the 
management of such potentially overlapping adverse events in patients treated with 
atezolizumab in combination with cabozantinib, adverse events should be managed 
according to the recommendations in Appendix 10(atezolizumab), and 
Appendix 11(cabozantinib) and applied to the component of the study t reatment judged 
to be the primary cause. If individual component causality for adverse events cannot be 
determined, conservative management should be followed to include dose 
modification/interruption of both agents.
Atezolizumab —F. Hoffmann- La Roche Ltd
96/Protocol WO41994, Version 3Table 7 Guidance for Managing Overlapping Toxicities
Toxicity Atezolizumab Cabozantinib
Pulm onary events Appendix 10, Table 1 Appendix 11, Respirator y 
Disorders
Hepatic events Appendix 10, Table 2 Appendix 11, Table 5
Gastrointestinal events Appendix 10, Table 3 Appendix 11, Table 1
Endocrine events Appendix 10, Table 4 Appendix 11, Endocrine 
Disorders
Dermatologic events Appendix 10, Table 9 Appendix 11, Table 3
Neurologic events Appendix 10, Table 10 Appendix 11, Nervous System 
Disorders
Renal events Appendix 10, Table 12 Appendix 11, Table 4
5.1.3.1 Dose Modification
Atezolizumab
There will be no dose reductions for atezolizumab in this study .For dose interruptions of 
atezolizumab seeSection 5.1.3.2 and Appendix 10.
Cabozantinib
Dose modifications for cabozantinib are as follows:
Twodose reduction levels of cabozantinib ( 40 mg QDand 20 mg QD) are permitted 
(see Table 8 )
Dose modification c riteria for treatment -related adverse event s of cabozantinib are 
shown inTable 9
Dose reinstitution and re -escalation after dose interruptions and/or reductions:
If the patient recovers from his or her toxicities to Grade 1 per 
NCICTCAE v5.0 or to the base line value (or lower) and the adverse event was 
unrelated to cabozantinib, then cabozantinib may be restarted with no change 
in dose.
If the patient recovers from his or her toxicities to Grade 1 or to the baseline 
value (or lower) and the adverse event was deemed possibly related to 
cabozantinib , then cabozantinib may be restarted at a reduced dose 
(see Table 9 ). Patients who initiated treatment with cabozantinib at 60mg and 
experience a possibly related adverse event of Grade 1 or 2 severity may be 
restarted with no dose change after recovery of the toxicities to Grade 1 or to 
the baseline value (or lower) if appropriate supportive care can preven t or 
minimize the risk of the adverse event .
Atezolizumab —F. Hoffmann- La Roche Ltd
97/Protocol WO41994, Version 3Patients receiving a dose of 20 mg QDwho have cabozantinib interrupted may 
be restarted at the same dose if deemed safe at the discretion of the 
investigator. Patients unable to tolerate a dose of 20 mg QDmust discontinue 
cabozantinib.
Re-escalation to the previous dose may be allowed at the discretion of the 
investigator but no sooner than 2 w eeks beyond resolution of adverse event s 
that led to the dose reduction, which have resolved o r recovered to Grade 1 
(orbaseline value) and deemed tolerable and easily managed by optimized 
supportive treatment. Dose re -escalation is not allowed following a 
cabozantinib -related dose reduction for Grade 4 hematologic toxicities or 
Grade 4adverse event s affecting major organs (e .g., CNS, cardiac, hepa tic, 
renal, pulmonary, GI).
Table 8Dose Reduction Levels forCabozantinib (Oral Dosing)
Assigned Starting DoseFirst Dose Level 
Reduction Second Dose Level Reduction
60 mg QD 40 mg QD 20mg QD a
QDonce a day .
aCabozantinib will be discontinued if a dose of 20 -mg QD of cabozantinib is not tolerated.
Atezolizumab —F. Hoffmann- La Roche Ltd
98/Protocol WO41994, Version 3Table 9Dose Modificat ions for Cabozantinib -Related A dverse Event s
Grade per NCI CTCA E v5 Recommended Guidelines for Management a
Grade 1 AEs Add supportive care as indicated. Continue cabozantinib 
at the current dose level if AE is manageable and 
tolerable.
Grade 2 AEs which are tolerable 
and are easily managed
Grade 2 AEs which are intolerable
andcannot be adequately 
managedContinue cabozantinib at the current dose level with 
supportive care.
Cabozantinib should be dose reduced or interruptedb
Note: It is recommended that dose interruptions be as 
brief as possible.
Grade 3 AEs
(except clinically non -relevant 
laborator y abnormalities)Cabozantinib should be interrupted unless the toxicity can 
be easily managed with a dose reduction of cabozantinib 
and optimal medical careb
Note: It is recommended that dose interruptions be as 
brief as possible.
Grade 4 AEs
(except clinically non -relevant 
laborator y abnormalities)Cabozantinib must be interrupted immediately .
In general, cabozantinib should be discontinued unless 
the following criteria are met:
Patient is deriving clear clinical benefit as determined 
by the investiga tor and agreed by the Sponsor
Toxicity can be managed with a dose reduction of 
cabozantinib following recovery to Grade 1 
(orbaseline) and optimal medical care
Sponsor must be contacted to discuss treatment 
continuation upon resolution of AEs.
AEadve rse event; NCI CTCAE National Cancer Institute Common Terminology Criteria for 
Adverse Events ; QDonce a day .
aCabozantinib will be discontinued if a dose of 20 -mg QD of cabozantinib is not tolerated.
bCabozantinib must be interrupted until the adverse event resolves to Grade 1.
Note: In exceptional cases, treatment with cabozantinib may  be continued at a reduced dose 
(without interruption) if, according to the investigator’s judg ment, the toxicity can be easily 
managed with a dose reduction of cabozantinib and optimal medical care.
For guidelines on dose modifications to manage specific adverse events associated
cabozantinib treatment, see Appendix 11.
5.1.3.2 Treatment Interruption
Dose interruptions of study treatment may occur at any time and independ ently at the 
discretion of the i nvestigator for management of adverse events . If either or both study 
treatments in the experimental arm (atezolizumab in combination with cabozantinib ) are 
interrupted more than 12 weeks, the Sponsor should be contacted to discuss potential 
treatment continuation.
Atezolizumab —F. Hoffmann- La Roche Ltd
99/Protocol WO41994, Version 3Patients in the experimental arm will be allowed to discontinue onecomponent of the 
study treatment but continue to receive the other; the investigator is encouraged to 
discuss such circumstances with the Sponsor.
Atezolizumab treatment may be temporarily suspended in patients who experience 
toxicity considered to be related to study treatment .  If corticosteroids are initiated for 
treatment of the toxicity, they must be tapered over 1 month to the equivalent of 
10mg/day oral prednisone before atezolizumab can b e resumed.  If atezolizumab is 
withheld for 12weeks after event onset, the patient will be discontinued from 
atezolizumab.  However , atezolizumab may be withheld for 12 weeks to allow for 
patients to taper off corticosteroids prior to resuming treatment.  Atezolizumab can be 
resumed after being withheld for 12 weeks if the Medical Monitor agrees that the 
patient is likely to deriv e clinical benefit.
For guidelines on treatment interrupt ion to manage specific adverse events associated
with atezolizumab and cabozantinib ,seeAppendix 10foratezolizumab and Appendix 11
for cabozantinib.
Dose interruptions for reasons other than toxicity (e.g., surgical procedures) may be 
allowed with Medical Monitor approval.  The investigator and the Medical Monitor will 
determine the acceptable length of treatment interruption.
5.2 SAFETY PA RAMETERS A ND DEFINITIONS
Safety assessments will consist of monitoring and recording adverse events, including 
serious adverse events and adverse events of special interest ,performing 
proto col-specified safety laboratory assessments ,measuring protocol -specified vital 
signs ,and conducting other protocol -specified tests that are deemed critical to the safety 
evaluation of the study.
Certain types of events require immediate reporting to the Sponsor, as outlined in 
Section 5.4.
5.2.1 Adverse Events
According to the ICH guideline for Good Clinical Practice, an adverse event is any 
untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product, regardless of causal attribution.  An adverse event can ;
therefore ,be any of the following:
Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal pro duct, 
whether or not considered related to the medicinal product
Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition ; see Sections 5.3.5.9
and5.3.5.10 for more information)
Atezolizumab —F. Hoffmann- La Roche Ltd
100/Protocol WO41994, Version 3Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline
Any deterioration in a laboratory value or other clinical test (e.g., ECG, X -ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study treatme nt
Adverse events that are related to a protocol -mandated intervention, including those 
that occur prior to assignment of study treatment (e.g., screening invasive 
procedures such as biopsies)
5.2.2 Serious A dverse Events (Immediately  Reportable to the 
Sponsor)
A serious adverse event is any adverse event that meets any of the following criteria:
Is fatal (i.e., the adverse event actually causes or leads to death)
Is life -threatening (i.e., the adverse event, in the view of the investigator, places the 
patient a t immediate risk of death)
This does not include any adverse event that ,had it occurred in a more severe 
form or was allowed to continue, might have caused death.
Requires or prolongs inpatient hospitalization (see Section 5.3.5.11 )
Results in persistent or significant disability/incapacity (i.e., the adverse event 
results in substantial disruption of the patient's ability to conduct normal life 
functi ons)
Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to 
study treatment
Is a significant medical event in the investigator's judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the outcomes 
listed above)
The terms "severe "and "serious "are notsynonymous.  Severity refers to the intensity of 
an adverse event ( e.g., rated as mild, moderate, or severe, or acco rding to 
NCICTCAE v5.0; see Section 5.3.3 ); the event itself may be of relatively minor medical 
significance (such as severe headache without any further findings).
Severity and serious ness need to be independently assessed for each adverse event 
recorded on the eCRF.
Serious adverse events are required to be reported by the investigator to the Sponsor 
immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for 
reporting instructions).
Atezolizumab —F. Hoffmann- La Roche Ltd
101/Protocol WO41994, Version 35.2.3 Adverse Events of Special Interest (Immediately  Reportable to 
the Sponsor)
Adverse events of special interest are require d to be reported by the investigator to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; 
seeSection 5.4.2 for reportin g instructions).  Adverse events of special interest for this 
study are as follows :
Cases of potential drug- induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by 
Hy's Law (see Section 5.3.5.7 )
Suspected transmission of an infectious agent by the study treatment, as defined 
below
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non -pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical s ymptoms or laboratory findings that indicate an 
infection in a patient exposed to a medicinal product.  This term applies only
when a contamination of study treatment is suspected.
Systemic lupus erythematosus
Events suggestive of hypersensitivity, IRRs, C RS, hemophagocytic 
lymphohistiocytosis , and macrophage activation syndrome
Nephritis
Ocular toxicities (e.g., uveitis, retinitis, optic neuritis)
Grade 2 cardiac disorders (e.g., atrial fibrillation, myocarditis, pericarditis)
Vasculitis
Autoimmune hemolytic anemia
Severe cutaneous reactions (e.g., Stevens -Johnson syndrome, dermatitis bullous, 
toxic epidermal necrolysis)
5.3 METHODS A ND TIMING F OR CA PTURING A ND ASSESSING 
SAFETY PARAMETERS
The investigator is responsible for ensuring that all adverse eve nts (see Sectio n5.2.1 for 
definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in 
accordance with instructions provided in this section and in Sections 5.45.6.
For each adverse event recorded on the Adverse Event eCRF, the investigator will 
assess seriousness (see Section 5.2.2 for seriousness criteria), severity 
(see Section 5.3.3 ), and causality (see Section 5.3.4 ).
Atezolizumab —F. Hoffmann- La Roche Ltd
102/Protocol WO41994, Version 35.3.1 Adverse Event Reporting Period
Investigators will seek information on adverse events at each patient contact.  
Alladverse events, whether reported by the patient or noted by study personnel, will be 
recorded in the patient's medical record and on the Adverse Event eCRF.
After informed consent has been obtained but prior to initiation of study treatment , only 
serious a dverse events caused by a protocol -mandated intervention (e.g., invasive 
procedures such as biopsies, discontinuation of medications) should be reported 
(see Section 5.4.2 for instructions for reporting serious adverse events).
After initiation of study treatment , alladverse events will be reported until 30daysafter 
the final dose of study treatment or until initiation of new systemic anti-cancer therapy, 
whichever occurs first, and serious adverse events and adverse events of special 
interest will continue to be reported until 90days after the final dose of study treatment
or until initiation of new systemic anti-cancer therapy, which ever occurs first.
Instructions for reporting adverse events that occur after the adverse event reporting 
period are provided in Section 5.6.
5.3.2 Eliciting A dverse Ev ent Information
A consistent methodology of non -directive questioning should be adopted for eliciting 
adverse event information at all patient evaluation timepoints.  Examples of non -directive 
questions include the following:
"How have you felt since your last clinic visit?"
"Have you had any new or changed health problems since you were last here?"
5.3.3 Assessment of Severity  of A dverse Events
The adverse event severity g rading scale for the NCI CTCAE v5.0 will be used for 
assessi ng adverse event severity.  Table 10will be used for assessing severity for 
adverse events that are not specifically listed in the NCI CTCAE v5.0.
Atezolizumab —F. Hoffmann- La Roche Ltd
103/Protocol WO41994, Version 3Table 10Adverse Event Severity Grading Scale for Events Not Specifically  
Listed in NCI CTCA E
Grade Severity
1 Mild; as ymptomatic or mild sy mptoms; clinical or diagnostic observations only; 
or intervention not indicated
2 Moderate; minimal, local, or non -invasive intervention indicated; or limiting 
age-appropriate instrumental activities of daily livinga
3 Severe or medically significant, but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indic ated; disabling; or 
limiting self-care activities of daily livingb,c
4 Life-threatening consequences or urgent intervention indicatedd
5 Death related to adverse eventd
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events .
Note:  Based on the most recent version of NCI CTCAE (v 5.0), which can be found at:   
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
aInstrumental activities of daily living refer to preparing meals, shopping for grocer ies or 
clothes, using the telephone, managing money, etc.
bExamples of self -care activities of daily living include bathing, dressing and undressing, 
feeding oneself, using the toilet, and taking medications, as performed by patients who are 
not bedridden.
cIf an event is assessed as a "significant medical event," it must be reported as a serious 
adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious 
adverse event in Section 5.2.2 .
dGrade 4 and 5 events must be reported as serious adverse events (see S ection 5.4.2 for 
reporting instructions), per the definition of serious adverse event in Section 5.2.2 .
5.3.4 Assessment of Causality  of Adverse Events
Investigators should use their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether an
adverse event is considered to be related to study treatment , indicating "yes"or "no"
accordingly.  The following guidance should be taken into consideration (see also
Table 11):
Temporal relationship of event onset to the initiation of study treatment
Course of the event, with special consideration of the effects of dose reduction, 
discontinuation of study treatment , or rei ntroduction of study treatment
(asapplicable)
Known association of the event with study treatment or with similar treatments
Known association of the event with the disease under study
Presence of risk factors in the patient or use of concomitant medicati ons known to 
increase the occurrence of the event
Presence of non -treatment -related factors that are known to be associated with the 
occurrence of the event
Atezolizumab —F. Hoffmann- La Roche Ltd
104/Protocol WO41994, Version 3Table 11Causal A ttribution Guidance
Is the adverse event suspected to be caused by study  treatment on the basis of facts, 
evidence, science -based rationales, and clinical judgment?
YES There is a plausible temporal relationship between the onset of the adverse event and 
administration of st udy treatment , and the adverse event cannot be readily explained by 
the patient's clinical state, intercurrent illness, or concomitant therapies; and/or the 
adverse event follows a known pattern of response to study treatment ; and/or the 
adverse event abates or resolves upon discontinuation of study treatment or dose 
reduction and, if applicable, reappears upon re -challenge.
NO An adverse event will be considered related, unless it fulfills the criteria specified below .  
Evidence exists that the adverse e vent has an etiology other than study  treatment
(e.g., preexisting medical condition, underlying disease, intercurrent illness, 
orconcomitant medication); and/or the adverse event has no plausible temporal 
relationship to administration of study treatment (e.g., cancer diagnosed 2 days after 
firstdose of study treatment ).
For patients receiving combination therapy, causality will be assessed individually for 
each protocol -mandated therapy.
5.3.5 Procedures for Recording A dverse Events
Investigators should use correct medical terminology/concepts when recording adverse 
events on the Adverse Event eCRF.  Avoid colloquialisms and abbreviations.
Only 1adverse event term should be recorded in the event field on the 
Adverse Event eCRF.
5.3.5.1 Infusion -Related Reactions
Adverse events that occur during or within 24 hours after study treatment administration 
and are judged to be related to study treatment infusion should be captured as a 
diagnosis (e.g., "infusion -related reaction") on the Adverse Event eCRF.  If possible,
avoid ambiguous terms such as "systemic reaction."  Associated signs and symptoms 
should be recorded on the dedicated Infusion -Related Reaction eCRF.  If a patient 
experiences both a local and systemic reaction to the same dose of study treatment , 
each re action should be recorded separately on the Adverse Event eCRF, with signs 
and symptoms also recorded separately on the dedicated 
Infusion -Related Reaction eCRF.
5.3.5.2 Diagnosis versus Signs and Sy mptoms
A diagnosis (if known) should be recorded on the Adverse Event eCRF rather than 
individual signs and symptoms (e.g., record only liver failure or hepatitis rather than 
jaundice, asterixis, and elevated transaminases).  However, if a constellation of signs 
and/or symptoms cannot be medically characterized as a sin gle diagnosis or syndrome 
at the time of reporting, each individual event should be recorded on the 
Atezolizumab —F. Hoffmann- La Roche Ltd
105/Protocol WO41994, Version 3Adverse Event eCRF.  If a diagnosis is subsequently established, all previously reported 
adverse events based on signs and symptoms should be nullified and replaced by 
1adverse event report based on the single diagnosis, with a starting date that 
corresponds to the starting date of the first symptom of the eventual diagnosis.
5.3.5.3 Adverse Events that a reSecondary  to Other Events
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by their primary cause, with the exception of 
severe or serious secondary events.  A medically significant secondary adverse event 
that is separated in time from the initiating event should be recorded as an independent 
event on the Adverse Event eCRF.  For example:
If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF
If vomiting resul ts in severe dehydration, both events should be reported separately 
on the eCRF
If a severe GIhemorrhage leads to renal failure, both events should be reported 
separately on the eCRF
If dizziness leads to a fall and consequent fracture, all 3events shoul d be reported 
separately on the eCRF
If neutropenia is accompanied by a ninfection, both events should be reported 
separately on the eCRF
All adverse events should be recorded separately on the Adverse Event eCRF if it is 
unclear as to whether the events are associated.
5.3.5.4 Persistent or Recurrent A dverse Events
A persistent adverse event is one that extends continuously, without resolution, between 
patient evaluation timepoints.  Such events should only be recorded once on the 
Adverse Event eCRF.  The initial severity (intensity or grade) of the event will be 
recorded at the time the event is first reported.  If a persistent adverse event becomes 
more severe, the most extreme severity should also be recorded on the 
Adverse Event eCRF.  If the event becomes serious, it should be reported to the 
Sponsor immediately (i.e., no more than 24 hours after learning that the event became 
serious; see Section 5.4.2 for reporting instructions).  The Adverse Event eCRF should 
be updated by changing the event from "non -serious" to "serious," providing the date 
that the event became serious, and completing all data fields related to serious adverse 
events.
A recurrent ad verse event is one that resolves between patient evaluation timepoints 
and subsequently recurs.  Each recurrence of an adverse event should be recorded as a 
separate event on the Adverse Event eCRF.
Atezolizumab —F. Hoffmann- La Roche Ltd
106/Protocol WO41994, Version 35.3.5.5 Abnormal Laboratory Values
Not every laboratory abnormali ty qualifies as an adverse event.  A laboratory test result 
must be reported as an adverse event if it meets any of the following criteria:
Is accompanied by clinical symptoms
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy
Is clinically significant in the investigator's judgment 
Note:  For oncology trials, certain ab normal values may not qualify as adverse 
events.
It is the investigator's responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an adverse event.
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., ALP and bilirubin 5 ULN associated with chole stasis ), only the diagnosis 
(i.e., chole stasis ) should be recorded on the Adverse Event eCRF.
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descriptor indicating whether the test result is above or below the normal range 
(e.g.,"elevated potassium, "as opposed to "abnormal potassium ").  If the laboratory 
abnormality can be characterized by a precise clinical term per standard definitions, the 
clinical term should be recorded as the adverse event.  For example, an elevated se rum 
potassium level of 7.0 mEq/L should be recorded as "hyperkalemia. "
Observations of the same clinically significant laboratory abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section 5.3.5.4 for 
details on recording persistent adverse events).
5.3.5.6 Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must
be reported as an adverse event if it meets any of the following criteria:
Is accompanied by clinical symptoms
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Results in a medical intervention or a change in concomitant therapy
Is clinically significant in the investigator's judgment
Atezolizumab —F. Hoffmann- La Roche Ltd
107/Protocol WO41994, Version 3It is the investigator's responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an adverse event.
If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g., high BP), only the diagnosis (i.e., hypertension) should be recorded on the 
Adverse Even t eCRF.
Observations of the same clinically significant vital sign abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section 5.3.5.4 for 
details on recording persistent adverse events).
5.3.5.7 Abnormal Liver Function Tests
The finding of an elevated ALT or AST ( 3ULN) in combination with either an elevated 
total bilirubin ( 2ULN) or clinical jaundice in the absence of cholestasis or other 
causes of hyperbilirubinemia is considered to be an indicator of severe liver injury 
(asdefined by Hy's Law).  Therefore, investigators must report as an adverse event the 
occurrence of either of the following:
Treatment -emergent ALT or AST 3ULN in combination with total bilirubin 
2ULN
Treatment -emergent ALT or AST 3ULN in combination with clinical jaundice
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see Section 5.3.5.2) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learnin g of 
the event), either as a serious adverse event or an adverse event of special interest 
(see Section 5.4.2 ).
5.3.5.8 Deaths
For this protocol, mortality is an efficacy endpoint.  Deaths that occur during the 
protocol -specified adverse event reporting period (see Section 5.3.1 ) that are attributed 
by the investigator solely to progression of RCC should be recorded on the Death 
Attributed to Progressive Disease eCRF.  All other deaths that occur during t he adverse 
event reporting period , regardless of relationship to study treatment , must be recorded 
on the Adverse Event eCRF and immediately reported to the Sponsor 
(see Section 5.4.2 ).An independent monitoring committee will monitor the frequency of 
deaths from all causes .
Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only 1such event should be reported.  
If the cause of death is unknown and cannot be ascertained at the time of reporting, 
"unexpla ined death "should be recorded on the Adverse Event eCRF.  If the cause of 
death later becomes available (e.g., after autopsy), "unexplained death "should be 
Atezolizumab —F. Hoffmann- La Roche Ltd
108/Protocol WO41994, Version 3replaced by the established cause of death.   The term "sudden death" should not be 
used unless com bined with the presumed cause of death (e.g., "sudden cardiac death").
Deaths that occur after the adverse event reporting period should be reported as 
described in Section 5.6.
5.3.5.9 Preexisting Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study.  
Such conditions should be recorded on the General Medical History and Baseline 
Conditions eCRF.
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of the condition worsens during the study.  
Whenrecording such events on the Adverse Event eCRF, it is important to convey the 
concept tha t the preexisting condition has changed by including applicable descriptors 
(e.g., "more frequent headaches ").
5.3.5.10 Lack of Efficacy  or Worsening of Renal Cell Carcinoma
Events that are clearly consistent with the expected pattern of progression of the 
underlyi ng disease should not be recorded as adverse events.  These data will be 
captured as efficacy assessment data only.  In most cases, the expected pattern of 
progression will be based on RECIST v1.1.  In rare cases, the determination of clinical 
progression will be based on symptomatic deterioration.  However, every effort should 
be made to document progression through use of objective criteria.  If there is any 
uncertainty as to whether an event is due to disease progression, it should be reported 
as an adve rse event.
5.3.5.11 Hospitalization or Prolonged Hospitalization
Any adverse event that results in hospitalization (i.e., inpatient admission to a hospital)
or prolonged hospitalization should be documented and reported as a serious adverse 
event (per the definitio n of serious adverse event in Section 5.2.2 ), except as outlined 
below.
An event that leads to hospitalization under the following circumstances should not be 
reported as an adverse event or a serious adverse event:
Hospitalization for respite care
Planned h ospitalization required by the protocol (e.g., for study treatment
administration or performance of an efficacy measurement for the study )
Hospitalization for a preexisting condition, provided that all of the following criteria 
are met:
The hospitalization was planned prior to the study or was scheduled during the 
study when elective surgery became necessary because of the expected 
normal pro gression of the disease .
Atezolizumab —F. Hoffmann- La Roche Ltd
109/Protocol WO41994, Version 3The patient has not experienced an adverse event .
Hospitalization due solely to progr ession of the underlying cancer
An event that leads to hospitalization under the following circumstances is not 
considered to be a serious adverse event, but should be reported as an adverse event 
instead:
Hospitalization that was necessary because of patient requirement for outpatient 
care outside of normal outpatient clinic operating hours
5.3.5.12 Cases of Overdose, Medication Error, Drug A buse, or Drug
Misuse
Overdose (accidental or intentional), medication error, drug abuse, and drug misuse}
(hereafter collectively referred to as "special situations"), are defined as follows:
Accidental overdose:  accidental administration of a drug in a quantity that is higher 
than the assigned dose
Intentional overdose:  intentional administration of a drug in a quantity that is higher 
than the assigned dose
Medication error:  accidental deviation in the administration of a drug
In some cases, a medication error may b e intercepted prior to administration of 
the drug.
Drug abuse:  intentional excessive use of a drug that may lead to addiction or 
dependence, physical harm, and/or psychological harm
Drug misuse:  intentional deviation in the administration of a drug that does not 
qualify as drug abuse
In cases where drug is to be self -administered by the patient, drug misuse 
could involve the drug being administered to someone other than the patient .
Special situations are not in themselves adverse events but may result in adverse 
events.  Each adverse event associated with a special situation should be recorded 
separately on the Adverse Event eCRF.  If the associated adverse event fulfills 
seriousness criteria, the event should be reported to the Sponsor imme diately 
(i.e., nomore than 24 hours after learning of the event; see Section 5.4.2 ).  
Foratezolizumab or cabozantinib , adverse events associated with special situations 
should be recorded as described below for each situation:
Accidental overdose:  Enter the adverse event term.  Check the 
"Accidental overdose" and "Medication error" boxes.
Intentional overdose:  Enter the adverse event term.  Check the 
"Intentional overdose" box.  If drug abuse is suspected, check the "Drug abuse" box.  
If drug abuse is not suspected, check the "Drug misuse" box.
Medication error that does not qualify as an overdose:  Enter the adverse event term.  
Check the "Medication error" box.
Atezolizumab —F. Hoffmann- La Roche Ltd
110/Protocol WO41994, Version 3Medication error that qualifies as an overdose:  Enter the adverse event term.  
Check the "Accidental overdose" and "Medication error" boxes.
Drug abuse that does not qualify as an overdose:  Enter the adverse event term.  
Check the "Drug abuse " box .
Drug abuse that qualifies as an overdose:  Enter the adverse event term.  Check the 
"Intentional overdose" and "Drug abuse" boxes .
Drug misuse that does not qualify as an overdose:  Enter the adverse event term.  
Check the "Drug misuse" box .
Drug mi suse that qualifies as an overdose:  Enter the adverse event term.  
Check the "Intentional overdose" and "Drug misuse" boxes .
In addition, all special situations associated with atezolizumab or cabozantinib,
regardless of whether they result in an adverse event, should be recorded on the 
Adverse Event eCRF as described below:
Accidental overdose:  Enter the drug name and "accidental overdose" as the event 
term.  Check the "Accidental overdose" and "Medication error" boxes.
Intentional overdose:  Enter the drug name and "intentional overdose" as the event 
term.  Check the "Intentional overdose" box.  If drug abuse is suspected, check the 
"Drug abuse" box.  If drug abuse is not suspected, check the "Drug misuse" box .
Medication error that does not qualify as an overdose:  Enter the name of the drug 
administered and a description of the error (e.g., wrong dose administered, wrong 
dosing schedule, incorrect route of administration, wrong drug, expired drug 
administered) as the event term.  Check the "Medication error" box.
Medication error that qualifies as an overdose:  Enter the drug name and 
"accidental overdose" as the event term.  Check the "Accidental overdose" and 
"Medication error" boxes.  Enter a description of the error in the additional case 
details.
Intercepted medication error:  Enter the drug name and "intercepted medication 
error" as the event term.  Check the "Medication error" box.  Enter a description of 
the error in the additional case details.
Drug abuse that does not qualify as an overdose:  Enter the drug name and 
"drug abuse" as the event term.  Check the "Drug abuse" box .
Drug abuse that qualifies as an overdose:  Enter the drug name and 
"intentional overdose" as the event term.  Check the "Intentional overdose" and 
"Drug abuse" boxes .
Drug misuse that does not qualify as an overdose:  Enter the drug name and 
"drug misuse" as the event term.  Check the "Drug misuse" box .
Drug misuse that qualifies as an overdose:  Enter the drug name and 
"intentional overdose" as the event term.  Check the " Intentional overdose" and 
"Drug misuse" boxes .
Atezolizumab —F. Hoffmann- La Roche Ltd
111/Protocol WO41994, Version 3Drug administered to someone other than the patient:  Enter the drug name and 
"patient supplied drug to third party" as the event term.  Check the "Drug misuse" 
box.
As an example, an accidental overdose that resulted in a headache would require 
2entries on the Adverse Event eCRF, 1entry to report the accidental overdose and 
1entry to report the headache.  The "Accidental overdose" and "Medication error" boxes 
would need to be checked for both entries .
5.3.5.13 Patient-Reported Outcome Data
Adverse event reports will not be derived from PRO data by the Sponsor . Sites are not 
expected to review the PRO data for adverse events.
5.3.5.14 Safety  Biomarker Data
Adverse event reports will not be derived from safety biomarker data by the Sponsor, 
and safety biomarker data will not be included in the formal safety analyses for this study.  
In addition, safety biomarker data will not inform decisions on patient management.
5.4 IMMEDIA TE REPORTING REQUIREMENTS FROM 
INVESTIGA TOR TO SPON SOR
Certain events require immediate reporting to allow the Sponsor to take appropriate 
measures to address potential new risks in a clinical trial.  The investigator must report 
such events to the Sponsor immediately; under no circumstances should reporting t ake 
place more than 24 hours after the investigator learns of the event.  The following is a list 
of events that the investigator must report to the Sponsor within 24 hours after learning 
of the event, regardless of relationship to study treatment :
Serious adverse events (defined in Section 5.2.2 ; see Section 5.4.2 for details on 
reporting requirements)
Adverse events of special interest (defined in Section 5.2.3 ; see Section 5.4.2 for 
details on reporting requirements)
Pregnancies (see Section 5.4.3 for details on reporting requirements )
For serious adverse events and adverse events of special interest, the investigator must 
report new significant follow -up information to the Sponsor imm ediately (i.e., no more 
than 24 hours after becoming aware of the information).  New significant information 
includes the following:
New signs or symptoms or a change in the diagnosis
Significant new diagnostic test results
Change in causality based on new information
Change in the event 'soutcome, including recovery
Additional narrative information on the clinical course of the event
Atezolizumab —F. Hoffmann- La Roche Ltd
112/Protocol WO41994, Version 3Investigators must also comply with local requirements for reporting serious adverse 
events to the local health authority a nd IRB/EC.
5.4.1 Emergency  Medical Contacts
Medical Monitor Contact Information for All Sites
Medical Monitor: , M.D.(Primary)
Telephone No.:
E-mail :
Medical Monitor: , M.D. (Secondary)
Telephone No.:
E-mail :
To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will 
access the Roche Medical Emergency List, escalate emergency medical calls, provide 
medical translation service (if necessary), connect the investigator with a Roche 
Medical Responsible (listed above and/or on the Roche Medical Emergency List), and 
track all calls.  The Emergency Medical Call Center Help Desk will be available 24 hours 
per day, 7 days per week.  Tol l-free numbers for the Help Desk, as well as 
Medical Monitor and Medical Responsible contact information, will be distributed to all 
investigators.
5.4.2 Reporting Requirements for Serious A dverse Ev ents and 
Adverse Events of Special Interest
5.4.2.1 Events that Occur prior to Study Treatment Initiation
After informed consent has been obtained but prior to initiation of study treatment , only 
serious adverse events caused by a protocol -mandated intervention should be reported.  
The paper Clinical Trial Serious Adverse Event/Adverse Event of Special Interest 
Reporting Form provided to investigators should be completed and submitted to the 
Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the 
event), either by faxing or by scanning and emaili ng the form using the fax number or 
e-mail address provided to investigators .
5.4.2.2 Events that Occur after Study  Treatment Initiation
After initiation of study treatment , serious adverse events and adverse events of special 
interest will be reported until 90 da ysafter the final dose of study treatment or until 
initiation of new systemic anti-cancer therapy, whichever occurs first .  
Investigators should record all case details that can be gathered immediately (i.e., within 
24 hours after learning of the event) on the Adverse Event eCRF and submit the report 
via the electronic data capture (EDC) system.  A report will be generated and sent to 
Roche Safety Risk Management by the EDC system.

Atezolizumab —F. Hoffmann- La Roche Ltd
113/Protocol WO41994, Version 3In the event that the EDC system is unavailable, thepaper Clinical Trial Serious Adverse 
Event/Adverse Event of Special Interest Reporting Form provided to investigators should 
be completed and submitted to the Sponsor or its designee immediately (i.e., no more 
than 24 hours after learning of the event), either by faxing or by scanning and emailing 
the form using the fax number or e- mail address provided to investigators .  Once the 
EDC system is available, all information will need to be entered and submitted via the 
EDC system.
Instructions for reporting serious adverse events that occur after the reporting period are 
provided in Section 5.6.
5.4.3 Reporting Requirements for Pregnancies
5.4.3.1 Pregnancies in Female Patients
Female patients of childbearing potential will be instructed to immediately inform the 
investigator if they become pregnant during the study andwithin 5 months after the final
dose atezolizumab and 4 months after the final dose of cabozantinib, whichever is later .  
A paper Clinical Trial Pregnancy Reporting Form should be completed and submitted to 
the Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the 
pregnancy), either by faxing or by scanning and emailing the form usi ng the fax number 
or e-mail address provided to investigators.  Pregnancy should not be recorded on the 
Adverse Event eCRF.  The investigator should discontinue study treatment and counsel 
the patient, discussing the risks of the pregnancy and the possible effects on the fetus.  
Monitoring of the patient should continue until conclusion of the pregnancy.  Any serious 
adverse events associated with the pregnancy (e.g., an event in the fetus, an event in 
the mother during or after the pregnancy, or a congenit al anomaly/birth defect in the 
child) should be reported on the Adverse Event eCRF.  In addition, the investigator will 
submit a Clinical Trial Pregnancy Reporting Form when updated information on the 
course and outcome of th e pregnancy becomes available.
5.4.3.2 Pregnancies in Female Partners of Male Patients
Male patients will be instructed through the Informed Consent Form to immediately 
inform the investigator if their partner becomes pregnant during the study or within 
4months after the final dose of cabozant inib.A paper Clinical Trial Pregnancy 
Reporting Form should be completed and submitted to the Sponsor or its designee 
immediately (i.e., no more than 24 hours after learning of the pregnancy), either by 
faxing or by scanning and emailing the form using t he fax number or e -mail address 
provided to investigators.  Attempts should be made to collect and report details of the 
course and outcome of any pregnancy in the partner of a male patient exposed to study 
treatment .  When permitted by the site, the pregn ant partner would need to sign an 
Authorization for Use and Disclosure of Pregnancy Health Information to allow for 
follow-up on her pregnancy.  Ifthe authorization has been signed, the investigator 
should submit a Clinical Trial Pregnancy Reporting Form when updated information on 
the course and outcome of the pregnancy becomes available.  An investigator who is 
contacted by the male patient or his pregnant partner may provide information on the 
Atezolizumab —F. Hoffmann- La Roche Ltd
114/Protocol WO41994, Version 3risks of t he pregnancy and the possible effects on the fetus, to support an informed 
decision in cooperation with the treating physician and/or obstetrician.
5.4.3.3 Abortions
A spontaneous abortion should be classified as a serious adverse event (as the Sponsor 
considers a bortions to be medically significant), recorded on the Adverse Event eCRF, 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event; see Section 5.4.2 ).
If a therapeutic or elective abortion was performed becau se of an underlying maternal or
embryo fetal toxicity, the toxicity should be classified as a serious adverse event, 
recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.4.2 ).  A therapeutic or 
elective abortion pe rformed for reasons other than an underlying maternal or 
embryofetal toxicity is not considered an adverse event.
All abortions should be reported as pregnancy outcomes on the paper Clinical Trial 
Pregnancy Reporting Form.
5.4.3.4 Congenital A nomalies /Birth Defects
Any congenital anoma ly/birth defect in a child born to a female patient exposed to study 
treatment orthefemale partner of a male patient exposed to study treatment should be 
classified as a serious adverse event, recorded on the Adverse Event eCRF, and 
reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event; see Section 5.4.2 ).
5.5 FOLLOW -UP OF PA TIENT S AFTER ADVERSE EVENTS
5.5.1 Investigator Follow -Up
The investigator should follow each adverse event until the event has resolved to baseline 
grade or better, the event is assessed as stable by the investigator, the patient is lost to 
follow -up, or the patient withdraw s consent.  Every effort should be made to follow all 
serious adverse events considered to be related to study treatment or trial -related 
procedures until a final outcome can be reported.
During the study period, resolution of adverse events (with dates) s hould be documented 
on the Adverse Event eCRF and in the patient's medical record to facilitate source data 
verification.
All pregnancies reported during the study should be followed until pregnancy outcome
(see Section 5.4.3 )
Atezolizumab —F. Hoffmann- La Roche Ltd
115/Protocol WO41994, Version 35.5.2 Sponsor Follow -Up
For serious adverse events, adverse events of special interest, and pregnancies, the 
Sponsor or a designee may follow up by telephone, fax, e -mail, and/or a monitoring visit 
to obtain additional case details and outcome information (e.g., from hospital discharge 
summaries, consultant reports, autopsy reports) in order to perform an independent 
medical assessment of the reported case.
5.6 ADVERSE EVENTS THAT OCCUR AFTER THE A DVERSE 
EVENT REPORTING PERI OD
After the end of the reporting period for serious adverse events and adverse events of 
special interest (defined as 90days after the final dose of study treatment or until 
initiation of new systemic anti -cancer the rapy, whichever occurs first ), all deaths, 
regardless of cause, should be reported through use of the Long -Term Survival 
Follow -Up eCRF.
In addition, if the investigator becomes aware of a serious adverse event that is believed 
to be related to prior expos ure to study treatment, the event should be reported through 
use of the Adverse Event eCRF.   However, if the EDC system is not available, the 
investigator should report these events directly to the Sponsor or its designee, either by 
faxing or by scanning a nd emailing the paper Clinical Trial Serious Adverse 
Event/Adverse Event of Special Interest Reporting Form using the fax number or e -mail
address provided to investigators.
5.7 EXPEDITED REPORTING TO HEA LTH AUTHORITIE S, 
INVESTIGA TORS, INSTITUTIONA L REVIEW BOA RDS, 
ANDETHICS COMMITTEES
The Sponsor will promptly evaluate all serious adverse events and adverse events of 
special interest against cumulative product experience to identify and expeditiously 
communicate possible new safety findings to investigators , IRBs, ECs, and applicable 
health authorities based on applicable legislation.
To determine reporting requirements for single adverse event cases, the Sponsor will 
assess the expectedness of these events through use of the reference safety 
information in the document slisted below :
Drug Document
Atezolizumab Atezolizumab Investigator's Brochure
Cabozantinib Cabozantinib Investigator’s Brochure
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.
Atezolizumab —F. Hoffmann- La Roche Ltd
116/Protocol WO41994, Version 3Reporting requirements will also be based on the investigator's assessment of causality 
and seriousness, with allowance for upgrading by the Sponsor as needed.
6. STATISTICA L CONSI DERA TIONS AND ANAL YSIS PLA N
This is a Phase III, randomized, open -label study designed to evaluate the efficacy and 
safety of atezolizumab plus cabozantinib as compared withcabozantinib monotherapy .
Analysis populations are defined as follows:
The ITT populations defined as all randomized patients whether or not the assigned 
treatment was received
The measurable disease populatio n is defined as patients in the IT Tpopulation with 
measurable disease at baseline
The DOR population is defined as patients with objective response
The PRO -evaluable popul ation is defined as patients with a non -missing baseline 
PRO assessment
The safety -evaluable population is defined as patients who received any amount of 
any component of the study treatments
6.1 DETERMINATION OF SAMPLE SIZE
Approximately 500 patients are planned for enrol lment globally over 20 months. 
Thesample size ca lculation is determined based on the below considerations.
Type I Error Control
The type I error ( ) for the entire study is 0.05 ( 2-sided).  The re are multiple primary 
efficacy endpoints for this study:  PFS by IRF assessment per RECIST v1.1 and OS in 
the ITTpopulation. To control the overall type I error rate (Bretz et al. 2009) at 0.05 
while accounting for 2primary endpoints, is split between PFS ( 0.02) and OS 
(0.03).  The type I error can be recycled (Burman et al. 2009) if PFS results in the 
ITTpopulation are statistically significant at 0.02, then 0.02 will be recycled to OS 
in the ITT population, and OS in the ITT population will be evaluated at 0.05. 
Thestudy will be considered as a positive study if statistical significance is achieved in 
favor of the experimental arm for either of the multiple primary endpoints, since the type I 
error ( ) for the entire study is controlled at 0.05.
Primary  Endpoint:  Progression -Free Survival by Independent Review 
Facilit y Assessment per RECIST v1.1 in the Intent -to-Treat Population
The analysis of the primary endpoint of PFS by IRF assessment per RECIST v1.1 will 
take place when approximately 325 IRF -assessed PFS events have occurred in the 
ITTpopulation (65% events patient rate) based on the following assumptions:
Two-sided, stratified log -rank test
  0.02 ( 2-sided)
Approximately 90% power
Atezolizumab —F. Hoffmann- La Roche Ltd
117/Protocol WO41994, Version 3Median PFS for the cabozantinib arm of 8.0 months and estimated median PFS in 
the atezolizumab and cabozantinib arm of 11.9 months (corresponding to HR of 
0.67)
5% annual loss to follow -up for PFS
No interim analysis
On the basis of these assumptions, it is projected that an observed HR of 0.77 or lower 
will result in a statistically significant difference between treatment arms (i.e., an HR of 
0.77 will be the minimum detectable difference [MDD] for the analysis; this corresponds 
to an improvement of 2.4 months in median PFS from 8.0 months in the cabozantinib
arm to 10.4 months in the atezolizumab and cabozantinib arm).
Primary  Endpoint:  Overall Survival in the Intent -to-Treat Population
The final analysis of the primary endpoint of OS will take place when approximately 
325OS events have occurred in the ITT population (65% events patient rate) based on 
the following assumptions:
Two-sided, stratified log -rank test
  0.03 ( 2-sided)
Approximately 85% power
Median OS in the caboz antinib arm of 22 months and estimated median OS in the 
atezolizumab and cabozantinib arm of 31.4 months (an increase of 9.4 months, 
corresponding to an HR of 0.70)
1% annual loss to follow -up for OS
Two interim OS analyses
At the final OS analysis, on the basis of these assumptions, it is projected that an 
observed OS HR of 0.78 or lower in the ITT population will result in a statistically 
significant difference between treatment arms (i.e., the MDD at the analysis; this 
corresponds to an improvement of 6.2 months in median OS, from 2 2 months in the 
control arm to 28.2 months in the atezolizumab and cabozantinib arm).
Sample Size
With the above assumptions on PFS and OS, the sample size is determined at 
500patients, where the PFS and OS final anal ysis will be conducted when 325 events
occur (65% events patient rate), respectively. The 500 patients are planned for 
enrollment globally over 20 months.
6.2 SUMMA RIES OF CONDUCT OF STUDY
Enrollment, major protocol deviations ,including major deviations of inclusion/exclusion 
criteria, and reasons for discontinuation from the study will be summarized by treatment 
arm. Study treatment administration and reasons for discontinuation from the study 
treatment will be summarized by treatment arm.
Atezolizumab —F. Hoffmann- La Roche Ltd
118/Protocol WO41994, Version 36.3 SUMMA RIES OF DEMOGRA PHIC AND BA SELINE 
CHA RACTERISTICS
Demographic variables such as age, sex, race/ethnicity, stratification factors 
(IMDCscore , line of therapy ,histology ), and baseline characteristics will be summarized 
by treatment arm for the ITT population.  Continuous variables will be summarized with 
use of means, standard deviations, medians, and ranges.  Categorical variables will be 
summarized by proportions.
The baseline value of any variable will be defined as the last available value prior to the 
first administration of study treatment.
6.4 EFFICA CY ANAL YSES
The analysis population for the efficacy analyses will consist of all randomized patients, 
with patients grouped according to their assigned treatment.
6.4.1 Multiple Primary  Efficacy  Endpoint s
The multiple primary efficacy endpoints are IRF -assessed PF S per RECIST v1.1 and OS.
Progression- free survival is defined as the time from randomization to disease 
progression, as determined by the IRF per RECIST v1.1, or death from any cause, 
whichever occurs first.  Data for patients who have not experienced dis ease progression 
or death will be censored at the last tumor assessment date.  Data for patients with no 
post-baseline tumor assessments will be censored at the randomization date.
Overall survival is defined as the time from randomization to death due to any cause.  
Data for patients who are not reported as having died at the date of analysis will be 
censored at the date when they were last known to be alive.  Patients who do not have 
post-baseline information will be censored at the date of randomization.
The following analyses will be performed for both PFS and OS endpoints described 
above.  P rogression- free survival and OS will be compared between treatment arms with 
use of the stratified log -rank test at the 2-sided level of significance. The HRwith a 
95% CI will be estimated with use of a stratified Cox regression model with the same 
stratification variables used for the stratified log -rank test . The randomization 
stratification factors are most recent ICI therapy ( adjuvant vs. first-line vs. second- line), 
histology (dominant clear -cell without sarcomatoid vs.dominant nonclear -cell [papillary 
or unclassified only] without sarcomatoid vs.any sarcomatoid component [ clear -cell or 
non clear -cell]), and the IMDC score (0, 1 2, 3).If at least 1stratum has less than 
10eventsat the time of analysis , the stratification factor thatcontains the level withthe 
smallest number of patient swill be removed from the stratified analyses. The final set of 
stratification factors used for the multiple pr imary endpoints will be applied to all other 
endpoints where stratified analyses are planned. The stratification factors will be 
obtained from the IxRS at the time of randomization.  Results from an unstratified 
analysis will also be provided.  Kaplan -Meier methodology will be used to estimate the 
Atezolizumab —F. Hoffmann- La Roche Ltd
119/Protocol WO41994, Version 3median PFS and OS for each treatment arm, and Kaplan -Meier curves will be produced.  
The Brookmeyer Crowley methodology will be used to construct the 95% CI for the 
median PFS and OS for each treatment arm (Brookmeyer and Crowley 1982).
6.4.2 Secondary  Efficacy Endpoints
The following secondary efficacy endpoints per RECIST v1.1 will be analyzed :
Investigator -assessed -PFS
Investigator -and IRF- assessed ORR
Investigator -and IRF- assessed duration of objective response
Statistical m ethods for treatment arm comparison ofinvestigator -assessed PFS asthe 
secondary endpoint will be the same as the methods for treatment comparisons for the 
primary efficacy endpoint of IRF-PFS.
6.4.2.1 Objective Response Rate
An objective response is defined as either a CR or PR (confirmation isrequired , i.e.,with 
CR or PR at twoconsecutive tumor assessments at least 28 days apart ) based on 
RECIST v1.1.  Patients not meeting this criterion, including patients without any 
post-baseline tumor assessm ents, will be considered non -responders.  
Objective response rate is defined as the proportion of patients who had an objective 
response among patients with measurable disease at baseline.   Unconfirmed response 
rate will also be evaluated .
Objective response rate will be compared between treatment arms with use of the 
stratified Cochran- Mantel -Haenszel test .  The stratification factors will be the same as 
those described in the analysis of the multiple primary efficacy endpoint sof PFS and OS .  
An estimate of ORR will be calculated for each treatment arm, and its 95% CI will be 
calculated with use of the Clopper -Pearson method.  The difference in ORR between 
treatment arms will be calculated, and its 95% CI will be calculated with use of the 
normal approximation to the binomial distribution.
6.4.2.2 Duration of Response
Duration of response is defined for patients who had a confirmed objective response as 
the time from the first occurrence of response (CR or PR) to disease progression or 
death, whichever occurs first.  Data for patients who have not experienced disease 
progression or death will be censored at the last tumor assessment date.  If no tumor 
assessments were performed after the date of the first occurrence of CR or PR, data for 
DOR will be c ensored at the date of the first occurrence of CR or PR.
Duration of response is based on a non- randomized subset of patients (those who 
achieved an objective response); therefore, formal hypothesis testing will not be 
performed for this endpoint.  Compari sons between twoarms will be made for 
descriptive purposes only.  Methods for comparison of DOR between treatment arms will 
Atezolizumab —F. Hoffmann- La Roche Ltd
120/Protocol WO41994, Version 3be the same as the methods for treatment comparison for the multiple primary efficacy 
endpoint sof PFS and OS .
6.4.3 Exploratory  Efficacy Endpoints
6.4.3.1 Analysesat Landmark Time points
The PFS and OS rates at various timepoints (i.e., every 6 months after randomization) 
will be estimated by the Kaplan- Meier methodology for each treatment arm and the 
95% CI will be calculated with use of Greenwood’s formula.
6.4.3.2 Subgroup A nalyses
To assess the consistency of study results in subgroups defined by demographic and 
baseline characteristics (e.g.,PD-L1 status, prior VE GFR-TKI use, most recent 
ICItherapy ( adjuvant vs. first-line treatment vs. sec ond-line treatment ), tumor histology ,
or IMDC risk group ), PFS, ORR, and OS in these subgroups investigator -assessed DOR
and IRF-assessed DORwill be examined.  Summaries of PFS and OS, including 
unstratified HRs estimated from Cox proportional hazards mod els and 
Kaplan -Meierestimates of the median, will be produced separately for each level of the 
categorical variables.  O bjective response rate will be summarized for each level of the 
categorical variables.
6.4.3.3 Time to R esponse
Time to response is defined as the time from randomization to first response of PR or 
CR among responders .
6.4.3.4 Time to Deterioration of Disease -Related Symptoms
Time to confirmed deterioration of disease -related symptoms is defined as the time from 
randomization date to the date of a patient’s first 4 -point or more score decrease from 
baseline on the FKSI -19 DRS- P scale held for at least two consecutive timepoints or
followed by death within 3 weeks (if Cycle s 112) or 6 weeks (if after Cycle 12) from the 
last PRO assessment .Kaplan -Meier methods will be applied to this endpoint.
6.4.3.5 Time to Deterioration of Phy sical Functioning
Time to confirmed deterioration of physical functioning is defined as the time from 
randomization date to the date of a patient’s first 10 -point or more score decrease from 
baseline onthe EORTC QLQ -C30 physical functioning scale held for at least 
2consecutive timepoints or followed by death within 3 weeks (if Cycle s 112) or 
6weeks (if after Cycle 12) from the last PRO assessment .Kaplan -Meier methods will be 
applied to this endpoint.
Atezolizumab —F. Hoffmann- La Roche Ltd
121/Protocol WO41994, Version 36.4.3.6 Time to Deterioration of Global Health Status /Quality of Life
Time to confirmed deterioration of (GHS/QoL) is defined as the time from randomization 
date to the date of a patient’s first 10 -point or more score decrease fro m baseline onthe 
EORTC QLQ -C30 GHS/QoL scale held for at least 2 consecutive timepoints or followed 
by death within 3 weeks (if Cycle s 112) or 6 weeks (if after Cycle 12) from the last 
PRO assessment .Kaplan -Meier methods will be applied to this endpoint.
6.4.3.7 Patient -Reported Outcome Descriptive Summaries
Compliance rates in the ITT population will be calculated as the number of patients who 
completed the assessment divided by the number of patients expected to compl ete the 
assessment at each time point for each treatment arm. Reasons for missing 
assessments, if available, will be summarized with use of frequencies and percentages.
Descriptive analyses will include summary statistics (mean, standard deviation , median, 
interquartile range [IQR], minimum , maximum) of PRO scores and score changes from 
baseline at each assessment time point by treatment arm. Additional time points of 
interest include PRO score at radiographic disease progression (i.e., a patient’s last
PRO assessment score within 30 days pri or to or on the day of diagnosis of disease 
progression) and tre atment discontinuation due to adverse event s (i.e., a patient’s last 
PRO assessment within the 30 days prior to tre atment discontinuation due to adverse 
event s). Graphs of mean scores and/or score chang es from baseline along with 2-sided 
95% CIs may be presented. Descriptive summ aries will be reported for the key scales 
(FKSI -19 DRS- P, EORTC QLQ -C30 physical functioning, and EORTC QLQ -C30 
GHS/QoL ) as well as the rema ining FKSI -19 and EORTC QLQ -C30 scales.
Cumulative distribution function plots of score change from baseline to Month 6 by 
treatment arm will be presented for each key scale (FKSI -19 DRS -P, EORTC QLQ -C30 
physical function, EORTC QLQ -C30 GHS/QoL ).
6.5 SAFETY ANAL YSES
The safety analys is population will consist of all randomized patients who received at 
least 1dose of study treatment , with patients grouped according to treatment received.
6.5.1 Analyses of Exposure, A dverse Event, Laboratory , Vital Sign s, 
and Data
Safety analyses will be per formed on the safety -evaluable population .  Specifically, a 
patient will be included in the atezolizumab and cabozantinib experimental arm in the 
safety analyses if the patient receives any amount of atezolizumab or cabozantinib, 
regardless of the initial treatment assignment at randomization.
Safety endpoints will include the incidence and severity of adverse events, with s everity 
determined according to the NCI CTCAE v5.0, including serious adverse events and 
adverse events of special interest, and clinical laboratory results following the 
administration of study drugs.  Drug exposure will be summarized, including duration,
Atezolizumab —F. Hoffmann- La Roche Ltd
122/Protocol WO41994, Version 3dosage, and dose intensity.  Verbatim description of adverse events will be mapped to 
the MedDRA thesaurus terms and graded according to the NCI CTCAE v5.0.  
Alladverse events will be summarized by treatment arm and NCI CTCAE grade.  
Inaddition, serious adverse events and adverse events leading to study treatment 
discontinuation or interruption will be summarized accordingly.  Multiple occurrences of 
the same event will be counted once at the maximum severity.  Laboratory data with 
values outside of the normal ranges will be identified.  Additionally, selected laboratory 
data, including ADA results, will be summarized by treatment arm.  Deaths and causes 
of deaths will be summarized.
6.5.2 Exploratory  Analyses of Patient -Reported Treatment 
Side -Effect Burden
Descriptive analysis of the patient -reported overall side -effect bother item (FKSI -19 GP5) 
will be performed by treatment arm at each visit in the safety -evaluable population. 
Distribution of responses will be summarized as frequencies and percentages. 
Changefrom baseline may be summarized as no change; improved by 1, 2, 3, or 
4levels; and worsened by 1, 2, 3, or 4levels. Stacked bar charts may also be used to 
illustrate the distribution of responses or the ch ange from baseline at each time point by 
treatment arm.
6.6 PHA RMA COKINETIC A NALYSES
Sparse concentrations of atezolizumab and cabozantinib will be reported as individual 
values and as group descriptive statistics as data allow (mean, standard deviation, 
coefficient of variation, median, range, geometric mean, and geometric mean coefficient 
of variation).  The concentration -time course will also be plotted for each drug.
6.7 IMMUNOGENICITY ANALY SES
The immunogenicity analysis population will consist of patients who received any 
amount of atezolizumab withat least one ADA assessment for atezol izumab.
The numbers and proportions of ADA-positive patients and ADA-negative patients at 
baseline (baseline prevalence) and after drug administration (post-baseline incidence) 
will be summarized by treatment group.  When determining post-baseline incidence, 
patients are considered to be ADA-positive if they are ADA-negative or have missing 
data at baseline but develop an ADA response following study drug exposure 
(treatment -induced ADA response), or if they are ADA-positive at baseline and the titer 
of 1or more post-baseline samp les is at least 0.60 titer unit greater than the titer of the 
baseline sample (treatment -enhanced ADA response).  Patients are considered to be 
ADA-negative if they are ADA-negative or have mi ssing data at baseline and all 
post-baseline samples are negative, or if they are ADA-positive at baseline but do not 
have any post-baseline samples with a titer t hat is at least 0.60 titer unit greater than the 
titer of the baseline sample (treatment unaffected).
Atezolizumab —F. Hoffmann- La Roche Ltd
123/Protocol WO41994, Version 3The relationship between ADA status and safety, efficacy, PK, and biomarker endpoints 
may be analyzed and reported via descriptive statistics .
6.8 BIOMA RKER ANAL YSES
Although no formal statistical analysis of exploratory biomarkers will be performed, data
may be analyzed in the context of this study and in aggregate with data from other 
studies.
6.9 HEA LTH STA TUS UTILIT Y ANAL YSES
Change from baseline in EQ-5D-5L health utility index -based an d VAS scores will be 
calculated at specified timepoints.
6.10 INTERIM ANAL YSES
6.10.1 Planned Interim A nalyses
Primary  Endpoint of Progression -Free Survival
There is no planned interim analysis of the primary endpoint of PFS.
Primary  Endpoint of Overall Survival
A total of three analyses of OS will be performed, including twointerim analyses and 
onefinal analysis.  The boundary for statistical significance at each OS analysis will be 
determined based on the Lan -DeMets implementation of the O’Brien- Fleming (OBF) 
function (Lan and DeMets 1983) to maintain the overall type Ierror rate 
(Hung etal.2007; Glimm et al. 2009) at either 0.03 or 0.05 level, depending on whether 
primary endpoint of PFS is significant at 0 .02 level.  The OBF boundary for statistical 
signif icance is provided in Table 12.  The OS endpoint will be considered positive in the 
ITT population if statistical significance is achieved in favor of the experimental arm for 
any of the twoOS interim analyses or the final analysis .
Table 12Operating Characteristics for Proposed Study Design for Several 
Possible True Underlying Hazard Ratios
OS Interim A nalysis 1 OS Interim A nalysi s 2 Final OS
Percent Information 53%
175 events80%
260 events100%
325 events
Timing (from FPI) 27 months
(PFS primary )39 month s 52 month s
OBF Boundary when 
0.03 (0.05)0.0019 (0.0045) 0.0125 (0.0231) 0.0259 (0.0424)
MDD when 0.03 (0.05) HR0.62
(HR0.65)HR0.73
(HR0.75)HR0.78
(HR0.80)
FPIfirst patient in; HR hazard ratio; MDD minimum detectable difference ; 
OBFO’Brien- Fleming; OS overall survival; PFS progression -free survival.
Atezolizumab —F. Hoffmann- La Roche Ltd
124/Protocol WO41994, Version 3The first interim analysis of OS will be performed at the time of the PFS primary analysis.  
A total of 175 OS events are expected at the first interim analysis of OS, which 
corresponds to 53% of the events information required for the final analysis of OS in the 
ITT population.  Statist ical significance will be declared if p 0.0019. If there are 
significantly fewer ( 160) OS events than the expected 175 OS events, then the first 
interim analysis will be delay eduntil 175 OS events occur. An administrative of 
0.000001 (negligible impact on overall type I error rate) will be spent on the OS 
hypothesis at the time of the planned PFS.
The second interim analysis of OS will be performed when approximately 260 deaths 
have occurred, which corresponds to approximately 80% of the events in formation 
required for the final analysis of OS in the ITT population.  Statistical significance will be 
declared if p 0.0125.
The final analysis of OS will be performed when 325 deaths (65% of 500 patients in the 
ITT population) have occurred.  Statisti cal significance will be declared if p 0.0259 when 
exactly 325 deaths have occurred at the time of the final OS analysis.
The actual OBF boundary will be calculated at time of analysis based on actual number 
of events observed.
7. DATA COLLECTION A ND MANAGEMENT
7.1 DATA QUA LITY ASSURA NCE
The Sponsor will be responsible for data management of this study, including quality 
checking of the data.  Data entered manually will be collected via EDC through use of 
eCRFs.  Sites will be responsible for data entry into the EDC system.  In the event of 
discrepant data, the Sponsor will request data clarification from the sites, which the sites 
will resolve electronically in the EDC system.
The Sponsor will produce an EDC Study Specification document that describes th e 
quality checking to be performed on the data.  Central laboratory data will be sent 
directly to the Sponsor, using the Sponsor's standard procedures to handle and process 
the electronic transfer of these data.
Electronic Case Report Forms and correction documentation will be maintained in the 
EDC system's audit trail.  System backups for data stored by the Sponsor and records 
retention for the study data will be consistent with the Sponsor's standard procedures.
Patient -reported outcome data will be colle cted on paper questionnaires . The data from 
the questionnaires will be entered into the EDC system by site staff.
Atezolizumab —F. Hoffmann- La Roche Ltd
125/Protocol WO41994, Version 37.2 ELECTRONIC CA SE REPO RT FORMS
Electronic Case Report Forms are to be completed through use of a Sponsor -designated 
EDC system.  Sites will receive t raining and have access to a manual for appropriate 
eCRF completion.  Electronic Case Report Forms will be submitted electronically to the 
Sponsor and should be handled in accordance with instructions from the Sponsor .
All eCRFs should be completed b y designated, trained site staff.  Electronic Case Report 
Forms should be reviewed and electronically signed and dated by the investigator or a 
designee.
At the end of the study, the investigator will receive patient data for his or her site in a 
readable format that must be kept with the study records.  Acknowledgement of receipt 
of the data is required.
7.3 SOURCE DA TA DOCUMENT ATION
Study monitors will perform ongoing source data verification and review to confirm that 
critical protocol data (i.e., source data) entered into the eCRFs by authorized site 
personnel are accurate, complete, and verifiable from source documents.
Source documents (paper or electronic) are those in which patient data are recorde d 
and documented for the first time.  They include, but are not limited to, hospital records, 
clinical and office charts, laboratory notes, memoranda, PROs , evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copie sof 
transcriptions that are certified after verification as being accurate and complete, 
microfiche, photographic negatives, microfilm or magnetic media, X -rays, patient files, 
and records kept at pharmacies, laboratories, and medico- technical departments
involved in a clinical trial.
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol data to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data.
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retenti on of records described in Section 7.5.
To facilitate source data verification and review , the investigators and institutions must 
provide the Sponsor direct access to applicable source documents and reports for 
trial-related monitoring, Sponsor audits, and IRB/EC review.  The study site must also 
allow inspection by applicable health authorities.
Atezolizumab —F. Hoffmann- La Roche Ltd
126/Protocol WO41994, Version 37.4 USE OF COMPUTERIZED SYSTEMS
When clinica l observations are entered directly into a study site'scomputerized medical 
record system (i.e., in lieu of original hardcopy records), the electronic record can serve 
as the source document if the system has been validated in accordance with health 
autho rity requirements pertaining to computerized systems used in clinical research.  
Anacceptable computerized data collection system allows preservation of the original 
entry of data.  If original data are modified, the system should maintain a viewable audi t 
trail that shows the original data as well as the reason for the change, name of the 
person making the change, and date of the change.
7.5 RETENTION OF RECORDS
Records and documents pertaining to the conduct of this study and the distribution of 
IMP, includi ngeCRFs, paper PRO data, Informed Consent Forms, laboratory test results, 
and medication inventory records, must be retained by the Principal Investigator for at 
least 15years after completion or discontinuation of the study or for the length of time 
required by relevant national or local health authorities, whichever is longer.  After that 
period of time, the documents may be destroyed, subject to local regulations.
No records may be disposed of without the written approval of the Sponsor.  
Written notification should be provided to the Sponsor prior to transferring any records to 
another party or moving them to another location.
Roche will retain study data for 25 years after the final study results have been reported 
or for the length of time required by relevant national or local health authorities, 
whichever is longer.
8. ETHICA L CONSIDERA TIONS
8.1 COMPLIA NCE WITH LA WSAND REGULATIONS
This study will be conducted in full conformance with the ICH E6 guideline for 
Good Clinical Practice and the principles of the Declaration of Helsinki, or the applicable 
laws and regulations of the country in which the research is conducted, whichever 
affords the greater protection to the individual.  The study will comply with the 
requirements o f the ICH E2A guideline (Clinical Safety Data Management:  
Definitions and Standards for Expedited Reporting).  Studies conducted in the 
United States or under a U.S. Investigational New Drug (IND ) Application will comply 
with FDA regulations and applicabl e local, state, and federal laws.  Studies conducted in 
the European Union or European Economic Area will comply with the E.U. Clinical Trial 
Directive (2001/20/EC) and applicable local, regional, and national laws .
8.2 INFORMED CONSENT
The Sponsor 'ssample In formed Consent Form (and ancillary sample Informed Consent 
Forms such as a nAssent Form or Mobile Nursing Informed Consent Form, if applicable) 
will be provided to each site.  If applicable, it will be provided in a certified translation of 
Atezolizumab —F. Hoffmann- La Roche Ltd
127/Protocol WO41994, Version 3the local language.  The Sponsor or its designee must review and approve any proposed 
deviations from the Sponsor's sample Informed Consent Forms or any alternate consent 
forms proposed by the site (collectively, the "Consent Forms") before IRB/EC 
submission.  The f inal IRB/EC approved Consent Forms must be provided to the 
Sponsor for health authority submission purposes according to local requirements.
If applicable, the Informed Consent Form will contain separate sections for any optional 
procedures.  The investiga tor or authorized designee will explain to each patient the 
objectives, methods, and potential risks associated with each optional procedure.  
Patients will be told that they are free to refuse to participate and may withdraw their 
consent at any time for any reason.  A separate, specific signature will be required to 
document a patient's agreement to participate in optional procedures.  Patients who 
decline to participate will not provide a separate signature.
The Consent Forms must be signed and dated by the patient or the patient's legally 
authorized representative before his or her participation in the study.  The case history or 
clinical records for each patient shall document the informed consent process and that 
written informed consent was obtained prior to participation in the study.
The Consent Forms should be revised whenever there are changes to study procedures 
or when new information becomes available that may affect the willingness of the patient 
to participate.  The final revised IRB/EC -approv ed Consent Forms must be provided to 
the Sponsor for health authority submission purposes.
If the Consent Forms are revised (through an amendment or an addendum) while a 
patient is participating in the study, the patient or a legally authorized representat ive 
must re -consent by signing the most current version of the Consent Forms or the 
addendum, in accordance with applicable laws and IRB/EC policy.  For any updated or 
revised Consent Forms, the case history or clinical records for each patient shall 
docum ent the informed consent process and that written informed consent was obtained 
using the updated/revised Consent Forms for continued participation in the study.
A copy of each signed Consent Form must be provided to the patient or the patient's 
legally au thorized representative.  All signed and dated Consent Forms must remain in 
each patient's study file or in the site file and must be available for verification by study 
monitors at any time.
For sites in the United States, each Consent Form may also inclu de patient authorization 
to allow use and disclosure of personal health information in compliance with the 
U.S. Health Insurance Portability and Accountability Act (HIPAA) of 1996.  If the site 
utilizes a separate Authorization Form for patient authorizati on for use and disclosure of 
personal health information under the HIPAA regulations, the review, approval, and
other processes outlined above apply except that IRB review and approval may not be 
required per study site policies.
Atezolizumab —F. Hoffmann- La Roche Ltd
128/Protocol WO41994, Version 38.3 INSTITUTIONA L REVIEW BOA RDOR ETHICS COMMITTEE
This protocol, the Informed Consent Forms, any information to be given to the patient, 
and relevant supporting information must be submitted to the IRB/EC by the 
Principal Investigator and reviewed and approved by the IRB/EC before the study is 
initiated.  In addition, any patient recruitment materials must be approved by the IRB/EC.
The Principal Investigator is responsible for providing written summaries of the status of 
the study to the IRB/EC annually or more frequently in accordanc e with the requirements, 
policies, and procedures established by the IRB/EC.  Investigators are also responsible 
for promptly informing the IRB/EC of any protoc ol amendments (see Section 9.6).
In addition to the requirements for reporting all adverse events to the Sponsor, 
investigators must comply with requirements for reporting serious adverse events to the 
local health authority and IRB/EC.  Investigators may receive written IND safety reports 
or other safety -related communications from the Sponsor .  Investigators are responsible 
for ensuring that such reports are reviewed and processed in accordance with health 
authority requirements and the policies and procedures established by their IRB/ EC and
archived in the site's study file.
8.4 CONFIDENTIA LITY
The Sponsor maintains confidentiality standards by coding each patient enrolled in the 
study through assignment of a unique patient identification number.  This means that 
patient names are not included in data sets that are transmitted to any Sponsor location.
Patient medical information obtained by this study is confidential and may be disclosed 
to third parties only as permitted by the Info rmed Consent Form (or separate 
authorization for use and disclosure of personal health information) signed by the patient, 
unless permitted or required by law.
Medical information may be given to a patient's personal physician or other appropriate 
medical personnel responsible for the patient's welfare, for treatment purposes.
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses will generally not be provided to study investigators or 
patients unles s required by law .The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy on study data publication 
(see Section 9.6).
Data generated by this study must be available for inspection upon request by 
representatives of national and local health authorities, Sponsor monitors, 
representatives, and collaborators, and the IRB/EC for each study site, as appropriate.
Study data, which may include data on genomic variants may be submitted to 
government or other health research databases or shared with researchers, government 
Atezolizumab —F. Hoffmann- La Roche Ltd
129/Protocol WO41994, Version 3agencies, companies, or other groups that are not participating in this study.  These data 
may be combined with or linked to other data and used for research purposes, to 
advance science and public health, or for analysis, development, and commercialization 
of products to treat and diagnose disease.  In addition, redacted CSRs and other 
summary reports will be provided upon request (see Section 9.6).
8.5 FINA NCIA L DISCLOSURE
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate health authorities.  
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study ( see definition of end of 
study in Section 3.2).
9. STUDY DOCUMENTATION , MONITORING , AND
ADMINISTRA TION
9.1 STUDY DOCUMENTATION
The investigator must maintain adequate and accurate records to enable the conduct of 
the study to be fully documented, including, but not limited to, the protocol, protocol 
amendments, Informed Consent Forms, and documentation of IRB/EC and 
governmental approval.  In addition, at the end of the study, the investigator will receive 
the patient data, including an audit trail containing a complete record of all changes to
data.
9.2 PROTOCOL DEVIA TION S
The investigator should document and explain any protocol deviations. The investigator 
should promptly report any deviations that might have an impact on patient safety and 
data integrity to t he Sponsor and to the IRB/EC in accordance with established IRB/EC 
policies and procedures.  The Sponsor will review all protocol deviations and assess 
whether any represent a serious breach of Good Clinical Practice guidelines and require 
reporting to health authorities.  As per the Sponsor's standard operating procedures, 
prospective requests to deviate from the protocol, including requests to waive protocol 
eligibility criteria, are not allowed.
9.3 MANAGEMENT OF STUDY QUA LITY
The Sponsor will implement a sy stem to manage the quality of the study, focusing on 
processes and data that are essential to ensuring patient safety and data integrity.  
Prior to study initiation, the Sponsor will identify potential risks associated with critical 
trial processes and data and will implement plans for evaluating and controlling these 
risks.  Risk evaluation and control will include the selection of risk -based parameters 
(e.g., adverse event rate, protocol deviation rate) and the establishment of quality 
tolerance limits for these parameters prior to study initiation.  Detection of deviations 
Atezolizumab —F. Hoffmann- La Roche Ltd
130/Protocol WO41994, Version 3from quality tolerance limits will trigger an evaluation to determine if action is needed.  
Details on the establishment and monitoring of quality tolerance limits will be provided in 
aQuality Tolerance Limit Management Plan.
9.4 SITE INSPECTIONS
Site visits will be conducted by the Sponsor or an authorized representative for 
inspection of study data, patients 'medical records, and eCRFs.  The investigator will 
permit national and local hea lth authorities; Sponsor monitors, representatives, and 
collaborators; and the IRBs/ECs to inspect facilities and records relevant to this study.
9.5 ADMINISTRA TIVE STRUC TURE
This trial will be sponsored and managed by F. Hoffmann -La Roche Ltd.  The Sponsor 
will provide clinical operations management, data management, and medical monitoring.
Approximately 140 180 sites globally will participate to randomize approximately 
500patients.  Screening and enrollment will occur through an IxRS.
Central facilities will be used for certain study assessments throughout the study 
(e.g., specified laboratory tests, biomarker analyses, and PK analyses ), as specified in 
Section 4.5.7 .  Accredited local laboratories will be used for routine monitoring; local 
laboratory ranges will be collected.
An iDMC will monitor and evaluate patient safety until the primary PFS analysis
throughout the study.  Tumor response and progressio n will be evaluated by an IRF.
9.6 DISSEMINA TION OF DA TA AN D PROTECTION OF TRA DE 
SECRETS
Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing 
information on the trial to healthcare professionals and to the public, at scientific 
congresses, in clinical trial registries, and in peer -reviewed journals.   The Sponsor will 
comply with all requirements for publication of study results.  Study data may be shared 
with others who are not participating in this study (see Section 8.4for details) , and 
redacted CSRs and other summary reports will be made available upon request.  
Formore information, refer to the Roche Global Policy on Sharing of Clinical Study 
Information Trials Data at the following website:
www.roche.com/roche_global_policy_on_sharing_of_clinical_study_information.pdf
The results of this study may be published or presented at scientific congresses.  For all 
clinical trials in patients involving an IMP for which a marketing authorization application 
has been filed or approved in any country, the Sponsor aims to submit a journal 
manuscript reporting primary clinical trial results within 6 months after the availability of 
the respective CSR.  In addition, for all clinical trials in patients involving an IMP for 
which a marketing authorization application has been filed or a pproved in any country, 
Atezolizumab —F. Hoffmann- La Roche Ltd
131/Protocol WO41994, Version 3the Sponsor aims to publish results from analyses of additional endpoints and 
exploratory data that are clinically meaningful and statistically sound.
The investigator must agree to submit all manuscripts or abstracts to the Sponsor prior 
to submission for publication or presentation.  This allows the Sponsor to protect 
proprietary information and to provide comments based on information from other 
studies that may not yet be available to the investigator.
In accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication of multicenter trials only in their entirety and not as individual center 
data.  In this case, a coordinating investigator will be designated by mutual agreement.
Authorship wi ll be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements.  Any formal publication 
of the study in which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by the investigator and the 
appropriate Sponsor personnel.
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of data fr om this study will become and remain the exclusive and unburdened 
property of the Sponsor , except where agreed otherwise.
9.7 PROTOCOL A MENDMENTS
Any protocol amendments will be prepared by the Sponsor.  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immedi ate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g., change in Medical Monitor or contact information).
Atezolizumab —F. Hoffmann- La Roche Ltd
132/Protocol WO41994, Version 310. REFERENCES
Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research 
and Treatment of Cancer QLQ -C30: a quality -of-life instrument for use in 
international clinical trials in oncology. J Natl Cancer Inst 1993;85:365 76.
Agarwal N, Vaishampayan U, Green M, et al. Phase 1b study (COSMIC -021) of 
cabozantinib in combination with atezolizumab i n solid tumors: results of the dose 
escalation stage in patients with treatment -naïve advanced RCC. Ann Oncol 
2018;29 (Suppl 8) :viii308.
Atkins MB, McDermott DF, Powles T, et al. IMmotion150: aphase II trial in untreated 
metastatic renal cell carcinoma (m RCC) patients (pts) of atezolizumab (atezo) and 
bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol
2017;35(Suppl 15) ;4505 .
Auvray M, Auclin E, Barthelemy P, et al. Second- line tar geted therapies after 
nivolumab- ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer 
2019;108:33 40.
Borghaei H, Paz -Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced 
non-squamous nonsmall -cell lung cancer. N Engl J Med 2015;373;1627 39.
Bretz F, Maurer W ,Brannath W,et al. A graphical approach to sequentially rejective 
multiple test procedures. Stat Med 2009;28:586 604.
Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 
1982:38;29 41.
Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53 72.
Burman CF, Sonesson C, Guilbaud O, et al. A recycling framework for the construction 
of Bonferroni -based multiple tests. Stat Med 2009;28:739 61.
Cabometyx(cabozantinib) Summary of Product Characteristics, Ipsen Pharma. 2019 
[cited: 26 Feb ruary 2020]. Available from:  
https://www.ema.europa.eu/en/documents/product -information/cabometyx -epar-
product -information_en.pdf
Cabometyx (cabozantinib) U.S. Package Insert , Exelixis. January 2019. 
[cited 21January 2020]. Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208692s003lbl.pdf
Capitanio U, Montorsi F. Renal cancer. Lancet 2016;387:894 906.
Chanzá NM, Xie W, Bilen MA, et al. Cabozantinib in advanced non clear -cell renal cell 
carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol 
2019;20:581 90.
Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced 
renal -cell carcinoma. N Engl J Med 2015;373:1814 23.
Atezolizumab —F. Hoffmann- La Roche Ltd
133/Protocol WO41994, Version 3Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced 
renal cell carcinoma (METEOR): final results from a randomised, open -label, 
phase 3 trial. Lancet Oncol 2016;17:917 27.
Choueiri TK, Halabi S, Sanford BL, et al. Cabozanti nib versus sunitinib as initial targeted 
therapy for patients with metastatic renal cell carcinoma of poor or intermediate 
risk: the Alliance A031203 CABOSUN trial. J Clin Oncol 2017 a;35:591 7.
Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus su nitinib as initial therapy for 
metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 
CABOSUN randomised trial): progression -free survival by independent review and 
overall survival update. Eur J Cancer 2018;94:115 25.
Choueiri TK, Rini BI, Larkin JM, et al. Avelumab plus axitinib vs sunitinib as first -line 
treatment of advanced renal cell carcinoma: phase 3 study (JAVELIN Renal 101). 
J Clin Onc 2017b;35 (Suppl 15):TPS4594.
Dabestani S, Thorstenson A, Lindblad P, et al. Renal cell carcinoma recurrences and 
metastases in primary non- metastatic patients: a population- based study. World J 
Urol 2016;34:1081 6.
Deng R, Bumbaca D, Pastuskovas CV, et al. Preclinical pharmacokinetics, 
pharmacodynamics, tissue distribution, and tu mor penetration of anti PD-L1 
monoclonal antibody, an immune checkpoint inhibitor. MAbs 2016;8:593 603.
[EMA] European Medicines Agency. Guideline on the evaluation of anti -cancer medicinal 
products in man [resource on the Internet]. 2012 [cited 21 January 2020] .
Available from: 
https://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/201
3/01/ WC500137128.pdf.
Escudier B, Eisen T, Stadler W M, et al. Sorafenib for t reatment of renal cell carcinoma: 
final efficacy and safety results of the phase III treatment approaches in renal 
cancer global evaluation trial. J Clin Oncol 2009;27:3312 8.
Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2 a for 
treatment of metastatic renal cell carcinoma: a randomised, double -blind phase III 
trial. Lancet 2007;370:2103 11.
EuroQol Group. EuroQol: a new facility for the measurement of health -related quality of 
life. Health Policy 1990;16:199 208.
[FDA] Food and Drug Administration. U.S. Department of Health and Human Services. 
Guidance for industry: clinical trial endpoints for the approval of cancer drugs and 
biologics. [resource on the Internet]. 2018 [cited: 21 January 2020]. Available from: 
https://www.fda.gov/media/71195/download .
Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients 
with previously treated non small -cell lung cancer (POPLAR): a multicen tre, 
open -label, phase 2 randomised controlled trial. Lancet 2016;387:1837 46.
Atezolizumab —F. Hoffmann- La Roche Ltd
134/Protocol WO41994, Version 3Fitzsimmons D, Johnson CD, George S, et al. Development of a disease specific quality 
of life (QoL) questionnaire module to supplement the EORTC core cancer QoL 
questionnaire, t he QLQ -C30 in patients with pancreatic cancer. EORTC Study 
Group on Quality of Life. Eur J Cancer 1999;35:939 41.
Frebel H, Nindl V, Schuepbach RA, et al. Programmed death 1 protects from fatal 
circulatory failure during systemic virus infection of mice. J Exp Med 
2012;209:2485 99.
Glimm E, Maurer W , Bretz F. Hierarchical testing of multiple endpoints in 
group -sequential trials. Stat Med 2010;29:219 28.
Hales RK, Banchereau J, Ribas A, et al. Assessing oncologic benefit in clinical trials of 
immunotherapy agents. Ann Oncol 2010;21:1944 51.
Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with 
metastatic renal cell carcinoma treated with vascular endothelial growth 
factor targeted agents: results from a large, multicenter study. J Clin Onc 
2009;27:5794 9.
Herbst RS, Baas P, Kim D W, et al. Pembrolizumab versus docetaxel for previously 
treated PD L1-positive, advanced non small -cell lung cancer (KEYNOTE -010): 
arandomised controlled trial. Lancet 2016;387;1540 50.
Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the 
anti-PD-L1 antibody atezolizumab in cancer patients. Nature 2014; 515:563 7.
Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new 
five-level versi on of EQ -5D (EQ -5D-5L). Qual Life Res 2011;20:1727 36.
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for 
advanced renal -cell carcinoma. N Engl J Med 2007;356:2271 81.
Hung HM, W ang SJ, O’Nei ll R. Statistical considerations for testing multiple endpoints in 
group sequential or adaptive clinical trials. J Biopharm Stat 2007;1 7:1201 10.
Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ -5D-5L 
compared to the EQ -5D-3L across eight patient groups: a multi -country study. 
Qual Life Res 2013;22:1717 27.
Johnson ML, Eaton K, Halmos B, et al. Phase 2 trial of mocetinostat in combination with 
durvalumab in NSCLC patients with progression on prior checkpoint inhibitor 
therapy. [abstract] SITC 2018:abstract 027.
KoJJ, Xie W , Kroeger N, et al. The International Metastatic Renal Cell Carcinoma 
Database Consortium model as a prognostic tool in patients with metastatic renal
cell carcinoma previously treated with first -linetargeted therapy: a 
population -based study. Lancet Oncol 2015;16:293 300.
Koshkin VS, Barata PC, Zhang T, et al. Clinical activity of nivolumab in patients with 
non clear -cell renal cell carcinoma. J Immunother Cancer 2018;6:9.
Atezolizumab —F. Hoffmann- La Roche Ltd
135/Protocol WO41994, Version 3Kwilas AR, Ardiani A, Donahue RN, et al. Dual effects of a targeted smal l-molecule 
inhibitor (cabozantinib) on immune -mediated killing of tumor cells and immune 
tumor microenvironment permissiveness when combined with a cancer vaccine. 
JTransl Med 2014;12:294.
Lacy S, Nielsen J, Yang B, et al. Population exposure- response ana lysis of cabozantinib 
efficacy and safety endpoints in patients with renal cell carcinoma. 
Cancer Chemother Pharmacol 2018;81:1061 –70.
Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. 
Biometrika 1983;70:659 63.
Le DT, Kim TW, Cutsem EV, et al. Phase II open -label study of pembrolizumab 
in treatment -refractory, microsatellite instability -high/mismatch 
repair -deficient metastatic colorectal cancer: KEYNOTE -164. J Clin Oncol 
2020;38:11 9.
Leal TA, Horn L, Velastegui K, et al. PS02. 08 evidence of clinical activity of sitravatinib 
in combination with nivolumab in NSCLC patients progressing on prior checkpoint 
inhibitor therapy: topic: medical oncology. J Thorac Oncol 
2017;12 (Suppl 1):S1567.
Lee C. Shah AY, Makker V, et al. 1187PD Phase II study of lenvatinib plus 
pembrolizumab for disease progression after PD -1/PD -L1 immune checkpoint 
inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): results of an 
interim analysis. Ann Oncol 2019;30(Suppl 5):mdz253 013.
Lu X, Horner JW , Paul E, et al. Effective combinatori al immunotherapy for 
castration -resistant prostate cancer. Nature 2017;543:728 32.
McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of 
response to atezolizumab alone or in combination with bevacizumab versus 
sunitinib in renal cell carcinoma. Nat Med 2018;24:749 57.
McDermott DF, Lee JL, Ziobro M, et al. First -line pembrolizumab (pembro) monotherapy 
for advanced non clear -cell renal cell carcinoma (nccRCC): results from 
KEYNOTE -427 cohort B. J Clin Oncol 2019;37(Suppl 7):546.
McGregor BA, McKay RR, Braun DA, et al. Results of a multicenter phase II stu dy of 
atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma 
with variant histology and/or aarcomatoid features. J Clin Oncol 2020;38:63 70.
Maroun R, Mitrofan L, Benjamin L, et al. Real life patterns of care and progression free 
survival in metastatic renal cell carcinoma patients: retrospective analysis of 
cross- sectional data. BMC Cancer 2018;18:214.
Merad M, Martin JC. Pathological inflamma tion in patients with COVID -19: a key role 
for monocytes and macrophages. Nat Rev Immunol 2020;20:355 62.
Atezolizumab —F. Hoffmann- La Roche Ltd
136/Protocol WO41994, Version 3Motzer RJ, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for 
advanced renal cell carcinoma [abstract] . N Engl J Med 2021 .
Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2035716 .
Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously 
treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454 63.
Motzer RJ, Bander NH, Nanus DM. Renal -cell carcinoma. N Engl J Med 
1996;335:865 75.
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced 
renal -cell carcinoma. N Engl J Med 2015 a;373:1803 13.
Motzer RJ, Escudier B, Oudard S, et al. Phase 3 tri al of everolimus for metastatic renal 
cell carcinoma : final results and analysis of prognostic factors. 
Cancer 2010;116:4256 65.
Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in 
patients with metastatic renal cell carcinoma: a randomised, phase 2, open -label, 
multicentre trial. Lancet Oncol 2015b;16:1473 82.
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic 
renal -cell carcinoma. N Engl J Med 2007;356:115 24.
Motzer RJ, Jonasch E, Michaelson MD, et al. NCCN guidelines insights: kidney cancer, 
version 2.2020. J Natl Compr Canc Netw 2019a;17:1278 85.
Motzer RJ, Penkov K, Haanen J. , et al. Avelumab plus axitinib versus sunitinib for 
advanced renal -cell carcinoma. N Engl JMed 2019b;380:1103 15.
Motzer RJ, Powles T, Atkins MB, et al. IMmotion151: arandomized phase III study of 
atezolizumab plus bevacizumab vs suni tinib in untreated metastatic renal cell 
carcinoma (mRCC). J Clin Oncol 2018b;36(Suppl 6):578.
Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib 
in advanced renal -cell carcinoma. N Engl J Med 2018a;378:1277 90.
Patnaik A, Swanson KD, Csizmadia E, et al. Cabozantinib eradicates advanced murine 
prostate cancer by activating antitumor innate immunity. Cancer Discov 
2017;7:750 65.
Pearman TP, Beaumont JL, Mroczek D, et al. Validity and usefulness of a single -item 
measure of patient -reported bother from side effects of cancer therapy. 
Cancer 2018;124:991 7.
Rao D, Butt Z, Rosenbloom S, et al. A compari son of the Renal Cell 
Carcinoma -Symptom Index (RCC -SI) and the Function al Assessment of Cancer 
Therapy -Kidney Symptom Index (FKSI). J Pain Symptom Manage 2009;38:291 8.
Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus 
sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. 
Lancet 2011;378:1931 9.
Atezolizumab —F. Hoffmann- La Roche Ltd
137/Protocol WO41994, Version 3Rini BI, Motzer RJ, Powles T, et al. Atezolizumab (atezo) bevacizumab (bev) versus 
sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and 
sarcomatoid (sarc) histology: IMmotion151 subgroup analysis. J Clin Oncol 
2019c;37(Suppl 15):4512.
Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for 
advanced renal -cell carcinoma. N Engl J Med 2019 b;380:1116 27.
Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in 
patients wi th previously untreated metastatic renal cell carcinoma (IMmotion151): a 
multicentre, open -label, phase 3, randomised controlled trial. 
Lancet 2019 a;393:2404 15.
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in 
patients with previously treated non small -cell lung cancer (OAK): 
aphase 3, open -label, multicentre randomised controlled trial. Lancet 
2017;389 :255 65.
Rosenberg JE, Hoffman -Censits J, Powles T, et al. Atezolizumab in patients with locally 
advanced and metastatic ur othelial carcinoma who have progressed following 
treatment with platinum -based chemotherapy: a single- arm, multicentre, phase 2 
trial. Lancet 2016;387:1909 20.
Rothrock NE, Jensen SE, Beaumont JL, et al. Development and initial validation of the 
NCCN/FACT symptom index for advanced kidney cancer. Value Health 
2013;16:789 96.
Sennino B, Kuhnert F, Tabruyn SP, et al. Cellular source and amount of vascular 
endothelial growth factor and platelet -derived growth factor in tumors determine 
response to angiogenesis inhibitors. Cancer Res 2009;69:4527 36.
Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for 
usein trials testing immunotherapeutics. Lancet Oncol 20 17;18:e143 52.
Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic 
renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 
2010 ;28:1061 8.
Tagrisso®(osimertinib) Summary of Product Characteristics, AstraZ eneca AB. 2019 
[cited 26 February 2020]. Available from: 
https://www.ema.europa.eu/en/documents/product -information/tagrisso -epar-
product -information_en.pdf.
Tagrisso (osimertinib) U.S. Package Insert, AstraZeneca. November 2015. 
[cited 21January 2020].  Available from:  
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf .
Tecentriq®(atezolizumab) Summary of Product Characteristics , Roche Regi stration 
GmbH. 2019 [cited 26 February 2020]. Available from: 
Atezolizumab —F. Hoffmann- La Roche Ltd
138/Protocol WO41994, Version 3https://www.ema.europa.eu/en/documents/product -information/tecentriq- epar-
product -information_en.pdf.
Tecentriq (atezolizumab) U.S. Package Insert, Genentech. June 2018 [cited 
21January 2020 ]. Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761034s010lbl.pdf.
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of 
antiPD-1 antibody in cancer. N Engl J Med 2012;366:2443 54.
Wells JC, Stukalin I, Norton C, et al. Third -line targeted therapy in metastatic renal cell 
carcinoma: results from the International Metastatic Renal Cell Carcinoma 
Database Consortium. Eur Urol 2017;71:204 9.
Xalkori(crizotinib) Summary of Product Characteristics , Pfizer Europe MA EEIG. 
22January 2020 [cited 26 February 2020]. Available from:
https://www.ema.europa.eu/en/documents/product -information/xalkori -epar-
product -information_en.pdf .
Xalkori (crizotinib) U.S. Package Insert, Pfizer. June 2019. [cited 21 January 2020].  
Available from:  https://labeling.pfizer.com/showlabeling.aspx?id=676.
Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 
inhibitor, simultaneously su ppresses metastasis, angiogenesis, and tumor growth. 
Mol Cancer Ther 2011;10:2298 308.
Zhang T, Gong J, Maia MC, et al. Systemic therapy for non –clear -cell renal cell 
carcinoma. Am Soc Clin Oncol Educ Book 2017;37:337 42.
Atezolizumab —F. Hoffmann- La Roche Ltd
139/Protocol WO41994 , Version 3Appendix 1Schedule of A ctivities
Assessment Window (Days) aScreeningbTreatment Cycles
(21-day cycles)Treatment 
Discontinuation
Follow -Up 
(1 month) Days –28 to –1 Days –14 to –1Day 1
(3 days)30 Days after Final 
Dose
Informed consent xc
Tumor tissue specimensdx
Demographic data x
Medical histor y, including cancer and RCC 
history, and baseline conditionsx
Patient- reported outcomeex x xf, g
Vital signshx x x
C-reactive protein x
Weight x x x
Height x
Complete physical examinationix x
Limited physical examinationjxk
Karnofsk yPerformance Status x xkx
ECG (12-lead) / Echocardiogramlxlx x
Hematologymx xkx
Chemistrynx xkx
Pregnancy testox xkx
Coagulation (INR, aPTT) x x
TSH, free T3 (or total T3), free T4px x x
Viral serologyqx
Appendix 1:Schedule of A ctivities (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
140/Protocol WO41994, Version 3Assessment Window (Days) aScreeningbTreatment Cycles
(21-day cycles)Treatment 
Discontinuation
Follow -Up 
(1 month) Days –28 to –1 Days –14 to –1Day 1
(3 days)30 Days after Final 
Dose
Urinalysis r, sx xk
UPCR x x k, t
PK samples See Appendix 2
ADA samples See Appendix 2
Blood sample for biomarkers
(central laborator y)See Appendix 2
Urine sample for biomarkers
(central laboratory)See Appendix 2
Blood sample for RBR (optional)ux
Tumor biopsy, if clinically feasible At time of radiographic progressionv
Tumor tissue biops y at other timepoints 
(optional) wAny tim e during study treatment, observation FU or survival FU
(at investigator's discretion)
Tumor response assessments xxxy, z
Concomitant medicationsaax x x
Adverse eventsbbx x x x
Atezolizumab administration xcc
Cabozantinib dispensing/reconciliation x dd
Survival follow -up and anti -cancer treatment xee
Appendix 1:Schedule of A ctivities (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
141/Protocol WO41994, Version 3ADAanti-drug antibody; CRP C-reactive protein; CT computed tomography; EORTC European Organisation for Research and Treatment of 
Cancer; EQ -5D-5LEuroQol 5-Dimension, 5 -Level Questionnaire; FKSI -19Functional Assessment of Cancer Therapy -Kidney Sy mptom Index 19; 
FUfollow -up; HBcAb hepatitis B core antibody; HBsAg hepatitis B surface antigen; HBV hepatitis B virus; HCV hepatitis C virus; LVEF left 
ventricular ejection fraction; MRI magnetic resonance imaging; NA not applica ble; PK pharmacokinetic; PRO patient -reported outcome; 
QLQ -C30Qualit y of Life Questionnaire Core 30 Questionnaire; RBR Research Biosample Repositor y; RCC renal cell carcinoma; RECIST 
v1.1Response Evaluation Criteria in Solid Tumors, Version 1.1; TSH thyroid- stimulating hormone; UPCR Urine Protein/Creatinine ratio.
Notes:  On treatment days, all assessments should be performed prior to dosing, unless otherwise specified.
aThe first dosing day (Day 1 of Cy cle 1) should occur within 3 days from the date of randomization.
bWritten informed consent is required for performing any study -specific tests or procedures.  Signing of the Informed Consent Form can occur 
outside the 28 -day screening period.  Results of standard ofcare tests or examina tions performed prior to obtaining informed consent and within 
28days prior to study entry (except where otherwise specified) may be used for screening assessments rather than repeating such tests.  
Ifre-screening is required, then HBV, HCV, HIV, and CRP from the initial screening may  be acceptable for screening assessment if performed 
60 day s from Day 1 of Cycle 1.
cInformed consent must be documented before any study -specific screening procedure is performed and may be obtained more than 28 days 
before initiation of study treatment.
dRepresentative archival tumor tissue sample and, if clinically feasible, a fresh tumor sample obtained at baseline for explor atory research on 
biom arkers (e.g., PD- L1 status via cen tral testing), including biomarker assay development.  SeeSection 4.5.7 for tissue sample requirements.
ePatient- reported outcome assessments (EORTC QLQ -C30, FKSI -19, and EQ -5D-5L questionnaires) will be completed before the patient 
receives any information on disease status and prior to the performance of non -PRO assessments that could bias patient’s rating and the 
administration of st udy treatment .  Study personnel should confirm all questionnaires for completeness before the patient leaves the 
investigational site.  P atient -reported outcome instruments will be completed by patients on Day 1 of each cycle for the first 12 c ycles and th en 
on Day 1 of every other cy cle during study treatment, and at the end -of-treatment visit.  For PROs after treatment discontinuation, please see 
footnotes fand g.
fPatients who discontinue study treatment for any reason other than progressive disease or loss of clinical benefit will complete the 
questionnaires (EORTC QLQ -C30, FKSI 19, and EQ -5D-5L) at the end -of-treatment visit and then until disease progression when going to the 
clinic for any study -related assessments.
gAll patients will complete the EORTC QLQ -C30, FKSI 19 and EQ -5D-5L questionnaires at 4subsequent survival follow -up visits (i.e., at 3, 6, 9, 
and 12 months after radiographic disease progression per RECIST v1.1) or, for patients who continue atezolizumab after radiographic disease
progression, loss of clinical benefit as determined by the investigator.  Survival follow -up assessments may  be conducted over the telephone.
Appendix 1:Schedule of A ctivities (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
142/Protocol WO41994, Version 3hVital signs include respiratory rate, pulse rate, systolic and diastolic blood pressure, and temperature.  For the first infusion, vital signs should be 
measured within 60 minutes prior to the infusion and, if clinically indicated, every 15 ( 5) minutes during the infusion and at 30 (10)minutes 
after the infusion.  For subsequent infusions, vital signs should be me asured within 60 minutes prior to the infusion and, if clinically indicated or if 
symptoms occurred during the previous infusion, during the infusion and at 30 (10)minutes after the infusion.
iThe complete physical examination includes evaluation of th e head, eyes, ears, nose, and throat, and the cardiovascular, dermatologic, 
musculoskeletal, respiratory, gastrointestinal, genitourinary, and neurologic sy stems.
jPerform a limited, sy mptom-directed examination at specified timepoints and as clinically i ndicated at other timepoints.
kIf screening laborator y assessments were performed within 72 hours prior to Day 1 of Cycle 1, they do not have to be repeated .  At all cycles 
subsequent to Day 1 of Cycle 1, Karnofsk yPerformance Status and limited physical examination must be performed within 96 hours prior to 
study treatment administration.
l12-lead ECG recordings will be obtained during screening (within 14 day s prior to initiation of study treatment), on Day 1 of Cy cle 1 (predose), on 
Day 1 of Cycle 2, on Day 1 of Cy cle 3, and ever y 4cycles thereafter (i.e., Day 1 of Cycle 7, Day 1 of Cy cle11, and so on) and at the 
end-of-treatment visit.  Patients should be resting in a supine position for at least 10 minutes prior to ECG recording.  E lectrocardiograms will be 
reviewed by the investigator to determine patient eligibility at screening.  Bas eline evaluation of LVEF (echocardiogram) should be considered for 
all patients, especially in those with cardiac risk factors and/or histor y of coronar y artery disease, and/or other arterial thromboembolic disease.  
If no clinical sy mptoms were present at screening, ECG does not need to be repeated on Day 1 of Cy cle 1.
mHematology includes WBC count, RBC count, hemoglobin, hematocrit, platelet count, and differential count (neutrophils, eosino phils, basophils, 
monocy tes, ly mphocy tes, other cells).
nChemi stry panel (serum or plasma) includes bicarbonate or total carbon dioxide (if considered standard of care for the region), so dium, 
potassium, magnesium, chloride, glucose, BUN or urea, creatinine, total protein, albumin, phosphate, calcium, total bilirubin , urate, ALP, ALT, 
AST, and LDH.
oAll women of childbearing potential will have a serum pregnancy test at screening, within 14 day s prior to initiation of stud y treatment.  
Urine pregnancy tests will be performed at every cycle (predose) during study treatment, at treatment discontinuation, and as clinically indicated .  
Ifaurine pregnanc y test is positive, it must be confirmed by a serum pregnancy test.
pThyroid-stimulating hormone , free T3 (or total T3 for sites where free T3 is not performed), and free T4 will be assessed at screening, on Day 1 
of Cy cle 1 and ever y 4cycles thereafter (i.e., Cycles 5, 9, 13, and so on) .
qAt screening, patients will be tested for HIV, HBsAg, total HBcAb, and HCV antibody .  If a patient has a negative HBsAg test and a positive total 
HBcAb test at screening, an HBV DNA test must also be performed to determine if the patient has an HBV infection.  If a patie nt has a positive 
HCV antibody test at screening, an HCV RNA test must also be performed to determine if the pati ent has an HCV infection.
rUrinalysis includes pH, specific gravity, glucose, protein, ketones, and blood; dipstick permitted.
sUrinalysis should be performed at screening and every 3 weeks or as clinically indicated during study treatment.
Appendix 1:Schedule of A ctivities (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
143/Protocol WO41994, Version 3tUPCR shoul d be performed at screening , Cycle 1 (not repeated if screening UPCR is performed within 72 hours of Day 1 of Cycle 1, please 
seefootnote k), Cycle 3, and ever y other cycle (i.e., every 6 weeks) thereafter during study treatment or more frequently as clin ically indicated.
uNot applicable for a site that has not been granted approval for RBR sampling.  Performed only for patients at participating sites who have 
provided written informed consent to participate.  The RBR blood sample can be accepted on Day 1of Cycle 1 and anytime thereafter and 
should only be collected at one timepoint during the study.
vPatients will undergo a tumor biopsy sample collection, if deemed clinically feasible by the investigator, at the time of first evidence of 
radiographic di sease progression per RECIST v1.1.  Biopsies should be performed within 40 days  after progression or prior to the next 
anti-cancer therapy, whichever is sooner . See Section 4.5.7 for tissue sample requirements and Section 4.5.11 for biopsy in relation to 
cabozantinib dosing.
wOptional tumor tissue bio psies are to be performed only for patients at participating sites who have provided written informed consent to 
participate.  Biopsies collected at the investigator’s discretion are preferred at the time of clinical events (e.g., clinica l response).  Pati ents must 
sign a separate Optional Biopsy Informed Consent Form to undergo optional biopsies.  See Section 4.5.7 for details.  See Appendix 2for 
schedule.  SeeSection 4.5.11 for instructions on cabozantinib dosing for patients undergoing biops y .
xAll measurable and evaluable lesions should be assessed and documented at screening.  Tumo r assessments performed as standard of care 
prior to obtaining informed consent and within 28 day s prior to initiation of study treatment do not have to be repeated at s creening.  All known 
sites of disease, including measurable and/or non -measurable disease, must be documented at screening and re -assessed at each subsequent 
tumor evaluation.  Screening assessments must include CT scans (with oral or IV contrast) or MRI scans of the chest, abdomen and pelvis.  
Aspiral CT scan of the chest may be obtained but is not a requirement.  If a CT scan with contrast is contraindicated (e.g., in patients with 
impaired renal clearance), a non -contrast CT scan of the chest may be performed, and MRI scans of the abdomen and pelvis should be 
performed.  A CT scan with contrast or MRI scan of the head must be done at screening to evaluate CNS metastasis in all patie nts (MRI scan 
must be performed if CT scan is contraindicated).  An MRI scan of the head is required to confirm or refute the diagnosis of CNS metastases at 
baseline in the event of an equivocal CT scan.  At subsequent (post -screening) tumor assessments, patients with a history of irradiation brain 
metastasis at screening are not required to undergo brain scan unless clinically indicated.  The same radiographic modality (e.g., CT scan with 
contrast) and procedures (e.g., the same contrast protocol for CT scans) used to assess disease sites at screening should be used for 
subsequent tum or assessments. Bone scans and CT scans of the neck should also be performed at baseline, if clinically indicated.
Bone scans and CT scans of the neck should also be performed if clinically indicated.  At the investigator's discretion, other methods of
assessment of measurable disease as per RECIST v1.1 may  be used.
Appendix 1:Schedule of A ctivities (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
144/Protocol WO41994, Version 3yPatients will undergo tumor assessments at baseline, ever y 9 weeks ( 7 day s) for the first 18 months following treatment initiation, and ever y 
12weeks ( 7 days) thereafter, regardless of dose delays, until radiographic disease progression per RECIST v1.1 or (for patients who continue 
study treatment after radiographic disease progression) loss of clinical benefit as determined by the investigator (see Section 3.1for details).  
Thus, tumor assessments are to continue according to schedule in patients who discontinue treatment for reasons other than di sease 
progression or loss of clinic al benefit, even if they start new anti -cancer therapy.  Patients who discontinue treatment for reasons other than 
radiographic disease progression per RECIST v1.1 (e.g., toxicity, sy mptomatic deterioration) will continue scheduled tumor as sessments at the
frequency described above until radiographic disease progression per RECIST v1.1, withdrawal of consent, death, or study term ination by the 
Sponsor, whichever occurs first. All patients, regardless of arm, will also undergo a follow -up post -disease progr ession tumor assessment after 
investigator assessment of radiographic disease progression per RECIST v1.1.  W hen feasible, this subsequent scan will take p lace on the 
same schedule as prior to progression at 9 weeks ( 7 day s) if disease progression occurred in the first 18 months, and at 12 weeks ( 7 days) if 
disease progression occurred after the first 18 months following treatment initiation .
zAll measurable and evaluable lesions should be re -assessed at each subsequent tumor evaluation.  The sam e radiographic procedures used to 
assess disease sites at screening should be used for subsequent tumor assessments (e.g., the same contrast protocol for CT scans).
aaMedication (e.g., prescription drugs, over -the-counter drugs, vaccines, herbal or homeop athic remedies, nutritional supplements) used by a 
patient in addition to protocol -mandated treatment from 7 day s prior to initiation of study treatment until the treatment discontinuation visit.
bbAfter informed consent has been obtained but prior to ini tiation of study treatment, only serious adverse events caused by a protocol -mandated 
intervention should be reported.  After initiation of study treatment, all adverse events will be reported until 30 daysafter the final dose of study 
treatment or until initiation of new systemic anti -cancer therapy, whichever occurs first, and serious adverse events and adverse events of 
special interest will continue to be reported until the end of the special reporting period defined as 90 days after the fina l dose of study treatment 
or until initiation of new systemic anti -cancer therapy, whichever occurs first.  After this period, all deaths, regardless of cause, should be 
reported.  In addition, the Sponsor should be notified if the investigator becomes aware of any serious adverse event that is believed to be 
related to prior exposure to study treatment (see Section 5.6).
ccThe initial infusion of atezolizumab will be delivered over 60 ( 15) minutes.  Subsequent infusions will be delivered over 30 ( 10) minutes if the 
previous infusion was tolerated without infusion -associated adverse events, or 60 ( 15) m inutes if the patient experienced an infusion -
associated adverse event with the previous infusion.
ddCabozantinib tablets will be given on Day 1 of Cy cle 1 after atezolizumab infusion.  On Day 1 of Cycle 1, the patient will fa st (with the exception 
of water) for at least 2 hours before recei ving cabozantinib.  Upon completion of the 2 -hours fast, the patient will receive the oral dose of 
cabozantinib with a minimum of 8 oz (240 mL) of water in the clinic and then the patient will continue to fast for 1 hour.  Patients will take tablets 
once d aily at home thereafter until study treatment is discontinued.  Tablets should be taken at approximately the same time QD, preferentially 
before going to bed, and should adhere to the fasting requirements described in Section 4.3.2.2 .
Appendix 1:Schedule of A ctivities (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
145/Protocol WO41994, Version 3eeAfter treatment discontinuation, information on survival follow -up and new anti -cancer therapy (including targeted therapy and immunotherapy) 
will be coll ected via telephone calls, patient medical records, and/or clinic visits approximately every 3 months ( 1month) until death, loss to 
follow -up, or study termination by the Sponsor, whichever occurs first.  If a patient requests to be withdrawn from follo w-up, this request must be 
documented in the source documents and signed by the investigator.  If the patient withdraws from the study, the study staff may use a public 
information source (e.g., county records) to obtain information about survival status o nly where allowed per local regulations.
Atezolizumab —F. Hoffmann- La Roche Ltd
146/Protocol WO41994 , Version 3Appendix 2Schedule of Pharmacokinetic, Immunogenicit y, and 
Biomarker Samples
Visit TimepointSample Type in Each Arm
Atezolizumab Cabo zantinib Cabo zantinib
Screening NA Archival biopsy
Fresh biopsyArchival biopsy
Fresh biopsy
Day 1 of 
Cycle1Prior to the first infusion Atezolizumab PK (serum)
Atezolizumab ADA (serum)
Biom arker (PBMC, plasma, 
serum , urine )
RBR (blood) a Biom arker (PBMC, 
plasma, serum , 
urine )
RBR (blood )a
30 (10) minutes after 
end of atezolizumab 
infusionAtezolizumab PK (serum) 
Day 1 of 
Cycle2Predose Atezolizumab PK (serum)
Atezolizumab ADA (serum)
Cabozantinib PK (plasma)
Biom arker (PBMC, plasm a, 
serum , urine )Biom arker (PBMC, 
plasma , serum , 
urine )
Cabozantinib PK 
(plasma)
Day 1 of 
Cycles3 and 4Predose Atezolizumab PK (serum)
Atezolizumab ADA (serum)
Cabozantinib PK (plasma)
Biom arker ( PBMC, 
plasma , serum , urine )Biom arker ( PBMC, 
plasma , serum , 
urine )
Cabozantinib PK 
(plasma)
Day 1 of Cycles 
8, 12 and 16Predose Atezolizumab PK (serum)
Atezolizumab ADA (serum)
At timing of 
fresh biopsy 
(during 
treatment or at 
progression)At visit Biom arker ( PBMC , plasma,
serum , urine )bBiom arker (PBMC, 
plasma, serum , 
urine )b
Appendix 2:Schedule of Pharmacokinetic , Immunogenicity, and Biomarker Samples 
(cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
147/Protocol WO41994 , Version 3Visit TimepointSample Type in Each A rm
Atezolizumab Cabo zantinib Cabo zantinib
Treatment 
discontinuation 
visit ( 30 days 
after final dose )NA Atezolizumab PK (serum)
Atezolizumab ADA (serum)
Cabozanti nib PK (plasma)
Biom arker ( PBMC , plasma,
serum , urine )Biom arker (PBMC, 
plasma, serum , 
urine )
Cabozanti nib PK 
(plasma)
ADAanti-drug antibody; PBMC peripheral blood mononuclear cell ; NAnot applicable; 
PKpharmacokinetic ; RBR Research Biosample Repository
Note:  Except for Day 1 of Cycle 1, all other study visits and assessments during the treatment 
period should be performed within 3 day s of the scheduled date.  Study assessments may  be 
delayed or moved ahead of the window to accommo date holidays, vacations, and unforeseen 
delays.
aNot applicable for a site that has not been granted approval for RBR sampling.  
Performed only for patients at participating sites who have provided written informed consent 
to participate.  The RBR blood sample can be accepted at C ycle 1, Day 1and anytime 
thereafter , and s hould only be collected at one timepoint during the study.
bBlood and urine collections should be performed within 40 daysafter progression or prior to 
the next anti -cancer therapy, whichever is sooner.  If the progression visit is at the same time 
as the treatment discontinuation visit, only one set of biomarker samples need sto be 
collected .
Atezolizumab —F. Hoffmann- La Roche Ltd
148/Protocol WO41994 , Version 3Appendix 3Response Evaluation Criteria in Solid Tumors , 
(RECIST) Version 1.1
Selected sections from the Response Evaluation Criteria in Solid Tumors (RECIST)
Version 1.1 (Eisenhauer et al. 2009) are presented below, with slight modifications from 
the original publication and the addition of explanatory text as needed for clarity.1
TUMOR ME ASURA BILITY
At baseline, tumor lesions/ lymph nodes will be categorized as measurable or 
non-measurable as described below.  All measurable and non -measurable lesions 
should be assessed at screening and at subsequent protocol -specified tumor 
assessment timepoints.  Additional assessments may be performed as clinically 
indicated for suspicion of progression.
DEFINITION OF MEA SUR ABLE LESIONS
Tumor Lesions
Tumor lesions must be accurately measured in at least one dimension (longest diameter 
in the plane of measurement is to be recorded) with a minim um size as follows:
10 mm by computed tomography (CT) or magnetic resonance imaging (MRI) scan 
(CT/MRI scan slice thickness/interval 5 mm)
10-mm caliper measurement by clinical examination (lesions that cannot be 
accurately measured with calipers should be recorded as non- measurable)
20 mm by chest X -ray
Malignant Ly mph Nodes
To be considered pathologically enlarged and measurable, a lymph node must be 
15 mm in the short axis when assessed by CT scan (CT scan slice thickness 
recommended to be 5 mm). Atbaseline and follow -up, only the short axis will be 
measured and followed.  Additional information on lymph node measurement is provided 
below (see "Identification of Target and Non -Target Lesions" and "Calculation of Sum of 
Diameters").
                                           
1For clarity and for consistency within this document, the section numbers and cross -references 
to other sections within the article have been deleted and minor changes have been made.
Appendix 3:Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
149/Protocol WO41994 , Version 3DEFINITION OF NON- MEA SURA BLE LESIO NS
Non-measurable tumor lesions encompass small lesions (longest diameter 10 mm or 
pathological lymph nodes with short axis 10 mm but 15 mm) as well as truly 
non-measurable lesions.  Lesions considered truly non -measurable include
leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast 
disease, lymphangitic involvement of skin or lung, peritoneal spread, and abdominal 
mass/abdominal organomegaly identified by physical examination that is not measurable
by reproducible imaging techniques.
SPECIA L CONSIDERA TIONS REG ARDING LESION MEA SURA BILITY
Bone lesions, cystic lesions, and lesions previously treated with local therapy require 
particular comment, as outlined below.
Bone Lesions:
Technetium -99m bone scan s, sodium fluoride positron emission tomography scans, 
and plain films are not considered adequate imaging techniques for measuring bone 
lesions.  However, these techniques can be used to confirm the presence or 
disappearance of bone lesions.
Lytic bone lesions or mixed lytic -blastic lesions with identifiable soft -tissue 
components that can be evaluated by cross -sectional imaging techniques such as 
CTor MRI can be considered measurable lesions if the soft -tissue component 
meets the definition of measurability described above
Blastic bone lesions are non -measurable
Cystic Lesions:
Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered malignant lesions (neither measurable nor non- measurable) since they 
are, by definition, simple cysts
Cystic lesions thought to represent cystic metastases can be considered 
measurable lesions if they meet the definition of measurability described above.  
However, if non -cystic lesions are present in the same patient, these are preferred 
for selection as target lesions
Lesions with Prior Local Treatment:
Tumor lesions situated in a previously irradiated area or in an area subjected to 
other loco -regional therapy are usually not considered measurable unless there has 
been dem onstrated progression in the lesion
Appendix 3:Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
150/Protocol WO41994 , Version 3METHODS FOR A SSESSIN G LESIONS
All measurements should be recorded in metric notation, with use of calipers if clinically 
assessed.  All baseline evaluations should be performed as close as possible to the 
treatment star t and never more than 4 weeks before the beginning of the treatment.
The same method of assessment and the same technique should be used to 
characterize each identified and reported lesion at baseline and during the study.  
Imaging -based evaluation should always be the preferred option.
CLINICA L LESIONS
Clinical lesions will only be considered measurable when they are superficial and 
10mm in diameter as assessed with use of calipers (e.g., skin nodules).  For the case 
of skin lesions, documentation by co lor photography, including a ruler to estimate the 
size of the lesion, is suggested.
CHEST X -RAY
Chest CT is preferred over chest X -ray, particularly when progression is an important 
endpoint, since CT is more sensitive than X -ray, particularly in identify ing new lesions.  
However, lesions on chest X -ray may be considered measurable if they are clearly 
defined and surrounded by aerated lung.
CT AND MRI SCA NS
Computed tomography is the best currently available and reproducible method to 
measure lesions selec ted for response assessment.  In this guideline, the definition of 
measurability of lesions on CT scan is based on the assumption that CT slice thickness 
is 5 mm.  W hen CT scans have slice thickness of 5 mm, the minimum size for a 
measurable lesion sho uld be twice the slice thickness.  M agnetic resonance imaging is 
also acceptable.
If prior to enrollment it is known that a patient is unable to undergo CT scans with IV 
contrast because of allergy or renal insufficiency, the decision as to whether a 
non-c ontrast CT or MRI (without IV contrast) will be used to evaluate the patient at 
baseline and during the study should be guided by the tumor type under investigation 
and the anatomic location of the disease.  For patients who develop contraindications to 
contrast after baseline contrast CT is done, the decision as to whether non -contrast CT 
or MRI (enhanced or non -enhanced) will be performed should also be based on the 
tumor type and the anatomic location of the disease and should be optimized to allow for 
comparison with the prior studies if possible.  Each case should be discussed with the 
radiologist to determine if substitution of these other approaches is possible and, if not, 
the patient should be considered not evalua ble from that point forward .  Care must be 
taken in measurement of target lesions and interpretation of non- target disease or new 
Appendix 3:Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
151/Protocol WO41994 , Version 3lesions on a different modality, since the same lesion may appear to have a different 
size using a new modality.
ENDOSCOPY, LA PAROSCOPY, ULTRA SOUN D, TUMOR MA RKERS, 
CYTOLOGY, HISTOLOGY
Endoscopy, laparoscopy, ultrasound, tumor markers, cytology, and histology cannot be 
used for objective tumor evaluation.
ASSESSMENT OF TUMOR BURDEN
To assess objective response or future progressio n, it is necessary to estimate the 
overall tumor burden at baseline and use this as a comparator for subsequent 
measurements.
IDENTIFICA TION OF TA RGET AND NON- TARGET LESIONS
When more than one measurable lesion is present at baseline, all lesions up to a 
maximum of fivelesions total (and a maximum of twolesions per organ) representative 
of all involved organs should be identified as target lesions and will be recorded and 
measured at baseline.  This means that, for instances in which patients have only oneor 
twoorgan sites involved, a maximum of twolesions ( onesite) and fourlesions 
(twosites), respectively, will be recorded.  Other lesions (albeit measurable) in those 
organs will be considered non -target lesions.
Target lesions should be selected on the basis of their size (lesions with the longest 
diameter) and should be representative of all involved organs, but in addition should lend 
themselves to reproducible repeated measurements .  It may be the case that, on 
occasion, the largest lesion does no t lend itself to reproducible measurement, in which 
circumstance the next largest lesion that can be measured reproducibly should be 
selected.
Lymph nodes merit special mention since they are normal anatomical structures that 
may be visible by imaging even if not involved by tumor.  As noted above, pathological 
nodes that are defined as measurable and may be identified as target lesions must meet 
the criterion of a short axis of 15 mm by CT scan.  Only the short axis of these nodes 
will contribute to the baseline sum.  The short axis of the node is the diameter normally 
used by radiologists to judge if a node is involved by solid tumor.  Lymph node size is 
normally reported as 2dimensions in the plane in which the image is obtained (for CT, 
this is almost always the axial plane; for MRI, the plane of acquisition may be axial, 
sagittal, or coronal).  The smaller of these measures is the short axis.  For example, an 
abdominal node that is reported as being 20 mm30 mm has a short axis of 20 mm and 
qualifies as a malignant, measurable node.  In this example, 20 mm should be recorded 
as the node measurement.  All other pathological nodes (those with short axis 10mm 
Appendix 3:Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
152/Protocol WO41994 , Version 3but 15mm) should be considered non- target les ions.  Nodes that have a short axis of 
10 mm are considered non -pathological and should not be recorded or followed.
All lesions (or sites of disease) not selected as target lesions (measurable or 
non-measurable), including pathological lymph nodes, shou ld be identified as non -target 
lesions and should also be recorded at baseline.  Measurements are not required.  It is 
possible to record multiple non- target lesions involving the same organ as a single item 
on the Case Report Form (CRF; e.g., "multiple en larged pelvic lymph nodes" or 
"multiple liver metastases").
CALCULA TION OF SUM O F DIA METERS
A sum of the diameters (longest diameter for non lymph node lesions, short axis for 
lymph node lesions) will be calculated for all target lesions at baseline and at each 
subsequent tumor assessment as a measure of tumor burden.
Measuring Ly mph Nodes
Lymph nodes identified as target lesions should always have the actual short axis 
measurement recorded (measured in the same anatomical plane as the baseline 
examination), even if the node regresses to 10 mm during the study.  Thus, when 
lymph nodes are included as target lesions, the sum of diameters may not be zero even 
if complete response (CR) criteria are met, since a normal lymph node is defined as 
having a short axis of 10 mm.
Measuring Lesions that Become Too Small to Measure
During the study, a ll target lesions (lymph node and non lymph node) recorded at 
baseline should have their actual measurements recorded at each subsequent 
evaluation, even when very small (e.g., 2 mm).  However, sometimes lesions or lymph 
nodes that are recorded as target l esions at baseline become so faint on CT scan that 
the radiologist may not feel comfortable assigning an exact measurement and may 
report them as being too small to measure.  When this occurs, it is important that a value 
be recorded on the CRF, as follows :
If it is the opinion of the radiologist that the lesion has likely disappeared, the 
measurement should be recorded as 0 mm
If the lesion is believed to be present and is faintly seen but too small to measure, a 
default value of 5 mm should be assigned and "too small to measure" should be 
ticked (Note:  It is less likely that this rule will be used for lymph nodes since they 
usually have a definable size when normal and are frequently surrounded by fat 
such as in the retroperitoneum; however, if a lymph node is believed to be present 
and is faintly seen but too small to measure, a default value of 5 mm should be 
assigned in this circumstance as well and "too small to measure" should also be 
ticked).
Appendix 3:Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
153/Protocol WO41994 , Version 3To reiterate, however, if the radiologist is able to pr ovide an actual measurement, that 
should be recorded, even if it is 5 mm, and in that case "too small to measure" should 
not be ticked.
Measuring Lesions That Split or Coalesce on Treatment
When non lymph node lesions fragment, the longest diameters of t he fragmented 
portions should be added together to calculate the sum of diameters.  Similarly, as 
lesions coalesce, a plane between them may be maintained that would aid in obtaining 
maximal diameter measurements of each individual lesion.  If the lesions have truly 
coalesced such that they are no longer separable, the vector of the longest diameter in 
this instance should be the maximum longest diameter for the coalesced lesion.
EVALUATION OF NON -TARGET LESIONS
Measurements are not required for non -target lesions, except that malignant lymph node 
non-target lesions should be monitored for reduction to 10 mm in short axis.  
Non-target lesions should be noted at baseline and should be identified as "present" or 
"absent" and (in rare cases) may be noted as " indicative of progression" at subsequent 
evaluations.  In addition, if a lymph node lesion shrinks to a non -malignant size 
(short axis10 mm), this should be captured on the CRF as part of the assessment of 
non-target lesions.
RESPONSE CRITERIA
CRITERIA  FOR TA RGET LESIONS
Definitions of the criteria used to determine objective tumor response for target lesions 
are provided below:
CR:  Disappearance of all target lesions
Any pathological lymph nodes must have reduction in short axis to 10 mm.
Partial response (PR):  At least a 30% decrease in the sum of diameters of all target 
lesions, taking as reference the baseline sum of diameters, in the absence of CR
Disease progression :  At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum of diameters at prior timepoints
(including baseline) 
In addition to the relative increase of 20%, the sum of diameters must also 
demonstrate an absolute increase of 5 mm.
Stable disease (SD):  Neither sufficient shr inkage to qualify for CR or PR nor 
sufficient increase to qualify for disease progression
Appendix 3:Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
154/Protocol WO41994 , Version 3CRITERIA  FOR NON -TARGET LESIONS
Definitions of the criteria used to determine the tumor response for the group of 
non-target lesions are provided below.  W hile some non-target lesions may actually be 
measurable, they need not be measured and instead should be assessed only 
qualitatively at the timepoints specified in the schedule of activities.
CR:  Disappearance of all non -target lesions and (if applicable) normaliza tion of 
tumor marker level
All lymph nodes must be non- pathological in size ( 10 mm short axis).
Non-CR/Non -disease progression :  Persistence of one or more non -target lesions 
and/or (if applicable) maintenance of tumor marker level above the normal limit s
Disease progression :  Unequivocal progression of existing non- target lesions
SPECIA L NOTES ON A SSESSMENT OF PROGRESSION OF NON -TARGET 
LESIONS
Patients with Measurable and Non -Measurable Disease
For patients with both measurable and non- measurable disease to achieve unequivocal 
progression on the basis of the non -target lesions, there must be an overall level of 
substantial worsening in non -target lesions in a magnitude that, even in the presence of 
SD or PR in target lesions, the overall tumor burd en has increased sufficiently to merit 
discontinuation of therapy.  A modest increase in the size of one or more non -target 
lesions is usually not sufficient to qualify for unequivocal progression status.  
Thedesignation of overall progression solely on t he basis of change in non -target 
lesions in the face of SD or PR in target lesions will ;therefore ,be extremely rare.
Patients with Non -Measurable Disease Only
For patients with non- measurable disease only, the same general concepts apply as 
noted above. However, in this instance there is no measurable disease assessment to 
factor into the interpretation of an increase in non -measurable disease burden.  
Because worsening in non-measurable disease cannot be easily quantified (by definition, 
if all lesions are truly non -measurable), a useful test that can be applied when assessing 
patients for unequivocal progression is to consider if the increase in overall disease 
burden based on the change in non -measurable disease is comparable in magnitude to 
the increa se that would be required to declare disease progression for measurable 
disease, that is, an increase in tumor burden representing an additional 73% increase in 
volume (which is equivalent to a 20% increase in diameter in a measurable lesion).  
Examples in clude an increase in a pleural effusion from "trace" to "large" or an increase 
in lymphangitic disease from localized to widespread .  If unequivocal progression is seen, 
the patient should be considered to have had overall disease progression at that point .  
While it would be ideal to have objective criteria to apply to non -measurable disease, the 
Appendix 3:Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
155/Protocol WO41994 , Version 3very nature of that disease makes it impossible to do so; therefore, the increase must be 
substantial.
NEW LESIONS
The appearance of new malignant lesions denotes disease progression; therefore, some
comments on detection of new lesions are important.  There are no specific criteria for 
theidentification of new radiographic lesions; however, the finding of a new lesion 
should be unequivocal, that is, not attributa ble to differences in scanning technique, 
change in imaging modality, or findings thought to represent something other than tumor 
(for example, some "new" bone lesions may be simply healing or flare of preexisting 
lesions).  This is particularly important when the patient's baseline lesions show PR or 
CR.  For example, necrosis of a liver lesion may be reported on a CT scan report as a
"new" cystic lesion, which it is not.
A lesion identified during the study in an anatomical location that was not scanned a t 
baseline is considered a new lesion and will indicate disease progression.
If a new lesion is equivocal, for example because of its small size, continued therapy and 
follow -up evaluation will clarify if it represents truly new disease.  If repeat scans c onfirm 
there is definitely a new lesion, progression should be declared using the date of the 
initial scan.
CRITERIA  FOR OVERA LLRESPONSE A T A SINGL E TIMEPOINT
Table 1 provides a summary of the overall response status calculation at each response 
assessment timepoint for patients who have measurable disease at baseline.
When patients have non- measurable (therefore ,non-target) disease only, Table 2 is to 
be used.
Appendix 3:Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
156/Protocol WO41994 , Version 3Table 1Criteria forOverall Response at a Single Timepoint:  
Patients with Target Lesions (with or without Non- Target Lesions)
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/non -DP No PR
CR Not all evaluated No PR
PR Non-DP or not all 
evaluatedNo PR
SD Non-DP or not all 
evaluatedNo SD
Not all evaluated Non-DP No NE
PD Any Yes or no DP
Any DP Yes or no DP
Any Any Yes DP
CRcomplete response; DPdisease progression ; NEnot evaluable; PR partial response; 
SDstable disease.
Table 2Criteria for Overall Response at a Single Timepoint:  
Patients with Non -Target Lesions Only
Non-Target Lesions New Lesions Overall Response
CR No CR
Non-CR/non -DP No Non-CR/non -DPa
Not all evaluated No NE
Unequivocal DP Yes or no DP
Any Yes DP
CRcomplete response; DPdisease progression; NEnot evaluable.
a"Non -CR/non -DP" is preferred over "stable disease" for non- target disease since stable 
disease is increasingly used as an endpoint for assessment of efficacy  in some trials; thus, 
assigning "stable disease" when no lesion s can be measured is not advised.
MISSING A SSESSMENTS AND NOT EVALUABLE DESIGNA TION
When no imaging/measurement is done at all at a particular timepoint, the patient is not 
evaluable at that timepoint.  If measurements are made on only a subset of target 
lesions at a timepoint, usually the case is also considered not evaluable at that tim epoint, 
unless a convincing argument can be made that the contribution of the individual missing 
lesions would not change the assigned timepoint response.  This would be most likely to 
happen in the case of disease progression .  For example, if a patient h ad a baseline 
Appendix 3:Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
157/Protocol WO41994 , Version 3sum of 50 mm with three measured lesions and during the study only twolesions were 
assessed, but those gave a sum of 80 mm, the patient will have achieved disease 
progression status, regardless of the contribution of the missing lesion.
SPEC IAL NOTES ON RESPONS E ASSESSMENT
Patients with a global deterioration in health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
"symptomatic deterioration."  Every effort sh ould be made to document objective 
progression even after discontinuation of treatment.  Symptomatic deterioration is not a 
descriptor of an objective response; it is a reason for stopping study therapy.  
Theobjective response status of such patients is t o be determined by evaluation of 
target and non- target lesions as shown in Table 1 and Table 2 .
For equivocal findings of progression (e.g., very small and uncertain new lesions; cystic 
changes or necrosis in existing lesions), treatment may continue until the next scheduled 
assessment.   If at the next scheduled assessment, progression is confirmed, the date of 
progression should be the earlier date when progression was suspected.
REFERENCES
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumors: r evised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228 47.
Atezolizumab —F. Hoffmann- La Roche Ltd
158/Protocol WO41994 , Version 3Appendix 4Modified RECIST for Immune -Based Therapeutics 
(iRECIST) v1.1
Conventional response criteria may not be adequate to characterize the anti -tumor 
activity of immunotherapeutic agents, which can produce delayed responses that may 
be preceded by initial apparent radiographic progression, including the appearance of 
new lesions.  Therefore, immunotherapy -specific response criteria adaptations to 
Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 
(Eisenhauer etal.2009) have been developed to allow for unconventional response and 
progression patterns.  These include modified RECIST for immune -based therapeutics 
(iRECIST; Seymour et al. 2017) v1.1,which was developed by the RECIST working 
group in an effort to create a common set of criteria that the cancer immunotherapy field
could apply to clinical trials.
Response evaluation through use of iRECIST requires collection of tumor assessment 
data after radiographic progression per RECIST v1.1.  Details regarding lesion 
evaluation are described below.  W hen not otherwise specified , RECIST v1.1 convention
will apply.
Criteria for determining overall response at a single timepoint per iRECIST are also 
summarized below.  Of note, overall response per iRECIST will not be captured in the 
eCRF but will instead be calculated programmatica lly by the Sponsor on the basis of 
investigator -assessed individual lesion data recorded in the eCRF.
Immune -modified RECIST response status is not a specific component of treatment 
discontinuation criteria, including decisions about whether to continue tr eatment beyond 
progression per RECIST v1.1.  Investigators should instead take into account radiologic 
data and clinical status in making such decisions, as described in Section 3.1.
EVALUATION OF LESION S TO SUPPORT iRECIST RESPONSE 
ASSESSMENT A FTER DIS EASE PROGRESSION PER RECIST v1.1
Immune -modified RECIS T is an extension of RECIST v1.1 that allows for response 
assessme nt following disease progression per RECIST v1.1.  R esponse Evaluation 
Criteria in Solid Tumors v1.1 rules for categorizing lesions as measurable or 
non-measurable and measuring lesions (see Appendix 3) also apply to iRECIST.  
After disease progression per RECIST v1.1, the same target and non- target lesions 
selected at baseline will continue to be followed, along with any new lesions that develop, 
to suppor t iRECIST response evaluations, as described below and summarized in 
Table 1 .  Once a lesion has been categorized as a target, non -target, or new lesion, it 
will remain classified as such.
Appendix 4:Modified RECIST.1 for Immune -Based Therapeutics Version 1.1(cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
159/Protocol WO41994 , Version 3TARGET LESIONS
The target lesions selected at baseline should continue to be measured at all tumor 
assessment timepoints after disease progression per RECIST v1.1, according to 
RECIST v1.1 conventions.
NON- TARGET LESIONS
Non-target lesions selected at baseline should continue to be followed at all tumor 
assessment timepoints after disease progression per RECIST v1.1.  At each timepoint, 
non-target lesions should continue to be categorized as "absent" (complete response 
[CR]), "unequivocal progression" relative to baseline ( disease progression ), or "present 
without unequivocal progression" (non -CR/non -disease progression ), as defined by 
RECIST v1.1.  In addition, any non -target lesions that were categorized as disease 
progre ssion at the previous timepoint should be evaluated to determine whether there 
has been any further increase in size .
NEW LESIONS
New lesions identified after baseline will be evaluated for measurability with use of the 
same criteria applied to prospective target lesions at baseline per RECIST v1.1 
(e.g., non lymph node lesions must be 10 mm on the longest diameter; new lymph 
nodes must be 15 mm on the short axis [see note below]).  All new lesions 
(measurable or non -measurable) must be assessed and rec orded at the time of 
identification and at all subsequent tumor assessment timepoints.
Up to a maximum of fivemeasurable new lesions total (with a maximum of twolesions 
per organ) should be selected and measured at each timepoint.  New lesions that are 
not measurable at first appearance but meet measurability criteria at a subsequent 
timepoint should be measured from that point on, if the maximum number of measurable 
new lesions has not been reached.  However, for calculation of the sum of diameters for 
new lesions, iRECIST excludes measurements from new lesions that were not 
measurable at first appearance.
All non- measurable new lesions (including those that subsequently become measurable) 
and additional measurable new lesions (in excess of fivetotal or twoper organ ) should 
be assessed to determine whether there is any increase in size relative to the previous 
assessment timepoint.
Note regarding new lymph node lesions :  If at first appearance the short axis of a lymph 
node lesion is 15 mm, it will be considered a measurable new lesion.  If at first 
appearance the short axis of a lymph node lesion is 10 mm and 15 mm, the lymph 
node will not be considered measurable but will still be considered a new lesion and 
should be identified as a non -measurable new lesion.  If at first appearance the short 
Appendix 4:Modified RECIST.1 for Immune -Based Therapeutics Version 1.1(cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
160/Protocol WO41994 , Version 3axis of a lymph node is 10 mm, the lymph node should not be considered pathological 
and should not be considered a new lesion.  A lymph node can subsequently become 
measurable, when the short axis is 15 mm.  Measurable new lymph node lesions 
should continue to be measured at all subsequent timepoints, even if the short axis 
decreases to 15mm (or even 10mm).
Table 1Guidelines for Evaluation of Lesions to Support iRECIST 
Response A ssessment after Disease Progression per 
RECIST v1.1
Lesion TypeEvaluation of Lesions to Support iRECIST Response 
Assessment after Disease Progression per RECIST v1.1
Target lesions Measurements should be continued according to RECIST v1.1 
conventions
Non-target lesions Non-target lesions should continue to be categorized as absent 
(CR), unequivocal progression ( disease progression ), or 
present without unequivocal progression (non -CR/non -disease 
progression ), as defined by RECIS Tv1.1.  In addition, any 
non-target lesions that were categorized as disease 
progression at the previous timepoint should be evaluated to 
determine whether there has been any further increase in size.
New lesions New lesions should be evaluated for measu rabilit y per 
RECIST v1.1
All new lesions (measurable or non -measurable) mu st be 
assessed and recorded at the time of identification and at all 
subsequent tumor assessment timepoints
Up to a maximum of fivemeasurable new lesions total (with a 
maximum of onelesion per organ) should be selected and 
measured at each timepoint
All non -measurable new lesions (including those that 
subsequently become measurable) and additional measurable 
new lesions (in excess of fivetotal or twoper organ ) should be 
assessed to determine whether there is any increase in size 
relative to the previous assessment timepoint
CRcomplete response; iRECIST modified RECIST for immune -based therapeutics ; 
RECIST v1.1Response Evaluation Criteria in Solid Tumors , Version 1.1.
SUMMA RY OF CRITERIA  FOR OVERA LL RESPONSE AT A SINGLE 
TIMEPOINT
Timepoint response per iRECIST will be calculated programmatically by the Sponsor.  
Acomplete description of the iRECIST criteria can be found in a publication by 
Seymour et al. (2017).
Appendix 4:Modified RECIST.1 for Immune -Based Therapeutics Version 1.1(cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
161/Protocol WO41994 , Version 3REFERE NCES
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228 47.
Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for
use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143 52.
Atezolizumab —F. Hoffmann- La Roche Ltd
162/Protocol WO41994 , Version 3Appendix 5European Organisation for Research and Treatment 
of Cancer Quality ofLife–Core 30 Questionnaire
(EORTC QLQ -C30)
Do not reproduce or distribute:  The Sponsor will provide sites with all instruments to 
be completed in this study.

Appendix 5:European Organisation for Research and Treatment of Cancer Quality
ofLife–Core 30 Questionnaire (EORTC QLQ -C30) (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
163/Protocol WO41994 , Version 3

Atezolizumab —F.Hoffmann- La Roche Ltd
164/Protocol WO41994, Version 3Appendix 6EuroQol 5 -Dimension , 5-Level Questionnaire
(EQ-5D-5L)
Do not reproduce or distribute:  The Sponsor will provide sites with all instruments to 
be completed in this study.
English version for the USA

Appendix 6:EuroQol 5 -Dimension, 5 -Level Questionnaire (EQ -5D-5L) (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
165/Protocol WO41994 , Version 3Under each heading, please check the ONE box that best describes 
your health TODAY.
MOBILITY
I have no problems walking
I have slight problems walking
I have moderate problems walking
I have severe problems walking
I am unable to walk
SELF -CARE
I have no problems washing or dressing m yself
I have slight problems washing or dressing m yself
I have moderate problems washing or dressing m yself
I have severe problems washing or dressing m yself
I am unable to wash or dress m yself
USU AL ACTIVITIES (e.g. ,work, study, housework, family or 
leisure activities)
I have no problems doing my  usual activities
I have slight problems doing m y usual activities
I have moderate problems doing m y usual activities
I have severe problems doing m y usual activities
I am unable to do m y usual activities
PAIN / DISCOMFORT
I have no pain or discomfort
I have slight pain or discomfort
I have moderate pain or discomfort
I have severe pain or discomfort
I have extreme pain or discomfort
ANXIETY / DEPRESSION
I am not anxious or depressed
I am slightly anxious or depressed
I am moderately anxious or depressed
I am severely anxious or depressed
I am extremely anxious or depressed
Appendix 6:EuroQol 5 -Dimension, 5 -Level Questionnaire (EQ -5D-5L) (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
166/Protocol WO41994 , Version 3We would like to know how good or bad your health is TODAY.
This scale is numbered from 0 to 100.
100 means the best health you can imagine.
0 means the worst health you can imagine.
Mark an X on the scale to indicate how your health is TODAY.
Now, please write the number y ou marked on the scale in the box below.
10
0203040506080
7090100
5152535455575
658595
Atezolizumab —F. Hoffmann- La Roche Ltd
167/Protocol WO41994 , Version 3Appendix 7 Functional A ssessment of Cancer Therapy -Kidne y
Symptom Index 19
Do not reproduce or distribute:  The Sponsor will provide sites with all instruments to 
be completed in this study.

Atezolizumab —F. Hoffmann- La Roche Ltd
168/Protocol WO41994 , Version 3Appendix 8Preexisting A utoimmune Diseases and Immune 
Deficienc ies
Patients should be carefully questioned regarding their history of acquired or congenital 
immune deficiencies or autoimmune disease.  Patients with any history of immune 
deficiencies or autoimmune disease listed in the table below are excluded from 
participating in the study.  Possible exceptions to this exclusion could be patients with a 
medical history of such entities as atopic disease or childhood arthralgias where the 
clinical suspicion of autoimmune disease is low.  Patients with a history of 
autoimmune- related hypothyroidism on a stable dose of thyroid replacement hormone 
may be eligible for this study.  In addition, transient autoimmune manifestations of an 
acute infectious disease that resolved upon treatment of the infectious agent are not 
excluded (e.g., acute Lyme arthritis).  Caution should be used when considering 
atezolizumab for patients who have previously experienced a severe or life -threatening 
skin adverse reaction while receiving another immunostim ulatory anti -cancer agent.  
Contact the Medical Monitor regarding any uncertainty over autoimmune exclusions .
Autoimmune Diseases and Immune Deficiencies
Acute disseminated
encephalom yelitis
Addison disease
Ankylosing spondylitis
Antiphospholipid antibody
syndrome
Aplastic anemia
Autoimmune hemolytic 
anem ia
Autoimmune hepatitis
Autoimmune
hypoparathy roidism
Autoimmune hypophysitis
Autoimmune m yocarditis
Autoimmune oophoritis
Autoimmune orchitis
Autoimmune 
thrombocy topenic purpura
Behçet disease
Bullous pemp higoid
Chronic fatigue syndrome
Chronic inflammatory
demyelinating
polyneuropathy
Churg -Strauss syndrome
Crohn disease Dermatom yositis
Diabetes mellitus type 1
Dysautonomia
Epidermolysis bullosa 
acquis ita
Gestational pemphigoid
Giant cell arteritis
Good p asture syndrome
Graves disease
Guillain -Barré syndrome
Hashimoto disease
IgA nephropathy
Inflammatory  bowel disease
Interstitial cystitis
Kawasaki disease
Lambert-Eaton m yasthenia
syndrome
Lupus erythematosus
Lyme disease ,chronic
Meniere s yndrom e
Mooren ulcer
Morphea
Multiple sclerosis
Myasthenia gravisNeurom yotonia
Opsoclonus m yoclonus
syndrome
Optic neuritis
Ord thyroiditis
Pemphigus
Pernicious anemia
Polyarteritis nodosa
Polyarthritis
Polyglandular autoimmune
syndrome
Primary biliar y cirrhosis
Psoriasis
Reiter syndrome
Rheumatoid arthritis
Sarcoidosis
Scleroderma
Sjögren s yndrome
Stiff-Person syndrome
Takayasu arteritis
Ulcerative colitis
Vitiligo
Vogt-Koyanagi -Harada 
disease
Wegener granulomatosis
Atezolizumab —F. Hoffmann- La Roche Ltd
169/Protocol WO41994 , Version 3Appendix 9 Anaphy laxis Precautions
These guidelines are intended as a reference and should not supersede pertinent local
or institutional standard operating procedures.
REQUIRED EQUIPMENT AND MEDICA TION
The following equipment and medication are needed in the event of a suspected 
anaphylactic reaction during study treatment infusion :
Monitoring devices:  ECG monitor, blood pressure monitor, oxygen saturation 
monitor, and thermometer
Oxygen
Epinephrine for subcutaneous, intramuscular , intravenous, and/or endotracheal 
administration in accordance with institutional guidelines
Antihistamines
Corticosteroids
Intravenous infusion solutions, tubing, catheters, and tape
PROCEDURES
In the event of a suspected anaphylactic reaction during study treatment infusion, 
thefollowing procedures should be performed:
1.Stop the study treatment infusion.
2.Call for additional medical assistance.
3.Maintain an adequate airway.
4.Ensure that appropriate monitoring is in place, with continuous ECG and pulse 
oxim etry monitoring if possible.
5.Administer antihistamines, epinephrine, or other medications and IV fluids as 
required by patient status and as directed by the physician in charge.
6.Continue to observe the patient and document observations .
Atezolizumab —F. Hoffmann- La Roche Ltd
170/Protocol WO41994 , Version 3Appendix 10Risks A ssociated with A tezolizumab and 
Guidelines for Management of A dverse Events A ssociated w ith 
Atezolizumab
Toxicities associated or possibly associated with atezolizumab treatment should be 
managed according to standard medical practice.  Additional tests, such as autoimmune 
serology or biopsies, should be used to evaluate for a possible immunogenic etiology.
Although most immune -mediated adverse events observed with immunomodulatory 
agents have been mild and self -limiting, such events should be recognized early and 
treated promptly to avoid potential major complications.  Discontinuation of atezolizumab 
may not have an immediate th erapeutic effect, and in severe cases, immune -mediated
toxicities may require acute management with topical corticosteroids, systemic 
corticosteroids, or other immunosuppressive agents. 
The investigator should consider the benefit risk balance a given pat ient may be 
experiencing prior to further administration of atezolizumab.  In patients who have met 
the criteria for permanent discontinuation, resumption of atezolizumab may be 
considered if the patient is deriving benefit and has fully recovered from the
immune -mediated event.  Patients can be re -challenged with atezolizumab only after 
approval has been documented by both the investigator (or an appropriate delegate) and 
the Medical Monitor.
DOSE MODIFICA TIONS
There will be no dose modifications for atezo lizumab in this study.
TREA TMENT INTERRUPTI ON
Atezolizumab treatment may be temporarily suspended in patients experiencing toxicity 
considered to be related to study treatment.  If corticosteroids are initiated for treatment 
of the toxicity, they must be t apered over 1month to the equivalent of 10mg/day oral 
prednisone before atezolizumab can be resumed.  If atezolizumab is withheld for 
12weeks after event onset, the patient will be discontinued from atezolizumab.  
However, atezolizumab may be withheld for 12 weeks to allow for patients to taper off 
corticosteroids prior to resuming treatment.  Atezolizumab can be resumed after being 
withheld for 12 weeks if the Medical Monitor agrees that the patient is likely to derive 
clinical benefit.  Atezolizumab treatment may be suspended for reasons other than 
toxicity (e.g., surgical procedures) with Medical Monitor approval.  The investigator and 
the Medical Monitor will determine the acceptable length of treatment interruption.
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
171/Protocol WO41994 , Version 3MANAGEMENT GUIDELINE S
PULMONA RY EVENTS
Dyspnea, cough, fatigue, hypoxia, pneumonitis, and pulmonary infiltrates have been 
associated with the administration of atezolizumab. Patients will be assessed for 
pulmonary signs and symptoms throughout the study and will have computed 
tomography (CT) scans of the chest performed at every tumor assessment.
All pulmonary events should be thoroughly evaluated for other commonly reported 
etiologies such as pneumonia or other infection , lymphangitic carcinomatosis, pulmonary 
embolism, heart failure, chronic obstructive pulmonary disease, or pulmonary 
hypertension.  Management guidelines for pulmonary events are provided in Table 1 .
Table 1Management Guidelines for Pulmonary  Events, Including 
Pneumonitis
Event Management
Pulm onary 
event, Grade 1Continue atezolizumab and monitor closely
Re-evaluate on serial imaging
Consider patient referral to pulmonary specialist
Pulm onary 
event, Grade 2Withhold atezolizumab for up to 12 weeks after event onseta
Refer patient to pulmonary and infectious disease specialists and 
consider bronchoscopy or BAL
Initiate treatment with corticosteroids equivalent to 1 2 mg/kg/day 
oral prednisone
If event resolves to Grade 1 or better, resume atezolizumabb
If event does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab and contact 
Medical Monitorc
For recurrent events, treat as a Grade 3 or 4 event
Pulm onary 
event,
Grade 3 or 4Permanently discontinue atezolizumab and contact Medical Monitorc
Bronchoscopy or BAL is re commended
Initiate treatment with corticosteroids equivalent to 1 2 mg/kg/day 
oral prednisone
If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent
If event resolves to Grade 1 or better, taper corticosteroids over 
1month
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
172/Protocol WO41994 , Version 3Table 1Management Guidelines for Pulmonary  Events, Including 
Pneumonitis (cont.)
BALbronchoscopic alveolar lavage.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to the equivalent of 
10mg/day oral prednisone.  The acc eptable length of the extended period of time must 
be agreed upon by the investigator and the Medical Monitor.
bIf corticosteroids have been initiated, they must be tapered over 1 month to the 
equivalent of 10 mg/day oral prednisone before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been document ed by both the investigator (or an 
appropriate delegate) and the Medical Monitor.
HEPA TIC EVENTS
Immune -mediated hepatitis has been associated with the administration of atezolizumab.   
Patients eligible for study treatment must have adequate liver function, as manifested 
by measurements of total bilirubin and hepatic transaminases, and liver function will be 
monitored throughout study treatment.  Management guidelines for hepatic events are 
provided in Table
2.
Patients with right upper -quadrant abdominal pain and/or unexplained nausea or 
vomiting should have liver function tests (LFTs) performed immediately and reviewed 
before administration of the next dose of study drug.
For patients with elevated LFTs, concurrent medication, viral hepatitis, and toxic or 
neoplastic etiologies should be considered and addressed, as appropriate.
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
173/Protocol WO41994 , Version 3Table 2Management Guidelines for Hepatic Events
Event Management
Hepatic event, 
Grade 1Continue atezolizumab
Monitor LFTs until values resolve to within normal limits or to baseline 
values
Hepatic event, 
Grade 2All events:
Monitor LFTs more frequently until return to baseline values
Events of 5 days’ duration:
Withhold atezolizumab for up to 12 weeks after event onseta
Initiate treatment with corticosteroids equivalent to 1 2mg/kg/day oral 
prednisone
If event resolves to Grade 1 or better, resume atezolizumabb
Ifevent does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab and contact 
Medical Monitorc
Hepatic event, 
Grade 3 or 4Permanently discontinue atezolizumab and contact Medical Monitor. c
Consider patien t referral to gastrointestinal specialist for evaluation and 
liver biopsy to establish etiology of hepatic injur y. 
Initiate treatment with corticosteroids equivalent to 1 2mg/kg/day oral 
prednisone.
If event does not improve within 48 hours after initiating corticosteroids, 
consider adding an immunosuppressive agent.
If event resolves to Grade 1 or better, taper corticosteroids over 1month.
LFTliver function test.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to the equivalent of  10mg/day oral 
prednisone.  The acceptable length of the extended period of time must be agreed upon by 
the investigator and the Medical Monitor.
bIf corticosteroids have been initiated, they must be tapered over 1 month to the equivalent of 
10 mg/day oral prednisone before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and 
have f ully recovered from the immune -mediated event.  Patients can be re- challenged with 
atezolizumab only after approval has been documented by both the investigator (or an 
appropriate delegate) and the Medical Monitor. 
GASTROINTESTINA L EVE NTS
Immune -mediated colitis has been associated with the administration of atezolizumab.  
Management guidelines for diarrhea or colitis are provided in Table 3 .
All events of diarrhea or colitis should be thoroughly evaluated for other more common 
etiologies.  For events of significant duration or magnitude or associated with signs of 
systemic inflammation or acute -phase reactants (e.g., increa sed C -reactive protein, 
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
174/Protocol WO41994 , Version 3platelet count, or bandemia):  Perform sigmoidoscopy (or colonoscopy, if appropriate) 
with colonic biopsy, with 35specimens for standard paraffin block to check for 
inflammation and lymphocytic infiltrates to confirm colitis diagnosis.
Table 3Management Guidelines for Gastr ointestinal Events
(Diarrhea orColitis)
Event Management
Diarrhea or colitis, 
Grade 1Continue atezolizumab
Initiate sy mptomatic treatment
Endoscopy is recommended if sy mptoms persist for 7days
Monitor closely
Diarrhea or colitis, 
Grade 2Withhold atezolizumab for up to 12 weeks after event onseta
Initiate sy mptomatic treatment
Patient referral to GI specialist is recommended
For recurrent events or events that persist 5 days, initiate treatment 
with corticosteroids equivalent to 1 2 mg/kg/day oral prednisone
If event resolves to Grade 1 or better, resume atezolizumabb
If event does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab and contact 
Medical Monito rc
Diarrhea or colitis, 
Grade 3Withhold atezolizumab for up to 12 weeks after event onseta
Refer patient to GI specialist for evaluation and confirmatory  biopsy
Initiate treatment with corticosteroids equivalent to 1 2 mg/kg/day IV 
methylprednisolone and convert to 12mg/kg/day oral prednisone or 
equivalent upon improvement
If event resolves to Grade 1 or better, resume atezolizumabb
If event does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab and contact 
Medical Monitorc
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
175/Protocol WO41994 , Version 3Table 3Management Guidelines for Gastr ointestinal Events 
(Diarrhea orColitis) (cont.)
Event Management
Diarrhea or colitis, 
Grade 4Permanently discontinue atezolizumab and contact Medical Monitor.c
Refer patient to GI specialist for evaluation and confirmation biopsy.
Initiate treatment with corticosteroids equivalent to 1 2 mg/kg/day IV 
methylprednisolone and convert to 1 2 mg/kg/day oral prednisone or 
equivalent upon improvement.
If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent.
If event resolves to Grade 1 or better , taper corticosteroids over 
1month.
GIgastrointestinal.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to the equivalent of 
10mg/day oral prednisone.  The acceptable length of the extended period of time must 
be agreed upon by the investigator and the Medical Monitor.
bIf corticosteroids have been initiated, they must be tapered over 1 month to the 
equivalent of 10 mg/day oral prednisone before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and 
have f ully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by both the investigator (or an 
appropriate delegate) and the Medical Monitor.
ENDOCRINE EVENTS
Thyroid disorders, adrenal insufficiency, diabetes mellitus, and pituitary disorders have 
been associated with the administration of atezolizumab.  Management guidelines for 
endocrine events are provided in Table 4 .
Patients with unexplained symptoms such as headache, fatigue, myalgias, impotence, 
constipation, or mental status changes should be investigated for the presence of thyroid, 
pituitary, or adrenal endocrinopathies.  The patient should be referred to an 
endocrinologist if an endocrinopathy is suspected.  Thyroid -stimulating hormone (TSH) 
and free triiodothyronine and thyroxine levels should be measured to determine whether 
thyroid abnormaliti es are present.  Pituitary hormone levels and function tests (e.g., TSH, 
growth hormone, luteinizing hormone, follicle -stimulating hormone, testosterone, 
prolactin, adrenocorticotropic hormone [ACTH] levels, and ACTH stimulation test) and 
magnetic resonanc e imaging (MRI) of the brain (with detailed pituitary sections) may 
help to differentiate primary pituitary insufficiency from primary adrenal insufficiency.
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
176/Protocol WO41994 , Version 3Table 4 Management Guidelines for Endocrine Events
Event Management
Asymptomatic 
hypothy roidismContinue atezolizumab
Initiate treatment with thyroid replacement hormone
Monitor TSH weekly
Symptomatic 
hypothy roidismWithhold atezolizumab
Initiate treatment with thyroid replacement hormone
Monitor TSH weekly
Consider patient referral to endocrinologist
Resume atezolizumab when sy mptoms are controlled, and thy roid 
function is improving
Asymptomatic 
hyperthy roidismTSH 0.1 mU/L and 0.5 mU/L:
Continue atezolizumab
Monitor TSH ever y 4 weeks
TSH 0.1 mU/L:
Follow guidelines for sy mptomatic hyperthyroidism
Symptomatic 
hyperthy roidismWithhold atezolizumab
Initiate treatment with anti -thyroid drug such as methimazole or 
carbimazole as needed
Consider patient referral to endocrinologist
Resume atezolizumab when sy mptoms are controlled, and thy roid 
function is improving
Permanently discontinue atezolizumab and contact 
Medical Monitor for life -threatening immune -mediated
hyperthy roidismc
Symptomatic adrenal 
insufficiency, Grade 24Withhold atezolizumab for up to 12 weeks after event onseta
Refer patient to endocrinologist
Perform appropriate imaging
Initiate treatment with corticosteroids equivalent to 1 2mg/kg/day 
IV methylprednisolone and convert to 12mg/kg/day oral 
prednisone or equivalent upon i mprovement
If event resolves to Grade 1 or better and patient is stable on 
replacement therapy, resume atezolizumabb
If event does not resolve to Grade 1 or better or patient is not 
stable on replacement therapy while withholding atezolizumab, 
permanently discontinue atezolizumab and contact 
Medical Monitorc
Hyperglycemia,
Grade 1 or 2Continue atezolizumab
Investigate for diabetes.  If patient has T ype 1 diabetes, treat as a 
Grade 3 event.  If patient does not have T ype 1 diabetes, treat as 
per institutional guidelines.
Monitor for glucose control
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
177/Protocol WO41994 , Version 3Table 4 Management Guidelines for Endocrine Events (cont.)
Event Management
Hyperglycemia
Grade 3 or 4Withhold atezolizumab
Initiate treatment with insulin
Monitor for glucose control
Resume atezolizumab when sy mptoms resolve, and glucose 
levels are stable
Hypophy sitis 
(pan-hypopituitarism), 
Grade 2 or 3Withhold atezolizumab for up to 12 weeks after event onseta
Refer patient to endocrinologist
Perform brain MRI (pituitary protocol)
Initiate treatment with corticosteroids equivalent to 1 2mg/kg/day 
IV methylprednisolone and convert to 12mg/kg/day oral 
prednisone or equivalent upon improvement
Initiate hormone replacement if clinically indicated
If event resolves to Grade 1 or better, resume atezolizumabb
If event does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab and contact 
Medical Monitorc
For recurrent hypophysitis, treat as a Grade 4 event
Hypophy sitis 
(pan-hypopitu itarism), 
Grade 4Permanently discontinue atezolizumab and contact 
Medical Monitorc
Refer patient to endocrinologist
Perform brain MRI (pituitary protocol)
Initiate treatment with corticosteroids equivalent to 1 2mg/kg/day 
IV methylprednisolone and convert to 12mg/kg/day oral 
prednisone or equivalent upon improvement
Initiate hormone replacement if clinically indicated
MRImagnetic resonance imaging .
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event 
onset) to allow for corticosteroids (if initiated) to be reduced to the equivalent of 
10mg/day oral prednisone.  The acceptable length of the extended period of time must 
be agreed upon by the investigator and the Medical Monitor.
bIf corticosteroids have been initiated, they must be tapered over 1 month to the 
equivalent of 10 mg/day oral prednisone before atezolizumab can be resumed.
cResumption of atezolizumab may be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  Patients can be re -challenged 
with atezolizumab only after approval has been documented by both the investigator 
(oran appropriate delegate) and the Medical Monitor.
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
178/Protocol WO41994 , Version 3OCULA R EVENTS
An ophthalmologist should evaluate visual complaints (e.g., uveitis, retinal events).  
Management guidelines for ocular events are provided in Table 5 .
Table 5 Management Guidelines for Ocular Events
Event Management
Ocular event, 
Grade 1Continue atezolizumab
Patient referral to ophthalmologist is strongly recommended
Initiate treatment with topical corticosteroid eye drops and topical 
immunosuppressive therapy
If symptoms persist, treat as a Grade 2 event
Ocular event, 
Grade 2Withhold atezolizumab for up to 12 weeks after event onseta
Patient referral to ophthalmologist is strongly recommended
Initiate treatment with topical corticosteroid eye drops and topical 
immunosuppressive therapy
If event resolves to Grade 1 or better, resume atezolizumabb
If event does not resolve to Grade 1 or better while withh olding 
atezolizumab, permanently discontinue atezolizumab and contact 
Medical Monitorc
Ocular event, 
Grade 3 or 4Permanently discontinue atezolizumab and contact Medical Monitorc
Refer patient to ophthalmologist
Initiate treatment with corticosteroids equivalent to 1 2 mg/kg/day oral 
prednisone
If event resolves to Grade 1 or better, taper corticosteroids over 
1month
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event onset) to 
allow for corticosteroids (if initiated) to be reduced to the equivalent of 10mg/day oral 
prednisone.  The acceptable length of the extended period of time must be agreed upon by the 
investigator and the Medical Monitor.
bIf corticosteroids have been initiated, they must be tapered over  1 month to the equivalent of 
10 mg/day oral prednisone before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and have 
fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by both the investigator (or an 
appropriate delegate) and the Medical Monitor.
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
179/Protocol WO41994 , Version 3IMMUNE -MEDI ATEDMYOC ARDITIS
Immune -mediated myocarditis has been associated with the administration of 
atezolizumab.  Immune -mediated myocarditis should be suspected in any patient 
presenting with signs or symptoms suggestive of myocarditis, including, but not limited to, 
laboratory (e.g., B -type natriuretic peptide) or cardiac imaging abnormalities, dyspnea, 
chest pain, palpitations, fatigue, decreased exercise tolerance, or syncope.  
Immune -mediated myocarditis needs to be distinguished from myocarditis resulting from 
infection (commonly viral, e.g., in a patient who reports a recent history of 
gastrointestinal illness), ischemic events, underlying arrhythmias, exacerbation of 
preexisting cardiac conditions, or progression of malignancy.
All patients with possible myocarditis should be urgently evaluated by performing cardiac 
enzy me assessment, an ECG, a chest X -ray, an echocardiogram, and a cardiac MRI as 
appropriate per institutional guidelines.  A cardiologist should be consulted.  
Anendomyocardial biopsy may be considered to enable a definitive diagnosis and 
appropriate treatm ent, if clinically indicated.
Patients with signs and symptoms of myocarditis, in the absence of an identified 
alternate etiology, should be treated according to the guidelines in Table 6 .
Table 6Management Guidelines for Immune -Mediated Myocarditis
Event Management
Immune -mediated 
myocarditis, Grade 2Withhold atezolizumab for up to 12 weeks after event onsetaand 
contact Medical Monitor
Refer patient to cardiologist
Initiate treatment as per institutional guidelines and consider 
antiarrhythmic drugs, temporary pacemaker, ECMO, or VAD as 
appropriate
Consider treatment with corticosteroids equivalent to 12mg/kg/day 
IV methylprednisolone and convert to 1 2mg/kg/day oral prednisone 
or equivalent upon improvement
If event resolves to Grade 1 or better, resume atezolizumabb
If event does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab and contact 
Medical Monitorc
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
180/Protocol WO41994 , Version 3Table 6Management Guidelines for Immune -Mediated Myocarditis (cont.)
Event Management
Immune -mediated 
myocarditis, Grade 3 4Permanently discontinue atezolizumab and contact Medical Monitorc
Refer patient to cardiologist
Initiate treatment as per institutional guidelines and consider 
antiarrhythmic drugs, temporary pacemaker, ECMO, or VAD as 
appropriate
Initiate treatment with corticosteroids equivalent to 1 2 mg/kg/day IV 
methylprednisolone and co nvert to 1 2mg/kg/day oral prednisone or 
equivalent upon improvement
If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent
If event resolves to Grade 1 or better , taper corticosteroids 
over1month
ECMO extracorporeal membrane oxygenation; VAD ventricular assist device.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event onset) to 
allow for corticosteroids (if initiated) to be reduced to the equivalent of 10mg/day oral 
prednisone.  The acceptable length of the extended period of time must be agreed upon by the 
investigator and the Medical Monitor.
bIf corticosteroids have been initiated, they must be tapered over 1 month to the equivalent of 
10 mg/day oral prednisone before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and have 
fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by both the investigator (or an 
appropriate delegate) and the Medical Monitor.
INFUSION -RELA TED REA CTIONS AND CYTOKINE RELEA SE SYNDROME
No premedication is indicated for the administration of Cycle 1 of atezolizumab.  
However, patients who experience an infusion -related reaction (IRR) or cytokine release 
syndrome (CRS) with atezolizumab may receive premedication with antihistamines ,
anti-pyretics , and /or analgesics (e.g., acetaminophen) for subsequent infusions.  
Metamizole (dipyrone) is prohibited in treating atezolizumab -associated IRRs because of 
its potential for causing agranulocytosis.
Infusion -related reactions are known to occur with the administration of monoclonal 
antibodies and have been reported with atezolizumab.  These reactions, which are 
thought to be due to release of cytokines and/or other chemical mediators, occur within 
24 hours of atezolizumab administr ation and are generally mild to moderate in severity.
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
181/Protocol WO41994 , Version 3Cytokine release syndrome is defined as a supraphysiologic response following 
administration of any immune therapy that results in activation or engagement of 
endogenous or infused T cells and/or other immune effector cells.  Symptoms can be 
progressive, always include fever at the onset, and may include hypotension, capillary 
leak (hypoxia), and end -organ dysfunction (Lee et al. 2019).  C ytokine release syndrome
has been well -documented with chimeric an tigen receptor T- cell therapies and bispecific 
T-cell engager antibody therapies but has also been reported with immunotherapies that 
target PD -1 or PD -L1 (Rotz et al. 2017; Adashek and Feldman 2019), including 
atezolizumab.
There may be significant overlap in signs and symptoms of IRRs and CRS, and in 
recognition of the challenges in clinically distinguishing between the two , consolidated
guidelines medical management of IRRs and CRS are provided in Table 7.
Severe COVID -19 appears to be associated with a CRS involving the inflammatory 
cytokines IL -6, IL -10, IL -2, and IFN -(Merad and Martin 2020).  If a patient develops 
suspected CRS during the study, a differential diagnosis should include COVID -19, 
which should be confirmed or refuted through assessment of exposure history, 
appropriate laboratory testing, and clinical or radiologic evaluations per investigator 
judgment.   If a diagnosis of COVID -19 is confirmed, the disease should be managed as 
per local or institutional guidelines.
Table 7Management Guidelines for Infusion- Related Reactions and 
Cytokine Release Syndrome
Event Management
Grade 1a
Feverbwith or without 
constitutional 
symptomsImmediately interrupt infusion
Upon s ymptom resolution, wait for 30 minutes and then restart 
infusion at rate to half the rate being given at the time of event onset
If the infusion is tolerated at the reduced rate for 30 minutes, the 
infusion rate may be increased to the original rate
If symptoms recur, discontinue infusion of this dose
Administer sy mptomatic treatment,cincluding maintenance of IV 
fluids for hydration
In case of rapid decline or prolo nged CRS ( 2 days) or in patients 
with significant sy mptoms and/or comorbidities, consider managing 
as per Grade 2
For subsequent infusions, consider administration of oral 
premedication with antihistamines, anti -pyretics, and/or analgesics, 
and monitor c losely for IRRs and/or CRS
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
182/Protocol WO41994 , Version 3Table 7Management Guidelines for Infusion- Related Reactions and 
Cytokine Release Syndrome (cont.)
Event Management
Grade 2a
Feverbwith 
hypotension not 
requiring vasopressors
and/or
Hypoxia requiring low -
flow oxygendby nasal 
cannula or blow -byImmediately interrupt infusion
Upon s ymptom resolution, wait for 30 minutes and then restart 
infusion at half the rate being given at the time of event onset
If symptoms recur, discontinue infusion of this dose
Administer sy mptomatic treatmentc
For hypotension, administer IV fluid bolus as needed
Monitor cardiopulmonary and other organ function closely (in the 
ICU, if appropriate).  Administer IV fluids as clinically indicated and
manage constitutional sy mptoms and organ toxici ties as per 
institutional practice.
Rule out other inflammatory conditions that can mimic CRS 
(e.g., sepsis).  If no improvement within 24 hours, initiate workup and 
assess for signs and sy mptoms of HLH or MAS as described in this 
appendix.
Consider IV cor ticosteroids (e.g., methylprednisolone 2 mg/kg/day or 
dexamethasone 10 mg every 6 hours)
Consider anti -cytokine therapye
Consider hospitalization until complete resolution of symptoms.   If no 
improvement within 24 hours, manage as per Grade 3 , that 
is,hospitalize patient (monitoring in the ICU is recommended), 
permanently discontinue atezolizumab, and contact Medical Monitor .
If symptoms resolve to Grade 1 or better for 3 consecutive days, the 
next dose of atezolizumab may be administered.  For subseque nt 
infusions, consider administration of oral premedication with 
antihistamines, anti -pyretics, and/or analgesics and monitor closely 
for IRRs and/or CRS.
If symptoms do not resolve to Grade 1 or better for 3 consecutive 
days, contact Medical Monitor.
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
183/Protocol WO41994 , Version 3Table7Management Guidelines for Infusion- Related Reactions and 
Cytokine Release Syndrome (cont.)
Event Management
Grade 3a
Feverbwith 
hypotension requiring 
a vasopressor (with
or without 
vasopressin)
and/or
Hypoxia requiring 
high-flow oxygendby 
nasal cannula, face 
mask, non -rebreather 
mask, or Venturi maskPermanently discontinue atezolizumab and contact Medical Monitorf
Administer sy mptomatic treatmentc
For hypotension, administer IV fluid bolus and vasopressor as 
needed
Monitor cardiopulm onary and other organ function closely; 
monitoring in the ICU is recommended.  Administer IV fluids as 
clinically indicated and manage constitutional sy mptoms and organ 
toxicities as per institutional practice.
Rule out other inflammatory conditions that c an mi mic CRS 
(e.g., sepsis).  If no improvement within 24 hours, initiate workup and 
assess for signs and sy mptoms of HLH or MAS as described in this 
appendix.
Administer IV corticosteroids (e.g., methylprednisolone 2 mg/kg/day 
or dexamethasone 10 mg every 6 hours)
Consider anti -cytokine therapye
Hospitalize patient until complete resolution of sy mptoms.  If no 
improvement within 24 hours, manage as per Grade 4, that is, admit 
patient to ICU and initiate hemody namic monitoring, mechanical 
ventilation, and/or IV fluids and vasopressors as needed; for patients 
who are refractory to anti -cytokine therapy, experimental treatments 
may be considered at the discretion of the investigator and in 
consultation with the Medical Monitor .
Grade 4a
Feverbwith 
hypotension requiring 
multiple vasopressors
(excluding 
vasopressin)
and/or
Hypoxia requiring 
oxygen by positive 
pressure (e.g., CPAP, 
Bi-PAP, intubation and 
mechanical ventilation)Permanently discontinue atezolizumab and contact Medical Monitorf
Administer sy mptomatic treatmentc
Admit patient to ICU and initiate hemodynamic monitoring, 
mechanical ventilation, and/or IV fluids and vasopressors as needed.  
Monitor other organ function closely.  Manage constitutional 
symptoms and organ toxicities as per institutional practice.
Rule out other inflammatory conditions that can mimic CRS 
(e.g., sepsis).  If no improvement within 24 hours, initiate workup and 
assess for signs and sy mptoms of HLH or MAS as described in this 
appendix.
Administer IV corticost eroids (e.g., methylprednisolone 2 mg/kg/day 
or dexamethasone 10 mg every 6 hours)
Consider anti -cytokine therapy.eFor patients who are refractory  to 
anti-cytokine therapy, experimental treatmentsgmay be considered 
at the discretion of the investigato r and in consultation with the 
Medical Monitor.
Hospitalize patient until complete resolution of sy mptoms
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
184/Protocol WO41994 , Version 3Table 7Management Guidelines for Infusion- Related Reactions and 
Cytokine Release Syndrome (cont.)
ASTCT American Society for Transplantation and Cellular Therapy; BiPAP bi-level positive 
airway pressure; CAR chimeric antigen receptor; CPAP continuous positive airway pressure; 
CRS cytokine release s yndrome; eCRF electronic Case Report Form; HLHhemo phagocytic 
lymphohistioc ytosis; ICU intensive care unit; IRR infusion -related reaction; MAS macrophage 
activation s yndrom e; NCCN National Cancer Comprehensive Network; NCI CTCAE National 
Cancer Institute Common Terminology Criteria for Adverse Events .
Note:  Themanagement guidelines have been adapted from NCCN guidelines for management 
of CAR T -cellrelated toxicities (Version 2.2019).
aGrading system for management guidelines is based on ASTCT consensus grading for CRS.  
Nation Cancer Institute Common Terminology Criteria for Adverse Events v5.0 should be used 
when reporting severity of IRRs, CRS, or organ toxicities associated with CRS on the 
Adverse Event eCRF.  Organ toxicities associated with CRS should not influence overall 
CRS grading.
bFever is defined as temperature 38C not attributable to any other cause.  In patients who 
develop CRS and then receive anti -pyretic, anti -cytokine, or corticosteroid therapy, fever is no 
longer required when s ubsequently determining event severity (grade) .  In this case, the grade
is driven by the presence of hypotension and/or hypoxia.
cSymptomatic treatment may include oral or IV antihistamines, anti- pyretics, analgesics, 
bronchodilators, and/or oxygen.  For bronchospasm, urticaria, or dy spnea, additional treatment 
may be adm inistered as per institutional practice.
dLow-flow is defined as ox ygen delivered at 6L/min, and high -flow is defined as oxygen 
delivered at  6L/min.
eThere are case reports where anti-cytokine therapy has been used for treatment of CRS with 
immune checkpoint inhibitors (Rotz et al. 2017; Adashek and Feldman 2019), but data are 
limited, and the role of such treatment in the setting of antibody -associated CRS has not been 
established .
fResumption of atezolizumab may  be considered in patients who are deriving benefit and have 
fully recovered from the event.  Patients can be re -challenged with atezolizumab only after 
approval has been documented by both the investigator (or an appropriate delegate) and the 
Medical Monitor.  For subsequent infusions, administer oral premedication with antihistamines, 
anti-pyretics, and/or analgesics, and monitor closely for IRRs and/or CRS.  Premedication with 
corticosteroids and extending the infusion t ime may also be considered after consulting the 
Medical Monitor and considering the benefit risk ratio.
gRefer to Riegler et al. (2019) for information on experimental treatments for CRS.
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
185/Protocol WO41994 , Version 3PANCRE ATIC EVENTS
Symptoms of abdominal pain associated with elevations of amylase and lipase, 
suggestive of pancreatitis, have been associated with the administration of atezolizumab.  
The differential diagnosis of acute abdominal pain should include pancreatitis.  
Appropr iate workup should include an evaluation for ductal obstruction, as well as serum 
amylase and lipase tests .  Management guidelines for pancreatic events, including 
pancreatitis, are provided in Table 8 .
Table 8 Management Guidelines for Pancreatic Events, Including 
Pancreatitis
Event Management
Amylase and/or lipase 
elevation, Grade 2Amylase and/or lipase 1.52.0ULN:
Continue atezolizumab
Monitor am ylase and lipase weekly
For prolonged elevation (e.g., 3 weeks), consider treatment 
with cortico steroids equivalent to 10 mg/day oral prednisone
Asymptomatic with amylase and/or lipase 2.05.0ULN:
Treat as a Grade 3 event
Amylase and/or lipase 
elevation, Grade 3 or 4Withhold atezolizumab for up to 12 weeks after event onseta
Refer patient to GI specialist
Monitor am ylase and lipase every other day
If no improvement, consider treatment with cortico steroids 
equivalent to 12mg/kg/day oral prednisone
If event resolves to Grade 1 or better, resume atezolizumabb
If event does not resolve to Grade 1 or better while 
withholding atezolizumab, permanently discontinue 
atezolizumab and contact Medical Monitorc
For recurrent events , permanently discontinue atezolizumab 
and contact Medical Monitorc
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
186/Protocol WO41994 , Version 3Table 8 Management Guidelines for Pancreatic Events, Including 
Pancreatitis (cont.)
Event Management
Immune -mediated 
pancreatitis, Grade 2 or 3Withhold atezolizumab for up to 12 weeks after event onseta
Refer patient to GI specialist
Initiate treatment with cortico steroids equivalent to 
12mg/kg/day IV methylprednisolone and convert to 
12mg/kg/day oral prednisone or equivalent upon 
improvement
If event resolves t o Grade 1 or better, resume atezolizumabb
If event does not resolve to Grade 1 or better while 
withholding atezolizumab, permanently discontinue 
atezolizumab and contact Medical Monitorc
For recurrent events, p ermanently discontinue atezolizumab 
and cont act Medical Monitorc
Immune -mediated 
pancreatitis, Grade 4Permanently discontinue atezolizumab and contact 
Medical Monitorc
Refer patient to GI specialist
Initiate treatment with cortico steroids equivalent to 
12mg/kg/day IV methylprednisolone and convert to 
12mg/kg/day oral prednisone or equivalent upon 
improvement
If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive 
agent
If event resolves to Grade 1 or better , taper corticosteroids 
over 1 month
GIgastrointestinal ; ULN upper limit of normal.
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event onset) 
to allow for corticosteroids (if initiated) to be reduced to the equivalent of  10mg/day oral
prednisone.  The acceptable length of the extended period of time must be agreed upon by 
the investigator and the Medical Monitor.
bIf corticosteroids have been initiated, they must be tapered over 1 month to the equivalent 
of 10 m g/day oral predniso ne before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and 
have fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has bee n documented by both the investigator (or an 
appropriate delegate) and the Medical Monitor.
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
187/Protocol WO41994 , Version 3DERMA TOLOGIC EVENTS
Treatment -emergent rash has been associated with atezolizumab.  The majority of 
cases of rash were mild in severity and self-limited , with or without pruritus.  
Adermatologist should evaluate persistent and/or severe rash or pruritus.  Although 
uncommon, cases of severe cutaneous adverse reactions such as Stevens -Johnson 
syndrome and toxic epidermal necrolysis have been reported with atezolizum ab.  
Abiopsy should be considered unless contraindicated.  Management guidelines for 
dermatologic events are provided in Table 9 .
Table 9Management Guidelines for Dermatologic Events
Event Management
Dermatologic 
event, Grade 1Continue atezolizumab
Consider treatment with topical cortico steroids and/or other sy mptomatic 
therapy (e.g., antihistamines)
Dermatologic 
event, Grade 2Continue atezolizumab
Consider patient referral to dermatologist for evaluation and, if 
indicated, biopsy
Initiate treatment with topical cortico steroids
Consider treatment with higher -potency topical cortico steroids if event 
does not improve
Dermatologi c 
event, Grade 3Withhold atezolizumab for up to 12 weeks after event onseta
Refer patient to dermatologist for evaluation and, if indicated, biopsy
Initiate treatment with cortico steroids equivalent to 10 mg/day  oral 
prednisone, increasing dose to 12 mg/kg/day if event does not improve 
within 48 72 hours
If event resolves to Grade 1 or better, resume atezolizumabb
If event does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab and contact 
Medical Monito.c
Dermatologic 
event, Grade 4Permanently discontinue atezolizumab and contact Medical Monitorc
Stevens -Johnson 
syndrome or toxic 
epidermal 
necrolysis
(any grade)Additional guidance for Stevens- Johnson syndrome or toxic 
epidermal necrolysis:
Withhold atezolizumab for suspected Stevens -Johnson syndrome or 
toxic epidermal necrolysis
Confirm diagnosis by referring patient to a specialist (dermatologist, 
ophthalmologist, or urologist as relevant) for evaluation and, if 
indicated, biopsy
Follow the applicable treatment and management guidelines above
If Stevens -Johnson syndrome or toxic epidermal necrolysis is 
confirmed, permanently discontinue atezolizumab
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
188/Protocol WO41994 , Version 3Table 9Management Guidelines for Dermatologic Events (cont.)
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event onset) to 
allow for corticosteroids (if initiated) to be reduced to the equivalent of 10mg/day oral 
prednisone.  The acceptable length of the extended period of time must be agreed upon by the 
investigator and the Medical Monitor.
bIf corticosteroids have been initiated, they must be tapered over 1 month to the equivalent of 
10 mg/day oral prednisone before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and have 
fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by both the investigator (or an 
appropriate delegate) and the Medical Monitor.
NEUROLOGIC DISORDERS
Myasthenia gravis and Guillain -Barrésyndrome have been observed with single -agent 
atezolizumab.  Patients may present with signs and symptoms of sensory and/or motor 
neuropathy.  Di agnostic workup is essential for an accurate characterization to 
differentiate between alternative etiologies.  Management guidelines for neurologic 
disorders are provided in Table 10.
Table 10Management Guidelines for Neurologic Disorders
Event Management
Immune -mediated 
neuropathy, 
Grade 1Continue atezolizumab
Investigate etiology
Immune -mediated 
neuropathy, 
Grade 2Withhold atezolizumab for up to 12 weeks after event onseta
Investigate etiology
Initiate treatment as per institutional guidelines
If event resolves to Grade 1 or better, resume atezolizumabb
If event does not resolve to Grade 1 or better while withholding 
atezo lizumab, permanently discontinue atezolizumab and contact 
Medical Monitorc
Immune -mediated 
neuropathy, 
Grade 3 or 4Permanently discontinue atezolizumab and contact Medical Monitorc 
Initiate treatment as per institutional guidelines
Myasthenia gravis 
and Guillain- Barré 
syndrome
(any grade)Permanently discontinue atezolizumab and contact Medical Monitorc
Refer patient to neurologist
Initiate treatment as per institutional guidelines
Consider initiation of cortico steroids equivalent to 1 2 mg/kg/day or al or 
IV prednisone
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
189/Protocol WO41994 , Version 3Table 10Management Guidelines for Neurologic Disorders (cont.)
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event onset) to 
allow for corticosteroids (if initiated) to be reduced to the equivalent of 10mg/day oral 
prednisone.  The acceptable length of the extended period of time must be agreed upon by the 
investigator and the Medical Monitor.
bIf corticosteroids have been initiated, they must be tapered over 1 month to the equivalent of 
10 mg/day oral prednisone before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and have 
fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by both the investigator (or an 
appropriate delegate) and the Medical Monitor.
IMMUNE -MEDI ATEDMENINGOENCEPHALITIS
Immune-mediated meningoencephalitis is an identified risk associated with the 
administration of atezolizumab.  Immune -mediated meningoencephalitis should be 
suspected in any patient presenting with signs or symptoms suggestive of meningitis or 
encephalitis, i ncluding, but not limited to, headache, neck pain, confusion, seizure, motor 
or sensory dysfunction, and altered or depressed level of consciousness.  
Encephalopathy from metabolic or electrolyte imbalances needs to be distinguished from 
potential meningoencephalitis resulting from infection (bacterial, viral, or fungal) or 
progression of malignancy, or secondary to a paraneoplastic process.
All patients being considered for meningoencephalitis should be urgently evaluated with 
a CT scan and/or MRI scan of the brain to evaluate for metastasis, inflammation, or 
edema.  If deemed safe by the treating physician, a lumbar puncture should be 
perfor med, and a neurologist should be consulted.
Patients with signs and symptoms of meningoencephalitis, in the absence of an 
identified alternate etiology, should be treated according to the guidelines in Table 11.
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
190/Protocol WO41994 , Version 3Table 11Management Guidelines for Immune -Mediated
Meningoencephalitis
Event Management
Immune -mediated 
meningoencephalitis, 
all gradesPermanently discontinue atezo lizumab and contact Medical Monitora
Refer patient to neurologist
Initiate treatment with cortico steroids equivalent to 1 2 mg/kg/day IV 
methylprednisolone and convert to 1 2mg/kg/day oral prednisone or 
equivalent upon improvement
If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent
If event resolves to Grade 1 or better , taper corticosteroids over 
1month
aResumption of atezolizumab may  be considered in patients who are deriving benefit and have 
fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by both the investigator (or an 
appropriate delegate) and the Medical Monitor.
RENA L EVENTS
Immune -mediated nephritis has been associated with the administration of atezolizumab.  
Eligible patients must have adequate renal function.  Renal function, including serum 
creatinine, should be monitored throughout study treatment.  Patients with abnormal 
renal function should be evaluated and treated for other more common etiologies 
(including prerenal and postrenal causes, and concomitant medications such as 
non-steroidal anti -inflamm atory drugs).  Refer the patient to a renal specialist if clinically 
indicated.  A renal biopsy may be required to enable a definitive diagnosis and 
appropriate treatment.
Patients with signs and symptoms of nephritis , in the absence of an identified alter nate 
etiology, should be treated according to the guidelines in Table 12.
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
191/Protocol WO41994 , Version 3Table 12Management Guidelines for Renal Events
Event Management
Renal event, 
Grade 1Continue atezolizumab.
Monitor kidney function, including creatinine, closely until values resolve 
to within normal limits or to baseline values
Renal event, 
Grade 2Withhold atezolizumab for up to 12 weeks after event onset a
Refer patient to renal specialist
Initiate treatment with corticosteroids equivalent to 1 2mg/kg/day oral 
prednisone
If event resolves to Grade 1 or better, resume atezolizumabb
If event does n ot resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab and contact 
Medical Monitorc
Renal event, 
Grade 3 or 4Permanently discontinue atezolizumab and contact Medical Monitor
Refer patient to renal specialist and consider renal biopsy
Initiate treatment with corticosteroids equivalent to 1 2mg/kg/day oral 
prednisone
If event does not improve within 48 hours after initiating corticosteroids, 
consider adding an immunosuppressive agent
If event resolves to Grade 1 or better, taper corticosteroids over 
1month
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after event onset) to 
allow for corticosteroids (if initiated) to be reduced to the equivalent of 10mg/day oral 
prednisone. The acceptable length of the extended period of time must be agreed upon by the 
investigator and the Medical Monitor.
bIf corticosteroids have been initiated, they must be tapered over 1 month to the equivalent of 
10mg/day oral prednisone before ate zolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit and have 
fully recovered from the immune -mediated event.  Patients can be re -challenged with 
atezolizumab only after approval has been documented by both the investigator (or an 
appropriate delegate) and the Medical Monitor.
IMMUNE -MEDI ATED MYOS ITIS
Immune -mediated myositis has been associated with the administration of atezolizumab.  
Myositis or inflammatory myopathies are a group of disorders sharing the common 
feature of inflammatory muscle injury; dermatomyositis and polymyositis are among the 
most common disorders.  Initial diagnosis is based on clinical (muscle weakness, muscle 
pain, skin rash in dermatomyositis), biochemical (serum creatin e kinase increase), and 
imaging (electromyography/MRI) features, and is confirmed with a muscle biopsy.
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
192/Protocol WO41994 , Version 3Patients with signs and symptoms of myositis, in the absence of an identified alternate 
etiology, should be treated according to the guidelines in Table 13.
Table 13Management Guidelines for Immune -Mediated Myositis
Event Management
Immune -mediated 
myositis, Grade 1Continue atezolizumab
Refer patient to rheumatologist or neurologist
Initiate treatment as per institutional guidelines
Immune -mediated 
myositis, Grade 2Withhold atezolizumab for up to 12 weeks after event onsetaand 
contact Medical Monitor
Refer patient to rheumatologist or neurologist
Initiate treatment as per institutional guidelines
Consider treatment with corticosteroids equivalent to 1 2mg/kg/day IV 
methylprednisolone and convert to 1 2mg/kg/day oral prednisone or 
equivalent upon improvement
If cortic osteroids are initiated and event does not improve within 
48hours after initiating corticosteroids, consider adding an 
immunosuppressive agent
If event resolves to Grade 1 or better, resume atezolizumabb
If event does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab and contact 
Medical Monitorc
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
193/Protocol WO41994 , Version 3Table 13Management Guidelines for Immune -Mediated My ositis (cont.)
Event Management
Immune -mediated 
myositis ,Grade 3Withhold atezolizumab for up to 12weeks after event onsetaand 
contact Medical Monitor
Refer patient to rheumatologist or neurologist
Initiate treatment as per institutional guidelines
Respiratory support may be required in more severe cases
Initiate treatment with corticosteroids equivalent to 1 2mg/kg/day IV 
methylprednisolone, or higher -dose bolus if patient is severely 
comprom ised (e.g., cardiac or respiratory s ymptoms, dysphagia, or 
weakness that severely limits mobility); convert to 1 2mg/kg/day oral 
prednisone or equivalent upon improvement
If event does not improve within 48 hours after initiating corticosteroids, 
consider adding an immunosuppressive agent
If event resolves to Grade 1 or better, resume atezolizumabb
If event does not resolve to Grade 1 or better while withholding 
atezolizumab, permanently discontinue atezolizumab and contact 
Medical Monitorc
For recurrent events, treat as a Grade 4 event.
Immune -mediated 
myositis ,Grade 4Permanently discontinue atezolizumab and contact Medical Monitorc
Refer patient to rheumatologist or neurologist
Initiate treatment as per institutional guidelines
Respiratory support may be required in more severe cases
Initiate treatment with corticosteroids equivalent to 1 2mg/kg/day IV 
methylprednisolone ,or higher -dose bolus if patient is severe ly
comprom ised (e.g., cardiac orrespiratory symptoms, dysphagia , or 
weakness that severely limits mobility ); convert to 1 2mg/kg/day oral 
prednisone or equivalent upon improvement
If event does not improve within 48 hours after initiating corticosteroids, 
consider adding an immunosuppressive agent
If event resolves to Grade 1 or better, taper corticosteroids over 
1month
aAtezolizumab may  be withheld for a longer period of time (i.e., 12 weeks after 
event on set) to allow for corticosteroids (if initiated) to be reduced to the equivalent 
of10mg/day oral prednisone.  The acceptable length of the extended period of 
time must be agreed upon by the investigator and the Medical Monitor.
bIf corticosteroids have been initiated, they must be tapered over 1 month to the 
equivalent of 10mg/day oral prednisone before atezolizumab can be resumed.
cResumption of atezolizumab may  be considered in patients who are deriving benefit 
and have fu lly recovered from the immune -mediated event.  Patients can be 
re-challenged with atezolizumab only after approval has been documented by both 
the investigator (or an appropriate delegate) and the Medical Monitor.
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
194/Protocol WO41994 , Version 3HEMOPHA GOCYTIC LYMPH OHISTIOCYTOSIS A ND MACROPHA GE 
ACTIVATION SYNDROME
Immune -mediated reactions may involve any organ system and may lead to 
hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS).
Clinical and laboratory features of severe CRS overlap with HLH, and HL H should be 
considered when CRS presentation is atypical or prolonged.
Patients with suspected HLH should be diagnosed according to published criteria by 
McClain and Eckstein (2014).  A patient should be classified as having HLH if fiveof the 
following eight criteria are met:
Fever 38.5°C
Splenomegaly
Peripheral blood cytopenia consisting of at least twoof the following:
–Hemoglobin 90g/L (9 g/dL) ( 100 g/L [10 g/dL] for infants 4 weeks old)
–Platel et count 100109/L (100,000/ L)
–ANC 1.0109/L (1000/L)
Fasting triglycerides 2.992 mmol/L (265 mg/dL) and/or fibrinogen 1.5g/L 
(150 mg/dL)
Hemophagocytosis in bone marrow, spleen, lymph node, or liver
Low or absent natural killer cell activity
Ferritin 500mg/L (500 ng/mL)
Soluble IL-2receptor (soluble CD25) elevated 2 standard deviations above 
age-adjusted laboratory -specific norms
Patients with suspected MAS should be diagnosed according to published criteria for 
systemic juvenile idiopathic arthritis by Ravelli et al. (2016).  A febrile patient should be 
classified as having MAS if the following criteria are met:
Ferritin 684mg/L (684 ng/mL)
At least twoof the following:
–Platelet count 181109/L (181,000/ L)
–AST 48U/L
–Triglycerides 1.761 mmol/L (156 mg/dL)
–Fibrinogen 3.6g/L (360 mg/dL)
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
195/Protocol WO41994 , Version 3Patients with suspected HLH or MAS should be treated according to the guidelines in 
Table 14.
Table 14Management Guidelines for Suspected Hemophagocytic 
Lymphohistiocytosis or Macrophage A ctivation Sy ndrome
Event Management
Suspected HLH 
or MASPermanently discontinue atezolizumab and contact Medical Monitor
Consider patient referral to hematologist
Initiate supportive care, including intensive care monitoring if 
indicated per institutional guidelines
Consider initiation of IV corticosteroids an immunosuppressive agent , 
and/or anti -cytokine therapy
If event does not respond to treatment within 24 hour s, contact 
Medical Monitor and initiate treatment as appropriate according to 
published guidelines (La Ros ée 2015; Schram and Berliner 2015; 
LaRosée et al. 2019)
If event does not improve within 48 hours after initiating 
corticosteroids, consider adding an immunosuppressive agent
If event resolves to Grade 1 or better, taper corticosteroids over 
1month
HLHhemophagocytic ly mphohistiocytosis; MAS macrophage activation syndrome.
REFERENCES
Adashek ML, Feldman M .Cytokine release syndrome resulting from anti programmed 
death -1 antibody: raising awareness among community oncologist. J Oncol 
Practice 2019;15:502 4.
La Ros ée P. Treatment of hemophagocytic lymphohistiocytosis in adults. Hematology 
Am Soc Hematol Educ Protram 2015;1:190 6.
La Ros ée P, Horne A, Hines M, et al. Recommendations for the management of 
hemophagocytic lymphohistiocytosis in adults. Blood 2019;133:2465 77.
Lee D W, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine 
release synd rome and neurologic toxicity associated with immune effector cells. 
Biol Blood Marrow Transplant 2019;25:625 38.
McClain KL, Eckstein O. Clinical features and diagnosis of hemophagocytic 
lymphohistiocytosis. Up to Date [resource on the Internet]. 2014 [upd ated 
29October 2018; cited: 17 May 2019]. Available from: 
https://www.uptodate.com/contents/clinical -features -and-diagnosis -of-
hemophagocytic -lymphohistiocytosis .
Appendix 10:Risks Associated with A tezolizumab and Guidelines for Management of 
Adverse Events A ssociated with A tezolizumab (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
196/Protocol WO41994 , Version 3Merad M, Martin JC. Pathological inflammation in patients with COVID -19: a key role 
for monocytes and macrophages. Nat Rev Immunol 2020;20:355 62.
Ravelli A, Minoia F, Davi S, et al. 2016 classification criteria for macrophage a ctivation 
syndrome complicating systemic juvenile idiopathic arthritis: a European League 
Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology 
International Trials Organisation Collaborative Initiative. Ann Rheum Dis 
2016;75:481 9.
Riegler LL, Jones GP, Lee D W. Current approaches in the grading and management of 
cytokine release syndrome after chimeric antigen receptor T -cell therapy. Ther Clin 
Risk Manag 2019;15:323 35.
Rotz SJ, Leino D, Szabo S, et al. Severe cytokine release syndr ome in a patient 
receiving PD -1-directed therapy. Pediatr Blood Cancer 2017;64:e26642.
Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult 
patient. Blood 2015;125:2908 14.
Atezolizumab —F. Hoffmann- La Roche Ltd
197/Protocol WO41994 , Version 3Appendix 11Risks A ssociated with Cabozantinib and Guidelines 
for Management of A dverse Events A ssociated w ith 
Cabozantinib
This appendix provides guidelines for management of patients who experience 
cabozantinib -associated adverse event s (e.g., GI disorders, hemorrhage, 
thromboembolic events, hypertension, osteonecrosis, proteinuria, hepatocellular toxicity, 
blood system disor ders, QTc prolongation, electrolyte disorders, endocrine disorders, 
and respiratory disorders).
DOSE MODIFICA TIONS
For information on dose modification, see Section 5.1.3.1 .
TREA TMENT INTERRUPTI ON
For information on treatment interruption, see Section 5.1.3.2.
MANAGEMENT GUIDELINE S
The most frequent a dverse events experienced by 20% of patients treated with 
cabozantinib in descending order of frequency were diarrhea, fatigue, nausea, 
decreased appetite, vomiting, weight decreased, palmar -plantar erythrodysesthesia 
(PPE) , constipation, hypertension, dysgeusia, dysphonia, and asthenia. For a full 
description of the safety profile of cabozantinib, refer to the C abozantinib 
Investigator Brochure.
Other medicall y important but less frequent adverse events include arterial th rombotic 
adverse event s (e.g., transient ischemic attack [TIA], and myocardial infarction [ MI]) and 
venous thrombotic adverse event s (e.g., deep venous thrombosis [ DVT]and pulmonary 
embolism [PE]), severe hemorrhagic events, proteinuria, wound healing com plications, 
GI perforation, abscesses ,including intra -abdominal and pelvic abscess, GI and non -GI 
fistula formation, osteonecrosis, and reversible posterior leukoencephalopathy syndrome 
(RPLS; preferred term: posterior reversible encephalopathy syndrome [PRES]).
Adverse events associated with laboratory test abnormalities that were experienced by 
5% of cabozantinib -treated patients in descending order of frequency were anemia, 
AST increased, ALT increased, hypothyroidism, hypokalemia, hypomagnesemia, 
thrombocytopenia, hypocalcemia, hypophosphatemia, lactate dehydrogenase (LDH) 
increased, lipase increased, neutropenia, hyponatremia, ALP increased, leukopenia, 
andhyperglycemia.
Adverse events may occur within the first few weeks in the course of treatment with 
cabozantinib, as cabozantinib is expected to reach steady -state exposure at 
approximately 2 weeks following first dose. Events that generally have an early onset 
include hypocalcemia, hypokalemia, thrombocytopenia, hypertension, PPE, abdominal 
Appendix 11:Risks Associated with Cabozantinib and Guidelines for Management 
of Adverse Events A ssociated with Cabozantinib (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
198/Protocol WO41994 , Version 3pain, mucosal inflammation, constipation, diarrhea, and vomiting. Adverse events 
should be managed with supportive care at the earliest signs of toxicity.
Dose reductions and treatment interruptions should be considered. Dose reductions are 
recommended for e vents that, if persistent, could become serious or intolerable 
(see Section 5.1.3 ).
Cabozantinib should be d iscontinued for the following adverse event s:
visceral perforation or fistula formation, severe hemorrhage, serious arterial 
thromboembolic events, nephrotic syndrom e, hypertensive emergency, persistent 
uncontrolled hypertension despite optimal medical management, and RPLS.
GASTROINTESTINA L DISORDERS
Gastrointestinal (GI) perforation, GI fistula, and intra -abdominal and pelvic abscess : 
After starting treatment with c abozantinib, patients should be monitored for early signs of 
GI perforation such as abdominal pain, nausea, emesis, constipation, and fever 
especially if known risk factors for developing GI perforation or fistula 
(Turnage andBadgwell 2016) are present. Discontinue cabozantinib and initiate 
appropriate management in patients who have been diagnosed with GI perforation or 
fistula.
Diarrhea: Patients should be instructed to notify their physician immediately at the first 
signs of poorly formed or loose stool or an increased frequency of bowel movements. 
Guidelines for the evaluation and management of diarrhea are shown in Table 1. 
Administration of anti -diarrheal /anti-motility agents is recommended at the first sign of 
diarrhea as initial management. Some patients may require concomitant treatment with 
more than one anti -diarrheal agent. When therapy with anti -diarrheal agents does not 
control the diarrhea to tolerable levels, cabozantinib should be temporarily interrupted or 
dose reduced. When the diarrhea is controlled, re -treatment with cabozantinib may be 
accepta ble per i nvestigator decision. In addition, general supportive measures should 
be implemented such as continuous oral isotonic hydration, correction of fluid and 
electrolyte abnormalities, small frequent meals, and stopping lactose -containing 
products, high -fat meals, and alcohol.
Recurrent or prolonged diarrhea can be associated with anal or perianal skin erosions 
which increase the risk for anal abscesses, fistulas, or proctitis. Good personal hygiene 
should be emphasized. Regular examinations of the perianal region should be 
performed whenever diarrhea has occurred during treatment with cabozantinib. 
Infections of the perianal region should be treated per local guidelines.
Appendix 11:Risks Associated with Cabozantinib and Guidelines for Management 
of Adverse Events A ssociated with Cabozantinib (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
199/Protocol WO41994 , Version 3Table 1Management of Diarrhea A ssociated with Cabozantinib
Status Management
Tolerable Grade 1 2 
(duration 48hours)Continue with study  treatment and consider dose reduction
Initiate treatment with an anti -diarrheal agent (e.g., loperamide 
4mg followed by 2 mg after each episode of diarrhea [maximum: 
16mg loperamide per day])
Dietary modifications (e.g., small lactose -free meals, b ananas 
and rice)
Intake of isotonic fluids (1 1.5 L/day)
Reassess after 24 hours:
−Diarrhea resolving to baseline bowel habits: gradually add 
solid foods and discontinue or decrease anti -diarrheal 
treatment after 12 h diarrhea -free interval
−Diarrhea not res olving: Continue/resume anti -diarrheal 
treatment
Intolerable Grade 2,
Grade 248 hours,
or Grade 3Interrupt study treatment
Ask patient to attend clinic
Rule out infection (e.g., stool sample for culture)
−Administer antibiotics as needed (e.g., if fever or Grade 3 4 
neutropenia persists 24hours)
Administer fluids (1 1.5 L/day orally or IV, as appropriate) for 
hydration or to correct electrolyte abnormalities
For Grade 3 4 or complicated lower -grade diarrhea consider 
hospitalization and IV hydration
Reassess after 24 h ours
−Diarrhea resolving to baseline bowel habits or Grade 1: 
consider restarting study treatment at reduced dose
−Diarrhea not resolving:  Start and or continue anti -diarrheal 
treatment (e.g., loperamide 4 mg followed by 2 mg after each 
episode of diarrhea [maximum: 16 mg loperamide per day]). 
Consider starting second- line anti -diarrheal or referral to 
gastroenterologist.
Nausea and vomiting: Anti-emetic agents are recommended as clinically appropriate for 
treatment or prophylaxis of nausea and vomiting, along with supportive care. 
Dehydration and electrolyte abnormalities may be associated with vomiting and 
monitoring for,and correction of fluid and electrolyte disturbances should be 
implemented. Anti-emetic medications should be assessed for potential drug 
interactions ( seeSection 4.4for further details).
Appendix 11:Risks Associated with Cabozantinib and Guidelines for Management 
of Adverse Events A ssociated with Cabozantinib (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
200/Protocol WO41994 , Version 3NON- GASTROINTESTINA LFISTULA
Complications from radiation therapy especially of the thoracic cavity ,including 
mediastinum ,have been identified as a possible predisposing risk factor for non -GI 
fistula formation in patients undergoing treatment with VEGF pathway inhibitors.
Discontinue cabozantinib and initiate appropriate management in patients who have 
been diagnosed with a non-GI fistula.
HEMORRHA GE
Hemorrhagic events, including serious and sometimes fatal events, have been reported 
with cabozantinib . Patients should be monitored for bleeding events with serial complete 
blood counts and physical examination while in the st udy. The risk of hemorrhage in 
cabozantinib -treated patients with brain metastases has not been thoroughly analyzed. 
Patients enrolled with treated and stable brain metastases should be monitored with a 
high index of suspicion if symptoms that could be d ue to a CNS hemorrhage occur.
Cabozantinib should be discontinued in patients with serious and life -threatening 
bleeding events or recent hemoptysis ( 2.5mL of red blood).
THROMBOEMBOLIC EVENT S 
Thromboembolic events are frequent in cancer patients due t o procoagulant changes 
induced by the malignancy or anti -cancer therapy. Deep vein thrombosis and PEhave 
been observed in clinical studies with cabozantinib, including fatal events . Patients who 
develop a PE and/or DVT should have study treatment interr upted until therapeutic 
anticoagulation is established .Treatment with cabozantinib may be resumed in patients 
with PE or DVT if it is determined that the event is uncomplicated and that the patient is 
deriving clinical benefit from cabozantinib treatment and that anti coagulation does not 
place them at a significant risk that outweighs the benefit of resuming treatment per the 
discretion of the i nvestigator and according to individual protocols. Low-molecular 
weight heparin (L MWH)or anti coagulation with direct factor Xa oral inhibitors 
rivaroxaban, edoxaban, or apixaban isallowed for the treatment of thromboembolic 
events if clinically indicated and the bene fit outweighs the risk per the i nvestigator’s 
discretion.
Note: Anticoagulation with the direct thrombin inhibitor dabig atran, or the direct factor 
Xa inhibitor betrixaban is not allowed. SeeSection s 4.4.1 and 4.4.6 for detailed 
information regarding the use of anti coagulants .
Arterial thrombotic events (e .g.,TIA, MI) have been observed in studies with 
cabozantinib .Further treatment with cabozantinib should be discontinued in patients 
Appendix 11:Risks Associated with Cabozantinib and Guidelines for Management 
of Adverse Events A ssociated with Cabozantinib (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
201/Protocol WO41994 , Version 3who develop an acute MI, cerebral infarction, or any other clinically significant arterial 
thromboembolic complication.
HYPERTENSION
Table 2 provides treatment guidelines for hypertension deemed related to cabozantinib. 
Blood pressure (BP)should be monitored in a constant position visit to visit, either sitting 
or supine in a rel axed setting. Decisions to reduce or interrupt the dose of study 
treatment must be based on BPreadings taken by a medical professional and must be 
confirmed with a second measurement at least 5 minutes following the first 
measurement.
Cabozantinib should be discontinued in patients with hypertensive emergency.
Table 2Management of Hy pertension A ssociated with Cabozantinib
Criteria for Dose Modifications Treatment/Cabozantinib Dose Modification
150 mm Hg (sy stolic) a
and160 mmHg
OR
100 mm Hg (diastolic)
and 110 mm HgOptimize antihypertensive medications by adding 
new or additional antihypertensive medications 
and/or increase dose of existing medications
Reduce cabozantinib treatment by one dose level 
if optimal antihypertensive therapy (usually to 
include 3 agents) does not result in 
BP150mmHg sy stolic and 100mmHg 
diastolic
If patient is s ymptomatic interrupt cabozantinib 
treatment
160 mm Hg (sy stolic)
OR
110 mm Hg (diastolic)Reduce cabozantinib by  one dose level or 
interr upt cabozantinib treatment per i nvestigator 
discretion
Add new or additional antihypertensive 
medications and/or increase dose of existing 
medications and monitor patient closely for 
hypotension. If optimized antihypertensive 
therapy (usually to include 3 agents) does not 
result in BP 150mmHg systolic and 
100mmHg diastolic, cabozantinib treatment 
should be dose reduced further or interrupted.
Cabozantinib treatment should be dose 
interrupted if upper limits of sy stolic B P 
(160mmHg) are sustained and not adequately 
manageable or if sy stolic BP is 180mmHg or 
sustained diastolic BP 110 mm Hg, or if patient 
is symptomatic
Restart cabozantinib treatment at the most 
tolerable dose and re -escalate only if BP falls to 
Appendix 11:Risks A ssociated with Cabozantinib and Guidelines for Management 
of Adverse Events A ssociated with Cabozantinib (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
202/Protocol WO41994 , Version 3Criteria for Dose Modifications Treatment/Cabozantinib Dose Modification
and is sustained at 150mmHg sy stolic and 
100mmHg diastolic
Appendix 11:Risks Associated with Cabozantinib and Guidelines for Management 
of Adverse Events A ssociated with Cabozantinib (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
203/Protocol WO41994 , Version 3Table 2Management of Hy pertension A ssociated with Cabozantinib
(cont.)
Criteria for Dose Modifications Treatment/Cabozantinib Dose Modification
Hypertensive emergency bDiscontinue cabozantinib treatment
BPblood pressure.
aThe Investigator may  decide to initiate or adjust antihypertensive treatment at a lower 
threshold than s ystolic BP 150 mmHg or diastolic BP 100 m mHg based on their clinical 
judgment and assessment of the i ndividual patient.
bHypertensive emergency is defined as uncontrolled elevated BP with clinical evidence of 
progressive or impending end- organ damage (e.g., m yocardial infarction/ischemia, intracranial 
hemorrhage, cerebral ischemia, pulmonary edema, encep halopathy, kidney damage).
STOMA TITIS AND MUCOS ITIS
Preventive measures may include a comprehensive oral examination to identify and 
treat any potential risk for complications before study treatment is initiated. Appropriate 
correction of local factors should be instituted as indicated, such as modification of 
ill-fitting dentures and appropriate care of gingivitis. During treatment with cabozantinib, 
good oral hygiene and standard local treatments such as non -traumatic and 
non-irritating cleansing, and oral rinses (e.g., with a weak solution of salt and baking 
soda) should be maintained. Lips should be kept moisturized with lip balm. The use of 
lipstick, lip -gloss, and Vaseline should be avoided.
Local treatment should be instituted at the earliest on set of symptoms. 
Obtain bacterial/viral culture if oral infection is suspected and treat infection as clinically 
indicated.
SKIN A ND SUBCUTANEOU S TISSUE DISORDERS
Wound healing and surgery :Cabozantinib has the potential to cause wound healing 
complicati ons and wound dehiscence, which may even occur long after a wound has 
been considered healed. Therefore, surgical and traumatic wounds must not only be 
completely healed prior to starting cabozantinib treatment but must also be monitored for 
wound dehisce nce, wound infection and other signs of impaired wound healing while the 
patient is being treated with cabozantinib. If dehiscence occurs, cabozantinib treatment 
should not be restarted until complete healing has taken place.
Treatment with cabozantinib s hould be stopped at least 28 days prior to scheduled 
surgery. The decision to resume treatment with cabozantinib after surgery should be 
based on clinical judgment of adequate wound healing.
Appendix 11:Risks Associated with Cabozantinib and Guidelines for Management 
of Adverse Events A ssociated with Cabozantinib (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
204/Protocol WO41994 , Version 3Palmar -plantar erythrodysesthesia (PPE; also known as hand -foot syndrome) :  Skinrash 
(including blister, erythematous rash, macular rash, skin exfoliation, dermatitis acneiform, 
and papular rash), pruritus, dry skin, erythema, pigmentary changes, and alopecia have 
been reported with cabozantinib. All patients in the study should be advised on 
prophylactic measures ,including the use of emollients, removal of calluses, avoidance 
of exposure of hands and feet to hot water leading to vasodilatation, protection of 
pressure -sensitive areas of hands and feet, and use of cot ton gloves and socks to 
prevent injury and keep the palms and soles dry.
Early manifestations include tingling, numbness, mild hyperkeratosis, and symmetrical 
red and swollen areas on the palms and soles. The lateral sides of the fingers or 
periungual zones may also be affected. Adequate interventions are required to prevent 
worsening of skin symptoms such as blisters, desquamations, ulcerations, or necrosis of 
affected areas. Analgesics may be required for pain control.
Aggressive management of sympto ms is recommended, including early dermatology 
referral. Treatment recommendations in response to PPE are summarized in Table 3 .
Appendix 11:Risks Associated with Cabozantinib and Guidelines for Management 
of Adverse Events A ssociated with Cabozantinib (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
205/Protocol WO41994 , Version 3Table 3Management of Hand -Foot Syndrome Associated with 
Cabozantinib
NCI CTCA E v5 Grade Action To Be Taken
Grade 1 Cabozantinib treatment may be continued at the current dose if PPE 
is clinically insignificant and tolerable.  Otherwise, cabozantinib 
should be reduced to the next lower dose level. a  Start urea 20% 
cream twice daily AND clobetasol 0.05% cream once daily .  
Reassess at least weekly; if PPE worsens at any time or does not 
improve after 2 weeks, proceed to the intervention guidelines for 
Grade 2.
Grade 2 Cabozantinib treatment may be continued if PPE is tolerated.  
Cabozantinib should be dose reduced or int errupted if PPE is 
intolerable.  Continue urea 20% cream twice daily AND high potency 
steroid cream (e.g., clobetasol 0.05%) once daily and add analgesics 
(e.g., NSAIDs/gamma -aminobut yric acid agonists) for pain control if 
needed.  Reassess at least weekly ; if PPE worsens or affects 
self-care, proceed to the intervention guidelines for Grade 3.
Grade 3 Interrupt cabozantinib treatment until severity decreases to Grade 1 
or 0.  Continue treatment of skin reaction with high potency steroid 
cream (e.g., clobe tasol 0.05%) twice daily AND analgesics.  
Resume cabozantinib at a reduced dose if PPE recovers to Grade 1.  
Discontinue the patient from study treatment if PPE does not improve 
within 6 weeks.
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events; 
NSAID nonsteroidal anti-inflammatory drug; PPE palm ar-plantar er ythrod ysesthesia.
aPermitted dose levels are defined by individual protocols.
Atezolizumab —F. Hoffmann- La Roche Ltd
206/Protocol WO41994 , Version 3OSTEONECROSIS
Osteonecrosis has been reported in patients treated with cabozantinib. Additional risk 
factors include use of bisphosphonates and denosumab, chemotherapy and 
anti-angiogenic drugs, use of corticosteroids, local radiotherapy, and dental or orofacial 
surgery procedures.
Osteonecrosis of the jaw (ONJ) can manifest as jaw pain, osteomyelitis, osteitis, bone 
erosion, tooth or periodontal infection, toothache, gingival ulceration, or gingival erosion. 
Persistent pain or slow healing of the mouth or jaw after dental surgery may also be 
manifestations of osteonecrosis.
Advise patients regarding oral hygiene practice and to quickly report symptoms to the 
investigator. Caution should be used in patients receiving bisphosphonates.
Invasive dental procedures should be avoided. In cases where dental procedures are 
unavoidable, treatment with cabozantinib should be interrupted for at least 4 weeks prior 
to the procedure and r esumed after complete wound healing has occurred.
Bone healing may often require a protracted time.
PROTEINURIA
Proteinuria has been reported with cabozantinib . Proteinuria should be monitored by 
measuring urine protein- to-creatinine ratio ( UPCR). Table 4 provides treatment 
guidelines for proteinuria deemed related to cabozantinib.
Cabozantinib should be discontinued in patients who develop ne phroti c syndrome 
(proteinuria 3.5 grams per day in combination with low blood protein levels, high 
cholesterol levels, high triglyceride levels, and edema).
Appendix 11:Risks Associated with Cabozantinib and Guidelines for Management 
of Adverse Events A ssociated with Cabozantinib (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
207/Protocol WO41994 , Version 3Table 4Management of Proteinuria A ssociated with Cabozantinib
Severity of Proteinuria 
(UPCR) Management of Proteinuria
1 mg/m g
(113.1 mg/mmol)No change in cabozantinib treatment or monitoring
1 and 3.5mg/mg
(113.1 and 395.9 mg/mmol)Consider confirming with a 24 -hourprotein assessment 
within 7 days
No change in cabozantinib treatment required if 
UPCR 2mg/mg or urine protein 2 g/24 h ours on 24 -hour
urine collection
Reduce dose or interrupt cabozantinib treatment if 
UPCR 2mg/mg on repeat UPCR testing or urine 
protein 2g/24 h ours on 24 -hoururine collection.  
Continue cabozantinib on a reduced dose if UPCR 
decreases to  2 mg/mg.  Consider interrupting 
cabozantinib treatment if UPCR remains 2 mg/m g despite 
a dose reduction until UPCR decreases to 2 mg/mg.  
Restart cabozantinib treatment at a reduced dose after a 
dose interruption unless otherwise approved by the 
Sponsor.
If UPCR 2mg/mg, repeat UPCR monitoring within 7 days 
and once per week.  If UPCR 2 mg/mg on two
consecutive readings, UPCR monitoring can revert to 
protocol -specific times.
(Second reading is confirmatory and can be done within 
1week of first reading ).
3.5 mg/mg
(395.9 mg/mmol)Interrupt cabozantinib treatment pending repeat UPCR 
monitoring within 7 days and/or 24 -hoururine protein
If 3.5 mg/mg on repeat UPCR monitoring, continue to 
interrupt cabozantinib treatment and check UPCR every 
7days.  If UPCR decreases to 2 mg/mg, restart 
cabozantinib treatment at a reduced dose and monitoring 
of UPCR until it remains 2mg/mg on twoconsecutive 
measurements. If UPCR monitoring is determined to be 
stable ( 20% change) for 1 month, then continue with 
UPCR monitoring per protocol or as clinically indicated .
Nephrotic syndrome Discontinue cabozantinib treatment
UPCR urine protein -to-creatinine ratio.
Appendix 11:Risks Associated with Cabozantinib and Guidelines for Management 
of Adverse Events A ssociated with Cabozantinib (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
208/Protocol WO41994 , Version 3NERVOUS SYSTEM DISOR DERS
Cabozantinib appears to represent minimal risk of adverse neurological effects based on 
nonclinical Good Laboratory Practice (GLP) -compliant toxicology studies. 
Dysphonia, dysgeusia, headache, dizziness, confusional state, convuls ion, depression, 
memory impairment, hypoesthesia, peripheral neuropathy, insomnia, ataxia, and 
encephalopathy have been observed in clinical studies with cabozantinib . 
Thedevelopment of any new or progressive, unexplained neurological symptoms should 
be assessed for underlying causes.
RPLS has been reported. RPLS should be considered in any patient presenting with 
seizures, headache, visual disturbances, confusion or altered mental function. 
Cabozantinib treatment should be discontinued in patients with RPLS.
HEPA TOCELLULA R TOXIC ITY
Elevations of aminotransferases (ALT and AST) and bilirubin have been observed during 
treatment with cabozantinib. It is recommended that patients with elevation of ALT, AST, 
and/or bilirubin have more frequent laboratory mo nitoring of these parameters.
Ifpossible, hepatotoxic concomitant medications should be discontinued in patients who 
develop increased values of ALT, AST, or bilirubin and other causes 
(e.g.,cancer -related, or infection) should be evaluated.
Management guidelines for hepatotoxicity related to cabozantinib treatment are provided 
inTable 5 .
Atezolizumab —F. Hoffmann- La Roche Ltd
209/Protocol WO41994 , Version 3Table 5Management of Hepatotoxicity  Associated with Cabozantinib
Severity of Transaminase (A LT or A ST) 
Elevations by NCI CTCA E Treatment/Cabozantinib Dose Modification
Grade 1 Dose adjustment is usually not required
Consider discontinuing concomitant 
hepatotoxic medications and adding 
supportive care as indicated
Grade 2 Interrupt cabozantinib
Restart cabozantinib, at the same dose or a 
reduced dose at i nvestigator discretion, after 
laborator y abnormalities have resolved to no 
higher than NCI CTCAE Grade 1 or baseline 
grade
Grade 3 Interrupt cabozantinib and consider more 
frequent monitoring of ALT and/or AST
Restart cabozantinib at a reduced dose after 
laborator yabnormalities have resolved to 
NCICTCAE Grade 1 or baseline grade
Discontinue if lab oratory abnormalities cannot 
be reversed despite interruption of 
cabozantinib
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events.
The following conditions require discontinuation of cabozantinib unless these laboratory 
abnormalities have recovered to Grade 1 or baseline grade after an interruption and the 
Sponsor has approved reinstitution of cabozantinib:
Drug -related ALT or AST 8upper limit of normal ( ULN)
Drug -related ALT or AST 3ULN in com bination with total bilirubin 2ULN 
without reasonable other explanation, consistent with drug -induced liver injury
INFECTIONS A ND INFES TATIONS
Infectio ns are commonly observed in patients with cancer . Predisposing risk factors 
include decreased immune status (e .g.,after myelosuppressive anti -cancer therapies, 
splenectomy), destructive growth of the underlying malignancy ,including bone marrow 
infiltration with suppression of normal hematopoiesis, as well as the presence of IV
devices.
Infections and abscesses should be treated with appropriate local care and systemic 
therapy. Cabozantinib should be interrupted until adequate healing has taken place.
BLOOD A ND LYMPHA TIC SYSTEM DISORDERS
Hematological toxicities (i .e., neutropenia and thrombocytopenia) and associated 
complications have been observed after administration of cabozantinib and may be 
Appendix 11:Risks Associated with Cabozantinib and Guidelines for Management 
of Adverse Events A ssociated with Cabozantinib (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
210/Protocol WO41994 , Version 3managed with dose interrupt ions and/or dose reductions. Patients with hematologic 
toxicities may require additional or more frequent laboratory tests according to 
institutional guidelines.
Dose reductions or dose interruptions for hematological toxicities are not mandated but 
can b e applied as clinically indicated. However ,for patients with thrombocytopenia dose 
modifications should be followed in accordance withTable 9 inSection 5.1.3.1 .  
Supportive care for thrombocytopenia or anemia, such as transfusions, may be 
managed according to institutional guidelines. The use of colony -stimulating growth 
factors should be considered. Febrile neutropenia or evidence of infection associated 
with neutropenia must be assessed immediately and treated appropriately and in a 
timely manner according to institutional guidelines.
FATIGUE
Commo n causes of fatigue, such as anemia, deconditioning, emotional distress 
(depression and/or anxiety), poor nutrition, dehydration, sleep disturbance, and 
hypothyroidism should be ruled out and treated according to standard of care. 
Pharmacological manageme nt should be considered after disease -specific morbidities 
have been excluded when not prohibited.
WEIGHT LOSS
Anorexia and weight loss should be managed according to local standard of care,
including nutritional support. Pharmacologic therapy should be considered for appetite 
enhancement when not prohibited by a particular protocol.
CORRECTED QT PROLONG ATION
The effect of orally administered cabozantinib 140 mg once a day ( QD)on corrected 
QTinterval ( QTc)was evaluated in a placebo- controlled study in patients with medullary 
thyroid cancer. A mean increase in QT interval corrected withuse of Fridericia’s formula 
(QTcF )of 1015ms was observed after 4 weeks after initiating cabozantinib treatment. 
A concentration -QTc relationship could not be definitively established. Changes in 
cardiac wave form morphology or new rhythms were not observed. No
cabozantinib -treated patient s in this study had a QTcF 480 ms. Review of the larger 
safety database ( approximately 5000 pa tients exposed to cabozantinib in clinical trials 
and in post -marketing experience) confirmed the absence of safety concerns associated 
with QT prolongation. There were no events of torsades de pointes reported.
Concomitant treatment with strong CYP 4503A4 inhibitors, which may increase 
cabozantinib plasma concentrations, should be avoided.
Appendix 11:Risks Associated with Cabozantinib and Guidelines for Management 
of Adverse Events A ssociated with Cabozantinib (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
211/Protocol WO41994 , Version 3If at any time in the study there is an increase in QTcF to an absolute value 480ms or 
an increase of 60 ms above baseline per the site’s ECG read, 2additional ECGs must 
be performed with intervals not less than 3 min utes apart within 30 min utes after the 
initial ECG.
If the average QTcF from the 3ECGs is 480 ms or the average increase is 60ms 
above baseline, the following actions must be taken:
Interrupt cabozantinib treatment
Immediately notify the Sponsor
Hospitalize symptomatic patients (e.g., with palpitations, dizziness, syncope, 
orthostatic hypotension) , or those with a significant ventricular arrhythmia on ECG for 
a thorough cardiology evaluation an d management
Consider cardiology consultation for asymptomatic patients for evaluation and 
management
Check electrolytes, especially magnesium, potassium and calcium; correct 
abnormalities as clinically indicated
Check concomitant medications for any medication that may have contributed to 
QTprolongation, and if possible, discontinue these medications 
(https://www.qtdrugs.org )
Repeat ECG triplicates hourly until the average QTcF is 480 ms and the average 
increase is 60 ms above baseline, or a consulting cardiologist or appropriate expert 
determines that the frequency of ECGs may revert to the schedule in the protocol
Patients with QTc prolongation and symptoms must be monitored closely until the 
QTc elevation and symptoms have resolved. Caboz antinib treatment may be restarted 
but only at a reduced dose level if all of the following conditions are met:
Symptoms are determined to be unrelated to the QT interval prolongation
The QTcF value 480 ms or increase of 60 ms above baseline is not con firmed by 
local cardiologist
Cabozantinib treatment has been interrupted through a minimum of 1 week following 
the return of the QT cF to 480 ms or increase of 60 ms above baseline
QT prolongation can be unequivocally associated with an event other than
cabozantinib administration and is treatable/has been resolved
Sponsor has reviewed all available information and has agreed to the continuation of 
study treatment
Following re- initiation of study treatment, ECGs must be repeated weekly for 2weeks, 
then every 2 weeks for 1 month, then according to the protocol -defined time points.
Appendix 11:Risks Associated with Cabozantinib and Guidelines for Management 
of Adverse Events A ssociated with Cabozantinib (cont.)
Atezolizumab —F. Hoffmann- La Roche Ltd
212/Protocol WO41994 , Version 3Cabozantinib treatment must be permanently discontinued if either of the following 
applies:
Cardiac evaluation confirms that symptoms are the consequence of QT interval 
prolonga tion
Recurrence of QTcF prolongation after re -initiation of study treatment is at a reduced 
dose
ELECTROLYTE DISORDER S
Serum electrolyte imbalance, including hyponatremia, hypokalemia, hypomagnesemia, 
and hypophosphatemia has been reported during treatment with cabozantinib. 
There are many causes for an electrolyte imbalance, including loss of body fluids 
(e.g.,from prolonged vomiting or diarrhea), inadequate diet, kidney disease, and use of 
certain concomitant medications (e .g., diuretics). Electrolyte imbalance may create a 
variety of symptoms (e .g., weakness, fatigue, confusion, muscle spasm, constipation, 
and irregular heartbeat). Serum electrolyte levels should be monitored closely while 
receiving cabozantinib. Clinically relevant electrolyte disorders should be managed 
according to the dose modification guidelines (see Section 5.1.3.1 , Table 9 ) and may 
include oral or IV replacement.
ENDOCRINE DISORDERS
Treatment -emergent el evation of thyroid- stimulating hormone (TSH) has been observed 
with cabozantinib treatment. Currently available data are insufficient to determine the 
mechanism of thyroid function test alterations and its clinical relevance. Management of 
thyroid dysfun ction (e .g.,symptomatic hypothyroidism) should follow accepted clinical 
practice guidelines.
RESPIRA TORY DISORDER S
Dyspnea has been reported in clinical studies with cabozantinib.  Symptoms should be 
managed according to locally accepted clinical practice ,including an assessment for 
underlying causes.  Pulmonary embolism should be considered as possible causes for 
new onset dyspnea given the risk of thrombosis associated with inhibition of VEGF 
signaling.  Furthermore, fistula formation and pneumonia have been reported in subjects 
treated with cabozantinib and should be considered as clinically indicated in subjects 
presenting with pulmonary symptoms.
Atezolizumab —F. Hoffmann- La Roche Ltd
213/Protocol WO41994 , Version 3Appendix 12International Metastatic Renal Cell Carcinoma
Database Consortium Risk Factors
Prognostic factors:
Less than 1year from time of diagnosis to systemic therapy
Karnofsky Performance S tatus 80%
Hem oglobin lower limit of normal (ULN; n ormal: 120g/L or 12 g/dL)
Corrected c alcium upper limit of normal (normal: 8.510.2 mg/dL)
Neutrophils ULN ( normal: 2.07.0109/L)
Platelet sULN (normal: 150,000 400,000)
Risk groups:
Favorable Risk: If patient has 0 factors
Intermediate Risk: If patient has 1 2 factor (s)
 Poor Risk: Ifpatient has 3 6 factors
Suggested corrected calcium formula:
Corrected calcium [0.8(normal albumin patient's albumin )]serum calcium
Atezolizumab —F. Hoffmann- La Roche Ltd
214/Protocol WO41994 , Version 3Appendix 13Definition of Sarcomatoid Renal Cell Carcinoma: 
Stanford Surgical Pathology  Criteria
SARCOMA TOID RENA L CELL CA RCINOMA
Definition
Renal cell carcinoma (RCC) of any type exhibiting at least focal sarcomatoid/spindle cell 
differentiation.
Diagnostic Criteria
Represents a form of high-grade transformation, not a distinct subtype of RCC
May occur in any of the standard subtypes of RCC
Reported to occur in 5 8% of RCCs
Less common in our experience.
Should not be reported as the subtype of RCC
Requires Evidence of Epithelial Differentiation
Concurrent areas of RCC of any type, OR
Immunohistochemical positivity for keratin or EMA
(Keratin and EMA expression may be appropriate for some sarcomas, 
including leiomyosarcomas) .
Requires a Spindle Cell Component Measuri ng at Least 
1 Low-Power(40) Field
May be discrete or intermixed with epithelial elements
May be very focal
Most Common Patterns are Fibrosarcoma and Malignant Fibrous 
Histiocy toma
Rare cases reported with patterns of rhabdomyosarcoma, chondrosarcoma,
osteosarcoma ,andhemangiopericy toma
Pattern does not appear to affect prognosis
Grade of Sarcoma is N ot Clinically  Significant
May range from low to high
Based on cellularity, atypia, mitotic figures .
Appendix 13:Definition of Sarcomatoid Renal Cell Carcinoma:  Stanford Surgical Pathology 
Criteria
Atezolizumab —F. Hoffmann- La Roche Ltd
215/Protocol WO41994 , Version 3REFERENCES
Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: an
examination of underlying histologic subtype and an analysis of associations with 
patient outcome. Am J Surg Pathol 2004;28:43 541.
Delahunt B, Cheville JC, Martig noni G, et al. The International Society of Urology
Pathology (ISUP) grading system for renal cell carcinoma and other prognostic
parameters. Am J Surg Pathol 2013;37:1490 504.
Stanford Medicine. Surgical Pathology Criteria [resource on the Internet]. 2011 
[cited: 24February 2020]. Available from: 
https://surg pathcriteria.stanford.edu/kidney/sarcomatoid -renal -cell-carcinoma/ .